{
  "timestamp": "2025-12-16T11:54:50.751262",
  "config": {
    "data_dir": "persistent_data/benchmark_articles_md",
    "model": "anthropic/claude-opus-4-5-20251101",
    "concurrency": 3,
    "temperature": 0.0
  },
  "output_directory": "outputs/pipeline_run_20251216_113624",
  "combined_file": "outputs/pipeline_run_20251216_113624/combined_20251216_113624.json",
  "summary": {
    "total_pmcids": 32,
    "benchmarked_pmcids": 32,
    "scores": {
      "var-pheno": 0.7902113699256968,
      "study-parameters": 0.6952695409120859,
      "var-drug": 0.6373729921630483,
      "var-fa": 0.8669945984033116
    },
    "overall": 0.7469482629993419,
    "timestamp": "2025-12-16T11:54:50.751273"
  },
  "pmcid_results": {
    "PMC3548984": {
      "var-pheno": {
        "overall_score": 0.43011362875501313,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.3,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Drug(s)": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Alleles": {
            "mean_score": 0.46085742115974426,
            "scores": [
              0.9529426097869873,
              0.945256233215332,
              0.9193233251571655,
              0.9011061787605286,
              0.8899458646774292,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.4,
            "scores": [
              1.0,
              1.0,
              0.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.3,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.4909777045249939,
            "scores": [
              0.9819554090499878,
              0.9819554090499878,
              0.9819554090499878,
              0.9819554090499878,
              0.9819554090499878,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.4381220042705536,
            "scores": [
              0.8762440085411072,
              0.8762440085411072,
              0.8762440085411072,
              0.8762440085411072,
              0.8762440085411072,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 10,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9529426097869873,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9819554090499878,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8762440085411072
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*4",
                "prediction": "CYP2D6*4"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "tamoxifen",
                "prediction": "tamoxifen"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "*3/*3 + *4/*4",
                "prediction": "*4"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Recurrence",
                "prediction": "Efficacy:Disease recurrence"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "EM/EM"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.945256233215332,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9819554090499878,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8762440085411072
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*3",
                "prediction": "CYP2D6*3"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "tamoxifen",
                "prediction": "tamoxifen"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "*3/*3 + *4/*4",
                "prediction": "*3"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Recurrence",
                "prediction": "Efficacy:Disease recurrence"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "EM/EM"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9193233251571655,
              "Is/Is Not associated": 0.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9819554090499878,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8762440085411072
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*6",
                "prediction": "CYP2D6*6"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "tamoxifen",
                "prediction": "tamoxifen"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "*1/*3 + *1/*4 + *1/*6",
                "prediction": "*6"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Recurrence",
                "prediction": "Efficacy:Disease recurrence"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "EM/EM"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9011061787605286,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9819554090499878,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8762440085411072
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*4",
                "prediction": "CYP2D6*10"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "tamoxifen",
                "prediction": "tamoxifen"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "*1/*3 + *1/*4 + *1/*6",
                "prediction": "*10"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Recurrence",
                "prediction": "Efficacy:Disease recurrence"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "EM/EM"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.8899458646774292,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9819554090499878,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8762440085411072
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*4",
                "prediction": "CYP2D6*41"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "tamoxifen",
                "prediction": "tamoxifen"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "*1/*3 + *1/*4 + *1/*6",
                "prediction": "*41"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Recurrence",
                "prediction": "Efficacy:Disease recurrence"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "EM/EM"
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "cyp2d6*1",
          "cyp2d6*3",
          "cyp2d6*4",
          "cyp2d6*4",
          "cyp2d6*6"
        ],
        "unmatched_ground_truth": [
          {
            "Variant Annotation ID": 1444933959,
            "Variant/Haplotypes": "CYP2D6*1",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "Efficacy",
            "Significance": "no",
            "Notes": "Note: PM/IM genotypes are missing; article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist.Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \u201cextensive\u201d metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u201cpoor\u201d metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
            "Sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
            "Alleles": "*1/*3 + *1/*4 + *1/*6",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Recurrence",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in women with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "1444933959",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "tamoxifen",
              "drug_id": "PA451581",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1444933959,
            "Variant/Haplotypes": "CYP2D6*3",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "Efficacy",
            "Significance": "no",
            "Notes": "Note: PM/IM genotypes are missing; article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist.Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \u201cextensive\u201d metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u201cpoor\u201d metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
            "Sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
            "Alleles": "*1/*3 + *1/*4 + *1/*6",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Recurrence",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in women with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "1444933959",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "tamoxifen",
              "drug_id": "PA451581",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1444933987,
            "Variant/Haplotypes": "CYP2D6*1",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "Efficacy",
            "Significance": "no",
            "Notes": "Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \u201cextensive\u201d metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u201cpoor\u201d metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
            "Sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
            "Alleles": "*1/*10 + *1/*41 + *10/*10 + *41/*41",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Recurrence",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in women with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "1444933987",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "tamoxifen",
              "drug_id": "PA451581",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1444933987,
            "Variant/Haplotypes": "CYP2D6*10",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "Efficacy",
            "Significance": "no",
            "Notes": "Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \u201cextensive\u201d metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u201cpoor\u201d metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
            "Sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
            "Alleles": "*1/*10 + *1/*41 + *10/*10 + *41/*41",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Recurrence",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in women with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "1444933987",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "tamoxifen",
              "drug_id": "PA451581",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1444933987,
            "Variant/Haplotypes": "CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "Efficacy",
            "Significance": "no",
            "Notes": "Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \u201cextensive\u201d metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u201cpoor\u201d metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
            "Sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
            "Alleles": "*1/*10 + *1/*41 + *10/*10 + *41/*41",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Recurrence",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in women with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "1444933987",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "tamoxifen",
              "drug_id": "PA451581",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          }
        ],
        "unmatched_predictions": []
      },
      "study-parameters": {
        "overall_score": 0.8613899985949198,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.9208499789237976,
            "scores": [
              0.9227590560913086,
              0.9216042160987854,
              0.9181866645812988
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 3,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9227590560913086,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1444933961,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1444933959,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "prospective",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 166.0,
                "prediction": 166
              },
              "Study Controls": {
                "ground_truth": 287.0,
                "prediction": 287
              },
              "Characteristics": {
                "ground_truth": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); PM/IM and EM/PM vs EM/EM",
                "prediction": "ABCSG8 Arm A, tamoxifen 5 years, PM/IM or PM/EM vs EM/EM, postmenopausal women with ER+ breast cancer"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.07",
                "prediction": "= 0.07"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 1.67,
                "prediction": 1.67
              },
              "Confidence Interval Start": {
                "ground_truth": 0.95,
                "prediction": 0.95
              },
              "Confidence Interval Stop": {
                "ground_truth": 2.93,
                "prediction": 2.93
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9216042160987854,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1444933989,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1444933987,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "prospective",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 166.0,
                "prediction": 166
              },
              "Study Controls": {
                "ground_truth": 287.0,
                "prediction": 287
              },
              "Characteristics": {
                "ground_truth": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); IM/IM and EM/IM vs EM/EM",
                "prediction": "ABCSG8 Arm A, tamoxifen 5 years, EM/IM or IM/IM vs EM/EM, postmenopausal women with ER+ breast cancer"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.6",
                "prediction": "= 0.60"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 1.23,
                "prediction": 1.23
              },
              "Confidence Interval Start": {
                "ground_truth": 0.58,
                "prediction": 0.58
              },
              "Confidence Interval Stop": {
                "ground_truth": 2.61,
                "prediction": 2.61
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9181866645812988,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1444933951,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1444933926,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "prospective",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 166.0,
                "prediction": 166
              },
              "Study Controls": {
                "ground_truth": 287.0,
                "prediction": 287
              },
              "Characteristics": {
                "ground_truth": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); PM/PM vs EM/EM",
                "prediction": "ABCSG8 Arm A, tamoxifen 5 years, PM/PM vs EM/EM, postmenopausal women with ER+ breast cancer"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.04",
                "prediction": "= 0.04"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 2.45,
                "prediction": 2.45
              },
              "Confidence Interval Start": {
                "ground_truth": 1.05,
                "prediction": 1.05
              },
              "Confidence Interval Stop": {
                "ground_truth": 5.73,
                "prediction": 5.73
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "prospective:endpoint: event (dis",
          "prospective:endpoint: event (dis",
          "prospective:endpoint: event (dis"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 153,
            "Study Controls": 270,
            "Characteristics": "ABCSG8 Arm B, tamoxifen followed by anastrozole 5 years, PM/PM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.47",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.6,
            "Confidence Interval Start": 0.15,
            "Confidence Interval Stop": 2.37,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 153,
            "Study Controls": 270,
            "Characteristics": "ABCSG8 Arm B, tamoxifen followed by anastrozole 5 years, PM/IM or PM/EM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.32",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.76,
            "Confidence Interval Start": 0.43,
            "Confidence Interval Stop": 1.31,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 153,
            "Study Controls": 270,
            "Characteristics": "ABCSG8 Arm B, tamoxifen followed by anastrozole 5 years, EM/IM or IM/IM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.96",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.02,
            "Confidence Interval Start": 0.52,
            "Confidence Interval Stop": 2.01,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 28,
            "Study Controls": null,
            "Characteristics": "ABCSG8 Arm A, years 1-2 tamoxifen, PM/PM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.25",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.54,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 41,
            "Study Controls": null,
            "Characteristics": "ABCSG8 Arm B, years 1-2 tamoxifen, PM/PM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.46",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.6,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 84,
            "Study Controls": null,
            "Characteristics": "ABCSG8 Arm A, years 3-5 tamoxifen, PM/PM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.09",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.4,
            "Confidence Interval Start": 0.86,
            "Confidence Interval Stop": 6.66,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 84,
            "Study Controls": null,
            "Characteristics": "ABCSG8 Arm A, years 3-5 tamoxifen, PM/IM or PM/EM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.09",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.7,
            "Confidence Interval Start": 0.91,
            "Confidence Interval Stop": 3.17,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 61,
            "Study Controls": null,
            "Characteristics": "ABCSG8 Arm B, years 3-5 anastrozole, PM/PM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.23",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.28,
            "Confidence Interval Start": 0.03,
            "Confidence Interval Stop": 2.3,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 61,
            "Study Controls": null,
            "Characteristics": "ABCSG8 Arm B, years 3-5 anastrozole, PM/IM or PM/EM vs EM/EM, postmenopausal women with ER+ breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.22",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.63,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC10880264": {
      "var-pheno": {
        "overall_score": 0.9469474685334025,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Gene": {
            "mean_score": 0.9948680060250419,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.964076042175293,
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 0.986052828175681,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.9023697972297668,
              1.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.8571428571428571,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.8571428571428571,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.9196667926652091,
            "scores": [
              0.9056613445281982,
              0.9056613445281982,
              0.9056613445281982,
              0.9056613445281982,
              0.9070549011230469,
              0.9704347252845764,
              0.9375325441360474
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.9786602173532758,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.8506215214729309,
              1.0
            ]
          }
        },
        "total_samples": 7,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9056613445281982,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": null,
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Psychomotor Agitation, Side Effect:Hyperkinesis, Side Effect:Impulse control disorder",
                "prediction": "Side Effect:Akathisia"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9056613445281982,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "poor",
                "prediction": "poor"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": null,
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Psychomotor Agitation, Side Effect:Hyperkinesis, Side Effect:Impulse control disorder",
                "prediction": "Side Effect:Akathisia"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9056613445281982,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "metabolizer",
                "prediction": "metabolizer"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": null,
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Psychomotor Agitation, Side Effect:Hyperkinesis, Side Effect:Impulse control disorder",
                "prediction": "Side Effect:Akathisia"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9056613445281982,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "metabolizer",
                "prediction": "metabolizer"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": null,
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Psychomotor Agitation, Side Effect:Hyperkinesis, Side Effect:Impulse control disorder",
                "prediction": "Side Effect:Akathisia"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 0.964076042175293,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9070549011230469,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "intermediate",
                "prediction": "intermediate"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": null,
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "Side Effect:Akathisia"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9023697972297668,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9704347252845764,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8506215214729309
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs6311",
                "prediction": "rs6311"
              },
              "Gene": {
                "ground_truth": "HTR2A",
                "prediction": "HTR2A"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "A/A"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "Side Effect:Self-injury, suicidality, and harm to others"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "G/G"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 6,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 0.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9375325441360474,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": null,
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
                "prediction": "Side Effect:Adverse events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "cyp2d6",
          "poor",
          "metabolizer",
          "cyp2c19",
          "intermediate",
          "metabolizer",
          "PA166154673"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2D6",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 metabolizers had increased TEASAP akathisia (p = 0.015) scores. Study in youth aged 12-17 years with familial risk for bipolar disorder.",
            "Sentence": "CYP2D6 intermediate metabolizers are associated with increased risk of Side Effect:Akathisia when treated with escitalopram in children with Disease:Depression and Disease:Anxiety compared to normal metabolizers.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Akathisia",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depression, Disease:Anxiety",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (p = 0.015) scores.",
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015; Fig. 2), but not with other TEASAP subscales (p = 0.14\u20130.99), maximum PAERS score (p = 0.51), or hyperarousal events (p = 0.55; Table 2).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6 intermediate metabolizer",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2D6",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism (IM and PM) had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 slower metabolizers are associated with increased risk of Side Effect:Disinhibition and impulsivity when treated with escitalopram in children with Disease:Depression and Disease:Anxiety compared to normal metabolizers.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Disinhibition and impulsivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depression, Disease:Anxiety",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels.",
              "We recruited outpatient youth aged 12\u201317 years who had at least one first-degree relative with bipolar I disorder and clinically significant depression and/or anxiety symptoms"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6 slower metabolizers",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "slower",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism (IM and PM) had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 slower metabolizers are associated with increased risk of Side Effect:Disinhibition and impulsivity when treated with escitalopram in children with Disease:Depression and Disease:Anxiety compared to normal metabolizers.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Disinhibition and impulsivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depression, Disease:Anxiety",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels.",
              "We recruited outpatient youth aged 12\u201317 years who had at least one first-degree relative with bipolar I disorder and clinically significant depression and/or anxiety symptoms"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6 slower metabolizers",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "metabolizers",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism (IM and PM) had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 slower metabolizers are associated with increased risk of Side Effect:Disinhibition and impulsivity when treated with escitalopram in children with Disease:Depression and Disease:Anxiety compared to normal metabolizers.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Disinhibition and impulsivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depression, Disease:Anxiety",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels.",
              "We recruited outpatient youth aged 12\u201317 years who had at least one first-degree relative with bipolar I disorder and clinically significant depression and/or anxiety symptoms"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6 slower metabolizers",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "rs6311",
            "Gene": "HTR2A",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "HTR2A A/A and A/G genotypes were associated with increased TEASAP 'self-injury, suicidality, and harm to others' subscale scores (p = 0.017) compared to G/G genotypes. The variant is -1438G>A (rs6311).",
            "Sentence": "HTR2A rs6311 A/G genotype is associated with increased risk of Side Effect:Self-injury, suicidality, and harm to others when treated with escitalopram in children with Disease:Depression and Disease:Anxiety compared to G/G genotype.",
            "Alleles": "A/G",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Self-injury, suicidality, and harm to others",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depression, Disease:Anxiety",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "G/G",
            "Comparison Metabolizer types": null,
            "Citations": [
              "HTR2A A/A and A/G genotypes were associated with increased TEASAP \"self-injury, suicidality, and harm to others\" subscale scores (p = 0.017).",
              "HTR2A genotype comparisons were made between homozygotes for the \u22121438G>A (rs6311) allele (G/G) and homozygotes and carriers for \u22121438A (A/A, A/G), based on the results of prior studies of associations between HTR2A and antidepressant-related adverse events",
              "Participants with HTR2A A/A or A/G genotypes had a greater increase in TEASAP \"Self-injury, Suicidality, and Harm to Others\" subscale scores relative to those with HTR2A G/G genotypes (p = 0.017)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs6311",
              "variant_id": "PA166154673",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "intermediate",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "CYP2C19 phenotype was not associated with increases in TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60). Slower CYP2C19 metabolizers tended to have greater TEASAP 'self-injury, suicidality, and harm to others' subscale scores (F = 2.32, df = 2, p = 0.09) but not statistically significant.",
            "Sentence": "CYP2C19 intermediate metabolizers are not associated with risk of Side Effect:Adverse events when treated with escitalopram in children with Disease:Depression and Disease:Anxiety.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Adverse events",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depression, Disease:Anxiety",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers tended to have greater TEASAP \"self-injury, suicidality, and harm to others\" subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60; Table 2).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19 intermediate metabolizer",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "metabolizer",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "CYP2C19 phenotype was not associated with increases in TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60). Slower CYP2C19 metabolizers tended to have greater TEASAP 'self-injury, suicidality, and harm to others' subscale scores (F = 2.32, df = 2, p = 0.09) but not statistically significant.",
            "Sentence": "CYP2C19 intermediate metabolizers are not associated with risk of Side Effect:Adverse events when treated with escitalopram in children with Disease:Depression and Disease:Anxiety.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Adverse events",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depression, Disease:Anxiety",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers tended to have greater TEASAP \"self-injury, suicidality, and harm to others\" subscale scores (F = 2.32, df = 2, p = 0.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (p = 0.39\u20130.92), maximum PAERS score (p = 0.27), or hyperarousal events (p = 0.60; Table 2).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and SLC6A4 genotype were not associated with adverse events."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19 intermediate metabolizer",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "5-HTTLPR",
            "Gene": "SLC6A4",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "There was no significant difference in clinical outcomes between participants with SLC6A4 L/L or L/S versus S/S genotypes, including TEASAP increases (p = 0.40\u20130.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).",
            "Sentence": "SLC6A4 5-HTTLPR S/S genotype is not associated with risk of Side Effect:Adverse events when treated with escitalopram in children with Disease:Depression and Disease:Anxiety compared to L/L and L/S genotypes.",
            "Alleles": "S/S",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Adverse events",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depression, Disease:Anxiety",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "L/L, L/S",
            "Comparison Metabolizer types": null,
            "Citations": [
              "There was no significant difference in clinical outcomes between participants with *SLC6A4 L/L* or *L/S* versus *S/S* genotypes, including TEASAP increases (*p* = 0.40\u20130.81), max PAERS score (*p* = 0.72), or hyperarousal frequency (*p* = 0.72).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "5-HTTLPR",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            }
          }
        ]
      },
      "var-drug": {
        "overall_score": 0.31389270853577994,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          },
          "PMID": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          },
          "Significance": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          },
          "Alleles": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          },
          "Specialty Population": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          },
          "Metabolizer types": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          },
          "isPlural": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          },
          "PD/PK terms": {
            "mean_score": 0.3104648192723592,
            "scores": [
              0.9313944578170776,
              0.0,
              0.0
            ]
          },
          "Multiple drugs And/or": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          },
          "Population types": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          },
          "Population Phenotypes or diseases": {
            "mean_score": 0.3201633095741272,
            "scores": [
              0.9604899287223816,
              0.0,
              0.0
            ]
          },
          "Multiple phenotypes or diseases And/or": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          },
          "Comparison Metabolizer types": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          },
          "Drug(s)": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 3,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 1.0,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.9313944578170776,
              "Multiple drugs And/or": 1.0,
              "Population types": 1.0,
              "Population Phenotypes or diseases": 0.9604899287223816,
              "Multiple phenotypes or diseases And/or": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19*1"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19"
              },
              "PMID": {
                "ground_truth": 38377518,
                "prediction": 38377518
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": null,
                "prediction": null
              },
              "Specialty Population": {
                "ground_truth": "Pediatric",
                "prediction": "Pediatric"
              },
              "Metabolizer types": {
                "ground_truth": "intermediate metabolizer",
                "prediction": "intermediate metabolizer"
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "PD/PK terms": {
                "ground_truth": "dose-adjusted trough concentrations of",
                "prediction": "dose-normalized AUC0-24 of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in children with",
                "prediction": "in children with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Other:Depression, Other:Anxiety Disorders",
                "prediction": "Disease:Depressive Disorder, Disease:Anxiety Disorders"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": "or",
                "prediction": "and"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Metabolizer types": {
                "ground_truth": "normal metabolizer",
                "prediction": "normal metabolizer"
              },
              "Drug(s)": {
                "ground_truth": "escitalopram",
                "prediction": "escitalopram"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "cyp2c19"
        ],
        "unmatched_ground_truth": [
          {
            "Variant Annotation ID": 1452390346,
            "Variant/Haplotypes": "intermediate",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "Metabolism/PK",
            "Significance": "yes",
            "Notes": "CPIC guidelines used to assign CYP2C19  metabolizer phenotypes based on CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17. \"CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p\u2009=\u20090.025), Ctrough (p\u2009=\u20090.013), and t1/2 (p\u2009=\u20090.0008) of escitalopram (Fig. 1).\u201d \"CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n\u2009=\u200917), normal metabolizer (NM n\u2009=\u200931), or intermediate metabolizer (IM n\u2009=\u200917), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).\"",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-adjusted trough concentrations of escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "dose-adjusted trough concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "PMID_norm": "38377518",
            "Variant Annotation ID_norm": "1452390346",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19 intermediate metabolizer",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1452390346,
            "Variant/Haplotypes": "metabolizer",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "Metabolism/PK",
            "Significance": "yes",
            "Notes": "CPIC guidelines used to assign CYP2C19  metabolizer phenotypes based on CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17. \"CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p\u2009=\u20090.025), Ctrough (p\u2009=\u20090.013), and t1/2 (p\u2009=\u20090.0008) of escitalopram (Fig. 1).\u201d \"CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n\u2009=\u200917), normal metabolizer (NM n\u2009=\u200931), or intermediate metabolizer (IM n\u2009=\u200917), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).\"",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-adjusted trough concentrations of escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "dose-adjusted trough concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "PMID_norm": "38377518",
            "Variant Annotation ID_norm": "1452390346",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19 intermediate metabolizer",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          }
        ],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2C19*2",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24 (p = 0.025). CYP2C19 phenotypes: IM n=17, NM n=31, RM n=17, UM n=1, PM n=0.",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-normalized AUC0-24 of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "dose-normalized AUC0-24 of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2C19*3",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24 (p = 0.025). CYP2C19 phenotypes: IM n=17, NM n=31, RM n=17, UM n=1, PM n=0.",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-normalized AUC0-24 of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "dose-normalized AUC0-24 of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2C19*4",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24 (p = 0.025). CYP2C19 phenotypes: IM n=17, NM n=31, RM n=17, UM n=1, PM n=0.",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-normalized AUC0-24 of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "dose-normalized AUC0-24 of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2C19*5",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24 (p = 0.025). CYP2C19 phenotypes: IM n=17, NM n=31, RM n=17, UM n=1, PM n=0.",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-normalized AUC0-24 of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "dose-normalized AUC0-24 of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2C19*6",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24 (p = 0.025). CYP2C19 phenotypes: IM n=17, NM n=31, RM n=17, UM n=1, PM n=0.",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-normalized AUC0-24 of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "dose-normalized AUC0-24 of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2C19*7",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24 (p = 0.025). CYP2C19 phenotypes: IM n=17, NM n=31, RM n=17, UM n=1, PM n=0.",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-normalized AUC0-24 of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "dose-normalized AUC0-24 of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2C19*8",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24 (p = 0.025). CYP2C19 phenotypes: IM n=17, NM n=31, RM n=17, UM n=1, PM n=0.",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-normalized AUC0-24 of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "dose-normalized AUC0-24 of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2C19*17",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater dose-normalized AUC0-24 (p = 0.025). CYP2C19 phenotypes: IM n=17, NM n=31, RM n=17, UM n=1, PM n=0.",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-normalized AUC0-24 of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "dose-normalized AUC0-24 of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2C19*1",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater trough concentrations (Ctrough; p = 0.013).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased trough concentrations of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "trough concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2C19*2",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater trough concentrations (Ctrough; p = 0.013).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased trough concentrations of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "trough concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2C19*3",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater trough concentrations (Ctrough; p = 0.013).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased trough concentrations of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "trough concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2C19*4",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater trough concentrations (Ctrough; p = 0.013).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased trough concentrations of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "trough concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2C19*5",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater trough concentrations (Ctrough; p = 0.013).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased trough concentrations of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "trough concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2C19*6",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater trough concentrations (Ctrough; p = 0.013).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased trough concentrations of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "trough concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2C19*7",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater trough concentrations (Ctrough; p = 0.013).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased trough concentrations of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "trough concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2C19*8",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater trough concentrations (Ctrough; p = 0.013).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased trough concentrations of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "trough concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2C19*17",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater trough concentrations (Ctrough; p = 0.013).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased trough concentrations of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "trough concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2C19*1",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater elimination half-lives (t1/2; p < 0.001).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased elimination half-life of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "elimination half-life of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2C19*2",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater elimination half-lives (t1/2; p < 0.001).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased elimination half-life of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "elimination half-life of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2C19*3",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater elimination half-lives (t1/2; p < 0.001).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased elimination half-life of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "elimination half-life of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2C19*4",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater elimination half-lives (t1/2; p < 0.001).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased elimination half-life of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "elimination half-life of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2C19*5",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater elimination half-lives (t1/2; p < 0.001).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased elimination half-life of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "elimination half-life of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2C19*6",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater elimination half-lives (t1/2; p < 0.001).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased elimination half-life of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "elimination half-life of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2C19*7",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater elimination half-lives (t1/2; p < 0.001).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased elimination half-life of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "elimination half-life of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2C19*8",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater elimination half-lives (t1/2; p < 0.001).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased elimination half-life of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "elimination half-life of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2C19*17",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Slower CYP2C19 metabolizers had greater elimination half-lives (t1/2; p < 0.001).",
            "Sentence": "CYP2C19 intermediate metabolizer is associated with increased elimination half-life of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "elimination half-life of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers had greater dose-normalized 24-hour area under the curve (AUC0\u201324; p = 0.025), trough concentrations (Ctrough; p = 0.013), and elimination half-lives (t1/2; p < 0.001).",
              "Among the 48 escitalopram-treated participants who provided samples for pharmacokinetic analysis, CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p = 0.025), Ctrough (p = 0.013), and t1/2 (p = 0.0008) of escitalopram",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2C19*1",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "Slower CYP2C19 metabolizers tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
            "Sentence": "CYP2C19 intermediate metabolizer is not associated with maximum concentration of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "maximum concentration of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2C19*2",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "Slower CYP2C19 metabolizers tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
            "Sentence": "CYP2C19 intermediate metabolizer is not associated with maximum concentration of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "maximum concentration of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2C19*3",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "Slower CYP2C19 metabolizers tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
            "Sentence": "CYP2C19 intermediate metabolizer is not associated with maximum concentration of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "maximum concentration of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2C19*4",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "Slower CYP2C19 metabolizers tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
            "Sentence": "CYP2C19 intermediate metabolizer is not associated with maximum concentration of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "maximum concentration of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2C19*5",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "Slower CYP2C19 metabolizers tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
            "Sentence": "CYP2C19 intermediate metabolizer is not associated with maximum concentration of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "maximum concentration of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2C19*6",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "Slower CYP2C19 metabolizers tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
            "Sentence": "CYP2C19 intermediate metabolizer is not associated with maximum concentration of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "maximum concentration of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2C19*7",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "Slower CYP2C19 metabolizers tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
            "Sentence": "CYP2C19 intermediate metabolizer is not associated with maximum concentration of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "maximum concentration of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2C19*8",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "Slower CYP2C19 metabolizers tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
            "Sentence": "CYP2C19 intermediate metabolizer is not associated with maximum concentration of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "maximum concentration of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2C19*17",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "Slower CYP2C19 metabolizers tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
            "Sentence": "CYP2C19 intermediate metabolizer is not associated with maximum concentration of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "maximum concentration of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2C19 metabolizers also tended to have higher dose-normalized Cmax, though this relationship was not statistically significant (p = 0.057).",
              "CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n = 17), normal metabolizer (NM n = 31), or intermediate metabolizer (IM n = 17), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).",
              "CYP2C19 phenotype was associated with (A) AUC0\u201324 (p = 0.025), (C) Ctrough (p = 0.013), and (D) elimination half-life (t1/2; p = 0.0008), but not (B) the Cmax (p = 0.057) of escitalopram."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2C19*1",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or most TEASAP subscales (p = 0.39-0.92).",
            "Sentence": "CYP2C19 phenotype is not associated with adverse events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "adverse events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (*p* = 0.39\u20130.92), maximum PAERS score (*p* = 0.27), or hyperarousal events (*p* = 0.60; Table 2).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events.",
              "However, in contrast to previous studies of youth (Aldrich et al., 2019) and adults (Joas et al., 2022; Veldic et al., 2019), we did not find a relationship between CYP2C19 phenotype and rates of adverse events."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2C19*2",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or most TEASAP subscales (p = 0.39-0.92).",
            "Sentence": "CYP2C19 phenotype is not associated with adverse events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "adverse events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (*p* = 0.39\u20130.92), maximum PAERS score (*p* = 0.27), or hyperarousal events (*p* = 0.60; Table 2).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events.",
              "However, in contrast to previous studies of youth (Aldrich et al., 2019) and adults (Joas et al., 2022; Veldic et al., 2019), we did not find a relationship between CYP2C19 phenotype and rates of adverse events."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2C19*3",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or most TEASAP subscales (p = 0.39-0.92).",
            "Sentence": "CYP2C19 phenotype is not associated with adverse events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "adverse events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (*p* = 0.39\u20130.92), maximum PAERS score (*p* = 0.27), or hyperarousal events (*p* = 0.60; Table 2).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events.",
              "However, in contrast to previous studies of youth (Aldrich et al., 2019) and adults (Joas et al., 2022; Veldic et al., 2019), we did not find a relationship between CYP2C19 phenotype and rates of adverse events."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2C19*4",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or most TEASAP subscales (p = 0.39-0.92).",
            "Sentence": "CYP2C19 phenotype is not associated with adverse events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "adverse events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (*p* = 0.39\u20130.92), maximum PAERS score (*p* = 0.27), or hyperarousal events (*p* = 0.60; Table 2).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events.",
              "However, in contrast to previous studies of youth (Aldrich et al., 2019) and adults (Joas et al., 2022; Veldic et al., 2019), we did not find a relationship between CYP2C19 phenotype and rates of adverse events."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2C19*5",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or most TEASAP subscales (p = 0.39-0.92).",
            "Sentence": "CYP2C19 phenotype is not associated with adverse events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "adverse events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (*p* = 0.39\u20130.92), maximum PAERS score (*p* = 0.27), or hyperarousal events (*p* = 0.60; Table 2).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events.",
              "However, in contrast to previous studies of youth (Aldrich et al., 2019) and adults (Joas et al., 2022; Veldic et al., 2019), we did not find a relationship between CYP2C19 phenotype and rates of adverse events."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2C19*6",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or most TEASAP subscales (p = 0.39-0.92).",
            "Sentence": "CYP2C19 phenotype is not associated with adverse events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "adverse events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (*p* = 0.39\u20130.92), maximum PAERS score (*p* = 0.27), or hyperarousal events (*p* = 0.60; Table 2).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events.",
              "However, in contrast to previous studies of youth (Aldrich et al., 2019) and adults (Joas et al., 2022; Veldic et al., 2019), we did not find a relationship between CYP2C19 phenotype and rates of adverse events."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2C19*7",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or most TEASAP subscales (p = 0.39-0.92).",
            "Sentence": "CYP2C19 phenotype is not associated with adverse events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "adverse events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (*p* = 0.39\u20130.92), maximum PAERS score (*p* = 0.27), or hyperarousal events (*p* = 0.60; Table 2).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events.",
              "However, in contrast to previous studies of youth (Aldrich et al., 2019) and adults (Joas et al., 2022; Veldic et al., 2019), we did not find a relationship between CYP2C19 phenotype and rates of adverse events."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2C19*8",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or most TEASAP subscales (p = 0.39-0.92).",
            "Sentence": "CYP2C19 phenotype is not associated with adverse events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "adverse events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (*p* = 0.39\u20130.92), maximum PAERS score (*p* = 0.27), or hyperarousal events (*p* = 0.60; Table 2).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events.",
              "However, in contrast to previous studies of youth (Aldrich et al., 2019) and adults (Joas et al., 2022; Veldic et al., 2019), we did not find a relationship between CYP2C19 phenotype and rates of adverse events."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2C19*17",
            "Gene": "CYP2C19",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "CYP2C19 phenotype was not associated with hyperarousal events (p = 0.60), maximum PAERS score (p = 0.27), or most TEASAP subscales (p = 0.39-0.92).",
            "Sentence": "CYP2C19 phenotype is not associated with adverse events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer, normal metabolizer, rapid metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "adverse events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores (*p* = 0.39\u20130.92), maximum PAERS score (*p* = 0.27), or hyperarousal events (*p* = 0.60; Table 2).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events.",
              "However, in contrast to previous studies of youth (Aldrich et al., 2019) and adults (Joas et al., 2022; Veldic et al., 2019), we did not find a relationship between CYP2C19 phenotype and rates of adverse events."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*1",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*2",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*2A",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*3",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*4",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*5",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*6",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*7",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*8",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*9",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*10",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*11",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*12",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*14",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*15",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*17",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0-24 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
            "Sentence": "CYP2D6 phenotype is not associated with pharmacokinetic parameters of escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "pharmacokinetic parameters of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2D6 phenotype was not associated with any dose-normalized pharmacokinetic parameters (AUC0\u201324 p = 0.52; Cmax p = 0.48; Ctrough p = 0.56; t1/2 p = 0.50).",
              "CYP2D6 phenotype was not significantly associated with any pharmacokinetic parameter.",
              "CYP2C19 phenotype influences escitalopram pharmacokinetics whereas CYP2D6 phenotype does not."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*1",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*2",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*2A",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*3",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*4",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*5",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*6",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*7",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*8",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*9",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*10",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*11",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*12",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*14",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*15",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*17",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p = 0.015).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased akathisia from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "akathisia from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (*p* = 0.015; [Fig. 2](#f2)), but not with other TEASAP subscales (*p* = 0.14\u20130.99), maximum PAERS score (*p* = 0.51), or hyperarousal events (*p* = 0.55; [Table 2](#tb2)).",
              "Slower CYP2D6 metabolizers had increased TEASAP akathisia (*p* = 0.015) scores.",
              "Slower CYP2D6 metabolism was associated with increased akathisia, and *HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*1",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*2",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*2A",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*3",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*4",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*5",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*6",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*7",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*8",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*9",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*10",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*11",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*12",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*14",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*15",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*17",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
            "Sentence": "CYP2D6 poor metabolizer and intermediate metabolizer are associated with increased disinhibition and impulsivity from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to normal metabolizer.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": "poor metabolizer, intermediate metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "disinhibition and impulsivity from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Comparison between an aggregate group with normal or faster than normal metabolism (NM or UM) and an aggregate group with slower than normal CYP2D6 metabolism (IM and PM) revealed that participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean = 3.0 vs. 1.1, p = 0.02).",
              "We used CPIC guidelines (Caudle et al., 2017; Hicks et al., 2015) to assign CYP2C19 and CYP2D6 metabolizer phenotypes based on the alleles detected (CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17; CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication).",
              "Children and adolescents aged 12\u201317 years with a first-degree relative with bipolar I disorder were treated with escitalopram and monitored for adverse effects, underwent pharmacogenetic testing, and provided serum escitalopram levels."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*2A, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*14, CYP2D6*15, CYP2D6*17, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 9,
            "Variant/Haplotypes": "rs6311",
            "Gene": "HTR2A",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Participants with HTR2A A/A or A/G genotypes had a greater increase in TEASAP 'Self-injury, Suicidality, and Harm to Others' subscale scores relative to those with HTR2A G/G genotypes (p = 0.017).",
            "Sentence": "Genotypes A/A + A/G are associated with increased self-injury, suicidality, and harm to others from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to genotype G/G.",
            "Alleles": "A/A + A/G",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "self-injury, suicidality, and harm to others from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "G/G",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Participants with *HTR2A A/A* or *A/G* genotypes had a greater increase in TEASAP \"Self-injury, Suicidality, and Harm to Others\" subscale scores relative to those with *HTR2A G/G* genotypes (*p* = 0.017).",
              "*HTR2A A/A* and *A/G* genotypes were associated with increased TEASAP \"self-injury, suicidality, and harm to others\" subscale scores (*p* = 0.017).",
              "*HTR2A A/A* or *A/G* genotypes were associated with increased risk of self-harm or harm to others."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs6311",
              "variant_id": "PA166154673",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 10,
            "Variant/Haplotypes": "rs6311",
            "Gene": "HTR2A",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "There was no significant difference between HTR2A genotype groups with respect to other TEASAP subscales (p = 0.15-0.45), PAERS score (p = 0.39), or hyperarousal events (p = 0.53).",
            "Sentence": "Genotypes A/A + A/G are not associated with hyperarousal events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to genotype G/G.",
            "Alleles": "A/A + A/G",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "hyperarousal events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "G/G",
            "Comparison Metabolizer types": null,
            "Citations": [
              "There was no significant difference between these genotype groups with respect to other TEASAP subscales (p = 0.15\u20130.45), PAERS score (p = 0.39), or the hyperarousal events (p = 0.53; Table 4).",
              "HTR2A genotype comparisons were made between homozygotes for the \u22121438G>A (rs6311) allele (G/G) and homozygotes and carriers for \u22121438A (A/A, A/G), based on the results of prior studies of associations between HTR2A and antidepressant-related adverse events"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs6311",
              "variant_id": "PA166154673",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 11,
            "Variant/Haplotypes": "SLC6A4",
            "Gene": "SLC6A4",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "There was no significant difference in clinical outcomes between participants with SLC6A4 L/L or L/S versus S/S genotypes, including TEASAP increases (p = 0.40-0.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).",
            "Sentence": "Genotype S/S is not associated with adverse events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to genotypes L/L + L/S.",
            "Alleles": "S/S",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "adverse events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "L/L + L/S",
            "Comparison Metabolizer types": null,
            "Citations": [
              "There was no significant difference in clinical outcomes between participants with *SLC6A4 L/L* or *L/S* versus *S/S* genotypes, including TEASAP increases (*p* = 0.40\u20130.81), max PAERS score (*p* = 0.72), or hyperarousal frequency (*p* = 0.72).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events.",
              "*SLC6A4* genotype comparisons were based on homozygosity for the \"short\" risk allele (*S/S*) versus homozygotes and carriers for the \"long\" allele (*L/L* and *L/S*), as rates of adverse events have tended to be highest among *S/S* genotyped groups in prior studies"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "SLC6A4 S/S, SLC6A4 L/S, SLC6A4 L/L",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 11,
            "Variant/Haplotypes": "S/S",
            "Gene": "SLC6A4",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "There was no significant difference in clinical outcomes between participants with SLC6A4 L/L or L/S versus S/S genotypes, including TEASAP increases (p = 0.40-0.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).",
            "Sentence": "Genotype S/S is not associated with adverse events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to genotypes L/L + L/S.",
            "Alleles": "S/S",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "adverse events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "L/L + L/S",
            "Comparison Metabolizer types": null,
            "Citations": [
              "There was no significant difference in clinical outcomes between participants with *SLC6A4 L/L* or *L/S* versus *S/S* genotypes, including TEASAP increases (*p* = 0.40\u20130.81), max PAERS score (*p* = 0.72), or hyperarousal frequency (*p* = 0.72).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events.",
              "*SLC6A4* genotype comparisons were based on homozygosity for the \"short\" risk allele (*S/S*) versus homozygotes and carriers for the \"long\" allele (*L/L* and *L/S*), as rates of adverse events have tended to be highest among *S/S* genotyped groups in prior studies"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "SLC6A4 S/S, SLC6A4 L/S, SLC6A4 L/L",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 11,
            "Variant/Haplotypes": "SLC6A4",
            "Gene": "SLC6A4",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "There was no significant difference in clinical outcomes between participants with SLC6A4 L/L or L/S versus S/S genotypes, including TEASAP increases (p = 0.40-0.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).",
            "Sentence": "Genotype S/S is not associated with adverse events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to genotypes L/L + L/S.",
            "Alleles": "S/S",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "adverse events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "L/L + L/S",
            "Comparison Metabolizer types": null,
            "Citations": [
              "There was no significant difference in clinical outcomes between participants with *SLC6A4 L/L* or *L/S* versus *S/S* genotypes, including TEASAP increases (*p* = 0.40\u20130.81), max PAERS score (*p* = 0.72), or hyperarousal frequency (*p* = 0.72).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events.",
              "*SLC6A4* genotype comparisons were based on homozygosity for the \"short\" risk allele (*S/S*) versus homozygotes and carriers for the \"long\" allele (*L/L* and *L/S*), as rates of adverse events have tended to be highest among *S/S* genotyped groups in prior studies"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "SLC6A4 S/S, SLC6A4 L/S, SLC6A4 L/L",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 11,
            "Variant/Haplotypes": "L/S",
            "Gene": "SLC6A4",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "There was no significant difference in clinical outcomes between participants with SLC6A4 L/L or L/S versus S/S genotypes, including TEASAP increases (p = 0.40-0.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).",
            "Sentence": "Genotype S/S is not associated with adverse events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to genotypes L/L + L/S.",
            "Alleles": "S/S",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "adverse events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "L/L + L/S",
            "Comparison Metabolizer types": null,
            "Citations": [
              "There was no significant difference in clinical outcomes between participants with *SLC6A4 L/L* or *L/S* versus *S/S* genotypes, including TEASAP increases (*p* = 0.40\u20130.81), max PAERS score (*p* = 0.72), or hyperarousal frequency (*p* = 0.72).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events.",
              "*SLC6A4* genotype comparisons were based on homozygosity for the \"short\" risk allele (*S/S*) versus homozygotes and carriers for the \"long\" allele (*L/L* and *L/S*), as rates of adverse events have tended to be highest among *S/S* genotyped groups in prior studies"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "SLC6A4 S/S, SLC6A4 L/S, SLC6A4 L/L",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 11,
            "Variant/Haplotypes": "SLC6A4",
            "Gene": "SLC6A4",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "There was no significant difference in clinical outcomes between participants with SLC6A4 L/L or L/S versus S/S genotypes, including TEASAP increases (p = 0.40-0.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).",
            "Sentence": "Genotype S/S is not associated with adverse events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to genotypes L/L + L/S.",
            "Alleles": "S/S",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "adverse events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "L/L + L/S",
            "Comparison Metabolizer types": null,
            "Citations": [
              "There was no significant difference in clinical outcomes between participants with *SLC6A4 L/L* or *L/S* versus *S/S* genotypes, including TEASAP increases (*p* = 0.40\u20130.81), max PAERS score (*p* = 0.72), or hyperarousal frequency (*p* = 0.72).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events.",
              "*SLC6A4* genotype comparisons were based on homozygosity for the \"short\" risk allele (*S/S*) versus homozygotes and carriers for the \"long\" allele (*L/L* and *L/S*), as rates of adverse events have tended to be highest among *S/S* genotyped groups in prior studies"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "SLC6A4 S/S, SLC6A4 L/S, SLC6A4 L/L",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 11,
            "Variant/Haplotypes": "L/L",
            "Gene": "SLC6A4",
            "Drug(s)": "escitalopram",
            "PMID": 38377518,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "There was no significant difference in clinical outcomes between participants with SLC6A4 L/L or L/S versus S/S genotypes, including TEASAP increases (p = 0.40-0.81), max PAERS score (p = 0.72), or hyperarousal frequency (p = 0.72).",
            "Sentence": "Genotype S/S is not associated with adverse events from escitalopram in children with Disease:Depressive Disorder and Disease:Anxiety Disorders as compared to genotypes L/L + L/S.",
            "Alleles": "S/S",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "adverse events from",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Depressive Disorder, Disease:Anxiety Disorders",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "L/L + L/S",
            "Comparison Metabolizer types": null,
            "Citations": [
              "There was no significant difference in clinical outcomes between participants with *SLC6A4 L/L* or *L/S* versus *S/S* genotypes, including TEASAP increases (*p* = 0.40\u20130.81), max PAERS score (*p* = 0.72), or hyperarousal frequency (*p* = 0.72).",
              "Escitalopram maximum concentration, AUC0\u201324, CYP2C19 phenotype, and *SLC6A4* genotype were not associated with adverse events.",
              "*SLC6A4* genotype comparisons were based on homozygosity for the \"short\" risk allele (*S/S*) versus homozygotes and carriers for the \"long\" allele (*L/L* and *L/S*), as rates of adverse events have tended to be highest among *S/S* genotyped groups in prior studies"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "SLC6A4 S/S, SLC6A4 L/S, SLC6A4 L/L",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "escitalopram",
              "drug_id": "PA10074",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.704678676923116,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.725,
            "scores": [
              1.0,
              1.0,
              0.9,
              0.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.9701801538467407,
            "scores": [
              0.970342755317688,
              0.965861439704895,
              0.9790748357772827,
              0.9654415845870972
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 0.875,
            "scores": [
              1.0,
              1.0,
              0.5,
              1.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 4,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.970342755317688,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452390309,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452390301,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 66.0,
                "prediction": 66
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Outpatient youth aged 12\u201317 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Self-injury, suicidality and harm to others",
                "prediction": "Youth aged 12-17 years with first-degree relative with bipolar I disorder treated with escitalopram, CYP2C19 phenotype and TEASAP self-injury, suicidality and harm to others subscale"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.09",
                "prediction": "= 0.09"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.965861439704895,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452390361,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452390352,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 66.0,
                "prediction": 66
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Outpatient youth aged 12\u201317 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Self-injury, suicidality and harm to others",
                "prediction": "Youth aged 12-17 years with first-degree relative with bipolar I disorder treated with escitalopram, HTR2A A/A or A/G vs G/G genotype and TEASAP self-injury, suicidality and harm to others subscale"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.017",
                "prediction": "= 0.017"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.9,
              "Study Controls": 1.0,
              "Characteristics": 0.9790748357772827,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452390397,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452390389,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 64.0,
                "prediction": 66
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Outpatient youth aged 12\u201317 years who had at least one first-degree relative with bipolar I disorder; TEASAP subscale Akathisia, hyperkinesis and somatic anxiety",
                "prediction": "Youth aged 12-17 years with first-degree relative with bipolar I disorder treated with escitalopram, CYP2D6 phenotype and TEASAP akathisia, hyperkinesis and somatic anxiety subscale"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.017",
                "prediction": "= 0.015"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=44, Hispanic Caucasian n=7, Black or African n = 7, Multiple or other n=8",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9654415845870972,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452390351,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452390346,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 48.0,
                "prediction": 66
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Outpatient youth aged 12\u201317 years who had at least one first-degree relative with bipolar I disorder; dose-normalized AUC0\u201324",
                "prediction": "Youth aged 12-17 years with first-degree relative with bipolar I disorder treated with escitalopram, CYP2C19 phenotype and AUC0-24"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.025",
                "prediction": "= 0.025"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Non-Hispanic Caucasian n=33, Hispanic Caucasian n=6, Black or African n = 6, Multiple or other n=6",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "None:Outpatient youth age",
          "None:Outpatient youth age",
          "None:Outpatient youth age",
          "None:Outpatient youth age"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 66,
            "Study Controls": null,
            "Characteristics": "Youth aged 12-17 years with first-degree relative with bipolar I disorder treated with escitalopram, CYP2C19 phenotype and Ctrough",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.013",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 66,
            "Study Controls": null,
            "Characteristics": "Youth aged 12-17 years with first-degree relative with bipolar I disorder treated with escitalopram, CYP2C19 phenotype and elimination half-life (t1/2)",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 66,
            "Study Controls": null,
            "Characteristics": "Youth aged 12-17 years with first-degree relative with bipolar I disorder treated with escitalopram, CYP2D6 slower vs normal/faster metabolism and TEASAP disinhibition and impulsivity subscale",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.02",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 66,
            "Study Controls": null,
            "Characteristics": "Youth aged 12-17 years with first-degree relative with bipolar I disorder treated with escitalopram, SLC6A4 S/S vs L/L or L/S genotype and adverse events",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "> 0.05",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 66,
            "Study Controls": null,
            "Characteristics": "Youth aged 12-17 years with first-degree relative with bipolar I disorder treated with escitalopram, CYP2C19 phenotype and hyperarousal events",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.60",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 66,
            "Study Controls": null,
            "Characteristics": "Youth aged 12-17 years with first-degree relative with bipolar I disorder treated with escitalopram, CYP2D6 phenotype and hyperarousal events",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.55",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 66,
            "Study Controls": null,
            "Characteristics": "Youth aged 12-17 years with first-degree relative with bipolar I disorder treated with escitalopram, HTR2A genotype and hyperarousal events",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.53",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 66,
            "Study Controls": null,
            "Characteristics": "Youth aged 12-17 years with first-degree relative with bipolar I disorder treated with escitalopram, SLC6A4 genotype and hyperarousal events",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.72",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 66,
            "Study Controls": null,
            "Characteristics": "Youth aged 12-17 years with first-degree relative with bipolar I disorder treated with escitalopram, CYP2D6 slower vs normal/faster metabolism and TEASAP mania subscale",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.07",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 66,
            "Study Controls": null,
            "Characteristics": "Youth aged 12-17 years with first-degree relative with bipolar I disorder treated with escitalopram, CYP2D6 slower vs normal/faster metabolism and TEASAP akathisia, hyperkinesis and somatic anxiety subscale",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.08",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC3839910": {
      "var-pheno": {
        "overall_score": 0.7010703401433097,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Drug(s)": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Alleles": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.7897553741931915,
            "scores": [
              0.9622160792350769,
              0.9620071053504944,
              0.9397730827331543,
              0.9397730827331543,
              0.9347628951072693,
              0.0
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 6,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9622160792350769,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-A*31:01",
                "prediction": "HLA-A*31:01"
              },
              "Gene": {
                "ground_truth": "HLA-A",
                "prediction": "HLA-A"
              },
              "Drug(s)": {
                "ground_truth": "carbamazepine",
                "prediction": "carbamazepine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*31:01",
                "prediction": "*31:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Carbamazepine-induced hypersensitivity syndrome",
                "prediction": "Side Effect:Drug-induced Hypersensitivity Syndrome"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9620071053504944,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-A*31:01",
                "prediction": "HLA-A*31:01"
              },
              "Gene": {
                "ground_truth": "HLA-A",
                "prediction": "HLA-A"
              },
              "Drug(s)": {
                "ground_truth": "carbamazepine",
                "prediction": "carbamazepine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*31:01",
                "prediction": "*31:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Disease:Maculopapular Exanthema",
                "prediction": "Side Effect:Maculopapular Exanthema"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9397730827331543,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:02",
                "prediction": "HLA-B*15:02"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "carbamazepine",
                "prediction": "carbamazepine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*15:02",
                "prediction": "*15:02"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Disease:Stevens-Johnson Syndrome",
                "prediction": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9397730827331543,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-A*31:01",
                "prediction": "HLA-A*31:01"
              },
              "Gene": {
                "ground_truth": "HLA-A",
                "prediction": "HLA-A"
              },
              "Drug(s)": {
                "ground_truth": "carbamazepine",
                "prediction": "carbamazepine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*31:01",
                "prediction": "*31:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Disease:Stevens-Johnson Syndrome",
                "prediction": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9347628951072693,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:02",
                "prediction": "HLA-B*15:02"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "carbamazepine",
                "prediction": "carbamazepine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*15:02",
                "prediction": "*15:02"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Disease:Maculopapular Exanthema",
                "prediction": "Side Effect:Drug-induced Hypersensitivity Syndrome, Side Effect:Maculopapular Exanthema"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "PA165954769",
          "PA165954769",
          "PA165954030",
          "PA165954030",
          "PA165954030"
        ],
        "unmatched_ground_truth": [
          {
            "Variant Annotation ID": 994398056,
            "Variant/Haplotypes": "HLA-B*15:02",
            "Gene": "HLA-B",
            "Drug(s)": "carbamazepine",
            "PMID": 23588310,
            "Phenotype Category": "Toxicity",
            "Significance": "no",
            "Notes": null,
            "Sentence": "HLA-B *15:02 is not associated with increased risk of Carbamazepine-induced hypersensitivity syndrome (HSS) when treated with carbamazepine in children.",
            "Alleles": "*15:02",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Carbamazepine-induced hypersensitivity syndrome (HSS)",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children",
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "23588310",
            "Variant Annotation ID_norm": "994398056",
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*15:02",
              "variant_id": "PA165954769",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "carbamazepine",
              "drug_id": "PA448785",
              "confidence": 1.0
            }
          }
        ],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "HLA-A*31:01",
            "Gene": "HLA-A",
            "Drug(s)": "carbamazepine",
            "PMID": 23588310,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR: 11.18 (95% CI: 2.53-69.27), P=2.6\u00d710^-4. Combined analysis of HSS and MPE: 9 of 32 (28.1%) cases carried HLA-A*31:01.",
            "Sentence": "HLA-A*31:01 is associated with increased risk of Drug-induced Hypersensitivity Syndrome or Maculopapular Exanthema when treated with carbamazepine in children with Epilepsy.",
            "Alleles": "*31:01",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug-induced Hypersensitivity Syndrome, Side Effect:Maculopapular Exanthema",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Epilepsy",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "HLA-A*31:01 was thus very strongly associated with CBZ-HSS or MPE in a combined analysis of the two reactions (OR: 11.2; P=2.6\u00d710^\u22124^; Table 2), with nine (28.1%) of the cases carrying HLA-A*31:01.",
              "HLA-A*31:01 was significantly associated with CBZ-HSS (odds ratio (OR): 26.4, p=0.0025) and maculopapular exanthems (OR: 8.6, p=0.0037), but not with CBZ-SJS.",
              "This study is the first to demonstrate the association of HLA-A*31:01 with CBZ hypersensitivity in children, providing important replication of this association and highlighting the importance of HLA-A*31:01 as a predictive biomarker across various ancestries."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-A*31:01",
              "variant_id": "PA165954030",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "carbamazepine",
              "drug_id": "PA448785",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "rs1061235",
            "Gene": "HLA-A",
            "Drug(s)": "carbamazepine",
            "PMID": 23588310,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR: 25.97 (95% CI: 3.07-340.87), P=8.2\u00d710^-4 for HSS; OR: 7.32 (95% CI: 2.03-28.65), P=7.4\u00d710^-4 for MPE. rs1061235 is a proxy SNP for HLA-A*31:01 in Europeans.",
            "Sentence": "rs1061235 is associated with increased risk of Drug-induced Hypersensitivity Syndrome or Maculopapular Exanthema when treated with carbamazepine in children with Epilepsy.",
            "Alleles": "T",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug-induced Hypersensitivity Syndrome, Side Effect:Maculopapular Exanthema",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Epilepsy",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "A highly significant association with CBZ-HSS and MPE was also observed for the HLA-A*31:01 proxy SNP rs1061235 with 14 (33%) CBZ hypersensitivity cases and only six (6.6%) control patients carrying the T allele (combined OR: 9.45; P=2.6\u00d710^\u22125^; Table 2).",
              "Overall, 20 (15%) children treated with CBZ carried the T allele of rs1061235, a single nucleotide polymorphism (SNP) previously shown to be in complete linkage disequilibrium with HLA-A*31:01 in Europeans (30).",
              "CBZ-HSS | 6 | 3 (50) | 26.36 (2.53\u2013307.89) | 0.0025 | 4 (66.7) | 25.97 (3.07\u2013340.87) | 8.2\u00d710\u22124 | ... CBZ-MPE | 26 | 6 (23.1) | 8.57 (1.67\u201357.50) | 0.0037 | 9 (34.6) | 7.32 (2.03\u201328.65) | 7.4\u00d710\u22124"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1061235",
              "variant_id": "PA166156975",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "carbamazepine",
              "drug_id": "PA448785",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "HLA-A*31:01",
            "Gene": "HLA-A",
            "Drug(s)": "carbamazepine",
            "PMID": 23588310,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR: 7.85 (95% CI: 1.82-47.80), P=0.0016. Combined analysis of all CBZ hypersensitivity reactions: 9 of 42 (21.4%) cases carried HLA-A*31:01.",
            "Sentence": "HLA-A*31:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine in children with Epilepsy.",
            "Alleles": "*31:01",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Epilepsy",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "When considering all CBZ hypersensitivity reactions combined, a highly significant association of HLA-A*31:01 was observed (OR: 7.85; P=0.0016; Table 2), even though the effect size was reduced compared to an analysis only including HSS and MPE cases.",
              "All CBZ cases | 42 | 9 (21.4) | 7.85 (1.82\u201347.80) | 0.0016",
              "This study is the first to demonstrate the association of HLA-A*31:01 with CBZ hypersensitivity in children, providing important replication of this association and highlighting the importance of HLA-A*31:01 as a predictive biomarker across various ancestries."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-A*31:01",
              "variant_id": "PA165954030",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "carbamazepine",
              "drug_id": "PA448785",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 9,
            "Variant/Haplotypes": "HLA-A*31:01",
            "Gene": "HLA-A",
            "Drug(s)": "carbamazepine",
            "PMID": 23588310,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Subgroup analysis in European patients only. OR: 10.05 (95% CI: 1.28-122.88), P=0.013 for HSS/MPE combined. 4 of 16 (25%) European CBZ cases with HSS/MPE carried HLA-A*31:01 vs 3.1% of European controls.",
            "Sentence": "HLA-A*31:01 is associated with increased risk of Drug-induced Hypersensitivity Syndrome or Maculopapular Exanthema when treated with carbamazepine in children of European ancestry with Epilepsy.",
            "Alleles": "*31:01",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug-induced Hypersensitivity Syndrome, Side Effect:Maculopapular Exanthema",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Epilepsy",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "A significant association was also observed with CBZ-induced MPE, with six of 26 (23.1%) CBZ-MPE cases carrying HLA-A*31:01 (OR: 8.6; P=0.0037; Table 2). HLA-A*31:01 was thus very strongly associated with CBZ-HSS or MPE in a combined analysis of the two reactions (OR: 11.2; P=2.6\u00d710^\u22124^; Table 2), with nine (28.1%) of the cases carrying HLA-A*31:01.",
              "As in the full cohort, a stronger association was observed when only considering patients with CBZ-HSS or MPE (OR: 10.05; P=0.013; Table 3).",
              "The frequency of HLA-A*31:01 in European CBZ-tolerant children (3.1%; Table 3) was similar to the frequency reported previously in a European study (3.9%)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-A*31:01",
              "variant_id": "PA165954030",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "carbamazepine",
              "drug_id": "PA448785",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.6409401473734114,
        "field_scores": {
          "Study Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.16666666666666666,
            "scores": [
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Controls": {
            "mean_score": 0.9833333333333334,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.9
            ]
          },
          "Characteristics": {
            "mean_score": 0.9307688772678375,
            "scores": [
              0.9468361139297485,
              0.9409934878349304,
              0.9246460199356079,
              0.9197869300842285,
              0.918486475944519,
              0.9338642358779907
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "P Value": {
            "mean_score": 0.5833333333333334,
            "scores": [
              0.5,
              0.5,
              0.5,
              0.5,
              0.5,
              1.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 0.3,
            "scores": [
              0.8,
              0.0,
              0.0,
              0.0,
              0.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 0.16666666666666666,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 0.15,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.9
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 6,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9468361139297485,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.8,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 993818102,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 993813998,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 42.0,
                "prediction": 42
              },
              "Study Controls": {
                "ground_truth": 91.0,
                "prediction": 91
              },
              "Characteristics": {
                "ground_truth": "pediatric patients from North America with a diverse ethnic background, 42 children with CBZ hypersensitivity and 91 CBZ-tolerant children from across Canada.",
                "prediction": "All CBZ hypersensitivity cases in pediatric patients - combined HLA-A*31:01 or HLA-B*15:02"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.0037",
                "prediction": "= 2.6e-4"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 8.6,
                "prediction": 8.14
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 2.25
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 37.34
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9409934878349304,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 994166721,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 994166507,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 42.0,
                "prediction": 6
              },
              "Study Controls": {
                "ground_truth": 91.0,
                "prediction": 91
              },
              "Characteristics": {
                "ground_truth": "pediatric patients from North America with a diverse ethnic background, 42 children with CBZ hypersensitivity and 91 CBZ-tolerant children from across Canada.",
                "prediction": "CBZ-HSS (carbamazepine-induced hypersensitivity syndrome) in pediatric patients - combined HLA-A*31:01 or HLA-B*15:02"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.002",
                "prediction": "= 0.0048"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 38.6,
                "prediction": 19.05
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 1.95
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 197.65
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9246460199356079,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 994531644,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 994531642,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 42.0,
                "prediction": 9
              },
              "Study Controls": {
                "ground_truth": 91.0,
                "prediction": 91
              },
              "Characteristics": {
                "ground_truth": "pediatric patients from North America with a diverse ethnic background, 42 children with CBZ hypersensitivity and 91 CBZ-tolerant children from across Canada.",
                "prediction": "CBZ-SJS/TEN (carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis) in pediatric patients - combined HLA-A*31:01 or HLA-B*15:02"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 1.0",
                "prediction": "= 0.017"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 1.09,
                "prediction": 9.87
              },
              "Confidence Interval Start": {
                "ground_truth": 0.04,
                "prediction": 1.18
              },
              "Confidence Interval Stop": {
                "ground_truth": 27.5,
                "prediction": 75.5
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9197869300842285,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 993944507,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 993944301,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 42.0,
                "prediction": 32
              },
              "Study Controls": {
                "ground_truth": 91.0,
                "prediction": 91
              },
              "Characteristics": {
                "ground_truth": "pediatric patients from North America with a diverse ethnic background, 42 children with CBZ hypersensitivity and 91 CBZ-tolerant children from across Canada.",
                "prediction": "CBZ-HSS/MPE combined in pediatric patients - combined HLA-A*31:01 or HLA-B*15:02"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 1.0",
                "prediction": "= 8.9e-5"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 1.33,
                "prediction": 7.94
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 2.0
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 38.55
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.918486475944519,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 993728141,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 992282434,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 42.0,
                "prediction": 26
              },
              "Study Controls": {
                "ground_truth": 91.0,
                "prediction": 91
              },
              "Characteristics": {
                "ground_truth": "pediatric patients from North America with a diverse ethnic background, 42 children with CBZ hypersensitivity and 91 CBZ-tolerant children from across Canada.",
                "prediction": "CBZ-MPE (carbamazepine-induced maculopapular exanthems) in pediatric patients - combined HLA-A*31:01 or HLA-B*15:02"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.0025",
                "prediction": "= 0.0095"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 26.4,
                "prediction": 6.09
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 1.31
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 32.25
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 0.0,
              "Study Controls": 0.9,
              "Characteristics": 0.9338642358779907,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 0.9,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 994398281,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 994398056,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 42.0,
                "prediction": 6
              },
              "Study Controls": {
                "ground_truth": 91.0,
                "prediction": 87
              },
              "Characteristics": {
                "ground_truth": "pediatric patients from North America with a diverse ethnic background, 42 children with CBZ hypersensitivity and 91 CBZ-tolerant children from across Canada.",
                "prediction": "CBZ-HSS (carbamazepine-induced hypersensitivity syndrome) in pediatric patients"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": 0.0
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "HLA-B*15:02"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": 0.011
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": "HLA-B*15:02"
              },
              "P Value": {
                "ground_truth": "= 1.0",
                "prediction": "= 1.000"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 4.44,
                "prediction": 4.44
              },
              "Confidence Interval Start": {
                "ground_truth": 0.16,
                "prediction": 0.16
              },
              "Confidence Interval Stop": {
                "ground_truth": 120.0,
                "prediction": 120.08
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "case/control:pediatric patients f",
          "case/control:pediatric patients f",
          "case/control:pediatric patients f",
          "case/control:pediatric patients f",
          "case/control:pediatric patients f",
          "case/control:pediatric patients f"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 6,
            "Study Controls": 91,
            "Characteristics": "CBZ-HSS (carbamazepine-induced hypersensitivity syndrome) in pediatric patients",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.5,
            "Allele Of Frequency In Cases": "HLA-A*31:01",
            "Frequency In Controls": 0.033,
            "Allele Of Frequency In Controls": "HLA-A*31:01",
            "P Value": "= 0.0025",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 26.36,
            "Confidence Interval Start": 2.53,
            "Confidence Interval Stop": 307.89,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 26,
            "Study Controls": 91,
            "Characteristics": "CBZ-MPE (carbamazepine-induced maculopapular exanthems) in pediatric patients",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.231,
            "Allele Of Frequency In Cases": "HLA-A*31:01",
            "Frequency In Controls": 0.033,
            "Allele Of Frequency In Controls": "HLA-A*31:01",
            "P Value": "= 0.0037",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 8.57,
            "Confidence Interval Start": 1.67,
            "Confidence Interval Stop": 57.5,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 9,
            "Study Controls": 91,
            "Characteristics": "CBZ-SJS/TEN (carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis) in pediatric patients",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.0,
            "Allele Of Frequency In Cases": "HLA-A*31:01",
            "Frequency In Controls": 0.033,
            "Allele Of Frequency In Controls": "HLA-A*31:01",
            "P Value": "= 1.000",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.33,
            "Confidence Interval Start": 0.06,
            "Confidence Interval Stop": 27.76,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 42,
            "Study Controls": 91,
            "Characteristics": "All CBZ hypersensitivity cases in pediatric patients",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.214,
            "Allele Of Frequency In Cases": "HLA-A*31:01",
            "Frequency In Controls": 0.033,
            "Allele Of Frequency In Controls": "HLA-A*31:01",
            "P Value": "= 0.0016",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 7.85,
            "Confidence Interval Start": 1.82,
            "Confidence Interval Stop": 47.8,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 32,
            "Study Controls": 91,
            "Characteristics": "CBZ-HSS/MPE combined (carbamazepine-induced hypersensitivity syndrome or maculopapular exanthems) in pediatric patients",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.281,
            "Allele Of Frequency In Cases": "HLA-A*31:01",
            "Frequency In Controls": 0.033,
            "Allele Of Frequency In Controls": "HLA-A*31:01",
            "P Value": "= 2.6e-4",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 11.18,
            "Confidence Interval Start": 2.53,
            "Confidence Interval Stop": 69.27,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 6,
            "Study Controls": 91,
            "Characteristics": "CBZ-HSS (carbamazepine-induced hypersensitivity syndrome) in pediatric patients",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.667,
            "Allele Of Frequency In Cases": "rs1061235T",
            "Frequency In Controls": 0.066,
            "Allele Of Frequency In Controls": "rs1061235T",
            "P Value": "= 8.2e-4",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 25.97,
            "Confidence Interval Start": 3.07,
            "Confidence Interval Stop": 340.87,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 26,
            "Study Controls": 91,
            "Characteristics": "CBZ-MPE (carbamazepine-induced maculopapular exanthems) in pediatric patients",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.346,
            "Allele Of Frequency In Cases": "rs1061235T",
            "Frequency In Controls": 0.066,
            "Allele Of Frequency In Controls": "rs1061235T",
            "P Value": "= 7.4e-4",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 7.32,
            "Confidence Interval Start": 2.03,
            "Confidence Interval Stop": 28.65,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 9,
            "Study Controls": 91,
            "Characteristics": "CBZ-SJS/TEN (carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis) in pediatric patients",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.0,
            "Allele Of Frequency In Cases": "rs1061235T",
            "Frequency In Controls": 0.066,
            "Allele Of Frequency In Controls": "rs1061235T",
            "P Value": "= 1.000",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.69,
            "Confidence Interval Start": 0.04,
            "Confidence Interval Stop": 13.27,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 42,
            "Study Controls": 91,
            "Characteristics": "All CBZ hypersensitivity cases in pediatric patients",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.333,
            "Allele Of Frequency In Cases": "rs1061235T",
            "Frequency In Controls": 0.066,
            "Allele Of Frequency In Controls": "rs1061235T",
            "P Value": "= 1.5e-4",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 6.96,
            "Confidence Interval Start": 2.25,
            "Confidence Interval Stop": 24.32,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 32,
            "Study Controls": 91,
            "Characteristics": "CBZ-HSS/MPE combined (carbamazepine-induced hypersensitivity syndrome or maculopapular exanthems) in pediatric patients",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.406,
            "Allele Of Frequency In Cases": "rs1061235T",
            "Frequency In Controls": 0.066,
            "Allele Of Frequency In Controls": "rs1061235T",
            "P Value": "= 2.6e-5",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 9.45,
            "Confidence Interval Start": 2.91,
            "Confidence Interval Stop": 34.5,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 26,
            "Study Controls": 87,
            "Characteristics": "CBZ-MPE (carbamazepine-induced maculopapular exanthems) in pediatric patients",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.0,
            "Allele Of Frequency In Cases": "HLA-B*15:02",
            "Frequency In Controls": 0.011,
            "Allele Of Frequency In Controls": "HLA-B*15:02",
            "P Value": "= 1.000",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.09,
            "Confidence Interval Start": 0.04,
            "Confidence Interval Stop": 27.51,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 9,
            "Study Controls": 87,
            "Characteristics": "CBZ-SJS/TEN (carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis) in pediatric patients",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.333,
            "Allele Of Frequency In Cases": "HLA-B*15:02",
            "Frequency In Controls": 0.011,
            "Allele Of Frequency In Controls": "HLA-B*15:02",
            "P Value": "= 0.0022",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 38.65,
            "Confidence Interval Start": 2.68,
            "Confidence Interval Stop": 2239.5,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 42,
            "Study Controls": 87,
            "Characteristics": "All CBZ hypersensitivity cases in pediatric patients",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.071,
            "Allele Of Frequency In Cases": "HLA-B*15:02",
            "Frequency In Controls": 0.011,
            "Allele Of Frequency In Controls": "HLA-B*15:02",
            "P Value": "= 0.101",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 6.51,
            "Confidence Interval Start": 0.5,
            "Confidence Interval Stop": 350.5,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 32,
            "Study Controls": 87,
            "Characteristics": "CBZ-HSS/MPE combined (carbamazepine-induced hypersensitivity syndrome or maculopapular exanthems) in pediatric patients",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.0,
            "Allele Of Frequency In Cases": "HLA-B*15:02",
            "Frequency In Controls": 0.011,
            "Allele Of Frequency In Controls": "HLA-B*15:02",
            "P Value": "= 1.000",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.86,
            "Confidence Interval Start": 0.03,
            "Confidence Interval Stop": 21.66,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 2,
            "Study Controls": 65,
            "Characteristics": "CBZ-HSS in European pediatric patients only",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.5,
            "Allele Of Frequency In Cases": "HLA-A*31:01",
            "Frequency In Controls": 0.031,
            "Allele Of Frequency In Controls": "HLA-A*31:01",
            "P Value": "= 0.088",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 25.92,
            "Confidence Interval Start": 0.27,
            "Confidence Interval Stop": 2437.8,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 14,
            "Study Controls": 65,
            "Characteristics": "CBZ-MPE in European pediatric patients only",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.214,
            "Allele Of Frequency In Cases": "HLA-A*31:01",
            "Frequency In Controls": 0.031,
            "Allele Of Frequency In Controls": "HLA-A*31:01",
            "P Value": "= 0.037",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 8.23,
            "Confidence Interval Start": 0.84,
            "Confidence Interval Stop": 109.23,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 4,
            "Study Controls": 65,
            "Characteristics": "CBZ-SJS/TEN in European pediatric patients only",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.0,
            "Allele Of Frequency In Cases": "HLA-A*31:01",
            "Frequency In Controls": 0.031,
            "Allele Of Frequency In Controls": "HLA-A*31:01",
            "P Value": "= 1.000",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.82,
            "Confidence Interval Start": 0.12,
            "Confidence Interval Stop": 68.1,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 20,
            "Study Controls": 65,
            "Characteristics": "All CBZ hypersensitivity cases in European pediatric patients only",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.2,
            "Allele Of Frequency In Cases": "HLA-A*31:01",
            "Frequency In Controls": 0.031,
            "Allele Of Frequency In Controls": "HLA-A*31:01",
            "P Value": "= 0.025",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 7.62,
            "Confidence Interval Start": 0.99,
            "Confidence Interval Stop": 91.4,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 16,
            "Study Controls": 65,
            "Characteristics": "CBZ-HSS/MPE combined in European pediatric patients only",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.25,
            "Allele Of Frequency In Cases": "HLA-A*31:01",
            "Frequency In Controls": 0.031,
            "Allele Of Frequency In Controls": "HLA-A*31:01",
            "P Value": "= 0.013",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 10.05,
            "Confidence Interval Start": 1.28,
            "Confidence Interval Stop": 122.88,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC3387531": {
      "var-pheno": {
        "overall_score": 0.872592315905624,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 0.6240928371747335,
            "scores": [
              0.9854477047920227,
              0.9579573273658752,
              0.8354120850563049,
              0.0,
              0.0,
              0.965739905834198
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Direction of effect": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.9341509342193604,
            "scores": [
              0.9370197057723999,
              0.9335771799087524,
              0.9335771799087524,
              0.9335771799087524,
              0.9335771799087524,
              0.9335771799087524
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.3333333333333333,
            "scores": [
              0.0,
              0.0,
              0.0,
              1.0,
              1.0,
              0.0
            ]
          }
        },
        "total_samples": 6,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9854477047920227,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9370197057723999,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-DRB1*01:01",
                "prediction": "HLA-DRB1*01"
              },
              "Gene": {
                "ground_truth": "HLA-DRB1",
                "prediction": "HLA-DRB1"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*01:01",
                "prediction": "*01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Drug Toxicity",
                "prediction": "Side Effect:Hepatic adverse events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9579573273658752,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9335771799087524,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*35:01",
                "prediction": "HLA-B*35"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*35:01",
                "prediction": "*35"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Drug Toxicity",
                "prediction": "Side Effect:Cutaneous adverse events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.8354120850563049,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9335771799087524,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs3745274",
                "prediction": "rs3745274"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "T",
                "prediction": "516G\u2192T"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Drug Toxicity",
                "prediction": "Side Effect:Cutaneous adverse events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "516GG"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9335771799087524,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs2054675",
                "prediction": "rs2054675"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "C",
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Drug Toxicity",
                "prediction": "Side Effect:Cutaneous adverse events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9335771799087524,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs3786547",
                "prediction": "rs3786547"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "C",
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Drug Toxicity",
                "prediction": "Side Effect:Cutaneous adverse events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.965739905834198,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9335771799087524,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-C*04:01",
                "prediction": "HLA-Cw*04"
              },
              "Gene": {
                "ground_truth": "HLA-C",
                "prediction": "HLA-C"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*04:01",
                "prediction": "*04"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Drug Toxicity",
                "prediction": "Side Effect:Cutaneous adverse events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "PA165955215",
          "PA165951320",
          "PA166155409",
          "PA166155378",
          "PA166155411",
          "hla-c+nevirapine"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "HLA-DQB1*05",
            "Gene": "HLA-DQB1",
            "Drug(s)": "nevirapine",
            "PMID": 21505298,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "HLA-DQB1*05 was significantly associated with hepatic adverse events among Whites, but not when considering isolated hepatic adverse events. Likely reflects linkage with HLA-DRB1*01.",
            "Sentence": "HLA-DQB1*05 is associated with increased risk of hepatic adverse events when treated with nevirapine in people with HIV infection (White population), but association not significant for isolated hepatic events.",
            "Alleles": "*05",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hepatic adverse events",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Similarly, *HLA-DQB1*05* was significantly associated with hepatic adverse events among Whites only, despite its high frequency among Asians and Blacks but not when considering isolated hepatic adverse events (data not shown).",
              "Results also indicated an association between *HLA-DQB*05* and hepatic adverse events in Whites, likely reflecting linkage between *HLA-DRB1*01* and *HLA-DQB1*05* [[27](#R27)]. However, among individuals with isolated hepatic adverse events the association with *HLA-DQB*05* was no longer significant, whereas the *HLA-DRB1*01* association increased."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-DQB1*05",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "HLA-Cw*08",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "PMID": 21505298,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "No association found between HLA-Cw*08 (present in 7% of participants) and cutaneous or hepatic adverse events. This did not replicate findings from studies in Sardinia and Japan.",
            "Sentence": "HLA-Cw*08 is not associated with risk of cutaneous or hepatic adverse events when treated with nevirapine in people with HIV infection.",
            "Alleles": "*08",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Cutaneous adverse events, Side Effect:Hepatic adverse events",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "We found no association between *HLA-Cw*08* (present in 7% of participants) and cutaneous or hepatic adverse events.",
              "This analysis did not replicate findings from studies in Sardinia and Japan that suggested an association between *HLA-Cw*08* and nevirapine-associated hypersensitivity"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-Cw*08",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 9,
            "Variant/Haplotypes": "rs1045642",
            "Gene": "ABCB1",
            "Drug(s)": "nevirapine",
            "PMID": 21505298,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "ABCB1 3435C\u2192T (rs1045642) was not significantly associated with cutaneous or hepatic adverse events. OR for hepatic adverse events among Blacks was 0.50 (95% CI 0.14-1.76; P=0.27).",
            "Sentence": "ABCB1 3435C\u2192T (rs1045642) is not associated with risk of cutaneous or hepatic adverse events when treated with nevirapine in people with HIV infection.",
            "Alleles": "3435C\u2192T",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Cutaneous adverse events, Side Effect:Hepatic adverse events",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "We found no statistically significant association between ABCB1 3435C\u2192T and nevirapine-associated cutaneous or hepatic adverse events, although the OR for hepatic adverse events among Blacks was 0.50 (95% CI 0.14\u20131.76; P= 0.27).",
              "Two previous studies involving individuals of African descent suggested that ABCB1 3435C\u2192T was associated with decreased nevirapine-associated hepatic adverse events [[5](#R5),[6](#R6)]. Whereas we found no statistically significant association between ABCB1 3435C\u2192T and nevirapine-associated adverse events, the ORs for ABCB1 3435C\u2192T and hepatic adverse events among Blacks was consistent with previous studies. There was no such association in Asians or Whites despite increased T-allele frequencies."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1045642",
              "variant_id": "PA166157284",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 10,
            "Variant/Haplotypes": "rs3745274",
            "Gene": "CYP2B6",
            "Drug(s)": "nevirapine",
            "PMID": 21505298,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "No association found between CYP2B6 genotypes and hepatic adverse events, consistent with limited previous data.",
            "Sentence": "CYP2B6 516G\u2192T (rs3745274) is not associated with risk of hepatic adverse events when treated with nevirapine in people with HIV infection.",
            "Alleles": "516G\u2192T",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hepatic adverse events",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "Hepatic adverse events were associated with HLA-DRB*01 (OR 3.02, Whites), but not CYP2B6 genotypes.",
              "No SNP was significantly associated with hepatic adverse events after correcting for multiple comparisons",
              "We found no association between CYP2B6 variants and hepatic adverse events, consistent with limited previous data"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs3745274",
              "variant_id": "PA166155409",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.5045304364628262,
        "field_scores": {
          "Study Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Study Controls": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.9012898802757263,
            "scores": [
              0.9027949571609497,
              0.9141216278076172,
              0.9067063331604004,
              0.9027949571609497,
              0.8881780505180359,
              0.893143355846405
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "P Value": {
            "mean_score": 0.16666666666666666,
            "scores": [
              0.5,
              0.5,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              0.0,
              0.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 0.16666666666666666,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              1.0
            ]
          }
        },
        "total_samples": 6,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9027949571609497,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1185002122,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1185002120,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 175.0,
                "prediction": 175
              },
              "Study Controls": {
                "ground_truth": 587.0,
                "prediction": 587
              },
              "Characteristics": {
                "ground_truth": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
                "prediction": "Nevirapine-associated cutaneous adverse events, all populations"
              },
              "Characteristics Type": {
                "ground_truth": "Disease",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.13",
                "prediction": "= 0.0025"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 1.66,
                "prediction": 1.66
              },
              "Confidence Interval Start": {
                "ground_truth": 1.29,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": 2.15,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Asian, Black, White",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9141216278076172,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1185002101,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1185002099,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 175.0,
                "prediction": 175
              },
              "Study Controls": {
                "ground_truth": 587.0,
                "prediction": 587
              },
              "Characteristics": {
                "ground_truth": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
                "prediction": "Nevirapine-associated cutaneous adverse events, prior antiretroviral status"
              },
              "Characteristics Type": {
                "ground_truth": "Disease",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.019",
                "prediction": "= 0.0097"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 1.76,
                "prediction": 0.57
              },
              "Confidence Interval Start": {
                "ground_truth": 1.36,
                "prediction": 0.37
              },
              "Confidence Interval Stop": {
                "ground_truth": 2.27,
                "prediction": 0.87
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Asian, Black, White",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9067063331604004,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1185002116,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1185002114,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 175.0,
                "prediction": 175
              },
              "Study Controls": {
                "ground_truth": 587.0,
                "prediction": 587
              },
              "Characteristics": {
                "ground_truth": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
                "prediction": "Nevirapine-associated cutaneous adverse events, all populations with CYP2B6 516TT and HLA-Cw*04"
              },
              "Characteristics Type": {
                "ground_truth": "Disease",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.029",
                "prediction": "< 0.05"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 1.74,
                "prediction": 6.31
              },
              "Confidence Interval Start": {
                "ground_truth": 1.34,
                "prediction": 2.53
              },
              "Confidence Interval Stop": {
                "ground_truth": 2.25,
                "prediction": 15.73
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Asian, Black, White",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9027949571609497,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 0.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1185002079,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1185002071,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 175.0,
                "prediction": 175
              },
              "Study Controls": {
                "ground_truth": 587.0,
                "prediction": 587
              },
              "Characteristics": {
                "ground_truth": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
                "prediction": "Nevirapine-associated cutaneous adverse events, all populations"
              },
              "Characteristics Type": {
                "ground_truth": "Disease",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.377,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*04:01",
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": 0.194,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*04:01",
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 8.7E-6",
                "prediction": "< 0.05"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 2.51,
                "prediction": 2.51
              },
              "Confidence Interval Start": {
                "ground_truth": 1.73,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.62,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Asian, Thai, Black, White",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8881780505180359,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 0.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1185002085,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1185002083,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 57.0,
                "prediction": 57
              },
              "Study Controls": {
                "ground_truth": 277.0,
                "prediction": 277
              },
              "Characteristics": {
                "ground_truth": "Symptomatic grade >= 3 hepatic transaminase elevation (ALT or AST >5x ULN) or acute hepatic failure",
                "prediction": "Nevirapine-associated hepatic adverse events, White population"
              },
              "Characteristics Type": {
                "ground_truth": "Disease",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.439,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*01:01",
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": 0.208,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*01:01",
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.0074",
                "prediction": "< 0.05"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 3.02,
                "prediction": 3.02
              },
              "Confidence Interval Start": {
                "ground_truth": 1.66,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": 5.49,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, Caucasian and Hispanic/Latino patients",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.893143355846405,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 0.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1185002093,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1185002091,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 52.0,
                "prediction": null
              },
              "Study Controls": {
                "ground_truth": 173.0,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
                "prediction": "Nevirapine-associated cutaneous adverse events, Thai population"
              },
              "Characteristics Type": {
                "ground_truth": "Disease",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.192,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*35:01",
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": 0.043,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*35:01",
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.022",
                "prediction": "< 0.05"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 5.65,
                "prediction": 5.65
              },
              "Confidence Interval Start": {
                "ground_truth": 2.03,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": 15.71,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "case/control:Severe cutaneous tox",
          "case/control:Severe cutaneous tox",
          "case/control:Severe cutaneous tox",
          "case/control:Severe cutaneous tox",
          "case/control:Symptomatic grade >=",
          "case/control:Severe cutaneous tox"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 71,
            "Study Controls": 233,
            "Characteristics": "Nevirapine-associated cutaneous adverse events, Asian population",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.05",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 3.47,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 27,
            "Study Controls": 77,
            "Characteristics": "Nevirapine-associated cutaneous adverse events, Black population with CYP2B6 516TT and HLA-Cw*04",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.05",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 18.9,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "African America/Afro-Caribbean",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 71,
            "Study Controls": 233,
            "Characteristics": "Nevirapine-associated cutaneous adverse events, Asian population with HLA-B*35 and HLA-Cw*04",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.05",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 18.34,
            "Confidence Interval Start": 5.1,
            "Confidence Interval Stop": 65.99,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 27,
            "Study Controls": 77,
            "Characteristics": "Nevirapine-associated cutaneous adverse events, Black population CYP2B6 516TT vs 516GG",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.0025",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 5.92,
            "Confidence Interval Start": 1.53,
            "Confidence Interval Stop": 26.8,
            "Biogeographical Groups": "African America/Afro-Caribbean",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 77,
            "Study Controls": 277,
            "Characteristics": "Nevirapine-associated cutaneous adverse events, White population",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.021",
            "Ratio Stat Type": "OR",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 71,
            "Study Controls": 233,
            "Characteristics": "Nevirapine-associated cutaneous adverse events, Asian population rs2054675 and rs3786547",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.041",
            "Ratio Stat Type": "OR",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC8973308": {
      "var-pheno": {
        "overall_score": 0.7165778254469236,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 0.8986579775810242,
            "scores": [
              0.8986579775810242
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.0,
            "scores": [
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.0,
            "scores": [
              0.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.9229668974876404,
            "scores": [
              0.9229668974876404
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.9050131440162659,
            "scores": [
              0.9050131440162659
            ]
          }
        },
        "total_samples": 1,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.8986579775810242,
              "Is/Is Not associated": 0.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9229668974876404,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9050131440162659
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs1800462",
                "prediction": "rs1800462"
              },
              "Gene": {
                "ground_truth": "TPMT",
                "prediction": "TPMT"
              },
              "Drug(s)": {
                "ground_truth": "mercaptopurine",
                "prediction": "mercaptopurine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "CG",
                "prediction": "C/G"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Febrile neutropenia, Side Effect:Discontinuation",
                "prediction": "Side Effect:Myelotoxicity, Side Effect:Liver Toxicity"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "C/C"
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "PA166156993"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "rs116855232",
            "Gene": "NUDT15",
            "Drug(s)": "mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "4/68 patients were heterozygous for NUDT15. No statistically significant association was identified between the genetic variants and the outcomes of interest (myelotoxicity, liver toxicity, 6-MP dose reduction/interruption).",
            "Sentence": "rs116855232 is not associated with risk of Side Effect:Myelotoxicity, Side Effect:Liver Toxicity when treated with mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia.",
            "Alleles": "C/T",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Myelotoxicity, Side Effect:Liver Toxicity",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "C/C",
            "Comparison Metabolizer types": null,
            "Citations": [
              "4/68 patients were heterozygous for NUDT15, and the same number of patients were heterozygous for rs1800462 and rs1142345, while for rs1800460, 6 heterozygous patients were identified. No statistically significant association was identified between the genetic variants and the outcomes of interest.",
              "No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP).",
              "No association was found between the outcomes of interest and the genetic variant of NUDT15 or any TPMT polymorphisms evaluated individually."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs116855232",
              "variant_id": "PA166154759",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "rs1800460",
            "Gene": "TPMT",
            "Drug(s)": "mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "6/68 patients were heterozygous for rs1800460. No statistically significant association was identified between the genetic variants and the outcomes of interest. Of the six heterozygous patients, three required a dosage decrease.",
            "Sentence": "rs1800460 is not associated with risk of Side Effect:Myelotoxicity, Side Effect:Liver Toxicity when treated with mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia.",
            "Alleles": "T/C",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Myelotoxicity, Side Effect:Liver Toxicity",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "C/C",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Genetic analyses were carried out of these for NUDT15 and TPMT (rs1800462 and rs1800460) on 68 patients, while for the rs1142345 polymorphism, typing was achieved in 42 patients. 4/68 patients were heterozygous for NUDT15, and the same number of patients were heterozygous for rs1800462 and rs1142345, while for rs1800460, 6 heterozygous patients were identified. No statistically significant association was identified between the genetic variants and the outcomes of interest.",
              "In the case of rs1800460, of the six heterozygous patients, three required a dosage decrease, and two were also heterozygous for rs1142345.",
              "No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1800460",
              "variant_id": "PA166156992",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "rs1142345",
            "Gene": "TPMT",
            "Drug(s)": "mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "4/42 patients were heterozygous for rs1142345. No statistically significant association was identified between the genetic variants and the outcomes of interest.",
            "Sentence": "rs1142345 is not associated with risk of Side Effect:Myelotoxicity, Side Effect:Liver Toxicity when treated with mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia.",
            "Alleles": "C/T",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Myelotoxicity, Side Effect:Liver Toxicity",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "T/T",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Seventy pediatric patients were included in the study. Genetic analyses were carried out of these for NUDT15 and TPMT (rs1800462 and rs1800460) on 68 patients, while for the rs1142345 polymorphism, typing was achieved in 42 patients. 4/68 patients were heterozygous for NUDT15, and the same number of patients were heterozygous for rs1800462 and rs1142345, while for rs1800460, 6 heterozygous patients were identified. No statistically significant association was identified between the genetic variants and the outcomes of interest.",
              "No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP).",
              "The outcomes of interest were side effects as myelotoxicity and liver toxicity and the dose reduction or interruption of 6-MP."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1142345",
              "variant_id": "PA166156978",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "TPMT*2",
            "Gene": "TPMT",
            "Drug(s)": "mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "TPMT haplotype analysis based on CPIC guidelines. 2 patients were *1/*2. No statistically significant association was found between TPMT diplotypes and outcomes of interest (p=0.616 for 6-MP reduction).",
            "Sentence": "TPMT*2 is not associated with risk of Side Effect:Myelotoxicity, Side Effect:Liver Toxicity when treated with mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia.",
            "Alleles": "*1/*2",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Myelotoxicity, Side Effect:Liver Toxicity",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No statistically significant association was identified between the genetic variants and the outcomes of interest.",
              "TPMT haplotypes were determined based on the combinations of SNPs rs1800462, rs1800460 and rs1142345 as follows: CCT = * 1, GCT = * 2, CTC = * 3A, CTT = * 3B and CCC = * 3C.",
              "No statistically significant association was found between any of the *TPMT* diplotypes studied and the outcomes of interest."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "TPMT*2",
              "variant_id": "PA165819269",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "TPMT*3A",
            "Gene": "TPMT",
            "Drug(s)": "mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "TPMT haplotype analysis based on CPIC guidelines. 4 patients were *1/*3A. No statistically significant association was found between TPMT diplotypes and outcomes of interest (p=0.616 for 6-MP reduction).",
            "Sentence": "TPMT*3A is not associated with risk of Side Effect:Myelotoxicity, Side Effect:Liver Toxicity when treated with mercaptopurine in children with Disease:Acute Lymphoblastic Leukemia.",
            "Alleles": "*1/*3A",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Myelotoxicity, Side Effect:Liver Toxicity",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No statistically significant association was identified between the genetic variants and the outcomes of interest.",
              "No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP).",
              "Similar analyses were carried out about the typing of TPMT, using the homozygosity variable for allele *1 versus carrying *2 or *3A as heterozygous, without evidence of any statistically significant association"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "TPMT*3A",
              "variant_id": "PA165819270",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 1.0
            }
          }
        ]
      },
      "var-drug": {
        "overall_score": 0.8258125201651925,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "PMID": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Significance": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 0.8959790170192719,
            "scores": [
              0.8984260559082031,
              0.8935319781303406
            ]
          },
          "Specialty Population": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Metabolizer types": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "isPlural": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "PD/PK terms": {
            "mean_score": 0.9216774106025696,
            "scores": [
              0.9216774106025696,
              0.9216774106025696
            ]
          },
          "Multiple drugs And/or": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Population types": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Population Phenotypes or diseases": {
            "mean_score": 0.9677683115005493,
            "scores": [
              0.9677683115005493,
              0.9677683115005493
            ]
          },
          "Multiple phenotypes or diseases And/or": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.9050131440162659,
            "scores": [
              0.9050131440162659,
              0.9050131440162659
            ]
          },
          "Comparison Metabolizer types": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 2,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 0.0,
              "Significance": 1.0,
              "Alleles": 0.8984260559082031,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 0.0,
              "Direction of effect": 0.0,
              "PD/PK terms": 0.9216774106025696,
              "Multiple drugs And/or": 1.0,
              "Population types": 1.0,
              "Population Phenotypes or diseases": 0.9677683115005493,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9050131440162659,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs116855232",
                "prediction": "rs116855232"
              },
              "Gene": {
                "ground_truth": "NUDT15",
                "prediction": "NUDT15"
              },
              "PMID": {
                "ground_truth": 35431360,
                "prediction": 35431360
              },
              "Phenotype Category": {
                "ground_truth": "Dosage",
                "prediction": "toxicity"
              },
              "Significance": {
                "ground_truth": "no",
                "prediction": "no"
              },
              "Alleles": {
                "ground_truth": "CT",
                "prediction": "C/T"
              },
              "Specialty Population": {
                "ground_truth": "Pediatric",
                "prediction": "Pediatric"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": null
              },
              "PD/PK terms": {
                "ground_truth": "dose of",
                "prediction": "toxicity to"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in children with",
                "prediction": "in children with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Other:Acute lymphoblastic leukemia",
                "prediction": "Disease:Acute lymphoblastic leukemia"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "C/C"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "mercaptopurine",
                "prediction": "6-mercaptopurine"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 0.0,
              "Significance": 1.0,
              "Alleles": 0.8935319781303406,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 0.0,
              "Direction of effect": 0.0,
              "PD/PK terms": 0.9216774106025696,
              "Multiple drugs And/or": 1.0,
              "Population types": 1.0,
              "Population Phenotypes or diseases": 0.9677683115005493,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9050131440162659,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs1800460",
                "prediction": "rs1800460"
              },
              "Gene": {
                "ground_truth": "TPMT",
                "prediction": "TPMT"
              },
              "PMID": {
                "ground_truth": 35431360,
                "prediction": 35431360
              },
              "Phenotype Category": {
                "ground_truth": "Dosage",
                "prediction": "toxicity"
              },
              "Significance": {
                "ground_truth": "no",
                "prediction": "no"
              },
              "Alleles": {
                "ground_truth": "CT",
                "prediction": "T/C"
              },
              "Specialty Population": {
                "ground_truth": "Pediatric",
                "prediction": "Pediatric"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": null
              },
              "PD/PK terms": {
                "ground_truth": "dose of",
                "prediction": "toxicity to"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in children with",
                "prediction": "in children with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Other:Acute lymphoblastic leukemia",
                "prediction": "Disease:Acute lymphoblastic leukemia"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "C/C"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "mercaptopurine",
                "prediction": "6-mercaptopurine"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "PA166154759",
          "PA166156992"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "rs116855232",
            "Gene": "NUDT15",
            "Drug(s)": "6-mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "dosage",
            "Significance": "no",
            "Notes": "No statistically significant association was identified between NUDT15 rs116855232 and dose reduction or interruption of 6-MP. Two of the four heterozygous patients required a decrease in 6-MP during follow-up.",
            "Sentence": "Genotype C/T is not associated with dose reduction of 6-mercaptopurine in children with acute lymphoblastic leukemia as compared to genotype C/C.",
            "Alleles": "C/T",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "dose reduction of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "C/C",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No statistically significant association was identified between the genetic variants and the outcomes of interest.",
              "Although no statistically significant associations were identified, two of the four patients heterozygous for *NUDT15* required a decrease in 6-MP during the follow-up period.",
              "No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs116855232",
              "variant_id": "PA166154759",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 0.9333333333333333
            }
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "rs1800462",
            "Gene": "TPMT",
            "Drug(s)": "6-mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "No statistically significant association was identified between TPMT rs1800462 and myelotoxicity or liver toxicity. 4/68 patients were heterozygous for rs1800462. Two of the four heterozygous patients presented febrile neutropenia.",
            "Sentence": "Genotype C/G is not associated with toxicity to 6-mercaptopurine in children with acute lymphoblastic leukemia as compared to genotype C/C.",
            "Alleles": "C/G",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "toxicity to",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "C/C",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No statistically significant association was identified between the genetic variants and the outcomes of interest.",
              "4/68 patients were heterozygous for NUDT15, and the same number of patients were heterozygous for rs1800462 and rs1142345, while for rs1800460, 6 heterozygous patients were identified.",
              "Concerning the genetic variants of TPMT, for rs1800462, two of the four heterozygous patients presented febrile neutropenia, and the same patients also required discontinuation 6-MP during the first six months of maintenance therapy."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1800462",
              "variant_id": "PA166156993",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 0.9333333333333333
            }
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "rs1800462",
            "Gene": "TPMT",
            "Drug(s)": "6-mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "dosage",
            "Significance": "no",
            "Notes": "No statistically significant association was identified between TPMT rs1800462 and dose reduction or interruption of 6-MP.",
            "Sentence": "Genotype C/G is not associated with dose reduction of 6-mercaptopurine in children with acute lymphoblastic leukemia as compared to genotype C/C.",
            "Alleles": "C/G",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "dose reduction of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "C/C",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No statistically significant association was identified between the genetic variants and the outcomes of interest.",
              "No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP).",
              "4/68 patients were heterozygous for NUDT15, and the same number of patients were heterozygous for rs1800462 and rs1142345, while for rs1800460, 6 heterozygous patients were identified. No statistically significant association was identified between the genetic variants and the outcomes of interest."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1800462",
              "variant_id": "PA166156993",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 0.9333333333333333
            }
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "rs1800460",
            "Gene": "TPMT",
            "Drug(s)": "6-mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "dosage",
            "Significance": "no",
            "Notes": "No statistically significant association was identified between TPMT rs1800460 and dose reduction or interruption of 6-MP. Of the six heterozygous patients, three required a dosage decrease.",
            "Sentence": "Genotype T/C is not associated with dose reduction of 6-mercaptopurine in children with acute lymphoblastic leukemia as compared to genotype C/C.",
            "Alleles": "T/C",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "dose reduction of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "C/C",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No statistically significant association was identified between the genetic variants and the outcomes of interest.",
              "In the case of rs1800460, of the six heterozygous patients, three required a dosage decrease, and two were also heterozygous for rs1142345.",
              "No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1800460",
              "variant_id": "PA166156992",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 0.9333333333333333
            }
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "rs1142345",
            "Gene": "TPMT",
            "Drug(s)": "6-mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "No statistically significant association was identified between TPMT rs1142345 and myelotoxicity or liver toxicity. 4 patients were heterozygous for rs1142345 (typing achieved in 42 patients).",
            "Sentence": "Genotype C/T is not associated with toxicity to 6-mercaptopurine in children with acute lymphoblastic leukemia as compared to genotype T/T.",
            "Alleles": "C/T",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "toxicity to",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "T/T",
            "Comparison Metabolizer types": null,
            "Citations": [
              "for the rs1142345 polymorphism, typing was achieved in 42 patients. 4/68 patients were heterozygous for NUDT15, and the same number of patients were heterozygous for rs1800462 and rs1142345, while for rs1800460, 6 heterozygous patients were identified. No statistically significant association was identified between the genetic variants and the outcomes of interest.",
              "No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1142345",
              "variant_id": "PA166156978",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 0.9333333333333333
            }
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "rs1142345",
            "Gene": "TPMT",
            "Drug(s)": "6-mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "dosage",
            "Significance": "no",
            "Notes": "No statistically significant association was identified between TPMT rs1142345 and dose reduction or interruption of 6-MP.",
            "Sentence": "Genotype C/T is not associated with dose reduction of 6-mercaptopurine in children with acute lymphoblastic leukemia as compared to genotype T/T.",
            "Alleles": "C/T",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "dose reduction of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "T/T",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No statistically significant association was identified between the genetic variants and the outcomes of interest.",
              "No statistically significant associations were identified between genetic variants in TPMT and NUDT15 with toxicity outcomes evaluated (myelotoxicity and liver toxicity, as well as the dose reduction or interruption of 6-MP).",
              "No statistically significant association was found between any of the polymorphisms studied and the outcomes of interest."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1142345",
              "variant_id": "PA166156978",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 0.9333333333333333
            }
          },
          {
            "Variant Annotation ID": 9,
            "Variant/Haplotypes": "TPMT*1",
            "Gene": "TPMT",
            "Drug(s)": "6-mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "No statistically significant association was found between TPMT diplotypes (*1/*1 vs *1/*2 or *1/*3A) and toxicity outcomes. Analysis performed in 42 patients with complete TPMT typing.",
            "Sentence": "TPMT *1/*2 or *1/*3A diplotypes are not associated with toxicity to 6-mercaptopurine in children with acute lymphoblastic leukemia as compared to *1/*1.",
            "Alleles": "*1/*2, *1/*3A",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "toxicity to",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Similar analyses were carried out about the typing of TPMT, using the homozygosity variable for allele *1 versus carrying *2 or *3A as heterozygous, without evidence of any statistically significant association (supplementary table 1S).",
              "No statistically significant association was found between any of the *TPMT* diplotypes studied and the outcomes of interest.",
              "for the rs1142345 polymorphism, typing was achieved in 42 patients"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "TPMT*1, TPMT*2, TPMT*3A",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 0.9333333333333333
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 9,
            "Variant/Haplotypes": "TPMT*2",
            "Gene": "TPMT",
            "Drug(s)": "6-mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "No statistically significant association was found between TPMT diplotypes (*1/*1 vs *1/*2 or *1/*3A) and toxicity outcomes. Analysis performed in 42 patients with complete TPMT typing.",
            "Sentence": "TPMT *1/*2 or *1/*3A diplotypes are not associated with toxicity to 6-mercaptopurine in children with acute lymphoblastic leukemia as compared to *1/*1.",
            "Alleles": "*1/*2, *1/*3A",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "toxicity to",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Similar analyses were carried out about the typing of TPMT, using the homozygosity variable for allele *1 versus carrying *2 or *3A as heterozygous, without evidence of any statistically significant association (supplementary table 1S).",
              "No statistically significant association was found between any of the *TPMT* diplotypes studied and the outcomes of interest.",
              "for the rs1142345 polymorphism, typing was achieved in 42 patients"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "TPMT*1, TPMT*2, TPMT*3A",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 0.9333333333333333
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 9,
            "Variant/Haplotypes": "TPMT*3A",
            "Gene": "TPMT",
            "Drug(s)": "6-mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "No statistically significant association was found between TPMT diplotypes (*1/*1 vs *1/*2 or *1/*3A) and toxicity outcomes. Analysis performed in 42 patients with complete TPMT typing.",
            "Sentence": "TPMT *1/*2 or *1/*3A diplotypes are not associated with toxicity to 6-mercaptopurine in children with acute lymphoblastic leukemia as compared to *1/*1.",
            "Alleles": "*1/*2, *1/*3A",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "toxicity to",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Similar analyses were carried out about the typing of TPMT, using the homozygosity variable for allele *1 versus carrying *2 or *3A as heterozygous, without evidence of any statistically significant association (supplementary table 1S).",
              "No statistically significant association was found between any of the *TPMT* diplotypes studied and the outcomes of interest.",
              "for the rs1142345 polymorphism, typing was achieved in 42 patients"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "TPMT*1, TPMT*2, TPMT*3A",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 0.9333333333333333
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 10,
            "Variant/Haplotypes": "TPMT*1",
            "Gene": "TPMT",
            "Drug(s)": "6-mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "dosage",
            "Significance": "no",
            "Notes": "No statistically significant association was found between TPMT diplotypes (*1/*1 vs *1/*2 or *1/*3A) and dose reduction or interruption of 6-MP. p=0.616 for 6-MP reduction.",
            "Sentence": "TPMT *1/*2 or *1/*3A diplotypes are not associated with dose reduction of 6-mercaptopurine in children with acute lymphoblastic leukemia as compared to *1/*1.",
            "Alleles": "*1/*2, *1/*3A",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "dose reduction of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Similar analyses were carried out about the typing of TPMT, using the homozygosity variable for allele *1 versus carrying *2 or *3A as heterozygous, without evidence of any statistically significant association (supplementary table 1S).",
              "No statistically significant association was found between any of the *TPMT* diplotypes studied and the outcomes of interest.",
              "6-MP Reduction Yes 8 2 0.616 No 28 4"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "TPMT*1, TPMT*2, TPMT*3A",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 0.9333333333333333
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 10,
            "Variant/Haplotypes": "TPMT*2",
            "Gene": "TPMT",
            "Drug(s)": "6-mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "dosage",
            "Significance": "no",
            "Notes": "No statistically significant association was found between TPMT diplotypes (*1/*1 vs *1/*2 or *1/*3A) and dose reduction or interruption of 6-MP. p=0.616 for 6-MP reduction.",
            "Sentence": "TPMT *1/*2 or *1/*3A diplotypes are not associated with dose reduction of 6-mercaptopurine in children with acute lymphoblastic leukemia as compared to *1/*1.",
            "Alleles": "*1/*2, *1/*3A",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "dose reduction of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Similar analyses were carried out about the typing of TPMT, using the homozygosity variable for allele *1 versus carrying *2 or *3A as heterozygous, without evidence of any statistically significant association (supplementary table 1S).",
              "No statistically significant association was found between any of the *TPMT* diplotypes studied and the outcomes of interest.",
              "6-MP Reduction Yes 8 2 0.616 No 28 4"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "TPMT*1, TPMT*2, TPMT*3A",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 0.9333333333333333
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 10,
            "Variant/Haplotypes": "TPMT*3A",
            "Gene": "TPMT",
            "Drug(s)": "6-mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "dosage",
            "Significance": "no",
            "Notes": "No statistically significant association was found between TPMT diplotypes (*1/*1 vs *1/*2 or *1/*3A) and dose reduction or interruption of 6-MP. p=0.616 for 6-MP reduction.",
            "Sentence": "TPMT *1/*2 or *1/*3A diplotypes are not associated with dose reduction of 6-mercaptopurine in children with acute lymphoblastic leukemia as compared to *1/*1.",
            "Alleles": "*1/*2, *1/*3A",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "dose reduction of",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Similar analyses were carried out about the typing of TPMT, using the homozygosity variable for allele *1 versus carrying *2 or *3A as heterozygous, without evidence of any statistically significant association (supplementary table 1S).",
              "No statistically significant association was found between any of the *TPMT* diplotypes studied and the outcomes of interest.",
              "6-MP Reduction Yes 8 2 0.616 No 28 4"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "TPMT*1, TPMT*2, TPMT*3A",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 0.9333333333333333
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 11,
            "Variant/Haplotypes": "rs116855232",
            "Gene": "NUDT15",
            "Drug(s)": "6-mercaptopurine",
            "PMID": 35431360,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "No association was found between NUDT15 rs116855232 and relapse. 1/9 patients who relapsed were heterozygous for NUDT15.",
            "Sentence": "Genotype C/T is not associated with relapse in children with acute lymphoblastic leukemia treated with 6-mercaptopurine as compared to genotype C/C.",
            "Alleles": "C/T",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "relapse in",
            "Multiple drugs And/or": null,
            "Population types": "in children with",
            "Population Phenotypes or diseases": "Disease:Acute lymphoblastic leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "C/C",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No statistically significant association was identified between the genetic variants and the outcomes of interest.",
              "In exploratory analyses, we evaluated whether there was an association between the genetic variants studied and the outcomes: relapses or death, reviewed as of October 2018, without showing any correlation",
              "No association was found between the outcomes of interest and the genetic variant of *NUDT15* or any *TPMT* polymorphisms evaluated individually."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs116855232",
              "variant_id": "PA166154759",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "mercaptopurine",
              "drug_id": "PA450379",
              "confidence": 0.9333333333333333
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.8348947061432733,
        "field_scores": {
          "Study Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              0.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.856753925482432,
            "scores": [
              0.8561464548110962,
              0.8560585975646973,
              0.8580567240715027
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 3,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8561464548110962,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1451769007,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1451769000,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort",
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 68.0,
                "prediction": 68
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Pediatric ALL",
                "prediction": "Colombian pediatric patients with acute lymphoblastic leukemia, TPMT rs1800460"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "disease"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": null,
                "prediction": ""
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8560585975646973,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1451768400,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1451768380,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort",
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 68.0,
                "prediction": 68
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Pediatric ALL",
                "prediction": "Colombian pediatric patients with acute lymphoblastic leukemia, TPMT rs1800462"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "disease"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": null,
                "prediction": ""
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8580567240715027,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1451769045,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1451769040,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort",
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 68.0,
                "prediction": 42
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Pediatric ALL",
                "prediction": "Colombian pediatric patients with acute lymphoblastic leukemia, TPMT rs1142345"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "disease"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": null,
                "prediction": ""
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "cohort:Pediatric ALL",
          "cohort:Pediatric ALL",
          "cohort:Pediatric ALL"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 68,
            "Study Controls": null,
            "Characteristics": "Colombian pediatric patients with acute lymphoblastic leukemia, NUDT15 rs116855232",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.03,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 42,
            "Study Controls": null,
            "Characteristics": "Colombian pediatric patients with acute lymphoblastic leukemia, TPMT *1/*1 vs *1/other diplotypes",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 42,
            "Study Controls": null,
            "Characteristics": "Colombian pediatric patients with acute lymphoblastic leukemia, TPMT haplotype *2",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.02,
            "Allele Of Frequency In Cases": "*2",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 42,
            "Study Controls": null,
            "Characteristics": "Colombian pediatric patients with acute lymphoblastic leukemia, TPMT haplotype *3A",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.05,
            "Allele Of Frequency In Cases": "*3A",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC10993165": {
      "var-pheno": {
        "overall_score": 0.905160134865178,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 0.9615678191184998,
            "scores": [
              0.9615678191184998,
              0.9615678191184998,
              0.9615678191184998
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Direction of effect": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.9597849448521932,
            "scores": [
              1.0,
              0.9396774172782898,
              0.9396774172782898
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 3,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 0.9615678191184998,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*13:01",
                "prediction": "HLA-B*13:01"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
                "prediction": "sulfamethoxazole, cotrimoxazole"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*13:01",
                "prediction": "*13:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Severe Cutaneous Adverse Reactions"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "tolerant controls"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 0.9615678191184998,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9396774172782898,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:02",
                "prediction": "HLA-B*15:02"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
                "prediction": "sulfamethoxazole, cotrimoxazole"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*15:02",
                "prediction": "*15:02"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Severe Cutaneous Adverse Reactions"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "tolerant controls"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 0.9615678191184998,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9396774172782898,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*38:02",
                "prediction": "HLA-B*38:02"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
                "prediction": "sulfamethoxazole, cotrimoxazole"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*38:02",
                "prediction": "*38:02"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Severe Cutaneous Adverse Reactions"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "tolerant controls"
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "PA165954769",
          "PA165954643",
          "PA165955505"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "HLA-A*11:01",
            "Gene": "HLA-A",
            "Drug(s)": "sulfamethoxazole, cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 2.10 (95% CI 1.11-4.00) compared with tolerant controls; OR 2.16 (95% CI 1.26-3.69) compared with healthy controls. Meta-analysis of 4 studies.",
            "Sentence": "HLA-A*11:01 is associated with increased risk of Side Effect:Severe Cutaneous Adverse Reactions when treated with sulfamethoxazole or cotrimoxazole.",
            "Alleles": "*11:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "tolerant controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Significant associations were found in *HLA-A*11:01* (OR, 2.10; 95% CI, 1.11-4.00), *HLA-B*13:01* (OR, 5.96; 95% CI, 1.58-22.56), *HLA-B*15:02* (OR, 2.23; 95% CI, 1.20-4.14), *HLA-B*38:02 *(OR, 3.47; 95% CI, 1.42-8.48), and *HLA-C*08:01* (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls.",
              "Significant associations were found in the *HLA-A*11:01* (OR, 2.16; 95% CI, 1.26-3.69), *HLA-B*07:05* (OR, 2.86; 95% CI, 1.49-5.52), *HLA-B*13:01* (OR, 5.35; 95% CI, 3.36-8.50), *HLA-B*15:02* (OR, 1.87; 95% CI, 1.39-2.52), *HLA-B*38:01* (OR, 4.26; 95% CI, 1.43-12.71), *HLA-B*38:02* (OR, 3.21; 95% CI, 1.81-5.68), *HLA-C*03:04* (OR, 3.33; 95% CI, 2.27-4.89), *HLA-C*04:06* (OR, 3.28; 95% CI, 1.22-8.81), *HLA-C*07:27* (OR, 11.38; 95% CI, 1.98-65.37), and *HLA-C*08:01* (OR, 1.47; 95% CI, 1.02-2.11) compared with healthy controls.",
              "significant associations were identified between the HLA-A*11:01, HLA-B*13:01, HLA-B*15:02, HLA-B*38:02, and HLA-C*08:01 genotypes and SMX/CTX-induced SCARs"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-A*11:01",
              "variant_id": "PA165953358",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "HLA-C*08:01",
            "Gene": "HLA-C",
            "Drug(s)": "sulfamethoxazole, cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 2.63 (95% CI 1.07-6.44) compared with tolerant controls; OR 1.47 (95% CI 1.02-2.11) compared with healthy controls.",
            "Sentence": "HLA-C*08:01 is associated with increased risk of Side Effect:Severe Cutaneous Adverse Reactions when treated with sulfamethoxazole or cotrimoxazole.",
            "Alleles": "*08:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "tolerant controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Significant associations were found in HLA-A*11:01 (OR, 2.10; 95% CI, 1.11-4.00), HLA-B*13:01 (OR, 5.96; 95% CI, 1.58-22.56), HLA-B*15:02 (OR, 2.23; 95% CI, 1.20-4.14), HLA-B*38:02 (OR, 3.47; 95% CI, 1.42-8.48), and HLA-C*08:01 (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls.",
              "Significant associations were found in the HLA-A*11:01 (OR, 2.16; 95% CI, 1.26-3.69), HLA-B*07:05 (OR, 2.86; 95% CI, 1.49-5.52), HLA-B*13:01 (OR, 5.35; 95% CI, 3.36-8.50), HLA-B*15:02 (OR, 1.87; 95% CI, 1.39-2.52), HLA-B*38:01 (OR, 4.26; 95% CI, 1.43-12.71), HLA-B*38:02 (OR, 3.21; 95% CI, 1.81-5.68), HLA-C*03:04 (OR, 3.33; 95% CI, 2.27-4.89), HLA-C*04:06 (OR, 3.28; 95% CI, 1.22-8.81), HLA-C*07:27 (OR, 11.38; 95% CI, 1.98-65.37), and HLA-C*08:01 (OR, 1.47; 95% CI, 1.02-2.11) compared with healthy controls.",
              "In this systematic review and meta-analysis of 6 studies involving 322 patients with SCARs, significant associations were identified between the HLA-A*11:01, HLA-B*13:01, HLA-B*15:02, HLA-B*38:02, and HLA-C*08:01 genotypes and SMX/CTX-induced SCARs."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-C*08:01",
              "variant_id": "PA166123426",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "HLA-B*15:02",
            "Gene": "HLA-B",
            "Drug(s)": "sulfamethoxazole, cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 3.01 (95% CI 1.56-5.80) compared with tolerant controls; OR 3.09 (95% CI 1.90-5.02) compared with healthy controls in SJS/TEN subgroup analysis.",
            "Sentence": "HLA-B*15:02 is associated with increased risk of Side Effect:Stevens-Johnson Syndrome and Side Effect:Toxic Epidermal Necrolysis when treated with sulfamethoxazole or cotrimoxazole.",
            "Alleles": "*15:02",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "tolerant controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In the SJS/TEN group, significant associations were found in HLA-B*07:05 (OR, 2.80; 95% CI, 1.41-5.58), HLA-B*13:01 (OR, 2.49; 95% CI, 1.74-3.58), HLA-B*15:02 (OR, 3.09; 95% CI, 1.90-5.02), HLA-B*38:01 (OR, 4.26; 95% CI, 1.43-12.71), HLA-B*38:02 (OR, 4.56; 95% CI, 2.65-7.85), HLA-C*04:06 (OR, 3.37; 95% CI, 1.16-9.78), HLA-C*07:27 (OR, 9.25; 95% CI, 1.22-70.20), and HLA-C*08:01 (OR, 1.66; 95% CI, 1.13-2.44) compared with healthy controls. Heterogeneities ranged from 0% to 55%. As for tolerant controls, significant associations were found in HLA-B*15:02 (OR, 3.01; 95% CI, 1.56-5.80), and HLA-B*38:02 (OR, 5.13; 95% CI, 1.96-13.47).",
              "The HLA-B*15:02 and HLA-B*38:02 genotypes were significantly associated with SMX/CTX-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), while the HLA-A*68:01 and HLA-B*39:01 genotypes were associated with SMX/CTX-induced drug reaction with eosinophilia and systemic symptoms; the HLA-B*13:01 allele showed an association with SMX/CTX-induced SJS/TEN and drug reaction with eosinophilia and systemic symptoms."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*15:02",
              "variant_id": "PA165954769",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "HLA-B*38:02",
            "Gene": "HLA-B",
            "Drug(s)": "sulfamethoxazole, cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 5.13 (95% CI 1.96-13.47) compared with tolerant controls; OR 4.56 (95% CI 2.65-7.85) compared with healthy controls in SJS/TEN subgroup analysis.",
            "Sentence": "HLA-B*38:02 is associated with increased risk of Side Effect:Stevens-Johnson Syndrome and Side Effect:Toxic Epidermal Necrolysis when treated with sulfamethoxazole or cotrimoxazole.",
            "Alleles": "*38:02",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "tolerant controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In the Stevens-Johnson syndrome/toxic epidermal necrolysis subgroup, significant associations were found in *HLA-B*15:02* (OR, 3.01; 95% CI, 1.56-5.80) and *HLA-B*38:02* (OR, 5.13; 95% CI, 1.96-13.47).",
              "The *HLA-B*15:02* and *HLA-B*38:02* genotypes were significantly associated with SMX/CTX-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), while the *HLA-A*68:01* and *HLA-B*39:01* genotypes were associated with SMX/CTX-induced drug reaction with eosinophilia and systemic symptoms",
              "In the SJS/TEN group, significant associations were found in *HLA-B*07:05* (OR, 2.80; 95% CI, 1.41-5.58), *HLA-B*13:01* (OR, 2.49; 95% CI, 1.74-3.58), *HLA-B*15:02* (OR, 3.09; 95% CI, 1.90-5.02), *HLA-B*38:01* (OR, 4.26; 95% CI, 1.43-12.71), *HLA-B*38:02* (OR, 4.56; 95% CI, 2.65-7.85), *HLA-C*04:06* (OR, 3.37; 95% CI, 1.16-9.78), *HLA-C*07:27* (OR, 9.25; 95% CI, 1.22-70.20), and *HLA-C*08:01* (OR, 1.66; 95% CI, 1.13-2.44) compared with healthy controls."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*38:02",
              "variant_id": "PA165955505",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "HLA-A*68:01",
            "Gene": "HLA-A",
            "Drug(s)": "sulfamethoxazole, cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 12.86 (95% CI 1.09-151.34) compared with tolerant controls; OR 7.03 (95% CI 1.45-34.15) compared with healthy controls in DRESS subgroup analysis.",
            "Sentence": "HLA-A*68:01 is associated with increased risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms when treated with sulfamethoxazole or cotrimoxazole.",
            "Alleles": "*68:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "tolerant controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In the drug reaction with eosinophilia and systemic symptoms subgroup, significant associations were found in *HLA-A*68:01* (OR, 12.86; 95% CI, 1.09-151.34), *HLA-B*13:01* (OR, 23.09; 95% CI, 3.31-161.00), *HLA-B*39:01* (OR, 4.56; 95% CI, 1.31-15.82).",
              "In the DRESS group, significant associations were found in *HLA-A*68:01* (OR, 7.03; 95% CI, 1.45-34.15), *HLA-B*13:01* (OR, 23.93; 95% CI, 12.69\u201345.15), *HLA-B*38:01* (OR, 4.26; 95% CI, 1.43-12.71), *HLA-B*39:01* (OR, 3.70; 95% CI, 1.64-8.35), *HLA-C*03:04* (OR, 3.93; 95% CI, 2.71-5.69), and *HLA-C*07:27* (OR, 14.80; 95% CI, 1.88-116.34) compared with healthy controls.",
              "the *HLA-A*68:01* and *HLA-B*39:01* genotypes were associated with SMX/CTX-induced drug reaction with eosinophilia and systemic symptoms"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-A*68:01",
              "variant_id": "PA165954243",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 9,
            "Variant/Haplotypes": "HLA-B*39:01",
            "Gene": "HLA-B",
            "Drug(s)": "sulfamethoxazole, cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 4.56 (95% CI 1.31-15.82) compared with tolerant controls; OR 3.70 (95% CI 1.64-8.35) compared with healthy controls in DRESS subgroup analysis.",
            "Sentence": "HLA-B*39:01 is associated with increased risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms when treated with sulfamethoxazole or cotrimoxazole.",
            "Alleles": "*39:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "tolerant controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In the drug reaction with eosinophilia and systemic symptoms subgroup, significant associations were found in *HLA-A*68:01* (OR, 12.86; 95% CI, 1.09-151.34), *HLA-B*13:01* (OR, 23.09; 95% CI, 3.31-161.00), *HLA-B*39:01* (OR, 4.56; 95% CI, 1.31-15.82).",
              "In the DRESS group, significant associations were found in *HLA-A*68:01* (OR, 7.03; 95% CI, 1.45-34.15), *HLA-B*13:01* (OR, 23.93; 95% CI, 12.69\u201345.15), *HLA-B*38:01* (OR, 4.26; 95% CI, 1.43-12.71), *HLA-B*39:01* (OR, 3.70; 95% CI, 1.64-8.35), *HLA-C*03:04* (OR, 3.93; 95% CI, 2.71-5.69), and *HLA-C*07:27* (OR, 14.80; 95% CI, 1.88-116.34) compared with healthy controls.",
              "the *HLA-A*68:01* and *HLA-B*39:01* genotypes were associated with SMX/CTX-induced drug reaction with eosinophilia and systemic symptoms"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*39:01",
              "variant_id": "PA165955543",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 10,
            "Variant/Haplotypes": "HLA-B*13:01",
            "Gene": "HLA-B",
            "Drug(s)": "sulfamethoxazole, cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 23.09 (95% CI 3.31-161.00) compared with tolerant controls; OR 23.93 (95% CI 12.69-45.15) compared with healthy controls in DRESS subgroup analysis.",
            "Sentence": "HLA-B*13:01 is associated with increased risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms when treated with sulfamethoxazole or cotrimoxazole.",
            "Alleles": "*13:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "tolerant controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In the drug reaction with eosinophilia and systemic symptoms subgroup, significant associations were found in *HLA-A*68:01* (OR, 12.86; 95% CI, 1.09-151.34), *HLA-B*13:01* (OR, 23.09; 95% CI, 3.31-161.00), *HLA-B*39:01* (OR, 4.56; 95% CI, 1.31-15.82).",
              "In the DRESS group, significant associations were found in *HLA-A*68:01* (OR, 7.03; 95% CI, 1.45-34.15), *HLA-B*13:01* (OR, 23.93; 95% CI, 12.69\u201345.15), *HLA-B*38:01* (OR, 4.26; 95% CI, 1.43-12.71), *HLA-B*39:01* (OR, 3.70; 95% CI, 1.64-8.35), *HLA-C*03:04* (OR, 3.93; 95% CI, 2.71-5.69), and *HLA-C*07:27* (OR, 14.80; 95% CI, 1.88-116.34) compared with healthy controls.",
              "The *HLA-B*13:01* allele showed an association with SMX/CTX-induced SJS/TEN and drug reaction with eosinophilia and systemic symptoms."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*13:01",
              "variant_id": "PA165954643",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 11,
            "Variant/Haplotypes": "HLA-B*07:05",
            "Gene": "HLA-B",
            "Drug(s)": "sulfamethoxazole, cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 2.86 (95% CI 1.49-5.52) compared with healthy controls. Meta-analysis of 3 studies.",
            "Sentence": "HLA-B*07:05 is associated with increased risk of Side Effect:Severe Cutaneous Adverse Reactions when treated with sulfamethoxazole or cotrimoxazole.",
            "Alleles": "*07:05",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "healthy controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Significant associations were found in the *HLA-A*11:01* (OR, 2.16; 95% CI, 1.26-3.69), *HLA-B*07:05* (OR, 2.86; 95% CI, 1.49-5.52), *HLA-B*13:01* (OR, 5.35; 95% CI, 3.36-8.50), *HLA-B*15:02* (OR, 1.87; 95% CI, 1.39-2.52), *HLA-B*38:01* (OR, 4.26; 95% CI, 1.43-12.71), *HLA-B*38:02* (OR, 3.21; 95% CI, 1.81-5.68), *HLA-C*03:04* (OR, 3.33; 95% CI, 2.27-4.89), *HLA-C*04:06* (OR, 3.28; 95% CI, 1.22-8.81), *HLA-C*07:27* (OR, 11.38; 95% CI, 1.98-65.37), and *HLA-C*08:01* (OR, 1.47; 95% CI, 1.02-2.11) compared with healthy controls.",
              "HLA-B*07:05 | 3 | 2.86 (1.49-5.52) | .002 | 0"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*07:05",
              "variant_id": "PA165954397",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 12,
            "Variant/Haplotypes": "HLA-B*38:01",
            "Gene": "HLA-B",
            "Drug(s)": "sulfamethoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 4.26 (95% CI 1.43-12.71) compared with healthy controls. Single study in European population.",
            "Sentence": "HLA-B*38:01 is associated with increased risk of Side Effect:Severe Cutaneous Adverse Reactions when treated with sulfamethoxazole.",
            "Alleles": "*38:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "healthy controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Significant associations were found in the *HLA-A*11:01* (OR, 2.16; 95% CI, 1.26-3.69), *HLA-B*07:05* (OR, 2.86; 95% CI, 1.49-5.52), *HLA-B*13:01* (OR, 5.35; 95% CI, 3.36-8.50), *HLA-B*15:02* (OR, 1.87; 95% CI, 1.39-2.52), *HLA-B*38:01* (OR, 4.26; 95% CI, 1.43-12.71), *HLA-B*38:02* (OR, 3.21; 95% CI, 1.81-5.68), *HLA-C*03:04* (OR, 3.33; 95% CI, 2.27-4.89), *HLA-C*04:06* (OR, 3.28; 95% CI, 1.22-8.81), *HLA-C*07:27* (OR, 11.38; 95% CI, 1.98-65.37), and *HLA-C*08:01* (OR, 1.47; 95% CI, 1.02-2.11) compared with healthy controls.",
              "Conversely, in those with European descent, *HLA-B*38* has been predominantly associated with SMX-induced SJS/TEN."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*38:01",
              "variant_id": "PA165955500",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 13,
            "Variant/Haplotypes": "HLA-C*03:04",
            "Gene": "HLA-C",
            "Drug(s)": "sulfamethoxazole, cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 3.33 (95% CI 2.27-4.89) compared with healthy controls. Meta-analysis of 2 studies.",
            "Sentence": "HLA-C*03:04 is associated with increased risk of Side Effect:Severe Cutaneous Adverse Reactions when treated with sulfamethoxazole or cotrimoxazole.",
            "Alleles": "*03:04",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "healthy controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Significant associations were found in the *HLA-A*11:01* (OR, 2.16; 95% CI, 1.26-3.69), *HLA-B*07:05* (OR, 2.86; 95% CI, 1.49-5.52), *HLA-B*13:01* (OR, 5.35; 95% CI, 3.36-8.50), *HLA-B*15:02* (OR, 1.87; 95% CI, 1.39-2.52), *HLA-B*38:01* (OR, 4.26; 95% CI, 1.43-12.71), *HLA-B*38:02* (OR, 3.21; 95% CI, 1.81-5.68), *HLA-C*03:04* (OR, 3.33; 95% CI, 2.27-4.89), *HLA-C*04:06* (OR, 3.28; 95% CI, 1.22-8.81), *HLA-C*07:27* (OR, 11.38; 95% CI, 1.98-65.37), and *HLA-C*08:01* (OR, 1.47; 95% CI, 1.02-2.11) compared with healthy controls.",
              "The primary outcomes were the prevalence of SCARs in individuals with different HLA alleles, including *HLA-A*11:01*,* HLA-B*07:05*,* HLA-B*13:01*,* HLA-B*15:02*,* HLA-B*38:01*,* HLA-B*38:02*,* HLA-C*03:04*,* HLA-C*04:06*,* HLA-C*07:27*, and *HLA-C*08:01*, compared with healthy controls"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-C*03:04",
              "variant_id": "PA165956881",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 14,
            "Variant/Haplotypes": "HLA-C*04:06",
            "Gene": "HLA-C",
            "Drug(s)": "sulfamethoxazole, cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 3.28 (95% CI 1.22-8.81) compared with healthy controls. Meta-analysis of 2 studies.",
            "Sentence": "HLA-C*04:06 is associated with increased risk of Side Effect:Severe Cutaneous Adverse Reactions when treated with sulfamethoxazole or cotrimoxazole.",
            "Alleles": "*04:06",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "healthy controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Significant associations were found in the *HLA-A*11:01* (OR, 2.16; 95% CI, 1.26-3.69), *HLA-B*07:05* (OR, 2.86; 95% CI, 1.49-5.52), *HLA-B*13:01* (OR, 5.35; 95% CI, 3.36-8.50), *HLA-B*15:02* (OR, 1.87; 95% CI, 1.39-2.52), *HLA-B*38:01* (OR, 4.26; 95% CI, 1.43-12.71), *HLA-B*38:02* (OR, 3.21; 95% CI, 1.81-5.68), *HLA-C*03:04* (OR, 3.33; 95% CI, 2.27-4.89), *HLA-C*04:06* (OR, 3.28; 95% CI, 1.22-8.81), *HLA-C*07:27* (OR, 11.38; 95% CI, 1.98-65.37), and *HLA-C*08:01* (OR, 1.47; 95% CI, 1.02-2.11) compared with healthy controls.",
              "HLA-C*04:06 | 2 | 3.28 (1.22-8.81) | .02 | 0"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-C*04:06",
              "variant_id": "PA165957089",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 15,
            "Variant/Haplotypes": "HLA-C*07:27",
            "Gene": "HLA-C",
            "Drug(s)": "cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 11.38 (95% CI 1.98-65.37) compared with healthy controls. Single study.",
            "Sentence": "HLA-C*07:27 is associated with increased risk of Side Effect:Severe Cutaneous Adverse Reactions when treated with cotrimoxazole.",
            "Alleles": "*07:27",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "healthy controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Significant associations were found in the HLA-A*11:01 (OR, 2.16; 95% CI, 1.26-3.69), HLA-B*07:05 (OR, 2.86; 95% CI, 1.49-5.52), HLA-B*13:01 (OR, 5.35; 95% CI, 3.36-8.50), HLA-B*15:02 (OR, 1.87; 95% CI, 1.39-2.52), HLA-B*38:01 (OR, 4.26; 95% CI, 1.43-12.71), HLA-B*38:02 (OR, 3.21; 95% CI, 1.81-5.68), HLA-C*03:04 (OR, 3.33; 95% CI, 2.27-4.89), HLA-C*04:06 (OR, 3.28; 95% CI, 1.22-8.81), HLA-C*07:27 (OR, 11.38; 95% CI, 1.98-65.37), and HLA-C*08:01 (OR, 1.47; 95% CI, 1.02-2.11) compared with healthy controls.",
              "The primary outcomes were the prevalence of SCARs in individuals with different HLA alleles, including HLA-A*11:01, HLA-B*07:05, HLA-B*13:01, HLA-B*15:02, HLA-B*38:01, HLA-B*38:02, HLA-C*03:04, HLA-C*04:06, HLA-C*07:27, and HLA-C*08:01, compared with healthy controls"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-C*07:27",
              "variant_id": "PA165957457",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "clotrimazole",
              "drug_id": "PA449057",
              "confidence": 0.88
            }
          },
          {
            "Variant Annotation ID": 16,
            "Variant/Haplotypes": "HLA-B*13:01",
            "Gene": "HLA-B",
            "Drug(s)": "sulfamethoxazole, cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 2.49 (95% CI 1.74-3.58) compared with healthy controls in SJS/TEN subgroup analysis. Meta-analysis of 5 studies.",
            "Sentence": "HLA-B*13:01 is associated with increased risk of Side Effect:Stevens-Johnson Syndrome and Side Effect:Toxic Epidermal Necrolysis when treated with sulfamethoxazole or cotrimoxazole.",
            "Alleles": "*13:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "healthy controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In the SJS/TEN group, significant associations were found in *HLA-B*07:05* (OR, 2.80; 95% CI, 1.41-5.58), *HLA-B*13:01* (OR, 2.49; 95% CI, 1.74-3.58), *HLA-B*15:02* (OR, 3.09; 95% CI, 1.90-5.02), *HLA-B*38:01* (OR, 4.26; 95% CI, 1.43-12.71), *HLA-B*38:02* (OR, 4.56; 95% CI, 2.65-7.85), *HLA-C*04:06* (OR, 3.37; 95% CI, 1.16-9.78), *HLA-C*07:27* (OR, 9.25; 95% CI, 1.22-70.20), and *HLA-C*08:01* (OR, 1.66; 95% CI, 1.13-2.44) compared with healthy controls.",
              "The *HLA-B*13:01* allele showed an association with SMX/CTX-induced SJS/TEN and DRESS, as evidenced by 3 studies involving Thai, Malaysian, and Taiwanese populations."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*13:01",
              "variant_id": "PA165954643",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 17,
            "Variant/Haplotypes": "HLA-B*07:05",
            "Gene": "HLA-B",
            "Drug(s)": "sulfamethoxazole, cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 2.80 (95% CI 1.41-5.58) compared with healthy controls in SJS/TEN subgroup analysis. Meta-analysis of 3 studies.",
            "Sentence": "HLA-B*07:05 is associated with increased risk of Side Effect:Stevens-Johnson Syndrome and Side Effect:Toxic Epidermal Necrolysis when treated with sulfamethoxazole or cotrimoxazole.",
            "Alleles": "*07:05",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "healthy controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In the SJS/TEN group, significant associations were found in *HLA-B*07:05* (OR, 2.80; 95% CI, 1.41-5.58), *HLA-B*13:01* (OR, 2.49; 95% CI, 1.74-3.58), *HLA-B*15:02* (OR, 3.09; 95% CI, 1.90-5.02), *HLA-B*38:01* (OR, 4.26; 95% CI, 1.43-12.71), *HLA-B*38:02* (OR, 4.56; 95% CI, 2.65-7.85), *HLA-C*04:06* (OR, 3.37; 95% CI, 1.16-9.78), *HLA-C*07:27* (OR, 9.25; 95% CI, 1.22-70.20), and *HLA-C*08:01* (OR, 1.66; 95% CI, 1.13-2.44) compared with healthy controls.",
              "Significant associations were found in the *HLA-A*11:01* (OR, 2.16; 95% CI, 1.26-3.69), *HLA-B*07:05* (OR, 2.86; 95% CI, 1.49-5.52), *HLA-B*13:01* (OR, 5.35; 95% CI, 3.36-8.50), *HLA-B*15:02* (OR, 1.87; 95% CI, 1.39-2.52), *HLA-B*38:01* (OR, 4.26; 95% CI, 1.43-12.71), *HLA-B*38:02* (OR, 3.21; 95% CI, 1.81-5.68), *HLA-C*03:04* (OR, 3.33; 95% CI, 2.27-4.89), *HLA-C*04:06* (OR, 3.28; 95% CI, 1.22-8.81), *HLA-C*07:27* (OR, 11.38; 95% CI, 1.98-65.37), and *HLA-C*08:01* (OR, 1.47; 95% CI, 1.02-2.11) compared with healthy controls."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*07:05",
              "variant_id": "PA165954397",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 18,
            "Variant/Haplotypes": "HLA-C*04:06",
            "Gene": "HLA-C",
            "Drug(s)": "sulfamethoxazole, cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 3.37 (95% CI 1.16-9.78) compared with healthy controls in SJS/TEN subgroup analysis. Meta-analysis of 2 studies.",
            "Sentence": "HLA-C*04:06 is associated with increased risk of Side Effect:Stevens-Johnson Syndrome and Side Effect:Toxic Epidermal Necrolysis when treated with sulfamethoxazole or cotrimoxazole.",
            "Alleles": "*04:06",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "healthy controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In the SJS/TEN group, significant associations were found in HLA-B*07:05 (OR, 2.80; 95% CI, 1.41-5.58), HLA-B*13:01 (OR, 2.49; 95% CI, 1.74-3.58), HLA-B*15:02 (OR, 3.09; 95% CI, 1.90-5.02), HLA-B*38:01 (OR, 4.26; 95% CI, 1.43-12.71), HLA-B*38:02 (OR, 4.56; 95% CI, 2.65-7.85), HLA-C*04:06 (OR, 3.37; 95% CI, 1.16-9.78), HLA-C*07:27 (OR, 9.25; 95% CI, 1.22-70.20), and HLA-C*08:01 (OR, 1.66; 95% CI, 1.13-2.44) compared with healthy controls."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-C*04:06",
              "variant_id": "PA165957089",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 19,
            "Variant/Haplotypes": "HLA-C*08:01",
            "Gene": "HLA-C",
            "Drug(s)": "sulfamethoxazole, cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 1.66 (95% CI 1.13-2.44) compared with healthy controls in SJS/TEN subgroup analysis. Meta-analysis of 4 studies.",
            "Sentence": "HLA-C*08:01 is associated with increased risk of Side Effect:Stevens-Johnson Syndrome and Side Effect:Toxic Epidermal Necrolysis when treated with sulfamethoxazole or cotrimoxazole.",
            "Alleles": "*08:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "healthy controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In the SJS/TEN group, significant associations were found in HLA-B*07:05 (OR, 2.80; 95% CI, 1.41-5.58), HLA-B*13:01 (OR, 2.49; 95% CI, 1.74-3.58), HLA-B*15:02 (OR, 3.09; 95% CI, 1.90-5.02), HLA-B*38:01 (OR, 4.26; 95% CI, 1.43-12.71), HLA-B*38:02 (OR, 4.56; 95% CI, 2.65-7.85), HLA-C*04:06 (OR, 3.37; 95% CI, 1.16-9.78), HLA-C*07:27 (OR, 9.25; 95% CI, 1.22-70.20), and HLA-C*08:01 (OR, 1.66; 95% CI, 1.13-2.44) compared with healthy controls.",
              "In East Asian populations, including Taiwanese, Thai, and Malaysian groups, the HLA-B*13:01 and HLA-B*15:02 alleles have shown significant associations with SMX/CTX-induced SCARs, particularly DRESS, while the HLA-C*08:01 allele has been associated with SMX/CTX-induced SJS/TEN."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-C*08:01",
              "variant_id": "PA166123426",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 20,
            "Variant/Haplotypes": "HLA-C*03:04",
            "Gene": "HLA-C",
            "Drug(s)": "sulfamethoxazole, cotrimoxazole",
            "PMID": 38568509,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "OR 3.93 (95% CI 2.71-5.69) compared with healthy controls in DRESS subgroup analysis. Meta-analysis of 3 studies.",
            "Sentence": "HLA-C*03:04 is associated with increased risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms when treated with sulfamethoxazole or cotrimoxazole.",
            "Alleles": "*03:04",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "healthy controls",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In the DRESS group, significant associations were found in *HLA-A*68:01* (OR, 7.03; 95% CI, 1.45-34.15), *HLA-B*13:01* (OR, 23.93; 95% CI, 12.69\u201345.15), *HLA-B*38:01* (OR, 4.26; 95% CI, 1.43-12.71), *HLA-B*39:01* (OR, 3.70; 95% CI, 1.64-8.35), *HLA-C*03:04* (OR, 3.93; 95% CI, 2.71-5.69), and *HLA-C*07:27* (OR, 14.80; 95% CI, 1.88-116.34) compared with healthy controls.",
              "Significant associations were found in the *HLA-A*11:01* (OR, 2.16; 95% CI, 1.26-3.69), *HLA-B*07:05* (OR, 2.86; 95% CI, 1.49-5.52), *HLA-B*13:01* (OR, 5.35; 95% CI, 3.36-8.50), *HLA-B*15:02* (OR, 1.87; 95% CI, 1.39-2.52), *HLA-B*38:01* (OR, 4.26; 95% CI, 1.43-12.71), *HLA-B*38:02* (OR, 3.21; 95% CI, 1.81-5.68), *HLA-C*03:04* (OR, 3.33; 95% CI, 2.27-4.89), *HLA-C*04:06* (OR, 3.28; 95% CI, 1.22-8.81), *HLA-C*07:27* (OR, 11.38; 95% CI, 1.98-65.37), and *HLA-C*08:01* (OR, 1.47; 95% CI, 1.02-2.11) compared with healthy controls."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-C*03:04",
              "variant_id": "PA165956881",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "sulfamethoxazole",
              "drug_id": "PA451544",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "error": "Empty predictions list",
        "overall_score": 0.0,
        "total_samples": 0
      }
    },
    "PMC554812": {
      "var-pheno": {
        "overall_score": 0.8160868749022483,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 0.9820648908615113,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.9103244543075562
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 0.7406517386436462,
            "scores": [
              0.9356411099433899,
              0.9296865463256836,
              0.9237272143363953,
              0.9142038226127625,
              0.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Direction of effect": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.2,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              1.0
            ]
          }
        },
        "total_samples": 5,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9356411099433899,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-C*03:02",
                "prediction": "HLA-C*0302"
              },
              "Gene": {
                "ground_truth": "HLA-C",
                "prediction": "HLA-C"
              },
              "Drug(s)": {
                "ground_truth": "allopurinol",
                "prediction": "allopurinol"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*03:02",
                "prediction": "*0302"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Severe Cutaneous Adverse Reactions"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9296865463256836,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-DRB1*03:01",
                "prediction": "HLA-DRB1*0301"
              },
              "Gene": {
                "ground_truth": "HLA-DRB1",
                "prediction": "HLA-DRB1"
              },
              "Drug(s)": {
                "ground_truth": "allopurinol",
                "prediction": "allopurinol"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*03:01",
                "prediction": "*0301"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Severe Cutaneous Adverse Reactions"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9237272143363953,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*58:01",
                "prediction": "HLA-B*5801"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "allopurinol",
                "prediction": "allopurinol"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*58:01",
                "prediction": "*5801"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Severe Cutaneous Adverse Reactions"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9142038226127625,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-A*33:03",
                "prediction": "HLA-A*3303"
              },
              "Gene": {
                "ground_truth": "HLA-A",
                "prediction": "HLA-A"
              },
              "Drug(s)": {
                "ground_truth": "allopurinol",
                "prediction": "allopurinol"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*33:03",
                "prediction": "*3303"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Severe Cutaneous Adverse Reactions"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 0.9103244543075562,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-C*03:02",
                "prediction": "rs1594"
              },
              "Gene": {
                "ground_truth": "HLA-C",
                "prediction": "CFLAR"
              },
              "Drug(s)": {
                "ground_truth": "allopurinol",
                "prediction": "allopurinol"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*03:02",
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Severe Cutaneous Adverse Reactions"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "PA166155581",
          "hla-b+allopurinol",
          "hla-drb1+allopurinol",
          "hla-c+allopurinol",
          "hla-a+allopurinol"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "HLA-B*5801",
            "Gene": "HLA-B",
            "Drug(s)": "allopurinol",
            "PMID": 15743917,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "All 51 patients with allopurinol-induced SJS, TEN, or HSS carried HLA-B*5801. SJS (13 cases), SJS/TEN overlap (5 cases), TEN (3 cases), and HSS (30 cases) were included.",
            "Sentence": "HLA-B*5801 is associated with increased risk of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, and Side Effect:Drug Hypersensitivity Syndrome when treated with allopurinol in people with Disease:Hyperuricemia.",
            "Alleles": "*5801",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Drug Hypersensitivity Syndrome",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Hyperuricemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The HLA-B*5801 allele was present in all (100%) 51 patients with allopurinol\u2013SCAR, but only in 20 (15%) of 135 tolerant patients [odds ratio 580.3 (95% confidence interval, 34.4\u20139780.9); corrected P value = 4.7 \u00d7 10\u201324] and in 19 (20%) of 93 of healthy subjects [393.51 (23.23\u20136665.26); corrected P value = 8.1 \u00d7 10\u201318].",
              "The clinical manifestations of the 51 patients with allopurinol\u2013SCAR, which included SJS (13 cases), SJS/TEN (5 cases), TEN (3 cases), and HSS (30 cases), are summarized in Table 1.",
              "All patients received allopurinol because of hyperuricemia with or without gouty arthritis (Table 2)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*5801",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "allopurinol",
              "drug_id": "PA448320",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "rs3117583",
            "Gene": "BAT3",
            "Drug(s)": "allopurinol",
            "PMID": 15743917,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "SNP in BAT3 (HLA-B associated transcript 3) in MHC class III region showed P<10^-7 association with allopurinol-SCAR in initial screen of 30 cases vs 60 tolerant controls.",
            "Sentence": "rs3117583 is associated with increased risk of Side Effect:Severe Cutaneous Adverse Reactions when treated with allopurinol in people with Disease:Hyperuricemia.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Hyperuricemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "In particular, three SNPs in the MHC class III region have P values <10\u20137 (\u2013log10 P value > 7, Fig. 1). These SNPs were rs3117583 of BAT3 (encoding for HLA-B associated transcript 3), rs1150793 of MSH5 (encoding mutS homolog), and rs2855804 of MICB (encoding MHC class I polypeptide-related sequence).",
              "The initial screen revealed strong association between allopurinol\u2013SCAR and SNPs in the MHC region, including BAT3 (encoding HLA-B associated transcript 3), MSH5 (mutS homolog 5), and MICB (MHC class I polypeptide-related sequence B) (P < 10\u20137).",
              "We initially screened 30 patients with allopurinol\u2013SCAR and 60 tolerant subjects for SNP association."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs3117583",
              "variant_id": "PA166161417",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "allopurinol",
              "drug_id": "PA448320",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "rs1150793",
            "Gene": "MSH5",
            "Drug(s)": "allopurinol",
            "PMID": 15743917,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "SNP in MSH5 (mutS homolog 5) in MHC class III region showed P<10^-7 association with allopurinol-SCAR in initial screen of 30 cases vs 60 tolerant controls.",
            "Sentence": "rs1150793 is associated with increased risk of Side Effect:Severe Cutaneous Adverse Reactions when treated with allopurinol in people with Disease:Hyperuricemia.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Hyperuricemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "In particular, three SNPs in the MHC class III region have P values <10\u20137 (\u2013log10 P value > 7, Fig. 1). These SNPs were rs3117583 of BAT3 (encoding for HLA-B associated transcript 3), rs1150793 of MSH5 (encoding mutS homolog), and rs2855804 of MICB (encoding MHC class I polypeptide-related sequence).",
              "We initially screened 30 patients with allopurinol\u2013SCAR and 60 tolerant subjects for SNP association. Of the total of 823 SNPs screened (197 SNPs in the MHC region and 626 SNPs of immune-related genes and drug metabolizing genes), 29 SNPs in the MHC region were found to have significant association (P < 0.01) with the allopurinol\u2013SCAR patients when compared to the tolerant group",
              "All patients received allopurinol because of hyperuricemia with or without gouty arthritis"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1150793",
              "variant_id": "PA166161390",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "allopurinol",
              "drug_id": "PA448320",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "rs2855804",
            "Gene": "MICB",
            "Drug(s)": "allopurinol",
            "PMID": 15743917,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "SNP in MICB (MHC class I polypeptide-related sequence B) in MHC class III region showed P<10^-7 association with allopurinol-SCAR in initial screen of 30 cases vs 60 tolerant controls.",
            "Sentence": "rs2855804 is associated with increased risk of Side Effect:Severe Cutaneous Adverse Reactions when treated with allopurinol in people with Disease:Hyperuricemia.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Hyperuricemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "In particular, three SNPs in the MHC class III region have P values <10\u20137 (\u2013log10 P value > 7, Fig. 1). These SNPs were rs3117583 of BAT3 (encoding for HLA-B associated transcript 3), rs1150793 of MSH5 (encoding mutS homolog), and rs2855804 of MICB (encoding MHC class I polypeptide-related sequence).",
              "We initially screened 30 patients with allopurinol\u2013SCAR and 60 tolerant subjects for SNP association. Of the total of 823 SNPs screened (197 SNPs in the MHC region and 626 SNPs of immune-related genes and drug metabolizing genes), 29 SNPs in the MHC region were found to have significant association (P < 0.01) with the allopurinol\u2013SCAR patients when compared to the tolerant group",
              "All patients received allopurinol because of hyperuricemia with or without gouty arthritis"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2855804",
              "variant_id": "PA166161439",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "allopurinol",
              "drug_id": "PA448320",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 9,
            "Variant/Haplotypes": "rs2268791",
            "Gene": "CFLAR",
            "Drug(s)": "allopurinol",
            "PMID": 15743917,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "SNP in CFLAR (CASP8 and FADD-like apoptosis regulator) on chromosome 2 showed P<0.01 association with allopurinol-SCAR. Association was confirmed in replication cohort.",
            "Sentence": "rs2268791 is associated with increased risk of Side Effect:Severe Cutaneous Adverse Reactions when treated with allopurinol in people with Disease:Hyperuricemia.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Hyperuricemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "Outside the MHC region, only three SNPs showed potential associations (P < 0.01). Two SNPs (rs2268791 and rs1594) were located in the CASP8 and FADD-like apoptosis regulator (CFLAR) gene on chromosome 2, and one SNP (rs2304224) belongs to KIR2DL1 (a killer cell Ig-like receptor) gene on chromosome 19.",
              "To replicate the initial screening results, we genotyped additional 21 patients with allopurinol\u2013SCAR, 75 allopurinoltolerant controls, and 93 subjects from the general population for all of the SNPs that had P values <0.01. We confirmed the initial observation of the positive association of allopurinol\u2013SCAR with the MHC and CFLAR loci, but not with the KIR2D1 locus.",
              "All patients received allopurinol because of hyperuricemia with or without gouty arthritis"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2268791",
              "variant_id": "PA166161419",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "allopurinol",
              "drug_id": "PA448320",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.779432461034684,
        "field_scores": {
          "Study Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.8571428571428571,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Study Controls": {
            "mean_score": 0.8571428571428571,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.9118223105158124,
            "scores": [
              0.9215628504753113,
              0.9215628504753113,
              0.9215628504753113,
              0.9565401077270508,
              0.8710511922836304,
              0.8710511922836304,
              0.8710511922836304,
              0.8658563494682312,
              0.9268218874931335,
              0.9485123157501221,
              0.9480222463607788,
              0.9512763023376465,
              0.9223563075065613,
              0.8682847023010254
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 0.6142857142857142,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.8,
              0.8,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 0.7898323025022235,
            "scores": [
              0.9425032734870911,
              0.9342316389083862,
              0.9301361441612244,
              0.9106189608573914,
              0.9425032734870911,
              0.9342316389083862,
              0.9301361441612244,
              0.9141463041305542,
              0.9141463041305542,
              0.9057378768920898,
              0.905430793762207,
              0.893829882144928,
              0.0,
              0.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 0.6285714285714287,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.8,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 0.7898323025022235,
            "scores": [
              0.9425032734870911,
              0.9342316389083862,
              0.9301361441612244,
              0.9106189608573914,
              0.9425032734870911,
              0.9342316389083862,
              0.9301361441612244,
              0.9141463041305542,
              0.9141463041305542,
              0.9057378768920898,
              0.905430793762207,
              0.893829882144928,
              0.0,
              0.0
            ]
          },
          "P Value": {
            "mean_score": 0.6785714285714286,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.5,
              0.5,
              0.5,
              0.5,
              0.5,
              0.0,
              0.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 0.5642857142857143,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.9,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 14,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9215628504753113,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.9425032734870911,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 0.9425032734870911,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184755058,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1184755056,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 51.0,
                "prediction": 51
              },
              "Study Controls": {
                "ground_truth": 135.0,
                "prediction": 135
              },
              "Characteristics": {
                "ground_truth": "cases n= 51, controls = 135 tolerant to allopurinol",
                "prediction": "Allopurinol-induced SCAR vs allopurinol-tolerant controls"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.67,
                "prediction": 0.67
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*33:03",
                "prediction": "A*3303"
              },
              "Frequency In Controls": {
                "ground_truth": 0.18,
                "prediction": 0.18
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*33:03",
                "prediction": "A*3303"
              },
              "P Value": {
                "ground_truth": "= 2.2E-4",
                "prediction": "= 2.2e-4"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 9.3,
                "prediction": 9.3
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9215628504753113,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.9342316389083862,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 0.9342316389083862,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184755034,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1184755032,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 51.0,
                "prediction": 51
              },
              "Study Controls": {
                "ground_truth": 135.0,
                "prediction": 135
              },
              "Characteristics": {
                "ground_truth": "cases n= 51, controls = 135 tolerant to allopurinol",
                "prediction": "Allopurinol-induced SCAR vs allopurinol-tolerant controls"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.94,
                "prediction": 0.94
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*03:02",
                "prediction": "Cw*0302"
              },
              "Frequency In Controls": {
                "ground_truth": 0.14,
                "prediction": 0.14
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*03:02",
                "prediction": "Cw*0302"
              },
              "P Value": {
                "ground_truth": "= 1.4E-19",
                "prediction": "= 1.4e-19"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 97.7,
                "prediction": 97.7
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9215628504753113,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.9301361441612244,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 0.9301361441612244,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184755075,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1184755073,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 51.0,
                "prediction": 51
              },
              "Study Controls": {
                "ground_truth": 135.0,
                "prediction": 135
              },
              "Characteristics": {
                "ground_truth": "cases n= 51, controls = 135 tolerant to allopurinol",
                "prediction": "Allopurinol-induced SCAR vs allopurinol-tolerant controls"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.65,
                "prediction": 0.65
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*03:01",
                "prediction": "DRB1*0301"
              },
              "Frequency In Controls": {
                "ground_truth": 0.13,
                "prediction": 0.13
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*03:01",
                "prediction": "DRB1*0301"
              },
              "P Value": {
                "ground_truth": "= 2.8E-6",
                "prediction": "= 2.8e-6"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 12.7,
                "prediction": 12.7
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9565401077270508,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.9106189608573914,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 0.9106189608573914,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184755119,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 981345654,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 51.0,
                "prediction": 51
              },
              "Study Controls": {
                "ground_truth": 135.0,
                "prediction": 135
              },
              "Characteristics": {
                "ground_truth": "Cases n= 51, controls = 135 tolerant to allopurinol. Statistics and allele frequencies here are for the HLA-B*5801 extended haplotype: B*5801-C*0302-A*3303-DRB1*0301.",
                "prediction": "Allopurinol-induced SCAR vs allopurinol-tolerant controls, B*5801, Cw*0302, A*3303, DRB1*0301 extended haplotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.41,
                "prediction": 0.41
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*58:01",
                "prediction": "B*5801, Cw*0302, A*3303, DRB1*0301"
              },
              "Frequency In Controls": {
                "ground_truth": 0.07,
                "prediction": 0.07
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*58:01",
                "prediction": "B*5801, Cw*0302, A*3303, DRB1*0301"
              },
              "P Value": {
                "ground_truth": "= 0.039",
                "prediction": "= 0.039"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 9.8,
                "prediction": 9.8
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8710511922836304,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.9425032734870911,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 0.9425032734870911,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184755059,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1184755056,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 51.0,
                "prediction": 51
              },
              "Study Controls": {
                "ground_truth": 93.0,
                "prediction": 93
              },
              "Characteristics": {
                "ground_truth": "cases n= 51, controls = 93 general population.",
                "prediction": "Allopurinol-induced SCAR vs general population controls"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.67,
                "prediction": 0.67
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*33:03",
                "prediction": "A*3303"
              },
              "Frequency In Controls": {
                "ground_truth": 0.22,
                "prediction": 0.22
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*33:03",
                "prediction": "A*3303"
              },
              "P Value": {
                "ground_truth": "= 4.7E-2",
                "prediction": "= 4.7e-2"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 7.3,
                "prediction": 7.3
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8710511922836304,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.9342316389083862,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 0.9342316389083862,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184755035,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1184755032,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 51.0,
                "prediction": 51
              },
              "Study Controls": {
                "ground_truth": 93.0,
                "prediction": 93
              },
              "Characteristics": {
                "ground_truth": "cases n= 51, controls = 93 general population.",
                "prediction": "Allopurinol-induced SCAR vs general population controls"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.94,
                "prediction": 0.94
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*03:02",
                "prediction": "Cw*0302"
              },
              "Frequency In Controls": {
                "ground_truth": 0.2,
                "prediction": 0.2
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*03:02",
                "prediction": "Cw*0302"
              },
              "P Value": {
                "ground_truth": "= 2.5E-13",
                "prediction": "= 2.5e-13"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 62.3,
                "prediction": 62.3
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 6,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8710511922836304,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.9301361441612244,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 0.9301361441612244,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184755076,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1184755073,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 51.0,
                "prediction": 51
              },
              "Study Controls": {
                "ground_truth": 93.0,
                "prediction": 93
              },
              "Characteristics": {
                "ground_truth": "cases n= 51, controls = 93 general population.",
                "prediction": "Allopurinol-induced SCAR vs general population controls"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.65,
                "prediction": 0.65
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*03:01",
                "prediction": "DRB1*0301"
              },
              "Frequency In Controls": {
                "ground_truth": 0.15,
                "prediction": 0.15
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*03:01",
                "prediction": "DRB1*0301"
              },
              "P Value": {
                "ground_truth": "= 8.5E-4",
                "prediction": "= 8.5e-4"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 10.3,
                "prediction": 10.3
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 7,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8658563494682312,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.8,
              "Allele Of Frequency In Cases": 0.9141463041305542,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 0.9141463041305542,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184754937,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 981345654,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 51.0,
                "prediction": 51
              },
              "Study Controls": {
                "ground_truth": 93.0,
                "prediction": 93
              },
              "Characteristics": {
                "ground_truth": "cases n= 51, controls = 93 general population.",
                "prediction": "Allopurinol-induced SCAR vs general population controls, B*5801 and Cw*0302 haplotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 1.0,
                "prediction": 0.94
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*58:01",
                "prediction": "B*5801, Cw*0302"
              },
              "Frequency In Controls": {
                "ground_truth": 0.2,
                "prediction": 0.2
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*58:01",
                "prediction": "B*5801, Cw*0302"
              },
              "P Value": {
                "ground_truth": "= 8.1E-18",
                "prediction": "= 2.6e-13"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 393.5,
                "prediction": 62.3
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 8,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9268218874931335,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.8,
              "Allele Of Frequency In Cases": 0.9141463041305542,
              "Frequency In Controls": 0.8,
              "Allele Of Frequency In Controls": 0.9141463041305542,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 981345658,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 981345654,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 51.0,
                "prediction": 51
              },
              "Study Controls": {
                "ground_truth": 135.0,
                "prediction": 135
              },
              "Characteristics": {
                "ground_truth": "cases n= 51, controls = 135 tolerant to allopurinol",
                "prediction": "Allopurinol-induced SCAR vs allopurinol-tolerant controls, B*5801 and Cw*0302 haplotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 1.0,
                "prediction": 0.94
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*58:01",
                "prediction": "B*5801, Cw*0302"
              },
              "Frequency In Controls": {
                "ground_truth": 0.15,
                "prediction": 0.14
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*58:01",
                "prediction": "B*5801, Cw*0302"
              },
              "P Value": {
                "ground_truth": "= 4.7E-24",
                "prediction": "= 1.4e-19"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 580.3,
                "prediction": 97.7
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 9,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9485123157501221,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.9057378768920898,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.9057378768920898,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.9,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184755134,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1184755073,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 51.0,
                "prediction": 51
              },
              "Study Controls": {
                "ground_truth": 93.0,
                "prediction": 93
              },
              "Characteristics": {
                "ground_truth": "Cases n= 51, controls = 135 tolerant to allopurinol. Statistics and allele frequencies here are for the HLA-B*5801 extended haplotype: B*5801-C*0302-A*3303-DRB1*0301.",
                "prediction": "Allopurinol-induced SCAR vs general population controls, B*5801, Cw*0302, A*3303 haplotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.41,
                "prediction": 0.67
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*03:01",
                "prediction": "B*5801, Cw*0302, A*3303"
              },
              "Frequency In Controls": {
                "ground_truth": 0.07,
                "prediction": 0.17
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*03:01",
                "prediction": "B*5801, Cw*0302, A*3303"
              },
              "P Value": {
                "ground_truth": "= 0.039",
                "prediction": "= 1.7e-3"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 9.8,
                "prediction": 9.6
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 10,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9480222463607788,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.905430793762207,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.905430793762207,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184755113,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1184755056,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 51.0,
                "prediction": 51
              },
              "Study Controls": {
                "ground_truth": 135.0,
                "prediction": 135
              },
              "Characteristics": {
                "ground_truth": "cases n= 51, controls = 135 tolerant to allopurinol. Statistics and allele frequencies here are for the HLA-B*5801 extended haplotype: B*5801-C*0302-A*3303-DRB1*0301.",
                "prediction": "Allopurinol-induced SCAR vs allopurinol-tolerant controls, B*5801, Cw*0302, A*3303 haplotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.41,
                "prediction": 0.67
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*33:03",
                "prediction": "B*5801, Cw*0302, A*3303"
              },
              "Frequency In Controls": {
                "ground_truth": 0.07,
                "prediction": 0.13
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*33:03",
                "prediction": "B*5801, Cw*0302, A*3303"
              },
              "P Value": {
                "ground_truth": "= 0.039",
                "prediction": "= 5.4e-7"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 9.8,
                "prediction": 13.9
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 11,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9512763023376465,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.893829882144928,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.893829882144928,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184755127,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1184755032,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 51.0,
                "prediction": 51
              },
              "Study Controls": {
                "ground_truth": 135.0,
                "prediction": 135
              },
              "Characteristics": {
                "ground_truth": "Cases n= 51, controls = 135 tolerant to allopurinol. Statistics and allele frequencies here are for the HLA-B*5801 extended haplotype: B*5801-C*0302-A*3303-DRB1*0301.",
                "prediction": "Allopurinol-induced SCAR vs allopurinol-tolerant controls, B*5801, Cw*0302, DRB1*0301 haplotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.41,
                "prediction": 0.59
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*03:02",
                "prediction": "B*5801, Cw*0302, DRB1*0301"
              },
              "Frequency In Controls": {
                "ground_truth": 0.07,
                "prediction": 0.08
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*03:02",
                "prediction": "B*5801, Cw*0302, DRB1*0301"
              },
              "P Value": {
                "ground_truth": "= 0.39",
                "prediction": "= 7.4e-7"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 9.8,
                "prediction": 16.1
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 12,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.9223563075065613,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 0.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184755146,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1184755144,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 30.0,
                "prediction": 51
              },
              "Study Controls": {
                "ground_truth": 60.0,
                "prediction": 93
              },
              "Characteristics": {
                "ground_truth": "cases n= 30, controls = 60 tolerant to allopurinol.",
                "prediction": "Allopurinol-induced SCAR vs general population controls, B*5801, Cw*0302, A*3303, DRB1*0301 extended haplotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": 0.41
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "B*5801, Cw*0302, A*3303, DRB1*0301"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": 0.1
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": "B*5801, Cw*0302, A*3303, DRB1*0301"
              },
              "P Value": {
                "ground_truth": "< 0.01",
                "prediction": "> 0.05"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 6.5
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 13,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.8682847023010254,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 0.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184755147,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1184755144,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 21.0,
                "prediction": 51
              },
              "Study Controls": {
                "ground_truth": 75.0,
                "prediction": 93
              },
              "Characteristics": {
                "ground_truth": "cases n= 21, controls = 75 general population.",
                "prediction": "Allopurinol-induced SCAR vs general population controls, B*5801, Cw*0302, DRB1*0301 haplotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": 0.59
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "B*5801, Cw*0302, DRB1*0301"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": 0.11
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": "B*5801, Cw*0302, DRB1*0301"
              },
              "P Value": {
                "ground_truth": "< 0.01",
                "prediction": "= 7.8e-4"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 393.5,
                "prediction": 11.9
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "case/control:cases n= 51, control",
          "case/control:cases n= 51, control",
          "case/control:cases n= 51, control",
          "case/control:Cases n= 51, control",
          "case/control:cases n= 51, control",
          "case/control:cases n= 51, control",
          "case/control:cases n= 51, control",
          "case/control:cases n= 51, control",
          "case/control:cases n= 51, control",
          "case/control:Cases n= 51, control",
          "case/control:cases n= 51, control",
          "case/control:Cases n= 51, control",
          "case/control:cases n= 30, control",
          "case/control:cases n= 21, control"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 51,
            "Study Controls": 135,
            "Characteristics": "Allopurinol-induced SCAR vs allopurinol-tolerant controls",
            "Characteristics Type": "drug",
            "Frequency In Cases": 1.0,
            "Allele Of Frequency In Cases": "B*5801",
            "Frequency In Controls": 0.15,
            "Allele Of Frequency In Controls": "B*5801",
            "P Value": "= 4.7e-24",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 580.3,
            "Confidence Interval Start": 34.4,
            "Confidence Interval Stop": 9780.9,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 51,
            "Study Controls": 93,
            "Characteristics": "Allopurinol-induced SCAR vs general population controls",
            "Characteristics Type": "drug",
            "Frequency In Cases": 1.0,
            "Allele Of Frequency In Cases": "B*5801",
            "Frequency In Controls": 0.2,
            "Allele Of Frequency In Controls": "B*5801",
            "P Value": "= 8.1e-18",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 393.51,
            "Confidence Interval Start": 23.23,
            "Confidence Interval Stop": 6665.26,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC384715": {
      "var-pheno": {
        "overall_score": 0.8224054848154386,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.0,
            "scores": [
              0.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 0.9271343350410461,
            "scores": [
              0.9271343350410461
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Direction of effect": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.9890821576118469,
            "scores": [
              0.9890821576118469
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.0,
            "scores": [
              0.0
            ]
          }
        },
        "total_samples": 1,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9271343350410461,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9890821576118469,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*57:01",
                "prediction": "HLA-B*5701"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "abacavir",
                "prediction": "abacavir"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*57:01",
                "prediction": "*5701"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Drug Hypersensitivity",
                "prediction": "Side Effect:Hypersensitivity"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "hla-b+abacavir"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "rs2227956",
            "Gene": "HSPA1L",
            "Drug(s)": "abacavir",
            "PMID": 15024131,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Hsp70-Hom M493T (rs2227956) was present in 94.4% of hypersensitive cases compared with 22.2% of tolerant controls (OR=59.7, Pc<0.00001).",
            "Sentence": "rs2227956 is associated with increased risk of Side Effect:Hypersensitivity when treated with abacavir in people with Disease:HIV Infection compared to non-carriers.",
            "Alleles": "M493T",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The Hsp70-Hom M493T allele was assessed in all 248 patients of the cohort by using an allele-specific sequence-specific primer and/or the standard NcoI restriction fragment-length polymorphism assays. We observed that the Hsp70-Hom M493T allele, carried on the 57.1 AH, was detected in 94.4% of the hypersensitive group compared with 22.2% of tolerant controls (17 of 18 individuals vs. 51 of 230 individuals, OR = 59.7, Pc < 0.00001).",
              "A haplotypic nonsynonymous polymorphism of Hsp70-Hom (HspA1L, resulting from the substitution of residue M493T in the peptide-binding subunit) was found in combination with HLA-B*5701 in 94.4% of hypersensitive cases and 0.4% of controls (odds ratio, 3,893; P < 0.00001)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2227956",
              "variant_id": "PA166157023",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "abacavir",
              "drug_id": "PA448004",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "HLA-B*5701",
            "Gene": "HLA-B, HSPA1L",
            "Drug(s)": "abacavir",
            "PMID": 15024131,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The combination of HLA-B*5701 and Hsp70-Hom M493T was found in 94.4% of hypersensitive cases and 0.4% of controls (OR=3,893, P<0.00001). Positive predictive value 93.8%, negative predictive value 99.5%.",
            "Sentence": "HLA-B*5701 and rs2227956 are associated with increased risk of Side Effect:Hypersensitivity when treated with abacavir in people with Disease:HIV Infection compared to non-carriers.",
            "Alleles": "*5701, M493T",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "A haplotypic nonsynonymous polymorphism of Hsp70-Hom (HspA1L, resulting from the substitution of residue M493T in the peptide-binding subunit) was found in combination with HLA-B*5701 in 94.4% of hypersensitive cases and 0.4% of controls (odds ratio, 3,893; P < 0.00001). Positive predictive value 93.8%, negative predictive value 99.5.",
              "HLA-B*5701 was present in 94.4% of hypersensitive cases compared with 1.7% of controls (odds ratio, 960; P < 0.00001).",
              "However, in combination with HLA-B*5701, the Hsp70-Hom M493T allele was strongly associated with abacavir hypersensitivity (17 of 18 individuals vs. 1 of 230 individuals, OR = 3,893, Pc < 0.00001)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*5701, rs2227956",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "abacavir",
              "drug_id": "PA448004",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "rs2227956",
            "Gene": "HLA-B, HSPA1L",
            "Drug(s)": "abacavir",
            "PMID": 15024131,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The combination of HLA-B*5701 and Hsp70-Hom M493T was found in 94.4% of hypersensitive cases and 0.4% of controls (OR=3,893, P<0.00001). Positive predictive value 93.8%, negative predictive value 99.5%.",
            "Sentence": "HLA-B*5701 and rs2227956 are associated with increased risk of Side Effect:Hypersensitivity when treated with abacavir in people with Disease:HIV Infection compared to non-carriers.",
            "Alleles": "*5701, M493T",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "A haplotypic nonsynonymous polymorphism of Hsp70-Hom (HspA1L, resulting from the substitution of residue M493T in the peptide-binding subunit) was found in combination with HLA-B*5701 in 94.4% of hypersensitive cases and 0.4% of controls (odds ratio, 3,893; P < 0.00001). Positive predictive value 93.8%, negative predictive value 99.5.",
              "HLA-B*5701 was present in 94.4% of hypersensitive cases compared with 1.7% of controls (odds ratio, 960; P < 0.00001).",
              "However, in combination with HLA-B*5701, the Hsp70-Hom M493T allele was strongly associated with abacavir hypersensitivity (17 of 18 individuals vs. 1 of 230 individuals, OR = 3,893, Pc < 0.00001)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*5701, rs2227956",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "abacavir",
              "drug_id": "PA448004",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "C4A6",
            "Gene": "C4A",
            "Drug(s)": "abacavir",
            "PMID": 15024131,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "C4A6 was present in 77.8% of hypersensitive cases and 3.0% of controls (OR=111, Pc<0.0001). Positive predictive value 72.2%, negative predictive value 98.3%.",
            "Sentence": "C4A6 is associated with increased risk of Side Effect:Hypersensitivity when treated with abacavir in people with Disease:HIV Infection compared to non-carriers.",
            "Alleles": "C4A6",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "C4A6 was present in 14 of 18 (77.8%) cases and 7 of 230 (3.0%) controls (OR = 111, Pc < 0.0001)",
              "We have previously shown that the presence of HLA-B*5701 strongly predicts abacavir hypersensitivity and have identified a potential susceptibility locus within a 300-kb region between the MEGT1 and C4A6 loci in the central MHC."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "C4A6",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "abacavir",
              "drug_id": "PA448004",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "HLA-DRB1*0701",
            "Gene": "HLA-DRB1, HLA-DQB1",
            "Drug(s)": "abacavir",
            "PMID": 15024131,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The haplospecific combination of HLA-DRB1*0701 and HLA-DQ3 was present in 77.8% of hypersensitive cases and 4.8% of controls (OR=70, Pc<0.0001). Positive predictive value 65.0%, negative predictive value 98.3%.",
            "Sentence": "HLA-DRB1*0701 and HLA-DQ3 are associated with increased risk of Side Effect:Hypersensitivity when treated with abacavir in people with Disease:HIV Infection compared to non-carriers.",
            "Alleles": "*0701, DQ3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "the haplospecific combination of HLA-DRB1*0701 and HLA-DQ3 was present in 14 of 18 (77.8%) cases and 11 of 230 (4.8%) controls (OR = 70, Pc < 0.0001)",
              "| HLA-DRB1*0701, HLA-DQ3 | 14 (77.8) | 11 (4.8) | 69.7 | 65.0 | 98.3 |",
              "Forty-eight individuals exposed to abacavir since the introduction of prospective genetic testing for HLA-B*5701 and/or HLA-DRB1*0701, HLA-DQ3 in December 2001 were classified by a clinician blinded to the results of genetic analysis using the updated diagnostic criteria."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-DRB1*0701, HLA-DQ3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "abacavir",
              "drug_id": "PA448004",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "HLA-DQ3",
            "Gene": "HLA-DRB1, HLA-DQB1",
            "Drug(s)": "abacavir",
            "PMID": 15024131,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The haplospecific combination of HLA-DRB1*0701 and HLA-DQ3 was present in 77.8% of hypersensitive cases and 4.8% of controls (OR=70, Pc<0.0001). Positive predictive value 65.0%, negative predictive value 98.3%.",
            "Sentence": "HLA-DRB1*0701 and HLA-DQ3 are associated with increased risk of Side Effect:Hypersensitivity when treated with abacavir in people with Disease:HIV Infection compared to non-carriers.",
            "Alleles": "*0701, DQ3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "the haplospecific combination of HLA-DRB1*0701 and HLA-DQ3 was present in 14 of 18 (77.8%) cases and 11 of 230 (4.8%) controls (OR = 70, Pc < 0.0001)",
              "| HLA-DRB1*0701, HLA-DQ3 | 14 (77.8) | 11 (4.8) | 69.7 | 65.0 | 98.3 |",
              "Forty-eight individuals exposed to abacavir since the introduction of prospective genetic testing for HLA-B*5701 and/or HLA-DRB1*0701, HLA-DQ3 in December 2001 were classified by a clinician blinded to the results of genetic analysis using the updated diagnostic criteria."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-DRB1*0701, HLA-DQ3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "abacavir",
              "drug_id": "PA448004",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "HLA-B*5701",
            "Gene": "HLA-B, C4A, HLA-DRB1, HLA-DQB1",
            "Drug(s)": "abacavir",
            "PMID": 15024131,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The 57.1 ancestral haplotype (HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3) was present in 77.8% of hypersensitive cases and 0% of controls (OR=1,485, Pc<0.0001). Positive predictive value 100%, negative predictive value 98.4%.",
            "Sentence": "HLA-B*5701, C4A6, HLA-DRB1*0701, and HLA-DQ3 are associated with increased risk of Side Effect:Hypersensitivity when treated with abacavir in people with Disease:HIV Infection compared to non-carriers.",
            "Alleles": "*5701, C4A6, *0701, DQ3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "When these markers were combined, the previously described *HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3* haplotype (1) was present in 14 of 18 (77.8%) cases and in none of the 230 controls (OR = 1,485, *P*_c_ < 0.0001).",
              "Testing also was performed on abacavir-tolerant individuals carrying markers of the 57.1 AH (*n* = 12, with 4 consenting to patch testing), including two who carried the *HLA-B*5701* allele, and on two individuals carrying the full 57.1 AH (*HLA-B*5701, C4A6*, and *HLA-DRB1*0701, HLA-DQ3*) who had not been exposed to abacavir."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "abacavir",
              "drug_id": "PA448004",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "C4A6",
            "Gene": "HLA-B, C4A, HLA-DRB1, HLA-DQB1",
            "Drug(s)": "abacavir",
            "PMID": 15024131,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The 57.1 ancestral haplotype (HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3) was present in 77.8% of hypersensitive cases and 0% of controls (OR=1,485, Pc<0.0001). Positive predictive value 100%, negative predictive value 98.4%.",
            "Sentence": "HLA-B*5701, C4A6, HLA-DRB1*0701, and HLA-DQ3 are associated with increased risk of Side Effect:Hypersensitivity when treated with abacavir in people with Disease:HIV Infection compared to non-carriers.",
            "Alleles": "*5701, C4A6, *0701, DQ3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "When these markers were combined, the previously described *HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3* haplotype (1) was present in 14 of 18 (77.8%) cases and in none of the 230 controls (OR = 1,485, *P*_c_ < 0.0001).",
              "Testing also was performed on abacavir-tolerant individuals carrying markers of the 57.1 AH (*n* = 12, with 4 consenting to patch testing), including two who carried the *HLA-B*5701* allele, and on two individuals carrying the full 57.1 AH (*HLA-B*5701, C4A6*, and *HLA-DRB1*0701, HLA-DQ3*) who had not been exposed to abacavir."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "abacavir",
              "drug_id": "PA448004",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "HLA-DRB1*0701",
            "Gene": "HLA-B, C4A, HLA-DRB1, HLA-DQB1",
            "Drug(s)": "abacavir",
            "PMID": 15024131,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The 57.1 ancestral haplotype (HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3) was present in 77.8% of hypersensitive cases and 0% of controls (OR=1,485, Pc<0.0001). Positive predictive value 100%, negative predictive value 98.4%.",
            "Sentence": "HLA-B*5701, C4A6, HLA-DRB1*0701, and HLA-DQ3 are associated with increased risk of Side Effect:Hypersensitivity when treated with abacavir in people with Disease:HIV Infection compared to non-carriers.",
            "Alleles": "*5701, C4A6, *0701, DQ3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "When these markers were combined, the previously described *HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3* haplotype (1) was present in 14 of 18 (77.8%) cases and in none of the 230 controls (OR = 1,485, *P*_c_ < 0.0001).",
              "Testing also was performed on abacavir-tolerant individuals carrying markers of the 57.1 AH (*n* = 12, with 4 consenting to patch testing), including two who carried the *HLA-B*5701* allele, and on two individuals carrying the full 57.1 AH (*HLA-B*5701, C4A6*, and *HLA-DRB1*0701, HLA-DQ3*) who had not been exposed to abacavir."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "abacavir",
              "drug_id": "PA448004",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "HLA-DQ3",
            "Gene": "HLA-B, C4A, HLA-DRB1, HLA-DQB1",
            "Drug(s)": "abacavir",
            "PMID": 15024131,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The 57.1 ancestral haplotype (HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3) was present in 77.8% of hypersensitive cases and 0% of controls (OR=1,485, Pc<0.0001). Positive predictive value 100%, negative predictive value 98.4%.",
            "Sentence": "HLA-B*5701, C4A6, HLA-DRB1*0701, and HLA-DQ3 are associated with increased risk of Side Effect:Hypersensitivity when treated with abacavir in people with Disease:HIV Infection compared to non-carriers.",
            "Alleles": "*5701, C4A6, *0701, DQ3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "When these markers were combined, the previously described *HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3* haplotype (1) was present in 14 of 18 (77.8%) cases and in none of the 230 controls (OR = 1,485, *P*_c_ < 0.0001).",
              "Testing also was performed on abacavir-tolerant individuals carrying markers of the 57.1 AH (*n* = 12, with 4 consenting to patch testing), including two who carried the *HLA-B*5701* allele, and on two individuals carrying the full 57.1 AH (*HLA-B*5701, C4A6*, and *HLA-DRB1*0701, HLA-DQ3*) who had not been exposed to abacavir."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "abacavir",
              "drug_id": "PA448004",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "HLA-B*5701",
            "Gene": "HLA-B, C4A",
            "Drug(s)": "abacavir",
            "PMID": 15024131,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The combination of HLA-B*5701 and C4A6 was present in 77.8% of hypersensitive cases and 0% of controls (OR=1,485, Pc<0.00001). Positive predictive value 100%, negative predictive value 98.4%.",
            "Sentence": "HLA-B*5701 and C4A6 are associated with increased risk of Side Effect:Hypersensitivity when treated with abacavir in people with Disease:HIV Infection compared to non-carriers.",
            "Alleles": "*5701, C4A6",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "When these markers were combined, the previously described *HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3* haplotype (1) was present in 14 of 18 (77.8%) cases and in none of the 230 controls (OR = 1,485, *P*_c_ < 0.0001).",
              "*C4A6* was present in 14 of 18 (77.8%) cases and 7 of 230 (3.0%) controls (OR = 111, *P*_c_ < 0.0001)",
              "Positive and negative predictive values were calculated within the retrospective abacavir-exposed cohort (n = 200), to exclude potential confounding caused by the active exclusion of abacavir use among those carrying 57.1 AH markers in the prospective cohort."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*5701, C4A6",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "abacavir",
              "drug_id": "PA448004",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "C4A6",
            "Gene": "HLA-B, C4A",
            "Drug(s)": "abacavir",
            "PMID": 15024131,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The combination of HLA-B*5701 and C4A6 was present in 77.8% of hypersensitive cases and 0% of controls (OR=1,485, Pc<0.00001). Positive predictive value 100%, negative predictive value 98.4%.",
            "Sentence": "HLA-B*5701 and C4A6 are associated with increased risk of Side Effect:Hypersensitivity when treated with abacavir in people with Disease:HIV Infection compared to non-carriers.",
            "Alleles": "*5701, C4A6",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "When these markers were combined, the previously described *HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3* haplotype (1) was present in 14 of 18 (77.8%) cases and in none of the 230 controls (OR = 1,485, *P*_c_ < 0.0001).",
              "*C4A6* was present in 14 of 18 (77.8%) cases and 7 of 230 (3.0%) controls (OR = 111, *P*_c_ < 0.0001)",
              "Positive and negative predictive values were calculated within the retrospective abacavir-exposed cohort (n = 200), to exclude potential confounding caused by the active exclusion of abacavir use among those carrying 57.1 AH markers in the prospective cohort."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*5701, C4A6",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "abacavir",
              "drug_id": "PA448004",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "HLA-B*5701",
            "Gene": "HLA-B, HLA-DRB1, HLA-DQB1",
            "Drug(s)": "abacavir",
            "PMID": 15024131,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The combination of HLA-B*5701 and HLA-DRB1*0701, HLA-DQ3 was present in 77.8% of hypersensitive cases and 0% of controls (OR=1,485, Pc<0.00001). Positive predictive value 100%, negative predictive value 98.4%.",
            "Sentence": "HLA-B*5701, HLA-DRB1*0701, and HLA-DQ3 are associated with increased risk of Side Effect:Hypersensitivity when treated with abacavir in people with Disease:HIV Infection compared to non-carriers.",
            "Alleles": "*5701, *0701, DQ3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "the haplospecific combination of *HLA-DRB1*0701* and *HLA-DQ3* was present in 14 of 18 (77.8%) cases and 11 of 230 (4.8%) controls (OR = 70, *P*_c_ < 0.0001). Hence, *HLA-B*5701* provided the strongest univariate association with susceptibility to abacavir hypersensitivity. When these markers were combined, the previously described *HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3* haplotype ([1](#ref1)) was present in 14 of 18 (77.8%) cases and in none of the 230 controls (OR = 1,485, *P*_c_ < 0.0001).",
              "| HLA-B*5701, HLA-DRB1*0701, HLA-DQ3 | 14 (77.8) | 0 | 1,485.0 | 100.0 | 98.4 |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*5701, HLA-DRB1*0701, HLA-DQ3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "abacavir",
              "drug_id": "PA448004",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "HLA-DRB1*0701",
            "Gene": "HLA-B, HLA-DRB1, HLA-DQB1",
            "Drug(s)": "abacavir",
            "PMID": 15024131,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The combination of HLA-B*5701 and HLA-DRB1*0701, HLA-DQ3 was present in 77.8% of hypersensitive cases and 0% of controls (OR=1,485, Pc<0.00001). Positive predictive value 100%, negative predictive value 98.4%.",
            "Sentence": "HLA-B*5701, HLA-DRB1*0701, and HLA-DQ3 are associated with increased risk of Side Effect:Hypersensitivity when treated with abacavir in people with Disease:HIV Infection compared to non-carriers.",
            "Alleles": "*5701, *0701, DQ3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "the haplospecific combination of *HLA-DRB1*0701* and *HLA-DQ3* was present in 14 of 18 (77.8%) cases and 11 of 230 (4.8%) controls (OR = 70, *P*_c_ < 0.0001). Hence, *HLA-B*5701* provided the strongest univariate association with susceptibility to abacavir hypersensitivity. When these markers were combined, the previously described *HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3* haplotype ([1](#ref1)) was present in 14 of 18 (77.8%) cases and in none of the 230 controls (OR = 1,485, *P*_c_ < 0.0001).",
              "| HLA-B*5701, HLA-DRB1*0701, HLA-DQ3 | 14 (77.8) | 0 | 1,485.0 | 100.0 | 98.4 |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*5701, HLA-DRB1*0701, HLA-DQ3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "abacavir",
              "drug_id": "PA448004",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "HLA-DQ3",
            "Gene": "HLA-B, HLA-DRB1, HLA-DQB1",
            "Drug(s)": "abacavir",
            "PMID": 15024131,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "The combination of HLA-B*5701 and HLA-DRB1*0701, HLA-DQ3 was present in 77.8% of hypersensitive cases and 0% of controls (OR=1,485, Pc<0.00001). Positive predictive value 100%, negative predictive value 98.4%.",
            "Sentence": "HLA-B*5701, HLA-DRB1*0701, and HLA-DQ3 are associated with increased risk of Side Effect:Hypersensitivity when treated with abacavir in people with Disease:HIV Infection compared to non-carriers.",
            "Alleles": "*5701, *0701, DQ3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "the haplospecific combination of *HLA-DRB1*0701* and *HLA-DQ3* was present in 14 of 18 (77.8%) cases and 11 of 230 (4.8%) controls (OR = 70, *P*_c_ < 0.0001). Hence, *HLA-B*5701* provided the strongest univariate association with susceptibility to abacavir hypersensitivity. When these markers were combined, the previously described *HLA-B*5701, C4A6, HLA-DRB1*0701, HLA-DQ3* haplotype ([1](#ref1)) was present in 14 of 18 (77.8%) cases and in none of the 230 controls (OR = 1,485, *P*_c_ < 0.0001).",
              "| HLA-B*5701, HLA-DRB1*0701, HLA-DQ3 | 14 (77.8) | 0 | 1,485.0 | 100.0 | 98.4 |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*5701, HLA-DRB1*0701, HLA-DQ3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "abacavir",
              "drug_id": "PA448004",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.841993309656779,
        "field_scores": {
          "Study Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Study Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.9356510043144226,
            "scores": [
              0.9367996454238892,
              0.934502363204956
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 0.897124320268631,
            "scores": [
              0.9137796759605408,
              0.8804689645767212
            ]
          },
          "Frequency In Controls": {
            "mean_score": 0.9,
            "scores": [
              1.0,
              0.8
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 0.897124320268631,
            "scores": [
              0.9137796759605408,
              0.8804689645767212
            ]
          },
          "P Value": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 2,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9367996454238892,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.9137796759605408,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 0.9137796759605408,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1444877014,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1444876870,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 18.0,
                "prediction": 18
              },
              "Study Controls": {
                "ground_truth": 230.0,
                "prediction": 230
              },
              "Characteristics": {
                "ground_truth": "Western Australian HIV Cohort Study; HLA-B*57:01 alone.",
                "prediction": "Western Australian HIV Cohort Study, abacavir-exposed individuals, abacavir hypersensitivity"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.944,
                "prediction": 0.944
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*57:01",
                "prediction": "HLA-B*5701"
              },
              "Frequency In Controls": {
                "ground_truth": 0.017,
                "prediction": 0.017
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*57:01",
                "prediction": "HLA-B*5701"
              },
              "P Value": {
                "ground_truth": "< 0.00001",
                "prediction": "< 0.00001"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 960.0,
                "prediction": 960.0
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, European, Asian Indian, African, indigenous Australian, Asian",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.934502363204956,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.8804689645767212,
              "Frequency In Controls": 0.8,
              "Allele Of Frequency In Controls": 0.8804689645767212,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1444877110,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1444876870,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 18.0,
                "prediction": 18
              },
              "Study Controls": {
                "ground_truth": 230.0,
                "prediction": 230
              },
              "Characteristics": {
                "ground_truth": "Western Australian HIV Cohort Study; HLA-B*57:01 in combination with rs2227956.",
                "prediction": "Western Australian HIV Cohort Study, abacavir-exposed individuals, abacavir hypersensitivity"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.944,
                "prediction": 0.944
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*57:01",
                "prediction": "HLA-B*5701, Hsp70-Hom M493T"
              },
              "Frequency In Controls": {
                "ground_truth": 0.004,
                "prediction": 0.0043
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*57:01",
                "prediction": "HLA-B*5701, Hsp70-Hom M493T"
              },
              "P Value": {
                "ground_truth": "< 0.00001",
                "prediction": "< 0.00001"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 3893.0,
                "prediction": 3893.0
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, European, Asian Indian, African, indigenous Australian, Asian",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "case/control:Western Australian H",
          "case/control:Western Australian H"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 18,
            "Study Controls": 230,
            "Characteristics": "Western Australian HIV Cohort Study, abacavir-exposed individuals, abacavir hypersensitivity",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.778,
            "Allele Of Frequency In Cases": "C4A6",
            "Frequency In Controls": 0.03,
            "Allele Of Frequency In Controls": "C4A6",
            "P Value": "< 0.00001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 111.5,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 18,
            "Study Controls": 230,
            "Characteristics": "Western Australian HIV Cohort Study, abacavir-exposed individuals, abacavir hypersensitivity",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.778,
            "Allele Of Frequency In Cases": "HLA-DRB1*0701, HLA-DQ3",
            "Frequency In Controls": 0.048,
            "Allele Of Frequency In Controls": "HLA-DRB1*0701, HLA-DQ3",
            "P Value": "< 0.00001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 69.7,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 18,
            "Study Controls": 230,
            "Characteristics": "Western Australian HIV Cohort Study, abacavir-exposed individuals, abacavir hypersensitivity",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.944,
            "Allele Of Frequency In Cases": "Hsp70-Hom M493T",
            "Frequency In Controls": 0.222,
            "Allele Of Frequency In Controls": "Hsp70-Hom M493T",
            "P Value": "< 0.00001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 59.7,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 18,
            "Study Controls": 230,
            "Characteristics": "Western Australian HIV Cohort Study, abacavir-exposed individuals, abacavir hypersensitivity",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.778,
            "Allele Of Frequency In Cases": "HLA-B*5701, C4A6",
            "Frequency In Controls": 0.0,
            "Allele Of Frequency In Controls": "HLA-B*5701, C4A6",
            "P Value": "< 0.00001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1485.0,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 18,
            "Study Controls": 230,
            "Characteristics": "Western Australian HIV Cohort Study, abacavir-exposed individuals, abacavir hypersensitivity",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.778,
            "Allele Of Frequency In Cases": "HLA-B*5701, HLA-DRB1*0701, HLA-DQ3",
            "Frequency In Controls": 0.0,
            "Allele Of Frequency In Controls": "HLA-B*5701, HLA-DRB1*0701, HLA-DQ3",
            "P Value": "< 0.00001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1485.0,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC2859392": {
      "var-drug": {
        "overall_score": 0.0,
        "field_scores": {},
        "total_samples": 0,
        "detailed_results": [],
        "aligned_variants": [],
        "unmatched_ground_truth": [
          {
            "Variant Annotation ID": 1448993666,
            "Variant/Haplotypes": "rs3745274",
            "Gene": "CYP2B6",
            "Drug(s)": "efavirenz",
            "PMID": 20338069,
            "Phenotype Category": "Efficacy",
            "Significance": "no",
            "Notes": "No significant difference in median CD4 T cell counts of each genotype at different time points was seen in efavirenz group (p = 0.818, 0.838, 0.783, 0.753 and 0.587 for baseline, weeks 12, 24, 36 and 48 of ART, respectively).",
            "Sentence": "Genotype TT is not associated with response to efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.",
            "Alleles": "TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "response to",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease, Disease:Tuberculosis",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "GG + GT",
            "Comparison Metabolizer types": null,
            "PMID_norm": "20338069",
            "Variant Annotation ID_norm": "1448993666",
            "Variant/Haplotypes_normalized": {
              "normalized": "rs3745274",
              "variant_id": "PA166155409",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "efavirenz",
              "drug_id": "PA449441",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 1184988061,
            "Variant/Haplotypes": "rs3745274",
            "Gene": "CYP2B6",
            "Drug(s)": "efavirenz",
            "PMID": 20338069,
            "Phenotype Category": "Metabolism/PK",
            "Significance": "yes",
            "Notes": "Association with significantly increased efavirenz plasma levels. Was significant at week 6, 12 of treatment and 1 month after rifampicin discontinuation.",
            "Sentence": "Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.",
            "Alleles": "TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "metabolism of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease, Disease:Tuberculosis",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "GG + GT",
            "Comparison Metabolizer types": null,
            "PMID_norm": "20338069",
            "Variant Annotation ID_norm": "1184988061",
            "Variant/Haplotypes_normalized": {
              "normalized": "rs3745274",
              "variant_id": "PA166155409",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "efavirenz",
              "drug_id": "PA449441",
              "confidence": 1.0
            }
          }
        ],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "G516T",
            "Gene": "CYP2B6",
            "Drug(s)": "efavirenz",
            "PMID": 20338069,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Mean 12-hour post-dose plasma efavirenz concentration in patients with TT genotype at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation (10.97 \u00b1 2.32, 13.62 \u00b1 4.21 and 8.48 \u00b1 1.30 mg/L, respectively) were significantly higher than those with GT (3.43 \u00b1 0.29, 3.35 \u00b1 0.27 and 3.21 \u00b1 0.22 mg/L, respectively) (p < 0.0001) or GG genotypes (2.88 \u00b1 0.33, 2.45 \u00b1 0.26 and 2.08 \u00b1 0.16 mg/L, respectively) (p < 0.0001).",
            "Sentence": "Genotype TT is associated with increased 12-hour post-dose plasma concentrations of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.",
            "Alleles": "TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "12-hour post-dose plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "GG + GT",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The mean 12-hour post-dose plasma efavirenz concentration in patients with TT genotype at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation (10.97 \u00b1 2.32, 13.62 \u00b1 4.21 and 8.48 \u00b1 1.30 mg/L, respectively) were significantly higher than those with GT (3.43 \u00b1 0.29, 3.35 \u00b1 0.27 and 3.21 \u00b1 0.22 mg/L, respectively) (p < 0.0001) or GG genotypes (2.88 \u00b1 0.33, 2.45 \u00b1 0.26 and 2.08 \u00b1 0.16 mg/L, respectively) (p < 0.0001).",
              "The mean plasma efavirenz concentration in patients with homozygous TT genotype at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation (10.97 \u00b1 2.32, 13.62 \u00b1 4.21 mg/L and 8.48 \u00b1 1.30 mg/L, respectively) were significantly higher than those with GT genotype (3.43 \u00b1 0.29, 3.35 \u00b1 0.27 mg/L and 3.21 \u00b1 0.22 mg/L, respectively) or GG genotype (2.88 \u00b1 0.33, 2.45 \u00b1 0.26 and 2.08 \u00b1 0.16 mg/L, respectively) (p < 0.0001)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "G516T",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "efavirenz",
              "drug_id": "PA449441",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "G516T",
            "Gene": "CYP2B6",
            "Drug(s)": "nevirapine",
            "PMID": 20338069,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Mean 12-hour post-dose plasma nevirapine concentration in patients carrying TT genotype at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation (14.09 \u00b1 9.49, 7.94 \u00b1 2.76 and 9.44 \u00b1 0.17 mg/L, respectively) tended to be higher than those carrying GT (5.65 \u00b1 0.54, 5.58 \u00b1 0.48 and 7.03 \u00b1 0.64 mg/L, respectively) or GG genotypes (5.42 \u00b1 0.48, 5.34 \u00b1 0.50 and 6.43 \u00b1 0.64 mg/L, respectively) (p = 0.003 at week 6, p = 0.409 at week 12, p = 0.448 after rifampicin discontinuation).",
            "Sentence": "Genotype TT is associated with increased 12-hour post-dose plasma concentrations of nevirapine in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.",
            "Alleles": "TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "12-hour post-dose plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "GG + GT",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Likewise, the mean 12-hour post-dose plasma nevirapine concentration in patients carrying TT genotype at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation (14.09 \u00b1 9.49, 7.94 \u00b1 2.76 and 9.44 \u00b1 0.17 mg/L, respectively) tended to be higher than those carrying GT (5.65 \u00b1 0.54, 5.58 \u00b1 0.48 and 7.03 \u00b1 0.64 mg/L, respectively) or GG genotypes (5.42 \u00b1 0.48, 5.34 \u00b1 0.50 and 6.43 \u00b1 0.64 mg/L, respectively) (p = 0.003, p = 0.409 and p = 0.448, respectively).",
              "Similar results were found in nevirapine group (Figure 1d, e, f) in that the mean plasma drug concentration of patients with TT genotype at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation (14.09 \u00b1 9.49, 7.94 \u00b1 2.76 and 9.44 \u00b1 0.17 mg/L, respectively) tended to be higher than those with GT genotype (5.65 \u00b1 0.54, 5.58 \u00b1 0.48 and 7.03 \u00b1 0.64 mg/L, respectively) or GG genotype (5.42 \u00b1 0.48, 5.34 \u00b1 0.50 and 6.43 \u00b1 0.64 mg/L, respectively) (p = 0.003, p = 0.409 and p = 0.448, respectively)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "G516T",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "G516T",
            "Gene": "CYP2B6",
            "Drug(s)": "efavirenz",
            "PMID": 20338069,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "88.89% (8/9) of patients with TT genotype in efavirenz group could achieve the HIV-1 RNA levels <50 copies/mL, which were higher than those with GT genotype (77.42%, 24/31) and GG genotype (68%, 17/25), although this difference was not statistically significant (p = 0.430).",
            "Sentence": "Genotype TT is not associated with response to efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.",
            "Alleles": "TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "response to",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "GG + GT",
            "Comparison Metabolizer types": null,
            "Citations": [
              "As shown in Table 2, when the proportion of patients with HIV-1 RNA level <50 copies/mL (log 1.69) were compared among CYP2B6-G516T genotypes at week 12 of ART, 88.89% (8/9) of patients with TT genotype in efavirenz group could achieve the HIV-1 RNA levels <50 copies/mL, which were higher than those with GT genotype (77.42%, 24/31) and GG genotype (68%, 17/25), although this difference was not statistically significant (p = 0.430).",
              "After 12 weeks of both drug regimens, there was a trend towards higher percentage of patients with CYP2B6-TT genotype who achieved HIV-1 RNA levels <50 copies/mL compared to those with GT or GG genotypes."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "G516T",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "efavirenz",
              "drug_id": "PA449441",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "G516T",
            "Gene": "CYP2B6",
            "Drug(s)": "nevirapine",
            "PMID": 20338069,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "100% (2/2) of those with TT genotype, 70.97% (23/31) of those with GT genotype and 60% (15/26) of those with GG genotype could achieve the HIV-1 RNA levels <50 copies/mL, but this difference did not reach statistical significance (p = 0.288) due to small numbers of patients with homozygous TT genotype.",
            "Sentence": "Genotype TT is not associated with response to nevirapine in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.",
            "Alleles": "TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "response to",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "GG + GT",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Similarly, in nevirapine group, 100% (2/2) of those with TT genotype, 70.97% (23/31) of those with GT genotype and 60% (15/26) of those with GG genotype could achieve the HIV-1 RNA levels <50 copies/mL, but this difference also did not reach statistical significance (p = 0.288) due to small numbers of patients with homozygous TT genotype in this study."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "G516T",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "T878C",
            "Gene": "CYP3A4",
            "Drug(s)": "efavirenz",
            "PMID": 20338069,
            "Phenotype Category": "metabolism/PK",
            "Significance": "not stated",
            "Notes": "Mean plasma efavirenz concentration at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 4.00 \u00b1 0.42, 4.20 \u00b1 0.72 and 3.48 \u00b1 0.34 mg/L, respectively, in patients with homozygous TT genotype and 9.62 \u00b1 6.35, 8.97 \u00b1 6.33 and 3.87 \u00b1 1.69 mg/L, respectively, in those with heterozygous TC genotype. Statistical evaluation was not done due to small numbers of heterozygous mutant TC.",
            "Sentence": "Genotype TC is associated with increased plasma concentrations of efavirenz in people with HIV Infections and Tuberculosis as compared to genotype TT.",
            "Alleles": "TC",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "TT",
            "Comparison Metabolizer types": null,
            "Citations": [
              "the mean plasma efavirenz concentration at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 4.00 \u00b1 0.42, 4.20 \u00b1 0.72 and 3.48 \u00b1 0.34 mg/L, respectively, in patients with homozygous TT genotype and 9.62 \u00b1 6.35, 8.97 \u00b1 6.33 and 3.87 \u00b1 1.69 mg/L, respectively, in those with heterozygous TC genotype.",
              "Although there was a trend towards higher plasma drug levels in patients with heterozygous mutant TC genotype, appropriate statistical evaluation of this difference was difficult due to small numbers of heterozygous mutant TC."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "T878C",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "efavirenz",
              "drug_id": "PA449441",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "T878C",
            "Gene": "CYP3A4",
            "Drug(s)": "nevirapine",
            "PMID": 20338069,
            "Phenotype Category": "metabolism/PK",
            "Significance": "not stated",
            "Notes": "Mean plasma nevirapine concentration at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 5.85 \u00b1 0.48, 5.50 \u00b1 0.34 and 6.80 \u00b1 0.45 mg/L, respectively, in patients with homozygous TT genotype, and 4.8, 8.69 and 9.12 mg/L, respectively, in one patient with heterozygous mutant TC genotype. Statistical evaluation was not done due to small numbers.",
            "Sentence": "Genotype TC is associated with increased plasma concentrations of nevirapine in people with HIV Infections and Tuberculosis as compared to genotype TT.",
            "Alleles": "TC",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "TT",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Similarly, the mean plasma nevirapine concentration at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 5.85 \u00b1 0.48, 5.50 \u00b1 0.34 and 6.80 \u00b1 0.45 mg/L, respectively, in patients with homozygous TT genotype, and 4.8, 8.69 and 9.12 mg/L, respectively, in one patient with heterozygous mutant TC genotype. Although there was a trend towards higher plasma drug levels in patients with heterozygous mutant TC genotype, appropriate statistical evaluation of this difference was difficult due to small numbers of heterozygous mutant TC.",
              "For CYP3A4-T878C, there were 95.4% (62/65) of homozygous TT and 4.6% (3/65) of heterozygous TC, and 98.3% (58/59) of homozygous TT and 1.69% (1/59) of heterozygous TC in efavirenz and nevirapine groups, respectively."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "T878C",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.6913467645645142,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.9524044394493103,
            "scores": [
              0.9524520039558411,
              0.9523568749427795
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 0.9177970290184021,
            "scores": [
              0.9177970290184021,
              0.9177970290184021
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              0.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 2,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9524520039558411,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.9177970290184021,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184988079,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1184988061,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort",
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 65.0,
                "prediction": 65
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "HIV-1/TB co-infected receiving efavirenz-based ART and an anti-TB drug regimen.",
                "prediction": "HIV/TB co-infected Thai adults receiving efavirenz 600 mg/day with rifampicin, CYP2B6-G516T TT vs GT genotype, plasma efavirenz concentration at week 12 of ART"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.62,
                "prediction": 0.1385
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "G",
                "prediction": "TT"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "< 0.0001",
                "prediction": "< 0.0001"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9523568749427795,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.9177970290184021,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1448993668,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993666,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort",
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 65.0,
                "prediction": 65
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "HIV-1/TB co-infected receiving efavirenz-based ART and an anti-TB drug regimen.",
                "prediction": "HIV/TB co-infected Thai adults receiving efavirenz 600 mg/day with rifampicin, CYP2B6-G516T TT vs GT genotype, plasma efavirenz concentration at week 6 of ART"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.62,
                "prediction": 0.1385
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "G",
                "prediction": "TT"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "> 0.05",
                "prediction": "< 0.0001"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "cohort:HIV-1/TB co-infected",
          "cohort:HIV-1/TB co-infected"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 65,
            "Study Controls": null,
            "Characteristics": "HIV/TB co-infected Thai adults receiving efavirenz 600 mg/day with rifampicin, CYP2B6-G516T TT vs GG genotype, plasma efavirenz concentration at week 6 of ART",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.1385,
            "Allele Of Frequency In Cases": "TT",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 65,
            "Study Controls": null,
            "Characteristics": "HIV/TB co-infected Thai adults receiving efavirenz 600 mg/day with rifampicin, CYP2B6-G516T TT vs GG genotype, plasma efavirenz concentration at week 12 of ART",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.1385,
            "Allele Of Frequency In Cases": "TT",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 65,
            "Study Controls": null,
            "Characteristics": "HIV/TB co-infected Thai adults receiving efavirenz 600 mg/day with rifampicin, CYP2B6-G516T TT vs GT genotype, plasma efavirenz concentration 1 month after rifampicin discontinuation",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.1385,
            "Allele Of Frequency In Cases": "TT",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 65,
            "Study Controls": null,
            "Characteristics": "HIV/TB co-infected Thai adults receiving efavirenz 600 mg/day with rifampicin, CYP2B6-G516T TT vs GG genotype, plasma efavirenz concentration 1 month after rifampicin discontinuation",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.1385,
            "Allele Of Frequency In Cases": "TT",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 59,
            "Study Controls": null,
            "Characteristics": "HIV/TB co-infected Thai adults receiving nevirapine 400 mg/day with rifampicin, CYP2B6-G516T genotypes comparison, plasma nevirapine concentration at week 6 of ART",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.0339,
            "Allele Of Frequency In Cases": "TT",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.003",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 59,
            "Study Controls": null,
            "Characteristics": "HIV/TB co-infected Thai adults receiving nevirapine 400 mg/day with rifampicin, CYP2B6-G516T genotypes comparison, plasma nevirapine concentration at week 12 of ART",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.0339,
            "Allele Of Frequency In Cases": "TT",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.409",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 59,
            "Study Controls": null,
            "Characteristics": "HIV/TB co-infected Thai adults receiving nevirapine 400 mg/day with rifampicin, CYP2B6-G516T genotypes comparison, plasma nevirapine concentration 1 month after rifampicin discontinuation",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.0339,
            "Allele Of Frequency In Cases": "TT",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.448",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 59,
            "Study Controls": null,
            "Characteristics": "HIV/TB co-infected Thai adults receiving nevirapine 400 mg/day with rifampicin, CYP2B6-G516T genotypes comparison, baseline log plasma HIV-1 viral load",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.041",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 65,
            "Study Controls": null,
            "Characteristics": "HIV/TB co-infected Thai adults receiving efavirenz 600 mg/day with rifampicin, CYP2B6-G516T genotypes comparison, proportion achieving HIV-1 RNA <50 copies/mL at week 12 of ART",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.430",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 59,
            "Study Controls": null,
            "Characteristics": "HIV/TB co-infected Thai adults receiving nevirapine 400 mg/day with rifampicin, CYP2B6-G516T genotypes comparison, proportion achieving HIV-1 RNA <50 copies/mL at week 12 of ART",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.288",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC3584248": {
      "var-drug": {
        "overall_score": 0.6755777801337995,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "PMID": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Significance": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Alleles": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Specialty Population": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Metabolizer types": {
            "mean_score": 0.5,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "isPlural": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "PD/PK terms": {
            "mean_score": 0.896434098482132,
            "scores": [
              0.9585481286048889,
              0.9585481286048889,
              0.9585481286048889,
              0.9585481286048889,
              0.9585481286048889,
              0.834320068359375,
              0.834320068359375,
              0.834320068359375,
              0.834320068359375,
              0.834320068359375
            ]
          },
          "Multiple drugs And/or": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Population types": {
            "mean_score": 0.9395437240600586,
            "scores": [
              0.9395437240600586,
              0.9395437240600586,
              0.9395437240600586,
              0.9395437240600586,
              0.9395437240600586,
              0.9395437240600586,
              0.9395437240600586,
              0.9395437240600586,
              0.9395437240600586,
              0.9395437240600586
            ]
          },
          "Population Phenotypes or diseases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Multiple phenotypes or diseases And/or": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Comparison Metabolizer types": {
            "mean_score": 0.5,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 10,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.0,
              "Specialty Population": 1.0,
              "Metabolizer types": 0.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.9585481286048889,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.9395437240600586,
              "Population Phenotypes or diseases": 1.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0,
              "Comparison Metabolizer types": 0.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*1",
                "prediction": "CYP2D6*1"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "PMID": {
                "ground_truth": 23476897,
                "prediction": 23476897
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
                "prediction": null
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": "slow metabolizer"
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "PD/PK terms": {
                "ground_truth": "concentrations of",
                "prediction": "plasma concentrations of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in women with",
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Disease:Breast Neoplasms",
                "prediction": "Disease:Breast Neoplasms"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*2 + *2/*2",
                "prediction": null
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": "normal metabolizer"
              },
              "Drug(s)": {
                "ground_truth": "endoxifen",
                "prediction": "endoxifen"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.0,
              "Specialty Population": 1.0,
              "Metabolizer types": 0.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.9585481286048889,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.9395437240600586,
              "Population Phenotypes or diseases": 1.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0,
              "Comparison Metabolizer types": 0.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*2",
                "prediction": "CYP2D6*2"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "PMID": {
                "ground_truth": 23476897,
                "prediction": 23476897
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
                "prediction": null
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": "slow metabolizer"
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "PD/PK terms": {
                "ground_truth": "concentrations of",
                "prediction": "plasma concentrations of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in women with",
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Disease:Breast Neoplasms",
                "prediction": "Disease:Breast Neoplasms"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*2 + *2/*2",
                "prediction": null
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": "normal metabolizer"
              },
              "Drug(s)": {
                "ground_truth": "endoxifen",
                "prediction": "endoxifen"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.0,
              "Specialty Population": 1.0,
              "Metabolizer types": 0.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.9585481286048889,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.9395437240600586,
              "Population Phenotypes or diseases": 1.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0,
              "Comparison Metabolizer types": 0.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*5",
                "prediction": "CYP2D6*5"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "PMID": {
                "ground_truth": 23476897,
                "prediction": 23476897
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
                "prediction": null
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": "slow metabolizer"
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "PD/PK terms": {
                "ground_truth": "concentrations of",
                "prediction": "plasma concentrations of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in women with",
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Disease:Breast Neoplasms",
                "prediction": "Disease:Breast Neoplasms"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*2 + *2/*2",
                "prediction": null
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": "normal metabolizer"
              },
              "Drug(s)": {
                "ground_truth": "endoxifen",
                "prediction": "endoxifen"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.0,
              "Specialty Population": 1.0,
              "Metabolizer types": 0.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.9585481286048889,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.9395437240600586,
              "Population Phenotypes or diseases": 1.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0,
              "Comparison Metabolizer types": 0.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*10",
                "prediction": "CYP2D6*10"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "PMID": {
                "ground_truth": 23476897,
                "prediction": 23476897
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
                "prediction": null
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": "slow metabolizer"
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "PD/PK terms": {
                "ground_truth": "concentrations of",
                "prediction": "plasma concentrations of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in women with",
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Disease:Breast Neoplasms",
                "prediction": "Disease:Breast Neoplasms"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*2 + *2/*2",
                "prediction": null
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": "normal metabolizer"
              },
              "Drug(s)": {
                "ground_truth": "endoxifen",
                "prediction": "endoxifen"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.0,
              "Specialty Population": 1.0,
              "Metabolizer types": 0.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.9585481286048889,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.9395437240600586,
              "Population Phenotypes or diseases": 1.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0,
              "Comparison Metabolizer types": 0.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*41",
                "prediction": "CYP2D6*41"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "PMID": {
                "ground_truth": 23476897,
                "prediction": 23476897
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
                "prediction": null
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": "slow metabolizer"
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "PD/PK terms": {
                "ground_truth": "concentrations of",
                "prediction": "plasma concentrations of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in women with",
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Disease:Breast Neoplasms",
                "prediction": "Disease:Breast Neoplasms"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*2 + *2/*2",
                "prediction": null
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": "normal metabolizer"
              },
              "Drug(s)": {
                "ground_truth": "endoxifen",
                "prediction": "endoxifen"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 0.0,
              "Significance": 0.0,
              "Alleles": 0.0,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 0.0,
              "Direction of effect": 0.0,
              "PD/PK terms": 0.834320068359375,
              "Multiple drugs And/or": 0.0,
              "Population types": 0.9395437240600586,
              "Population Phenotypes or diseases": 1.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*1",
                "prediction": "CYP2D6*1"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "PMID": {
                "ground_truth": 23476897,
                "prediction": 23476897
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "efficacy"
              },
              "Significance": {
                "ground_truth": "no",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
                "prediction": null
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "increased"
              },
              "PD/PK terms": {
                "ground_truth": "concentrations of",
                "prediction": "risk of disease recurrence with"
              },
              "Multiple drugs And/or": {
                "ground_truth": "and",
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in women with",
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Disease:Breast Neoplasms",
                "prediction": "Disease:Breast Neoplasms"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*2 + *2/*2",
                "prediction": null
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen",
                "prediction": "endoxifen"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 6,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 0.0,
              "Significance": 0.0,
              "Alleles": 0.0,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 0.0,
              "Direction of effect": 0.0,
              "PD/PK terms": 0.834320068359375,
              "Multiple drugs And/or": 0.0,
              "Population types": 0.9395437240600586,
              "Population Phenotypes or diseases": 1.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*2",
                "prediction": "CYP2D6*2"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "PMID": {
                "ground_truth": 23476897,
                "prediction": 23476897
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "efficacy"
              },
              "Significance": {
                "ground_truth": "no",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
                "prediction": null
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "increased"
              },
              "PD/PK terms": {
                "ground_truth": "concentrations of",
                "prediction": "risk of disease recurrence with"
              },
              "Multiple drugs And/or": {
                "ground_truth": "and",
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in women with",
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Disease:Breast Neoplasms",
                "prediction": "Disease:Breast Neoplasms"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*2 + *2/*2",
                "prediction": null
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen",
                "prediction": "endoxifen"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 7,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 0.0,
              "Significance": 0.0,
              "Alleles": 0.0,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 0.0,
              "Direction of effect": 0.0,
              "PD/PK terms": 0.834320068359375,
              "Multiple drugs And/or": 0.0,
              "Population types": 0.9395437240600586,
              "Population Phenotypes or diseases": 1.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*5",
                "prediction": "CYP2D6*5"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "PMID": {
                "ground_truth": 23476897,
                "prediction": 23476897
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "efficacy"
              },
              "Significance": {
                "ground_truth": "no",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
                "prediction": null
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "increased"
              },
              "PD/PK terms": {
                "ground_truth": "concentrations of",
                "prediction": "risk of disease recurrence with"
              },
              "Multiple drugs And/or": {
                "ground_truth": "and",
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in women with",
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Disease:Breast Neoplasms",
                "prediction": "Disease:Breast Neoplasms"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*2 + *2/*2",
                "prediction": null
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen",
                "prediction": "endoxifen"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 8,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 0.0,
              "Significance": 0.0,
              "Alleles": 0.0,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 0.0,
              "Direction of effect": 0.0,
              "PD/PK terms": 0.834320068359375,
              "Multiple drugs And/or": 0.0,
              "Population types": 0.9395437240600586,
              "Population Phenotypes or diseases": 1.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*10",
                "prediction": "CYP2D6*10"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "PMID": {
                "ground_truth": 23476897,
                "prediction": 23476897
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "efficacy"
              },
              "Significance": {
                "ground_truth": "no",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
                "prediction": null
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "increased"
              },
              "PD/PK terms": {
                "ground_truth": "concentrations of",
                "prediction": "risk of disease recurrence with"
              },
              "Multiple drugs And/or": {
                "ground_truth": "and",
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in women with",
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Disease:Breast Neoplasms",
                "prediction": "Disease:Breast Neoplasms"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*2 + *2/*2",
                "prediction": null
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen",
                "prediction": "endoxifen"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 9,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 0.0,
              "Significance": 0.0,
              "Alleles": 0.0,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 0.0,
              "Direction of effect": 0.0,
              "PD/PK terms": 0.834320068359375,
              "Multiple drugs And/or": 0.0,
              "Population types": 0.9395437240600586,
              "Population Phenotypes or diseases": 1.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*41",
                "prediction": "CYP2D6*41"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "PMID": {
                "ground_truth": 23476897,
                "prediction": 23476897
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "efficacy"
              },
              "Significance": {
                "ground_truth": "no",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
                "prediction": null
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "increased"
              },
              "PD/PK terms": {
                "ground_truth": "concentrations of",
                "prediction": "risk of disease recurrence with"
              },
              "Multiple drugs And/or": {
                "ground_truth": "and",
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in women with",
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Disease:Breast Neoplasms",
                "prediction": "Disease:Breast Neoplasms"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*2 + *2/*2",
                "prediction": null
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen",
                "prediction": "endoxifen"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "cyp2d6*1",
          "cyp2d6*2",
          "cyp2d6*5",
          "cyp2d6*10",
          "cyp2d6*41",
          "cyp2d6*1",
          "cyp2d6*2",
          "cyp2d6*5",
          "cyp2d6*10",
          "cyp2d6*41"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2D6*3",
            "Gene": "CYP2D6",
            "Drug(s)": "endoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "p < 0.0001 for trend (normal > intermediate > slow). CYP2D6 genotype explained 8.6% (r-squared = 0.086) of variance in endoxifen concentrations. Normal metabolizers (N=34): 48.2 \u00b1 39.7 ng/ml, Intermediate (N=107): 39.3 \u00b1 26.6 ng/ml, Slow (N=83): 25.0 \u00b1 22.3 ng/ml.",
            "Sentence": "CYP2D6 slow metabolizer genotypes are associated with decreased plasma concentrations of endoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Endoxifen plasma concentrations by CYP2D6 genotype metabolic status in Filipino (n = 138) and Vietnamese (n = 86) patients (p = 0.0001 for trend: normal > intermediate > slow).",
              "On the basis of the genotype-predicted phenotype, genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6).",
              "The data, presented in Figure 1 and Table 3, show wide inter-individual variability in endoxifen concentrations. There was a significant association of reduced endoxifen plasma concentrations with functionally important CYP2D6 genotypes."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "endoxifen",
              "drug_id": "PA166124478",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2D6*4",
            "Gene": "CYP2D6",
            "Drug(s)": "endoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "p < 0.0001 for trend (normal > intermediate > slow). CYP2D6 genotype explained 8.6% (r-squared = 0.086) of variance in endoxifen concentrations. Normal metabolizers (N=34): 48.2 \u00b1 39.7 ng/ml, Intermediate (N=107): 39.3 \u00b1 26.6 ng/ml, Slow (N=83): 25.0 \u00b1 22.3 ng/ml.",
            "Sentence": "CYP2D6 slow metabolizer genotypes are associated with decreased plasma concentrations of endoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Endoxifen plasma concentrations by CYP2D6 genotype metabolic status in Filipino (n = 138) and Vietnamese (n = 86) patients (p = 0.0001 for trend: normal > intermediate > slow).",
              "On the basis of the genotype-predicted phenotype, genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6).",
              "The data, presented in Figure 1 and Table 3, show wide inter-individual variability in endoxifen concentrations. There was a significant association of reduced endoxifen plasma concentrations with functionally important CYP2D6 genotypes."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "endoxifen",
              "drug_id": "PA166124478",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2D6*6",
            "Gene": "CYP2D6",
            "Drug(s)": "endoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "p < 0.0001 for trend (normal > intermediate > slow). CYP2D6 genotype explained 8.6% (r-squared = 0.086) of variance in endoxifen concentrations. Normal metabolizers (N=34): 48.2 \u00b1 39.7 ng/ml, Intermediate (N=107): 39.3 \u00b1 26.6 ng/ml, Slow (N=83): 25.0 \u00b1 22.3 ng/ml.",
            "Sentence": "CYP2D6 slow metabolizer genotypes are associated with decreased plasma concentrations of endoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Endoxifen plasma concentrations by CYP2D6 genotype metabolic status in Filipino (n = 138) and Vietnamese (n = 86) patients (p = 0.0001 for trend: normal > intermediate > slow).",
              "On the basis of the genotype-predicted phenotype, genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6).",
              "The data, presented in Figure 1 and Table 3, show wide inter-individual variability in endoxifen concentrations. There was a significant association of reduced endoxifen plasma concentrations with functionally important CYP2D6 genotypes."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "endoxifen",
              "drug_id": "PA166124478",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2D6*3",
            "Gene": "CYP2D6",
            "Drug(s)": "endoxifen",
            "PMID": 23476897,
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "High endoxifen concentrations (>70 ng/ml) were associated with higher risk of recurrence. Quadratic trend fitted to Cox proportional hazards regression model, likelihood ratio p-value = 0.002. 25% of recurrences had endoxifen concentrations above 70 ng/ml. J-shaped relationship suggested between endoxifen concentrations and recurrence risk.",
            "Sentence": "High endoxifen plasma concentrations are associated with increased risk of disease recurrence in people with Disease:Breast Neoplasms as compared to intermediate endoxifen concentrations.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "risk of disease recurrence with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "High endoxifen concentrations were associated with higher risk of recurrence; with a quadratic trend fitted to a stratified Cox proportional hazards regression model, the likelihood ratio p-value was 0.002.",
              "We expected that low endoxifen concentrations (below therapeutic values) might increase the hazard of recurrence. Instead, we found that the greatest increase in risk was associated with high endoxifen concentrations (above 70 ng/ml) and that 25% of recurrences had such high concentrations.",
              "The trend also showed that when a recurrence had very low endoxifen levels (below 20), 8 of 9 matched controls had higher values (suggesting a wide J-shaped relationship)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "endoxifen",
              "drug_id": "PA166124478",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2D6*4",
            "Gene": "CYP2D6",
            "Drug(s)": "endoxifen",
            "PMID": 23476897,
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "High endoxifen concentrations (>70 ng/ml) were associated with higher risk of recurrence. Quadratic trend fitted to Cox proportional hazards regression model, likelihood ratio p-value = 0.002. 25% of recurrences had endoxifen concentrations above 70 ng/ml. J-shaped relationship suggested between endoxifen concentrations and recurrence risk.",
            "Sentence": "High endoxifen plasma concentrations are associated with increased risk of disease recurrence in people with Disease:Breast Neoplasms as compared to intermediate endoxifen concentrations.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "risk of disease recurrence with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "High endoxifen concentrations were associated with higher risk of recurrence; with a quadratic trend fitted to a stratified Cox proportional hazards regression model, the likelihood ratio p-value was 0.002.",
              "We expected that low endoxifen concentrations (below therapeutic values) might increase the hazard of recurrence. Instead, we found that the greatest increase in risk was associated with high endoxifen concentrations (above 70 ng/ml) and that 25% of recurrences had such high concentrations.",
              "The trend also showed that when a recurrence had very low endoxifen levels (below 20), 8 of 9 matched controls had higher values (suggesting a wide J-shaped relationship)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "endoxifen",
              "drug_id": "PA166124478",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2D6*6",
            "Gene": "CYP2D6",
            "Drug(s)": "endoxifen",
            "PMID": 23476897,
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "High endoxifen concentrations (>70 ng/ml) were associated with higher risk of recurrence. Quadratic trend fitted to Cox proportional hazards regression model, likelihood ratio p-value = 0.002. 25% of recurrences had endoxifen concentrations above 70 ng/ml. J-shaped relationship suggested between endoxifen concentrations and recurrence risk.",
            "Sentence": "High endoxifen plasma concentrations are associated with increased risk of disease recurrence in people with Disease:Breast Neoplasms as compared to intermediate endoxifen concentrations.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "risk of disease recurrence with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "High endoxifen concentrations were associated with higher risk of recurrence; with a quadratic trend fitted to a stratified Cox proportional hazards regression model, the likelihood ratio p-value was 0.002.",
              "We expected that low endoxifen concentrations (below therapeutic values) might increase the hazard of recurrence. Instead, we found that the greatest increase in risk was associated with high endoxifen concentrations (above 70 ng/ml) and that 25% of recurrences had such high concentrations.",
              "The trend also showed that when a recurrence had very low endoxifen levels (below 20), 8 of 9 matched controls had higher values (suggesting a wide J-shaped relationship)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "endoxifen",
              "drug_id": "PA166124478",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2D6*1",
            "Gene": "CYP2D6",
            "Drug(s)": "4-hydroxytamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.13 for trend. CYP2D6 genotype explained only 1% (r-squared = 0.010) of variance in 4-OHTAM concentrations. Normal metabolizers: 2.2 \u00b1 1.8 ng/ml, Intermediate: 1.9 \u00b1 1.2 ng/ml, Slow: 1.7 \u00b1 1.7 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of 4-hydroxytamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "CYP2D6 genotypes were also associated with concentrations of 4-hydroxytamoxifen, another active metabolite of tamoxifen, although this association was less strong, consistent with the partial role CYP2D6 plays in its formation.",
              "| 4-OHTAM | 1.9 \u00b1 1.5 | 2.2 \u00b1 1.8 | 1.9 \u00b1 1.2 | 1.7 \u00b1 1.7 | 0.010 (0.13) |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "4-hydroxytamoxifen",
              "drug_id": null,
              "confidence": 0.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2D6*2",
            "Gene": "CYP2D6",
            "Drug(s)": "4-hydroxytamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.13 for trend. CYP2D6 genotype explained only 1% (r-squared = 0.010) of variance in 4-OHTAM concentrations. Normal metabolizers: 2.2 \u00b1 1.8 ng/ml, Intermediate: 1.9 \u00b1 1.2 ng/ml, Slow: 1.7 \u00b1 1.7 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of 4-hydroxytamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "CYP2D6 genotypes were also associated with concentrations of 4-hydroxytamoxifen, another active metabolite of tamoxifen, although this association was less strong, consistent with the partial role CYP2D6 plays in its formation.",
              "| 4-OHTAM | 1.9 \u00b1 1.5 | 2.2 \u00b1 1.8 | 1.9 \u00b1 1.2 | 1.7 \u00b1 1.7 | 0.010 (0.13) |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "4-hydroxytamoxifen",
              "drug_id": null,
              "confidence": 0.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2D6*3",
            "Gene": "CYP2D6",
            "Drug(s)": "4-hydroxytamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.13 for trend. CYP2D6 genotype explained only 1% (r-squared = 0.010) of variance in 4-OHTAM concentrations. Normal metabolizers: 2.2 \u00b1 1.8 ng/ml, Intermediate: 1.9 \u00b1 1.2 ng/ml, Slow: 1.7 \u00b1 1.7 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of 4-hydroxytamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "CYP2D6 genotypes were also associated with concentrations of 4-hydroxytamoxifen, another active metabolite of tamoxifen, although this association was less strong, consistent with the partial role CYP2D6 plays in its formation.",
              "| 4-OHTAM | 1.9 \u00b1 1.5 | 2.2 \u00b1 1.8 | 1.9 \u00b1 1.2 | 1.7 \u00b1 1.7 | 0.010 (0.13) |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "4-hydroxytamoxifen",
              "drug_id": null,
              "confidence": 0.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2D6*4",
            "Gene": "CYP2D6",
            "Drug(s)": "4-hydroxytamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.13 for trend. CYP2D6 genotype explained only 1% (r-squared = 0.010) of variance in 4-OHTAM concentrations. Normal metabolizers: 2.2 \u00b1 1.8 ng/ml, Intermediate: 1.9 \u00b1 1.2 ng/ml, Slow: 1.7 \u00b1 1.7 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of 4-hydroxytamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "CYP2D6 genotypes were also associated with concentrations of 4-hydroxytamoxifen, another active metabolite of tamoxifen, although this association was less strong, consistent with the partial role CYP2D6 plays in its formation.",
              "| 4-OHTAM | 1.9 \u00b1 1.5 | 2.2 \u00b1 1.8 | 1.9 \u00b1 1.2 | 1.7 \u00b1 1.7 | 0.010 (0.13) |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "4-hydroxytamoxifen",
              "drug_id": null,
              "confidence": 0.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2D6*5",
            "Gene": "CYP2D6",
            "Drug(s)": "4-hydroxytamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.13 for trend. CYP2D6 genotype explained only 1% (r-squared = 0.010) of variance in 4-OHTAM concentrations. Normal metabolizers: 2.2 \u00b1 1.8 ng/ml, Intermediate: 1.9 \u00b1 1.2 ng/ml, Slow: 1.7 \u00b1 1.7 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of 4-hydroxytamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "CYP2D6 genotypes were also associated with concentrations of 4-hydroxytamoxifen, another active metabolite of tamoxifen, although this association was less strong, consistent with the partial role CYP2D6 plays in its formation.",
              "| 4-OHTAM | 1.9 \u00b1 1.5 | 2.2 \u00b1 1.8 | 1.9 \u00b1 1.2 | 1.7 \u00b1 1.7 | 0.010 (0.13) |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "4-hydroxytamoxifen",
              "drug_id": null,
              "confidence": 0.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2D6*6",
            "Gene": "CYP2D6",
            "Drug(s)": "4-hydroxytamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.13 for trend. CYP2D6 genotype explained only 1% (r-squared = 0.010) of variance in 4-OHTAM concentrations. Normal metabolizers: 2.2 \u00b1 1.8 ng/ml, Intermediate: 1.9 \u00b1 1.2 ng/ml, Slow: 1.7 \u00b1 1.7 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of 4-hydroxytamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "CYP2D6 genotypes were also associated with concentrations of 4-hydroxytamoxifen, another active metabolite of tamoxifen, although this association was less strong, consistent with the partial role CYP2D6 plays in its formation.",
              "| 4-OHTAM | 1.9 \u00b1 1.5 | 2.2 \u00b1 1.8 | 1.9 \u00b1 1.2 | 1.7 \u00b1 1.7 | 0.010 (0.13) |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "4-hydroxytamoxifen",
              "drug_id": null,
              "confidence": 0.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2D6*10",
            "Gene": "CYP2D6",
            "Drug(s)": "4-hydroxytamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.13 for trend. CYP2D6 genotype explained only 1% (r-squared = 0.010) of variance in 4-OHTAM concentrations. Normal metabolizers: 2.2 \u00b1 1.8 ng/ml, Intermediate: 1.9 \u00b1 1.2 ng/ml, Slow: 1.7 \u00b1 1.7 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of 4-hydroxytamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "CYP2D6 genotypes were also associated with concentrations of 4-hydroxytamoxifen, another active metabolite of tamoxifen, although this association was less strong, consistent with the partial role CYP2D6 plays in its formation.",
              "| 4-OHTAM | 1.9 \u00b1 1.5 | 2.2 \u00b1 1.8 | 1.9 \u00b1 1.2 | 1.7 \u00b1 1.7 | 0.010 (0.13) |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "4-hydroxytamoxifen",
              "drug_id": null,
              "confidence": 0.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "4-hydroxytamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.13 for trend. CYP2D6 genotype explained only 1% (r-squared = 0.010) of variance in 4-OHTAM concentrations. Normal metabolizers: 2.2 \u00b1 1.8 ng/ml, Intermediate: 1.9 \u00b1 1.2 ng/ml, Slow: 1.7 \u00b1 1.7 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of 4-hydroxytamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "CYP2D6 genotypes were also associated with concentrations of 4-hydroxytamoxifen, another active metabolite of tamoxifen, although this association was less strong, consistent with the partial role CYP2D6 plays in its formation.",
              "| 4-OHTAM | 1.9 \u00b1 1.5 | 2.2 \u00b1 1.8 | 1.9 \u00b1 1.2 | 1.7 \u00b1 1.7 | 0.010 (0.13) |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "4-hydroxytamoxifen",
              "drug_id": null,
              "confidence": 0.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2D6*1",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.39 for trend. CYP2D6 genotype explained only 0.3% (r-squared = 0.003) of variance in tamoxifen concentrations. Normal metabolizers: 207.7 \u00b1 256.7 ng/ml, Intermediate: 167.7 \u00b1 150.5 ng/ml, Slow: 226.1 \u00b1 316.2 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of tamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "Tamoxifen (TAM) | 195.3 \u00b1 240.9 | 207.7 \u00b1 256.7 | 167.7 \u00b1 150.5 | 226.1 \u00b1 316.2 | 0.003 (0.39)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "tamoxifen",
              "drug_id": "PA451581",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2D6*2",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.39 for trend. CYP2D6 genotype explained only 0.3% (r-squared = 0.003) of variance in tamoxifen concentrations. Normal metabolizers: 207.7 \u00b1 256.7 ng/ml, Intermediate: 167.7 \u00b1 150.5 ng/ml, Slow: 226.1 \u00b1 316.2 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of tamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "Tamoxifen (TAM) | 195.3 \u00b1 240.9 | 207.7 \u00b1 256.7 | 167.7 \u00b1 150.5 | 226.1 \u00b1 316.2 | 0.003 (0.39)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "tamoxifen",
              "drug_id": "PA451581",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2D6*3",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.39 for trend. CYP2D6 genotype explained only 0.3% (r-squared = 0.003) of variance in tamoxifen concentrations. Normal metabolizers: 207.7 \u00b1 256.7 ng/ml, Intermediate: 167.7 \u00b1 150.5 ng/ml, Slow: 226.1 \u00b1 316.2 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of tamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "Tamoxifen (TAM) | 195.3 \u00b1 240.9 | 207.7 \u00b1 256.7 | 167.7 \u00b1 150.5 | 226.1 \u00b1 316.2 | 0.003 (0.39)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "tamoxifen",
              "drug_id": "PA451581",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2D6*4",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.39 for trend. CYP2D6 genotype explained only 0.3% (r-squared = 0.003) of variance in tamoxifen concentrations. Normal metabolizers: 207.7 \u00b1 256.7 ng/ml, Intermediate: 167.7 \u00b1 150.5 ng/ml, Slow: 226.1 \u00b1 316.2 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of tamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "Tamoxifen (TAM) | 195.3 \u00b1 240.9 | 207.7 \u00b1 256.7 | 167.7 \u00b1 150.5 | 226.1 \u00b1 316.2 | 0.003 (0.39)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "tamoxifen",
              "drug_id": "PA451581",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2D6*5",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.39 for trend. CYP2D6 genotype explained only 0.3% (r-squared = 0.003) of variance in tamoxifen concentrations. Normal metabolizers: 207.7 \u00b1 256.7 ng/ml, Intermediate: 167.7 \u00b1 150.5 ng/ml, Slow: 226.1 \u00b1 316.2 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of tamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "Tamoxifen (TAM) | 195.3 \u00b1 240.9 | 207.7 \u00b1 256.7 | 167.7 \u00b1 150.5 | 226.1 \u00b1 316.2 | 0.003 (0.39)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "tamoxifen",
              "drug_id": "PA451581",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2D6*6",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.39 for trend. CYP2D6 genotype explained only 0.3% (r-squared = 0.003) of variance in tamoxifen concentrations. Normal metabolizers: 207.7 \u00b1 256.7 ng/ml, Intermediate: 167.7 \u00b1 150.5 ng/ml, Slow: 226.1 \u00b1 316.2 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of tamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "Tamoxifen (TAM) | 195.3 \u00b1 240.9 | 207.7 \u00b1 256.7 | 167.7 \u00b1 150.5 | 226.1 \u00b1 316.2 | 0.003 (0.39)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "tamoxifen",
              "drug_id": "PA451581",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2D6*10",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.39 for trend. CYP2D6 genotype explained only 0.3% (r-squared = 0.003) of variance in tamoxifen concentrations. Normal metabolizers: 207.7 \u00b1 256.7 ng/ml, Intermediate: 167.7 \u00b1 150.5 ng/ml, Slow: 226.1 \u00b1 316.2 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of tamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "Tamoxifen (TAM) | 195.3 \u00b1 240.9 | 207.7 \u00b1 256.7 | 167.7 \u00b1 150.5 | 226.1 \u00b1 316.2 | 0.003 (0.39)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "tamoxifen",
              "drug_id": "PA451581",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.39 for trend. CYP2D6 genotype explained only 0.3% (r-squared = 0.003) of variance in tamoxifen concentrations. Normal metabolizers: 207.7 \u00b1 256.7 ng/ml, Intermediate: 167.7 \u00b1 150.5 ng/ml, Slow: 226.1 \u00b1 316.2 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of tamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "Tamoxifen (TAM) | 195.3 \u00b1 240.9 | 207.7 \u00b1 256.7 | 167.7 \u00b1 150.5 | 226.1 \u00b1 316.2 | 0.003 (0.39)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "tamoxifen",
              "drug_id": "PA451581",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2D6*1",
            "Gene": "CYP2D6",
            "Drug(s)": "N-desmethyltamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.060 for trend. CYP2D6 genotype explained only 1.6% (r-squared = 0.016) of variance in NDMTAM concentrations. Normal metabolizers: 325.5 \u00b1 371.1 ng/ml, Intermediate: 297.0 \u00b1 238.5 ng/ml, Slow: 437.2 \u00b1 560.6 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of N-desmethyltamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "NDMTAM | 353.3 \u00b1 409.0 | 325.5 \u00b1 371.1 | 297.0 \u00b1 238.5 | 437.2 \u00b1 560.6 | 0.016 (0.060)",
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "On the basis of the genotype-predicted phenotype, genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "endoxifen",
              "drug_id": "PA166124478",
              "confidence": 0.8260869565217391
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2D6*2",
            "Gene": "CYP2D6",
            "Drug(s)": "N-desmethyltamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.060 for trend. CYP2D6 genotype explained only 1.6% (r-squared = 0.016) of variance in NDMTAM concentrations. Normal metabolizers: 325.5 \u00b1 371.1 ng/ml, Intermediate: 297.0 \u00b1 238.5 ng/ml, Slow: 437.2 \u00b1 560.6 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of N-desmethyltamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "NDMTAM | 353.3 \u00b1 409.0 | 325.5 \u00b1 371.1 | 297.0 \u00b1 238.5 | 437.2 \u00b1 560.6 | 0.016 (0.060)",
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "On the basis of the genotype-predicted phenotype, genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "endoxifen",
              "drug_id": "PA166124478",
              "confidence": 0.8260869565217391
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2D6*3",
            "Gene": "CYP2D6",
            "Drug(s)": "N-desmethyltamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.060 for trend. CYP2D6 genotype explained only 1.6% (r-squared = 0.016) of variance in NDMTAM concentrations. Normal metabolizers: 325.5 \u00b1 371.1 ng/ml, Intermediate: 297.0 \u00b1 238.5 ng/ml, Slow: 437.2 \u00b1 560.6 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of N-desmethyltamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "NDMTAM | 353.3 \u00b1 409.0 | 325.5 \u00b1 371.1 | 297.0 \u00b1 238.5 | 437.2 \u00b1 560.6 | 0.016 (0.060)",
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "On the basis of the genotype-predicted phenotype, genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "endoxifen",
              "drug_id": "PA166124478",
              "confidence": 0.8260869565217391
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2D6*4",
            "Gene": "CYP2D6",
            "Drug(s)": "N-desmethyltamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.060 for trend. CYP2D6 genotype explained only 1.6% (r-squared = 0.016) of variance in NDMTAM concentrations. Normal metabolizers: 325.5 \u00b1 371.1 ng/ml, Intermediate: 297.0 \u00b1 238.5 ng/ml, Slow: 437.2 \u00b1 560.6 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of N-desmethyltamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "NDMTAM | 353.3 \u00b1 409.0 | 325.5 \u00b1 371.1 | 297.0 \u00b1 238.5 | 437.2 \u00b1 560.6 | 0.016 (0.060)",
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "On the basis of the genotype-predicted phenotype, genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "endoxifen",
              "drug_id": "PA166124478",
              "confidence": 0.8260869565217391
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2D6*5",
            "Gene": "CYP2D6",
            "Drug(s)": "N-desmethyltamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.060 for trend. CYP2D6 genotype explained only 1.6% (r-squared = 0.016) of variance in NDMTAM concentrations. Normal metabolizers: 325.5 \u00b1 371.1 ng/ml, Intermediate: 297.0 \u00b1 238.5 ng/ml, Slow: 437.2 \u00b1 560.6 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of N-desmethyltamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "NDMTAM | 353.3 \u00b1 409.0 | 325.5 \u00b1 371.1 | 297.0 \u00b1 238.5 | 437.2 \u00b1 560.6 | 0.016 (0.060)",
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "On the basis of the genotype-predicted phenotype, genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "endoxifen",
              "drug_id": "PA166124478",
              "confidence": 0.8260869565217391
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2D6*6",
            "Gene": "CYP2D6",
            "Drug(s)": "N-desmethyltamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.060 for trend. CYP2D6 genotype explained only 1.6% (r-squared = 0.016) of variance in NDMTAM concentrations. Normal metabolizers: 325.5 \u00b1 371.1 ng/ml, Intermediate: 297.0 \u00b1 238.5 ng/ml, Slow: 437.2 \u00b1 560.6 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of N-desmethyltamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "NDMTAM | 353.3 \u00b1 409.0 | 325.5 \u00b1 371.1 | 297.0 \u00b1 238.5 | 437.2 \u00b1 560.6 | 0.016 (0.060)",
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "On the basis of the genotype-predicted phenotype, genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "endoxifen",
              "drug_id": "PA166124478",
              "confidence": 0.8260869565217391
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2D6*10",
            "Gene": "CYP2D6",
            "Drug(s)": "N-desmethyltamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.060 for trend. CYP2D6 genotype explained only 1.6% (r-squared = 0.016) of variance in NDMTAM concentrations. Normal metabolizers: 325.5 \u00b1 371.1 ng/ml, Intermediate: 297.0 \u00b1 238.5 ng/ml, Slow: 437.2 \u00b1 560.6 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of N-desmethyltamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "NDMTAM | 353.3 \u00b1 409.0 | 325.5 \u00b1 371.1 | 297.0 \u00b1 238.5 | 437.2 \u00b1 560.6 | 0.016 (0.060)",
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "On the basis of the genotype-predicted phenotype, genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "endoxifen",
              "drug_id": "PA166124478",
              "confidence": 0.8260869565217391
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "N-desmethyltamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "p = 0.060 for trend. CYP2D6 genotype explained only 1.6% (r-squared = 0.016) of variance in NDMTAM concentrations. Normal metabolizers: 325.5 \u00b1 371.1 ng/ml, Intermediate: 297.0 \u00b1 238.5 ng/ml, Slow: 437.2 \u00b1 560.6 ng/ml.",
            "Sentence": "CYP2D6 genotype metabolic status is not associated with plasma concentrations of N-desmethyltamoxifen in people with Disease:Breast Neoplasms as compared to normal metabolizer genotypes.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "slow metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "NDMTAM | 353.3 \u00b1 409.0 | 325.5 \u00b1 371.1 | 297.0 \u00b1 238.5 | 437.2 \u00b1 560.6 | 0.016 (0.060)",
              "The effect of CYP2D6 genotype metabolic status on each of the metabolites (tamoxifen, NDMTAM, endoxifen, and 4-OHTAM) was assessed using a test for linear trend. The proportion of variance explained by the linear trend model (r-squared) was also calculated.",
              "On the basis of the genotype-predicted phenotype, genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "endoxifen",
              "drug_id": "PA166124478",
              "confidence": 0.8260869565217391
            },
            "_expanded_from_multi_variant": true
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.6998352140188218,
        "field_scores": {
          "Study Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Study Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.8725282102823257,
            "scores": [
              0.9024986624717712,
              0.879123330116272,
              0.856102705001831,
              0.8523881435394287
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 0.25,
            "scores": [
              1.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 0.25,
            "scores": [
              1.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 0.125,
            "scores": [
              0.5,
              0.0,
              0.0,
              0.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 4,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9024986624717712,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1444930473,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1444930388,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "clinical trial",
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 224.0,
                "prediction": 224
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "endpoint: endoxifen concentration after 4 month; slow vs normal metabolizer; p = 0.0001 for trend: normal > intermediate > slow",
                "prediction": "Filipino and Vietnamese women with operable breast cancer receiving adjuvant tamoxifen - CYP2D6 genotype and endoxifen concentration association"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.0001",
                "prediction": "< 0.0001"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.879123330116272,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1444930476,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1444930474,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "clinical trial",
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 224.0,
                "prediction": 224
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "endpoint: tamoxifen concentration after 4 month; slow vs normal metabolizer; p = 0.39 for trend: normal > intermediate > slow",
                "prediction": "Vietnamese women with operable breast cancer receiving adjuvant tamoxifen"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": 0.585
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "*10"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.39",
                "prediction": ""
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.856102705001831,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1444930497,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1444930474,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "clinical trial",
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 224.0,
                "prediction": 224
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "endpoint: 4-hydroxytamoxifen concentration after 4 month; slow vs normal metabolizer; p = 0.13 for trend: normal > intermediate > slow",
                "prediction": "Vietnamese women with operable breast cancer receiving adjuvant tamoxifen"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": 0.24
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "*1"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.13",
                "prediction": ""
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8523881435394287,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1444930499,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1444930474,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "clinical trial",
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 224.0,
                "prediction": 224
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "endpoint: N-desmethyltamoxifen concentration after 4 month; slow vs normal metabolizer; p = 0.06 for trend: normal > intermediate > slow",
                "prediction": "Vietnamese women with operable breast cancer receiving adjuvant tamoxifen"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": 0.11
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "*2"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.06",
                "prediction": ""
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "clinical trial:endpoint: endoxifen ",
          "clinical trial:endpoint: tamoxifen ",
          "clinical trial:endpoint: 4-hydroxyt",
          "clinical trial:endpoint: N-desmethy"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 224,
            "Study Controls": null,
            "Characteristics": "Vietnamese women with operable breast cancer receiving adjuvant tamoxifen",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.05,
            "Allele Of Frequency In Cases": "*5",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 224,
            "Study Controls": null,
            "Characteristics": "Vietnamese women with operable breast cancer receiving adjuvant tamoxifen",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.01,
            "Allele Of Frequency In Cases": "*41",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 224,
            "Study Controls": null,
            "Characteristics": "Vietnamese women with operable breast cancer receiving adjuvant tamoxifen",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.005,
            "Allele Of Frequency In Cases": "*4",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 224,
            "Study Controls": null,
            "Characteristics": "Filipino women with operable breast cancer receiving adjuvant tamoxifen",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.524,
            "Allele Of Frequency In Cases": "*10",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 224,
            "Study Controls": null,
            "Characteristics": "Filipino women with operable breast cancer receiving adjuvant tamoxifen",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.3,
            "Allele Of Frequency In Cases": "*1",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 224,
            "Study Controls": null,
            "Characteristics": "Filipino women with operable breast cancer receiving adjuvant tamoxifen",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.124,
            "Allele Of Frequency In Cases": "*2",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 224,
            "Study Controls": null,
            "Characteristics": "Filipino women with operable breast cancer receiving adjuvant tamoxifen",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.024,
            "Allele Of Frequency In Cases": "*5",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 224,
            "Study Controls": null,
            "Characteristics": "Filipino women with operable breast cancer receiving adjuvant tamoxifen",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.028,
            "Allele Of Frequency In Cases": "*41",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 24,
            "Study Controls": 24,
            "Characteristics": "Filipino and Vietnamese women with operable breast cancer receiving adjuvant tamoxifen - nested case-control study of endoxifen and recurrence",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.002",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC3113609": {
      "var-pheno": {
        "overall_score": 0.9064379201995002,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Direction of effect": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.9386275211970011,
            "scores": [
              0.9620071053504944,
              0.9504010677337646,
              0.9034743905067444
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 3,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9620071053504944,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-A*31:01",
                "prediction": "HLA-A*31:01"
              },
              "Gene": {
                "ground_truth": "HLA-A",
                "prediction": "HLA-A"
              },
              "Drug(s)": {
                "ground_truth": "carbamazepine",
                "prediction": "carbamazepine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*31:01",
                "prediction": "*31:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Disease:Maculopapular Exanthema",
                "prediction": "Side Effect:Maculopapular Exanthema"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9504010677337646,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-A*31:01",
                "prediction": "HLA-A*31:01"
              },
              "Gene": {
                "ground_truth": "HLA-A",
                "prediction": "HLA-A"
              },
              "Drug(s)": {
                "ground_truth": "carbamazepine",
                "prediction": "carbamazepine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*31:01",
                "prediction": "*31:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Disease:Drug Hypersensitivity",
                "prediction": "Side Effect:Hypersensitivity Syndrome"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9034743905067444,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-A*31:01",
                "prediction": "HLA-A*31:01"
              },
              "Gene": {
                "ground_truth": "HLA-A",
                "prediction": "HLA-A"
              },
              "Drug(s)": {
                "ground_truth": "carbamazepine",
                "prediction": "carbamazepine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*31:01",
                "prediction": "*31:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Disease:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "PA165954030",
          "PA165954030",
          "PA165954030"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "HLA-A*31:01",
            "Gene": "HLA-A",
            "Drug(s)": "carbamazepine",
            "PMID": 21428769,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Pooled analysis of all 145 subjects with carbamazepine-induced hypersensitivity: OR=9.12, 95% CI 4.03-20.65, P=1.0\u00d710^-7. Sensitivity 26%, specificity 96%. Presence of allele increases risk from 5.0% to 26.0%, absence reduces risk to 3.8%.",
            "Sentence": "HLA-A*31:01 is associated with increased risk of Side Effect:Drug Hypersensitivity when treated with carbamazepine in people with Disease:Epilepsy.",
            "Alleles": "*31:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Epilepsy",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "A pooled analysis of all 145 subjects with carbamazepine-induced hypersensitivity and 257 control subjects without adverse drug reactions showed a strong association between hypersensitivity and the HLA-A\u26053101 allele (odds ratio, 9.12; 95% CI, 4.03 to 20.65; P = 1.0\u00d710\u22127). On the basis of this pooled collection, we calculated that the presence of HLA-A\u26053101 had a sensitivity of 26% and a specificity of 96% as a predictor of carbamazepine-associated hypersensitivity.",
              "The presence of the HLA-A\u26053101 allele was associated with carbamazepine-induced hypersensitivity reactions among subjects of Northern European ancestry. The presence of the allele increased the risk from 5.0% to 26.0%, whereas its absence reduced the risk from 5.0% to 3.8%."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-A*31:01",
              "variant_id": "PA165954030",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "carbamazepine",
              "drug_id": "PA448785",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "HLA-A*31:01",
            "Gene": "HLA-A",
            "Drug(s)": "carbamazepine",
            "PMID": 21428769,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "One subject with AGEP carried the HLA-A*3101 allele. AGEP is characterized by sterile pustules, neutrophilic inflammation, and high levels of interleukin-8 in skin.",
            "Sentence": "HLA-A*31:01 is associated with increased risk of Side Effect:Acute Generalized Exanthematous Pustulosis when treated with carbamazepine.",
            "Alleles": "*31:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Acute Generalized Exanthematous Pustulosis",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "We recruited one subject with acute generalized exanthematous pustulosis (AGEP), who had a typical pustular reaction with high fever,18 from a collaborating clinic in Switzerland. We then analyzed the data from this subject together with data from the subjects with the hypersensitivity syndrome.",
              "During the course of this study, samples from 4 additional subjects with the hypersensitivity syndrome and from 1 additional subject with AGEP became available from the Liverpool and EPIGEN centers. Of these 5 subjects, 2 (including the single subject with AGEP) tested positive for HLA-A\u26053101.",
              "The one subject in our study who had AGEP, a reaction characterized by sterile pustules, neutrophilic inflammation, and high levels of interleukin-8 in skin,33 also was found to carry the HLA-A\u26053101 allele."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-A*31:01",
              "variant_id": "PA165954030",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "carbamazepine",
              "drug_id": "PA448785",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "rs1061235",
            "Gene": "HLA-A",
            "Drug(s)": "carbamazepine",
            "PMID": 21428769,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "rs1061235 is a proxy SNP for HLA-A*3101 (r^2=1 in European populations). Top hit in GWAS with P=3.5\u00d710^-8. Variant seen in 40.0% of case subjects but only 4.9% of control subjects.",
            "Sentence": "rs1061235 is associated with increased risk of Side Effect:Hypersensitivity Syndrome when treated with carbamazepine in people with Disease:Epilepsy.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity Syndrome",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Epilepsy",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "We identified a strong signal in the MHC region on chromosome 6, with several SNPs around HLA-A reaching genome-wide significance (P = 3.5\u00d710^\u22128^) (Fig. 1A and 1B). This variant was seen in 40.0% of case subjects but in only 4.9% of control subjects. The top hit (rs1061235) had previously been shown to be a proxy for the HLA-A\u26053101 allele in persons of European descent.",
              "Genotyping of the rs1061235 SNP in samples from all Liverpool subjects (including case subjects with maculopapular exanthema, the hypersensitivity syndrome, or SJS\u2013TEN and clinical control subjects) was performed by KBioscience. This allele has previously been shown to be in complete linkage disequilibrium (r^2^ = 1) with the HLA-A\u26053101 allele in populations of European descent.",
              "The HLA-A\u26053101 allele, which has a prevalence of 2 to 5% in Northern European populations, was significantly associated with the hypersensitivity syndrome (P = 3.5\u00d710^\u22128^)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1061235",
              "variant_id": "PA166156975",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "carbamazepine",
              "drug_id": "PA448785",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "HLA-B*15:02",
            "Gene": "HLA-B",
            "Drug(s)": "carbamazepine",
            "PMID": 21428769,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "HLA-B*1502 is strongly correlated with carbamazepine-induced SJS-TEN in Han Chinese and other Asian populations but not in European populations. This study focused on Europeans where HLA-B*1502 is not associated.",
            "Sentence": "HLA-B*15:02 is not associated with risk of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis when treated with carbamazepine in people with Disease:Epilepsy.",
            "Alleles": "*15:02",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Epilepsy",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "The HLA-B\u26051502 allele has been shown to be strongly correlated with carbamazepine-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis (SJS\u2013TEN) in the Han Chinese and other Asian populations but not in European populations.",
              "HLA-B\u26051502, a predictor of carbamazepine hypersensitivity reactions in Asian populations, seems to be phenotype-specific in that it predicts the development of SJS\u2013TEN but not the development of the hypersensitivity syndrome or maculopapular exanthema."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*15:02",
              "variant_id": "PA165954769",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "carbamazepine",
              "drug_id": "PA448785",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.6888888888888889,
        "field_scores": {
          "Study Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Study Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              0.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              0.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "P Value": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 3,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.0,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184466918,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1184466916,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 106.0,
                "prediction": 106
              },
              "Study Controls": {
                "ground_truth": 257.0,
                "prediction": 257
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "Carbamazepine-induced maculopapular exanthema - combined analysis vs clinical controls"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "HLA-A*3101"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": "HLA-A*3101"
              },
              "P Value": {
                "ground_truth": "= 8.0E-7",
                "prediction": "= 8.0e-7"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 8.33,
                "prediction": 8.33
              },
              "Confidence Interval Start": {
                "ground_truth": 3.59,
                "prediction": 3.59
              },
              "Confidence Interval Stop": {
                "ground_truth": 19.36,
                "prediction": 19.36
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.0,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184466915,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1184466909,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 27.0,
                "prediction": 27
              },
              "Study Controls": {
                "ground_truth": 257.0,
                "prediction": 257
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "Carbamazepine-induced hypersensitivity syndrome (including AGEP) - Liverpool and EPIGEN combined vs clinical controls"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "HLA-A*3101"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": "HLA-A*3101"
              },
              "P Value": {
                "ground_truth": "= 0.03",
                "prediction": "= 0.03"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 12.41,
                "prediction": 12.41
              },
              "Confidence Interval Start": {
                "ground_truth": 1.27,
                "prediction": 1.27
              },
              "Confidence Interval Stop": {
                "ground_truth": 121.03,
                "prediction": 121.03
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.0,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1184466924,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1184466922,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 12.0,
                "prediction": 12
              },
              "Study Controls": {
                "ground_truth": 257.0,
                "prediction": 257
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "Carbamazepine-induced SJS-TEN vs clinical controls"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": 0.42
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "HLA-A*3101"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": 0.04
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": "HLA-A*3101"
              },
              "P Value": {
                "ground_truth": "= 8.0E-5",
                "prediction": "= 8.0e-5"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 25.93,
                "prediction": 25.93
              },
              "Confidence Interval Start": {
                "ground_truth": 4.93,
                "prediction": 4.93
              },
              "Confidence Interval Stop": {
                "ground_truth": 116.18,
                "prediction": 116.18
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "case/control",
          "case/control",
          "case/control"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "GWAS",
            "Study Cases": 22,
            "Study Controls": 2691,
            "Characteristics": "Liverpool cohort - carbamazepine-induced hypersensitivity syndrome vs UK National Blood Services Collection controls",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.4,
            "Allele Of Frequency In Cases": "HLA-A*3101",
            "Frequency In Controls": 0.049,
            "Allele Of Frequency In Controls": "HLA-A*3101",
            "P Value": "= 3.5e-8",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "GWAS",
            "Study Cases": 43,
            "Study Controls": 1296,
            "Characteristics": "EPIGEN cohort - carbamazepine-induced maculopapular exanthema vs 1958 British Birth Cohort controls",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.27,
            "Allele Of Frequency In Cases": "HLA-A*3101",
            "Frequency In Controls": 0.04,
            "Allele Of Frequency In Controls": "HLA-A*3101",
            "P Value": "= 1.11e-6",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 145,
            "Study Controls": 257,
            "Characteristics": "Pooled analysis - all carbamazepine-induced hypersensitivity reactions vs clinical controls",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": "HLA-A*3101",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": "HLA-A*3101",
            "P Value": "= 1.0e-7",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 9.12,
            "Confidence Interval Start": 4.03,
            "Confidence Interval Stop": 20.65,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC11603346": {
      "var-pheno": {
        "overall_score": 0.934570636600256,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.25,
            "scores": [
              1.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 0.9765650928020477,
            "scores": [
              0.948112964630127,
              0.9890725016593933,
              0.9890725016593933,
              0.9800024032592773
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Direction of effect": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 4,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.948112964630127,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2B6*6",
                "prediction": "CYP2B6*6"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*1/*6 + *6/*6",
                "prediction": "*6"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Drug-induced liver injury",
                "prediction": "Side Effect:Drug-induced liver injury"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "*1/*1"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9890725016593933,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2B6*1",
                "prediction": "CYP2B6*1/*6"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*1/*6 + *6/*6",
                "prediction": "*1/*6"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Drug-induced liver injury",
                "prediction": "Side Effect:Drug-induced liver injury"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "*1/*1"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9890725016593933,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2B6*1",
                "prediction": "CYP2B6*1/*6"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*1/*6 + *6/*6",
                "prediction": "*1/*6"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Drug-induced liver injury",
                "prediction": "Side Effect:Drug-induced liver injury"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "*1/*1"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9800024032592773,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2B6*1",
                "prediction": "CYP2B6*6/*6"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*1/*6 + *6/*6",
                "prediction": "*6/*6"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Drug-induced liver injury",
                "prediction": "Side Effect:Drug-induced liver injury"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "*1/*1"
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "cyp2b6*1",
          "cyp2b6*6",
          "cyp2b6*1",
          "cyp2b6*6"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2B6*6/*6",
            "Gene": "CYP2B6",
            "Drug(s)": "nevirapine",
            "PMID": 39604537,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "Meta-analysis of 2 studies. OR=0.45 (95% CI: 0.15-1.32), P=0.14. No significant association between homozygous *6/*6 and NVP-induced liver injury.",
            "Sentence": "CYP2B6*6/*6 is not associated with risk of Side Effect:Drug-induced liver injury when treated with nevirapine in people with Disease:HIV infection.",
            "Alleles": "*6/*6",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug-induced liver injury",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "However, there was no significant association between *CYP2B6* homozygous **6* with ARVDILI risk (Fig. 4).",
              "*6/*6 | 0 | 0.85 | Fixed | 4 | 102 | 19 | 297 | 533 | 2 | 0.45 | 0.15\u20131.32 | 0.14"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs28399499",
              "variant_id": "PA166155478",
              "confidence": 0.875
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2B6*6",
            "Gene": "CYP2B6",
            "Drug(s)": "nevirapine",
            "PMID": 39604537,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Meta-analysis of 2 studies. Combined *1/*6 + *6/*6 analysis: OR=0.42 (95% CI: 0.21-0.84), P=0.01. CYP2B6*6 carriers showed decreased susceptibility to NVP-induced liver injury compared to normal metabolizers (*1/*1).",
            "Sentence": "CYP2B6*6 is associated with decreased risk of Side Effect:Drug-induced liver injury when treated with nevirapine in people with Disease:HIV infection.",
            "Alleles": "*6",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug-induced liver injury",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": "normal metabolizer",
            "Citations": [
              "Meta-analysis showed that *CYP2B6 *1/*6* allele and combination of **1/*6* + **6/*6* alleles were significantly associated with a reduction in susceptibility to NVP-induced liver injury, compared with normal metabolizer (Fig. 4), with pooled OR and 95% CI of 0.44 (0.22\u20130.91) and 0.42 (0.21\u20130.84), respectively, as well as *P* value less than 0.05 (Table 2).",
              "On the contrary, in NVP's circumstance, the meta-analysis results showed that *CYP2B6* *1/*6 and a combination of *1/*6 and *6/*6 were dominantly found in the controls group, thus indicating that the poor metabolizer form of CYP2B6 may reduce the risk of ARVDILI."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2B6*6",
              "variant_id": "PA165818762",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.7571339627106984,
        "field_scores": {
          "Study Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Study Controls": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.8570094406604767,
            "scores": [
              0.8678342700004578,
              0.8461846113204956
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              0.0
            ]
          }
        },
        "total_samples": 2,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.8678342700004578,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452721009,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452721001,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "meta-analysis",
                "prediction": "meta-analysis"
              },
              "Study Cases": {
                "ground_truth": 795.0,
                "prediction": 106
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 689
              },
              "Characteristics": {
                "ground_truth": "3 studies (Yimer 2011, Mugusi, Yimer 2012): DILI",
                "prediction": "CYP2B6 *1/*6 + *6/*6 vs *1/*1, Efavirenz-induced liver injury, African population"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.003",
                "prediction": "= 0.003"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 1.94,
                "prediction": 1.94
              },
              "Confidence Interval Start": {
                "ground_truth": 1.24,
                "prediction": 1.24
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.01,
                "prediction": 3.01
              },
              "Biogeographical Groups": {
                "ground_truth": "Sub-Saharan African",
                "prediction": "Sub-Saharan African"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.8461846113204956,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452720988,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452720980,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "meta-analysis",
                "prediction": "meta-analysis"
              },
              "Study Cases": {
                "ground_truth": 504.0,
                "prediction": 38
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 782
              },
              "Characteristics": {
                "ground_truth": "2 studies (Carr, Giacomelli): DILI",
                "prediction": "CYP2B6 *1/*6 + *6/*6 vs *1/*1, Nevirapine-induced liver injury, African and Caucasian populations"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.01",
                "prediction": "= 0.01"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 0.42,
                "prediction": 0.42
              },
              "Confidence Interval Start": {
                "ground_truth": 0.21,
                "prediction": 0.21
              },
              "Confidence Interval Stop": {
                "ground_truth": 0.84,
                "prediction": 0.84
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, \"The meta-analysis of the link between CYP2B6 genotypes and EFV-induced liver injury was only derived from the African population, as well as NVP-induced liver injury were obtained from only African and Caucasian populations. \"",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "meta-analysis:3 studies (Yimer 201",
          "meta-analysis:2 studies (Carr, Gia"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": 106,
            "Study Controls": 689,
            "Characteristics": "CYP2B6 *1/*6 vs *1/*1, Efavirenz-induced liver injury, African population",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.01",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.83,
            "Confidence Interval Start": 1.15,
            "Confidence Interval Stop": 2.9,
            "Biogeographical Groups": "Sub-Saharan African",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": 106,
            "Study Controls": 689,
            "Characteristics": "CYP2B6 *6/*6 vs *1/*1, Efavirenz-induced liver injury, African population",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.007",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.48,
            "Confidence Interval Start": 1.28,
            "Confidence Interval Stop": 4.79,
            "Biogeographical Groups": "Sub-Saharan African",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": 38,
            "Study Controls": 782,
            "Characteristics": "CYP2B6 *1/*6 vs *1/*1, Nevirapine-induced liver injury, African and Caucasian populations",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.03",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.44,
            "Confidence Interval Start": 0.22,
            "Confidence Interval Stop": 0.91,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": 38,
            "Study Controls": 782,
            "Characteristics": "CYP2B6 *6/*6 vs *1/*1, Nevirapine-induced liver injury, African and Caucasian populations",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.14",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.45,
            "Confidence Interval Start": 0.15,
            "Confidence Interval Stop": 1.32,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC11430164": {
      "var-fa": {
        "overall_score": 0.7453756936286624,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.9473684210526315,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 0.9473684210526315,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Drug(s)": {
            "mean_score": 0.9473684210526315,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "PMID": {
            "mean_score": 0.9473684210526315,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.9473684210526315,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Significance": {
            "mean_score": 0.8947368421052632,
            "scores": [
              0.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Alleles": {
            "mean_score": 0.8548822936258818,
            "scores": [
              0.8911381959915161,
              0.9142707586288452,
              0.896486222743988,
              0.9037529230117798,
              0.8956841230392456,
              0.8830364942550659,
              0.8993148803710938,
              0.8984567523002625,
              0.8982097506523132,
              0.89796382188797,
              0.889622151851654,
              0.8954018354415894,
              0.8915122747421265,
              0.8942780494689941,
              0.9016335010528564,
              0.9150903224945068,
              0.9366949200630188,
              0.940216600894928,
              0.0
            ]
          },
          "Specialty Population": {
            "mean_score": 0.9473684210526315,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Assay type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Metabolizer types": {
            "mean_score": 0.9473684210526315,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "isPlural": {
            "mean_score": 0.9473684210526315,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.8947368421052632,
            "scores": [
              0.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.8947368421052632,
            "scores": [
              0.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Functional terms": {
            "mean_score": 0.9473684210526315,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Gene/gene product": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Multiple drugs And/or": {
            "mean_score": 0.9473684210526315,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Cell type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.9473684210526315,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Comparison Metabolizer types": {
            "mean_score": 0.9473684210526315,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          }
        },
        "total_samples": 19,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 0.0,
              "Alleles": 0.8911381959915161,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 0.0,
              "Direction of effect": 0.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*1",
                "prediction": "CYP3A4*10"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "no"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*10"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": null
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.9142707586288452,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*2",
                "prediction": "CYP3A4*2"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*2"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.896486222743988,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*3",
                "prediction": "CYP3A4*3"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*3"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.9037529230117798,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*4",
                "prediction": "CYP3A4*4"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*4"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.8956841230392456,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*5",
                "prediction": "CYP3A4*5"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*5"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.8830364942550659,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*9",
                "prediction": "CYP3A4*9"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*9"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 6,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.8993148803710938,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*14",
                "prediction": "CYP3A4*14"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*14"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 7,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.8984567523002625,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*15",
                "prediction": "CYP3A4*15"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*15"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 8,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.8982097506523132,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*16",
                "prediction": "CYP3A4*16"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*16"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 9,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.89796382188797,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*17",
                "prediction": "CYP3A4*17"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*17"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 10,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.889622151851654,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*19",
                "prediction": "CYP3A4*19"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*19"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 11,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.8954018354415894,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*24",
                "prediction": "CYP3A4*24"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*24"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 12,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.8915122747421265,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*28",
                "prediction": "CYP3A4*28"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*28"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 13,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.8942780494689941,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*29",
                "prediction": "CYP3A4*29"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*29"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 14,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.9016335010528564,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*31",
                "prediction": "CYP3A4*31"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*31"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 15,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.9150903224945068,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*1",
                "prediction": "CYP3A4*11"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*11 + *18 + *33",
                "prediction": "*11"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 16,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.9366949200630188,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*18",
                "prediction": "CYP3A4*18"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*11 + *18 + *33",
                "prediction": "*18"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 17,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.940216600894928,
              "Specialty Population": 1.0,
              "Assay type": 0.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 0.0,
              "When treated with/exposed to/when assayed with": 0.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*33",
                "prediction": "CYP3A4*33"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*11 + *18 + *33",
                "prediction": "*33"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "in insect microsomes"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "insect cells"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "cyp3a4*1",
          "cyp3a4*2",
          "cyp3a4*3",
          "cyp3a4*4",
          "cyp3a4*5",
          "cyp3a4*9",
          "cyp3a4*14",
          "cyp3a4*15",
          "cyp3a4*16",
          "cyp3a4*17",
          "cyp3a4*19",
          "cyp3a4*24",
          "cyp3a4*28",
          "cyp3a4*29",
          "cyp3a4*31",
          "cyp3a4*1",
          "cyp3a4*18",
          "cyp3a4*33"
        ],
        "unmatched_ground_truth": [
          {
            "Variant Annotation ID": 1452626560,
            "Variant/Haplotypes": "CYP3A4*11",
            "Gene": "CYP3A4",
            "Drug(s)": "ticagrelor",
            "PMID": 39346054,
            "Phenotype Category": "Metabolism/PK",
            "Significance": "yes",
            "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
            "Sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
            "Alleles": "*11 + *18 + *33",
            "Specialty Population": null,
            "Assay type": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Functional terms": "clearance of",
            "Gene/gene product": null,
            "When treated with/exposed to/when assayed with": null,
            "Multiple drugs And/or": null,
            "Cell type": null,
            "Comparison Allele(s) or Genotype(s)": "*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "39346054",
            "Variant Annotation ID_norm": "1452626560",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP3A4*1, CYP3A4*11, CYP3A4*18, CYP3A4*33",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "ticagrelor",
              "drug_id": "PA165374673",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          }
        ],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 14,
            "Variant/Haplotypes": "CYP3A4*23",
            "Gene": "CYP3A4",
            "Drug(s)": "ticagrelor",
            "PMID": 39346054,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CLint was 92.82% of wild-type, not significantly different from wild-type. CYP3A4 variants expressed in baculovirus insect cell expression system. Vmax 3990.33\u00b1164.24 pmol/min/nmol P450, Km 5.42\u00b10.76 \u03bcM, CLint 742.86\u00b173.74 \u03bcL/min/nmol P450.",
            "Sentence": "CYP3A4*23 is not associated with altered clearance of ticagrelor when assayed with CYP3A4 as compared to CYP3A4*1.",
            "Alleles": "*23",
            "Specialty Population": null,
            "Assay type": "in insect microsomes",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Functional terms": "clearance of",
            "Gene/gene product": "CYP3A4",
            "When treated with/exposed to/when assayed with": "when assayed with",
            "Multiple drugs And/or": null,
            "Cell type": "insect cells",
            "Comparison Allele(s) or Genotype(s)": "*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "39346054",
            "Variant Annotation ID_norm": "14",
            "Citations": [
              "four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type",
              "CYP3A4*23 | 484C \u2192T | R162W | 3,990.33 \u00b1164.24** | 5.42 \u00b10.76** | 742.86 \u00b173.74 | 92.82%"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP3A4*23",
              "variant_id": "PA166115836",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "ticagrelor",
              "drug_id": "PA165374673",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 18,
            "Variant/Haplotypes": "CYP3A4*30",
            "Gene": "CYP3A4",
            "Drug(s)": "ticagrelor",
            "PMID": 39346054,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "No detectable enzymatic activity toward ticagrelor. CYP3A4*30 (R130STOP) results in a truncated protein that lacks the catalytic domain, exhibiting complete loss of function.",
            "Sentence": "CYP3A4*30 is associated with decreased activity of CYP3A4 when assayed with ticagrelor as compared to CYP3A4*1.",
            "Alleles": "*30",
            "Specialty Population": null,
            "Assay type": "in insect microsomes",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Functional terms": "activity of",
            "Gene/gene product": "CYP3A4",
            "When treated with/exposed to/when assayed with": "when assayed with",
            "Multiple drugs And/or": null,
            "Cell type": "insect cells",
            "Comparison Allele(s) or Genotype(s)": "*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "39346054",
            "Variant Annotation ID_norm": "18",
            "Citations": [
              "CYP3A4*30 (R130STOP) could not be determined because of no detectable enzymatic activity toward ticagrelor.",
              "Studies have revealed that the nucleotide changes of c.388C>T (CYP3A4*30) leads to a premature termination codon at position 130, resulting in a truncated protein that lacks the catalytic domain (Hu et al., 2017). Thus, CYP3A4*30 may exhibit complete loss of function.",
              "CYP3A4*30 displayed weak or no activity."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP3A4*30",
              "variant_id": "PA166245586",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "ticagrelor",
              "drug_id": "PA165374673",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 20,
            "Variant/Haplotypes": "CYP3A4*32",
            "Gene": "CYP3A4",
            "Drug(s)": "ticagrelor",
            "PMID": 39346054,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CLint was 103.77% of wild-type, not significantly different from wild-type. CYP3A4 variants expressed in baculovirus insect cell expression system. Vmax 3329.33\u00b1304.63 pmol/min/nmol P450, Km 4.06\u00b10.86 \u03bcM, CLint 833.05\u00b197.79 \u03bcL/min/nmol P450.",
            "Sentence": "CYP3A4*32 is not associated with altered clearance of ticagrelor when assayed with CYP3A4 as compared to CYP3A4*1.",
            "Alleles": "*32",
            "Specialty Population": null,
            "Assay type": "in insect microsomes",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Functional terms": "clearance of",
            "Gene/gene product": "CYP3A4",
            "When treated with/exposed to/when assayed with": "when assayed with",
            "Multiple drugs And/or": null,
            "Cell type": "insect cells",
            "Comparison Allele(s) or Genotype(s)": "*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "39346054",
            "Variant Annotation ID_norm": "20",
            "Citations": [
              "four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type",
              "CYP3A4*32 | 1004T \u2192C | I335T | 3,329.33 \u00b1304.63** | 4.06 \u00b10.86** | 833.05 \u00b197.79 | 103.77%"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP3A4*32",
              "variant_id": "PA166245588",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "ticagrelor",
              "drug_id": "PA165374673",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 22,
            "Variant/Haplotypes": "CYP3A4*34",
            "Gene": "CYP3A4",
            "Drug(s)": "ticagrelor",
            "PMID": 39346054,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "CLint was 111.93% of wild-type, not significantly different from wild-type. CYP3A4 variants expressed in baculovirus insect cell expression system. Vmax 3599.33\u00b159.52 pmol/min/nmol P450, Km 4.04\u00b10.18 \u03bcM, CLint 893.15\u00b153.76 \u03bcL/min/nmol P450.",
            "Sentence": "CYP3A4*34 is not associated with altered clearance of ticagrelor when assayed with CYP3A4 as compared to CYP3A4*1.",
            "Alleles": "*34",
            "Specialty Population": null,
            "Assay type": "in insect microsomes",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Functional terms": "clearance of",
            "Gene/gene product": "CYP3A4",
            "When treated with/exposed to/when assayed with": "when assayed with",
            "Multiple drugs And/or": null,
            "Cell type": "insect cells",
            "Comparison Allele(s) or Genotype(s)": "*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "39346054",
            "Variant Annotation ID_norm": "22",
            "Citations": [
              "four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type",
              "CYP3A4*34 | 1279A \u2192G | I427V | 3,599.33 \u00b159.52** | 4.04 \u00b10.18** | 893.15 \u00b153.76 | 111.93%"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP3A4*34",
              "variant_id": "PA166245590",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "ticagrelor",
              "drug_id": "PA165374673",
              "confidence": 1.0
            }
          }
        ]
      }
    },
    "PMC4916189": {
      "var-pheno": {
        "overall_score": 0.9589111395180225,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.875,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.625,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 0.9453656375408173,
            "scores": [
              0.9786410927772522,
              0.957622230052948,
              0.9047178030014038,
              0.9427328109741211,
              1.0,
              0.9504790902137756,
              0.941425621509552,
              0.8873064517974854
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Direction of effect": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.9647137597203255,
            "scores": [
              0.9646217823028564,
              0.9646217823028564,
              0.9999999403953552,
              0.9646217823028564,
              0.9412816166877747,
              0.9412816166877747,
              0.9412816166877747,
              0.9999999403953552
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.9719576984643936,
            "scores": [
              1.0,
              1.0,
              0.962837278842926,
              0.9421090483665466,
              0.9529182314872742,
              1.0,
              1.0,
              0.9177970290184021
            ]
          }
        },
        "total_samples": 8,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9786410927772522,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9646217823028564,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs4803419",
                "prediction": "rs4803419"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "CT/TT"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Central Nervous System Disorder",
                "prediction": "Side Effect:CNS-related adverse events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "CC"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.957622230052948,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9646217823028564,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs28399499",
                "prediction": "rs28399499"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "CC + CT",
                "prediction": "TC/CC"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Central Nervous System Disorder",
                "prediction": "Side Effect:CNS-related adverse events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "TT",
                "prediction": "TT"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9047178030014038,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9999999403953552,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.962837278842926
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs3745274",
                "prediction": "rs3745274"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "T",
                "prediction": "GT, TT"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Efficacy:virological response",
                "prediction": "Efficacy:Virological response"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "G",
                "prediction": "GG"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9427328109741211,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9646217823028564,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9421090483665466
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs1045642",
                "prediction": "rs1045642"
              },
              "Gene": {
                "ground_truth": "ABCB1",
                "prediction": "ABCB1"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "AA",
                "prediction": "TT"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Central Nervous System Disorder",
                "prediction": "Side Effect:CNS-related adverse events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "GG",
                "prediction": "CC"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 0.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9412816166877747,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9529182314872742
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs2472677",
                "prediction": "rs2472677"
              },
              "Gene": {
                "ground_truth": "NR1I2",
                "prediction": "NR1I2"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "other"
              },
              "Alleles": {
                "ground_truth": "TT",
                "prediction": "TT"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Discontinuation",
                "prediction": "Other:Treatment discontinuation"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC + CT",
                "prediction": "CC"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 0.0,
              "Alleles": 0.9504790902137756,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9412816166877747,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs3745274",
                "prediction": "rs3745274"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "other"
              },
              "Alleles": {
                "ground_truth": "GT + TT",
                "prediction": "GT"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Discontinuation",
                "prediction": "Other:Treatment discontinuation"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "GG",
                "prediction": "GG"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 6,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 0.0,
              "Alleles": 0.941425621509552,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9412816166877747,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs3745274",
                "prediction": "rs3745274"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "other"
              },
              "Alleles": {
                "ground_truth": "GT + TT",
                "prediction": "TT"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Discontinuation",
                "prediction": "Other:Treatment discontinuation"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "GG",
                "prediction": "GG"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 7,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.8873064517974854,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9999999403953552,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9177970290184021
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs3745274",
                "prediction": "rs28399499"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "T",
                "prediction": "TC/CC"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Efficacy:virological response",
                "prediction": "Efficacy:Virological response"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "G",
                "prediction": "TT"
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "PA166155409",
          "PA166156358",
          "PA166155409",
          "PA166157284",
          "PA166155478",
          "PA166155420",
          "cyp2b6+efavirenz",
          "cyp2b6+efavirenz"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "rs8192726",
            "Gene": "CYP2A6",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "other",
            "Significance": "yes",
            "Notes": "CYP2A6*9B CA/AA carriers had 100% increased risk of overall discontinuation (HR 2.00, 95% CI 1.14-3.52, p=0.016).",
            "Sentence": "CYP2A6*9B CA/AA is associated with increased risk of treatment discontinuation when treated with efavirenz in people with HIV infection.",
            "Alleles": "CA/AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Other:Treatment discontinuation",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Possession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively), whereas NR1I2 63396TT carriers were at decreased risk (22 %).",
              "Following adjustment for age, sex and dose, and stratifying by country, CYP2B6 516GT, TT and CYP2A6*9B heterozygote or homozygous variant (CA or AA) patients had an 80, 166 and 100 % increased risk of overall discontinuation, respectively, whereas NR1I2 63396TT carriers had a 22 % reduced risk (Table 4)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs8192726",
              "variant_id": "PA166155447",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "efavirenz",
              "drug_id": "PA449441",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 10,
            "Variant/Haplotypes": "rs4803419",
            "Gene": "CYP2B6",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "CYP2B6 15582C>T was not associated with achieving pVL <200 copies/mL at 96 weeks (p=1.000).",
            "Sentence": "CYP2B6 15582C>T is not associated with virological response when treated with efavirenz in people with HIV infection.",
            "Alleles": "CT/TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Efficacy:Virological response",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table 3).",
              "CYP2B6 15582C>T CC 294/301 (97.7) 7/301 (2.3) 1.000 CT/TT 238/244 (97.5) 6/244 (2.5)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs4803419",
              "variant_id": "PA166155420",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "efavirenz",
              "drug_id": "PA449441",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 11,
            "Variant/Haplotypes": "rs8192726",
            "Gene": "CYP2A6",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "CYP2A6*9B was not associated with achieving pVL <200 copies/mL at 96 weeks (p=0.470).",
            "Sentence": "CYP2A6*9B is not associated with virological response when treated with efavirenz in people with HIV infection.",
            "Alleles": "CA/AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Efficacy:Virological response",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2A6*9B\nCC\t440/450 (97.8)\t10/450 (2.2)\t0.470\nCA/AA\t89/92 (96.7)\t3/92 (3.3)",
              "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table 3).",
              "Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs8192726",
              "variant_id": "PA166155447",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "efavirenz",
              "drug_id": "PA449441",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 12,
            "Variant/Haplotypes": "rs28399454",
            "Gene": "CYP2A6",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "CYP2A6*17 was not associated with achieving pVL <200 copies/mL at 96 weeks (p=0.634).",
            "Sentence": "CYP2A6*17 is not associated with virological response when treated with efavirenz in people with HIV infection.",
            "Alleles": "CT/TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Efficacy:Virological response",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP2A6*17 (rs28399454)",
              "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table 3).",
              "CYP2A6*17\nCC\t477/488 (97.7)\t11/488 (2.3)\t0.634\nCT/TT\t54/56 (96.4)\t2/56 (3.6)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs28399454",
              "variant_id": "PA166155475",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "efavirenz",
              "drug_id": "PA449441",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 13,
            "Variant/Haplotypes": "rs35599367",
            "Gene": "CYP3A4",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "CYP3A4*22 was not associated with achieving pVL <200 copies/mL at 96 weeks (p=0.487).",
            "Sentence": "CYP3A4*22 is not associated with virological response when treated with efavirenz in people with HIV infection.",
            "Alleles": "GA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Efficacy:Virological response",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "GG",
            "Comparison Metabolizer types": null,
            "Citations": [
              "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table 3).",
              "CYP3A4*22 GG 506/518 (97.7) 12/518 (2.3) 0.487 GA 26/27 (96.3) 1/27 (3.7)",
              "Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs35599367",
              "variant_id": "PA166157487",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "efavirenz",
              "drug_id": "PA449441",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 14,
            "Variant/Haplotypes": "rs1045642",
            "Gene": "ABCB1",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "ABCB1 3435C>T was not associated with achieving pVL <200 copies/mL at 96 weeks (p=0.797).",
            "Sentence": "ABCB1 3435C>T is not associated with virological response when treated with efavirenz in people with HIV infection.",
            "Alleles": "CT, TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Efficacy:Virological response",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table 3).",
              "ABCB1 3435C>T | CC | 232/239 (97.1) | 7/239 (2.9) | 0.797 | CT | 227/232 (97.8) | 5/232 (2.2) | | TT | 74/75 (98.7) | 1/75 (1.3) |",
              "Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1045642",
              "variant_id": "PA166157284",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "efavirenz",
              "drug_id": "PA449441",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 15,
            "Variant/Haplotypes": "rs2472677",
            "Gene": "NR1I2",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "NR1I2 63396C>T was not associated with achieving pVL <200 copies/mL at 96 weeks (p=0.462).",
            "Sentence": "NR1I2 63396C>T is not associated with virological response when treated with efavirenz in people with HIV infection.",
            "Alleles": "CT, TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Efficacy:Virological response",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table 3).",
              "NR1I2 63396 C>T | CC | 135/139 (97.1) | 4/139 (2.9) | 0.462 | CT | 269/277 (97.1) | 8/277 (2.9) | | TT | 126/127 (99.2) | 1/127 (0.8) |",
              "Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2472677",
              "variant_id": "PA166156358",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "efavirenz",
              "drug_id": "PA449441",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 16,
            "Variant/Haplotypes": "rs6785049",
            "Gene": "NR1I2",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "NR1I2 7635A>G was not associated with achieving pVL <200 copies/mL at 96 weeks (p=0.610).",
            "Sentence": "NR1I2 7635A>G is not associated with virological response when treated with efavirenz in people with HIV infection.",
            "Alleles": "AG, GG",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Efficacy:Virological response",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "AA",
            "Comparison Metabolizer types": null,
            "Citations": [
              "NR1I2 7635A>G |  |  |  |\n| GG | 283/292 (96.9) | 9/292 (3.1) | 0.610 |\n| GA | 183/186 (98.4) | 3/186 (1.6) |   |\n| AA | 64/65 (98.5) | 1/65 (1.5) |   |",
              "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table 3).",
              "Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs6785049",
              "variant_id": "PA166156411",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "efavirenz",
              "drug_id": "PA449441",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 17,
            "Variant/Haplotypes": "rs2307424",
            "Gene": "NR1I3",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "NR1I3 540C>T was not associated with achieving pVL <200 copies/mL at 96 weeks (p=0.324).",
            "Sentence": "NR1I3 540C>T is not associated with virological response when treated with efavirenz in people with HIV infection.",
            "Alleles": "CT, TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Efficacy:Virological response",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table 3).",
              "NR1I3 540C>T | CC | 258/265 (97.4) | 7/265 (2.6) | 0.324 | CT | 192/198 (97.0) | 6/198 (3.0) | | TT | 83/83 (100) | 0/83 (0.0) |",
              "Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2307424",
              "variant_id": "PA166153700",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "efavirenz",
              "drug_id": "PA449441",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 18,
            "Variant/Haplotypes": "rs3003596",
            "Gene": "NR1I3",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "NR1I3 1089T>C was not associated with achieving pVL <200 copies/mL at 96 weeks (p=0.718).",
            "Sentence": "NR1I3 1089T>C is not associated with virological response when treated with efavirenz in people with HIV infection.",
            "Alleles": "TC, CC",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Efficacy:Virological response",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "TT",
            "Comparison Metabolizer types": null,
            "Citations": [
              "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table 3).",
              "NR1I3 1089T>C | TT | 140/143 (97.9) | 3/143 (2.1) | 0.718 | TC | 258/266 (97.0) | 8/266 (3.0) | | CC | 135/137 (98.5) | 2/137 (1.5) |",
              "Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs3003596",
              "variant_id": "PA166153729",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "efavirenz",
              "drug_id": "PA449441",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.6561904761904762,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.7714285714285715,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.8,
              0.8,
              0.8,
              0.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 0.7857142857142857,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.5,
              0.5,
              0.5
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 0.42857142857142855,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 0.42857142857142855,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 0.42857142857142855,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 7,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.0,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1448993833,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993831,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, clinical trial",
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 606.0,
                "prediction": 606
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "ENCORE1 study, HIV-infected treatment-naive adults, CNS adverse events (multivariable), ABCB1 3435TT carriers"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.006",
                "prediction": "= 0.006"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 2.14,
                "prediction": 2.14
              },
              "Confidence Interval Start": {
                "ground_truth": 1.25,
                "prediction": 1.25
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.67,
                "prediction": 3.67
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.0,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1448993812,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993810,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, clinical trial",
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 606.0,
                "prediction": 606
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "ENCORE1 study, HIV-infected treatment-naive adults, CNS adverse events (multivariable), CYP2B6 983TC/CC carriers"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.01",
                "prediction": "= 0.010"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 0.3,
                "prediction": 0.3
              },
              "Confidence Interval Start": {
                "ground_truth": 0.12,
                "prediction": 0.12
              },
              "Confidence Interval Stop": {
                "ground_truth": 0.75,
                "prediction": 0.75
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.0,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1448993822,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993820,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, clinical trial",
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 606.0,
                "prediction": 606
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "ENCORE1 study, HIV-infected treatment-naive adults, CNS adverse events (multivariable), CYP2B6 15582CT/TT carriers"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.011",
                "prediction": "= 0.011"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 1.59,
                "prediction": 1.59
              },
              "Confidence Interval Start": {
                "ground_truth": 1.11,
                "prediction": 1.11
              },
              "Confidence Interval Stop": {
                "ground_truth": 2.27,
                "prediction": 2.27
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.8,
              "Study Controls": 1.0,
              "Characteristics": 0.0,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1448993785,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993783,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, clinical trial",
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 569.0,
                "prediction": 606
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "ENCORE1 study, HIV-infected treatment-naive adults, efavirenz discontinuation due to adverse events, EFV600 vs EFV400"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.016",
                "prediction": "= 0.016"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 2.54
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 1.19
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 5.43
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.8,
              "Study Controls": 1.0,
              "Characteristics": 0.0,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1448993769,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993767,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, clinical trial",
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 573.0,
                "prediction": 606
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "ENCORE1 study, HIV-infected treatment-naive adults, efavirenz 400mg vs 600mg, CNS adverse events, CYP2B6 983TC/CC carriers"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.01",
                "prediction": "= 0.015"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.35
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.15
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 0.81
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.8,
              "Study Controls": 1.0,
              "Characteristics": 0.0,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1448993796,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993794,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, clinical trial",
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 570.0,
                "prediction": 606
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "ENCORE1 study, HIV-infected treatment-naive adults, efavirenz 400mg vs 600mg, CNS adverse events, CYP2B6 15582CT/TT carriers"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.008",
                "prediction": "= 0.040"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 1.46
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 1.02
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 2.09
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 6,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.0,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1448993766,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993759,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, clinical trial",
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 546.0,
                "prediction": 606
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "ENCORE1 study, HIV-infected treatment-naive adults, efavirenz 400mg vs 600mg, CNS adverse events, ABCB1 3435TT carriers"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.42",
                "prediction": "= 0.003"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 2.31
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 1.33
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 4.02
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "cohort, clinical trial",
          "cohort, clinical trial",
          "cohort, clinical trial",
          "cohort, clinical trial",
          "cohort, clinical trial",
          "cohort, clinical trial",
          "cohort, clinical trial"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 606,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation, CYP2B6 516GT carriers",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.047",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.8,
            "Confidence Interval Start": 1.01,
            "Confidence Interval Stop": 3.21,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 606,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation, CYP2B6 516TT carriers",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.010",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 2.66,
            "Confidence Interval Start": 1.26,
            "Confidence Interval Stop": 5.6,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 606,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation, CYP2A6*9B CA/AA carriers",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.016",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 2.0,
            "Confidence Interval Start": 1.14,
            "Confidence Interval Stop": 3.52,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 606,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation, NR1I2 63396TT carriers",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.008",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.22,
            "Confidence Interval Start": 0.07,
            "Confidence Interval Stop": 0.67,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 606,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, pVL <200 copies/mL at 96 weeks, logC12",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.204",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 5.25,
            "Confidence Interval Start": 0.41,
            "Confidence Interval Stop": 67.9,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 261,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation univariable, CYP2B6 516GT",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.154",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.48,
            "Confidence Interval Start": 0.86,
            "Confidence Interval Stop": 2.54,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 59,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation univariable, CYP2B6 516TT",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.010",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 2.53,
            "Confidence Interval Start": 1.25,
            "Confidence Interval Stop": 5.12,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 39,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation univariable, CYP2B6 983TC/CC",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.082",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.93,
            "Confidence Interval Start": 0.92,
            "Confidence Interval Stop": 4.03,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 253,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation univariable, CYP2B6 15582CT/TT",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.212",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.73,
            "Confidence Interval Start": 0.45,
            "Confidence Interval Stop": 1.2,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 104,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation univariable, CYP2A6*9B CA/AA",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.024",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.85,
            "Confidence Interval Start": 1.09,
            "Confidence Interval Stop": 3.14,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 58,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation univariable, CYP2A6*17 CT/TT",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.240",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.55,
            "Confidence Interval Start": 0.2,
            "Confidence Interval Stop": 1.5,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 204,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation univariable, NR1I3 540CT",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.013",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.49,
            "Confidence Interval Start": 0.27,
            "Confidence Interval Stop": 0.86,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 84,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation univariable, NR1I3 540TT",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.098",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.51,
            "Confidence Interval Start": 0.23,
            "Confidence Interval Stop": 1.13,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 28,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation univariable, CYP3A4*22 GA",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.284",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.65,
            "Confidence Interval Start": 0.66,
            "Confidence Interval Stop": 4.1,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 238,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation univariable, ABCB1 3435CT",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.017",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.53,
            "Confidence Interval Start": 0.31,
            "Confidence Interval Stop": 0.89,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 77,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation univariable, ABCB1 3435TT",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.046",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.39,
            "Confidence Interval Start": 0.15,
            "Confidence Interval Stop": 0.98,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 292,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation univariable, NR1I2 63396CT",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.635",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.88,
            "Confidence Interval Start": 0.53,
            "Confidence Interval Stop": 1.48,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 129,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation univariable, NR1I2 63396TT",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.002",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.19,
            "Confidence Interval Start": 0.07,
            "Confidence Interval Stop": 0.54,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 194,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation univariable, NR1I2 7635GA",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.478",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.83,
            "Confidence Interval Start": 0.49,
            "Confidence Interval Stop": 1.4,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 66,
            "Study Controls": null,
            "Characteristics": "ENCORE1 study, HIV-infected treatment-naive adults, overall discontinuation univariable, NR1I2 7635AA",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.402",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.69,
            "Confidence Interval Start": 0.29,
            "Confidence Interval Stop": 1.63,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC5561238": {
      "var-pheno": {
        "overall_score": 0.6752018445684004,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.7906976744186046,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 0.8837209302325582,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Drug(s)": {
            "mean_score": 0.8837209302325582,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.8837209302325582,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Alleles": {
            "mean_score": 0.8819194671719573,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.9865566492080688,
              0.9795907139778137,
              0.979455292224884,
              0.9769344329833984,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.8837209302325582,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.18604651162790697,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.8200040251709694,
            "scores": [
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9259295463562012,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.9279525279998779,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 0.8837209302325582,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 43,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:32",
                "prediction": "HLA-B*15:32"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*15:32",
                "prediction": "*15:32"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:35",
                "prediction": "HLA-B*15:35"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*15:35",
                "prediction": "*15:35"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:12",
                "prediction": "HLA-B*15:12"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*15:12",
                "prediction": "*15:12"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:01",
                "prediction": "HLA-B*15:01"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*15:01",
                "prediction": "*15:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:27",
                "prediction": "HLA-B*15:27"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*15:27",
                "prediction": "*15:27"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:25",
                "prediction": "HLA-B*15:25"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*15:25",
                "prediction": "*15:25"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 6,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*15:24",
                "prediction": "HLA-B*15:24"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*15:24",
                "prediction": "*15:24"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 7,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9259295463562012,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*52:01",
                "prediction": "HLA-B*52:01"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*52:01",
                "prediction": "*52:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 8,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*67:01",
                "prediction": "HLA-B*67:01"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*67:01",
                "prediction": "*67:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 9,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*78:01",
                "prediction": "HLA-B*78:01"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*78:01",
                "prediction": "*78:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 10,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*51:02",
                "prediction": "HLA-B*51:02"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*51:02",
                "prediction": "*51:02"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 11,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*39:01",
                "prediction": "HLA-B*39:01"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*39:01",
                "prediction": "*39:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 12,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-C*05:01",
                "prediction": "HLA-C*05:01"
              },
              "Gene": {
                "ground_truth": "HLA-C",
                "prediction": "HLA-C"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*05:01",
                "prediction": "*05:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 13,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*51:01",
                "prediction": "HLA-B*51:01"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*51:01",
                "prediction": "*51:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 14,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*39:10",
                "prediction": "HLA-B*39:10"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*39:10",
                "prediction": "*39:10"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 15,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*38:02",
                "prediction": "HLA-B*38:02"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*38:02",
                "prediction": "*38:02"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 16,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*38:01",
                "prediction": "HLA-B*38:01"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*38:01",
                "prediction": "*38:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 17,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-DRB1*04:04",
                "prediction": "HLA-DRB1*04:04"
              },
              "Gene": {
                "ground_truth": "HLA-DRB1",
                "prediction": "HLA-DRB1"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*04:04",
                "prediction": "*04:04"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 18,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*56:01",
                "prediction": "HLA-B*56:01"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*56:01",
                "prediction": "*56:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 19,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*35:05",
                "prediction": "HLA-B*35:05"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*35:05",
                "prediction": "*35:05"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 20,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-DRB1*01:02",
                "prediction": "HLA-DRB1*01:02"
              },
              "Gene": {
                "ground_truth": "HLA-DRB1",
                "prediction": "HLA-DRB1"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*01:02",
                "prediction": "*01:02"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 21,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*39:09",
                "prediction": "HLA-B*39:09"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*39:09",
                "prediction": "*39:09"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 22,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-C*04:06",
                "prediction": "HLA-C*04:06"
              },
              "Gene": {
                "ground_truth": "HLA-C",
                "prediction": "HLA-C"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*04:06",
                "prediction": "*04:06"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 23,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*55:02",
                "prediction": "HLA-B*55:02"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*55:02",
                "prediction": "*55:02"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 24,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-DRB1*01:03",
                "prediction": "HLA-DRB1*01:03"
              },
              "Gene": {
                "ground_truth": "HLA-DRB1",
                "prediction": "HLA-DRB1"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*01:03",
                "prediction": "*01:03"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 25,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*55:01",
                "prediction": "HLA-B*55:01"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*55:01",
                "prediction": "*55:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 26,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*13:02",
                "prediction": "HLA-B*13:02"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*13:02",
                "prediction": "*13:02"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 27,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*39:06",
                "prediction": "HLA-B*39:06"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*39:06",
                "prediction": "*39:06"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 28,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-C*04:03",
                "prediction": "HLA-C*04:03"
              },
              "Gene": {
                "ground_truth": "HLA-C",
                "prediction": "HLA-C"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*04:03",
                "prediction": "*04:03"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 29,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*54:01",
                "prediction": "HLA-B*54:01"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*54:01",
                "prediction": "*54:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 30,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-DRB1*01:01",
                "prediction": "HLA-DRB1*01:01"
              },
              "Gene": {
                "ground_truth": "HLA-DRB1",
                "prediction": "HLA-DRB1"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*01:01",
                "prediction": "*01:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 31,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-C*04:01",
                "prediction": "HLA-C*04:01"
              },
              "Gene": {
                "ground_truth": "HLA-C",
                "prediction": "HLA-C"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*04:01",
                "prediction": "*04:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 32,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*39:05",
                "prediction": "HLA-B*39:05"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*39:05",
                "prediction": "*39:05"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 33,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-C*18:01",
                "prediction": "HLA-C*18:01"
              },
              "Gene": {
                "ground_truth": "HLA-C",
                "prediction": "HLA-C"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*18:01",
                "prediction": "*18:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 34,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9865566492080688,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*56:06",
                "prediction": "HLA-B*56:04"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*56:06",
                "prediction": "*56:04"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 35,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9795907139778137,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-DRB1*04:04",
                "prediction": "HLA-DRB1*04:05"
              },
              "Gene": {
                "ground_truth": "HLA-DRB1",
                "prediction": "HLA-DRB1"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*04:04",
                "prediction": "*04:05"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 36,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.979455292224884,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-DRB1*04:04",
                "prediction": "HLA-DRB1*04:08"
              },
              "Gene": {
                "ground_truth": "HLA-DRB1",
                "prediction": "HLA-DRB1"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*04:04",
                "prediction": "*04:08"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 37,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9769344329833984,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9279525279998779,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-B*51:02",
                "prediction": "HLA-B*51:07"
              },
              "Gene": {
                "ground_truth": "HLA-B",
                "prediction": "HLA-B"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*51:02",
                "prediction": "*51:07"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
                "prediction": "Side Effect:Cutaneous Hypersensitivity Reaction"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "PA165956680",
          "PA165956686",
          "PA165956231",
          "PA165955543",
          "PA165954823",
          "PA165957192",
          "PA165956201",
          "PA165954826",
          "PA165954792",
          "PA165955566",
          "PA165955505",
          "PA165955500",
          "PA165951511",
          "PA165956528",
          "PA165955262",
          "PA165951340",
          "PA165955565",
          "PA165954745",
          "PA165954816",
          "PA165957089",
          "PA165956471",
          "PA165951348",
          "PA165956463",
          "PA165954649",
          "PA165954812",
          "PA165955561",
          "PA165957085",
          "PA165956438",
          "PA165951320",
          "PA165956366",
          "PA165957046",
          "PA165955559",
          "PA165958003",
          "PA165954811",
          "hla-b+nevirapine",
          "hla-drb1+nevirapine",
          "hla-b+nevirapine",
          "hla-drb1+nevirapine"
        ],
        "unmatched_ground_truth": [
          {
            "Variant Annotation ID": 1448925913,
            "Variant/Haplotypes": "HLA-C*05:09",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
            "Sentence": "HLA-C *05:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*05:09",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448925913",
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-C*05:09",
              "variant_id": "PA165957217",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 1448926149,
            "Variant/Haplotypes": "HLA-B*57:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
            "Sentence": "HLA-B *57:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*57:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926149",
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*57:01",
              "variant_id": "PA165987830",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 1448925893,
            "Variant/Haplotypes": "HLA-C*04:07",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
            "Sentence": "HLA-C *04:07 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*04:07",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448925893",
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-C*04:07",
              "variant_id": "PA165957090",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 1449155757,
            "Variant/Haplotypes": "rs28399499",
            "Gene": "CYP2B6",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "The authors analyze rs28399499 T>C and rs3745274 G>A/T together as \"slow metabolizer\" genotypes.",
            "Sentence": "Allele C is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections as compared to allele T.",
            "Alleles": "C",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "T",
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1449155757",
            "Variant/Haplotypes_normalized": {
              "normalized": "rs28399499",
              "variant_id": "PA166155478",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 1449155771,
            "Variant/Haplotypes": "rs3745274",
            "Gene": "CYP2B6",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "The authors analyze rs28399499 T>C and rs3745274 G>A/T together as \"slow metabolizer\" genotypes.",
            "Sentence": "Allele T is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections as compared to allele G.",
            "Alleles": "T",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "G",
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1449155771",
            "Variant/Haplotypes_normalized": {
              "normalized": "rs3745274",
              "variant_id": "PA166155409",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          }
        ],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 39,
            "Variant/Haplotypes": "HLA-DRB1*04:10",
            "Gene": "HLA-DRB1",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Part of HLA-DRB1 P4 pocket risk cluster. OR=2.00 [1.23-3.24] for risk HLA-DRB1 alleles cluster.",
            "Sentence": "HLA-DRB1*04:10 is associated with increased risk of cutaneous hypersensitivity reaction when treated with nevirapine in people with HIV infection.",
            "Alleles": "*04:10",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Cutaneous Hypersensitivity Reaction",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "A HLA-DRB1 P4 pocket of the peptide binding groove common to the alleles HLA-*DRB1*01:*(*01*/02/03) and *-DRB1**04*:*(*04*/05/08/10) shows a significant secondary association with cutaneous NVP HSR.",
              "Risk HLA-DRB1 alleles HLA-DRB1*01:(01/02/03), -DRB1*04:(04/05/08/10) | 2.00 [1.23\u20133.24]"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-DRB1*04:10",
              "variant_id": "PA165951542",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 40,
            "Variant/Haplotypes": "HLA-DRB1*04:01",
            "Gene": "HLA-DRB1",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Protective allele differing from risk group only at position \u03b271 within P4 pocket. 2 cases, 26 controls, P=0.01 in Caucasians.",
            "Sentence": "HLA-DRB1*04:01 is associated with decreased risk of cutaneous hypersensitivity reaction when treated with nevirapine in people with HIV infection.",
            "Alleles": "*04:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Cutaneous Hypersensitivity Reaction",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In contrast, the predominantly Caucasian alleles *HLA-DRB1*04:01* and -*DRB1*04:15* differed from the risk group only at position \u03b271 within the P4 pocket, and yet appeared to be protective in this ancestral group (2 cases, 26 controls, p = 0.01).",
              "This suggests that \u03b271, which is key in dictating the nature of the peptide amino acid that is accommodated in the P4 pocket of the antigen binding groove, is of particular importance in NVP HSR."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-DRB1*04:01",
              "variant_id": "PA165951493",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 41,
            "Variant/Haplotypes": "HLA-DRB1*04:15",
            "Gene": "HLA-DRB1",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Protective allele differing from risk group only at position \u03b271 within P4 pocket.",
            "Sentence": "HLA-DRB1*04:15 is associated with decreased risk of cutaneous hypersensitivity reaction when treated with nevirapine in people with HIV infection.",
            "Alleles": "*04:15",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Cutaneous Hypersensitivity Reaction",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV Infection",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In contrast, the predominantly Caucasian alleles *HLA-DRB1*04:01* and -*DRB1*04:15* differed from the risk group only at position \u03b271 within the P4 pocket, and yet appeared to be protective in this ancestral group (2 cases, 26 controls, p = 0.01)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-DRB1*04:15",
              "variant_id": "PA165951548",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "nevirapine",
              "drug_id": "PA450616",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "error": "Empty predictions list",
        "overall_score": 0.0,
        "total_samples": 0
      }
    },
    "PMC8790808": {
      "var-pheno": {
        "overall_score": 0.8854166666666666,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Direction of effect": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 4,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-DQA1*02:01",
                "prediction": "HLA-DQA1*02:01"
              },
              "Gene": {
                "ground_truth": "HLA-DQA1",
                "prediction": "HLA-DQA1"
              },
              "Drug(s)": {
                "ground_truth": "pegaspargase",
                "prediction": "pegaspargase"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*02:01",
                "prediction": "*02:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Hypersensitivity",
                "prediction": "Side Effect:Hypersensitivity"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-DQB1*02:02",
                "prediction": "HLA-DQB1*02:02"
              },
              "Gene": {
                "ground_truth": "HLA-DQB1",
                "prediction": "HLA-DQB1"
              },
              "Drug(s)": {
                "ground_truth": "pegaspargase",
                "prediction": "pegaspargase"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*02:02",
                "prediction": "*02:02"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Hypersensitivity",
                "prediction": "Side Effect:Hypersensitivity"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "HLA-DRB1*07:01",
                "prediction": "HLA-DRB1*07:01"
              },
              "Gene": {
                "ground_truth": "HLA-DRB1",
                "prediction": "HLA-DRB1"
              },
              "Drug(s)": {
                "ground_truth": "pegaspargase",
                "prediction": "pegaspargase"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*07:01",
                "prediction": "*07:01"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Hypersensitivity",
                "prediction": "Side Effect:Hypersensitivity"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs9958628",
                "prediction": "rs9958628"
              },
              "Gene": {
                "ground_truth": "ARHGAP28",
                "prediction": "ARHGAP28"
              },
              "Drug(s)": {
                "ground_truth": "pegaspargase",
                "prediction": "pegaspargase"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "T",
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Hypersensitivity",
                "prediction": "Side Effect:Hypersensitivity"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "A",
                "prediction": null
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "PA165951292",
          "PA165958162",
          "PA165951644",
          "PA166250701"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "HLA-DRB1*04:02",
            "Gene": "HLA-DRB1",
            "Drug(s)": "pegaspargase",
            "PMID": 33768542,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Meta-analysis P = 6.30E-5, OR = 4.49 in EA patients.",
            "Sentence": "HLA-DRB1*04:02 is associated with increased risk of Side Effect:Hypersensitivity when treated with pegaspargase in people with Disease:Acute Lymphoblastic Leukemia.",
            "Alleles": "*04:02",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In a meta-analysis combining results from the three cohorts, among 97 HLA alleles, HLA-DQB1*02:02, HLA-DRB1*07:01, HLA-DQA1*02:01, and HLA-DRB1*04:02 had the strongest association with reactions to pegaspargase (Pmeta = 3.8\u00d710\u22129 OR 2.13, Pmeta = 2.2\u00d710\u22125 OR 1.96, Pmeta = 2.7\u00d710\u22125 OR 1.96, and Pmeta = 6.3\u00d710\u22125 OR 4.61 respectively, Table 2, Figure 1A)",
              "HLA-DRB1*04:02 | 6.30E-5 | 4.49 | 0.00 | 0.819 | 0.008"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-DRB1*04:02",
              "variant_id": "PA165951501",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "pegaspargase",
              "drug_id": "PA164760860",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "HLA-DRB1*04:05",
            "Gene": "HLA-DRB1",
            "Drug(s)": "pegaspargase",
            "PMID": 33768542,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Meta-analysis P = 5.44E-4, OR = 3.75 in EA patients.",
            "Sentence": "HLA-DRB1*04:05 is associated with increased risk of Side Effect:Hypersensitivity when treated with pegaspargase in people with Disease:Acute Lymphoblastic Leukemia.",
            "Alleles": "*04:05",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "HLA-DRB1*04:05 | 5.44E-4 | 3.75 | 0.00 | 0.711 | 0.007 | 1.78E-1 | 3.39 | 0.006 | 1.60E-2 | 3.18 | 0.009 | 2.50E-2 | 7.22 | 0.004",
              "HLA-DQB1*02:02, HLA-DRB1*07:01, HLA-DQA1*02:01, and HLA-DRB1*04:02 had the strongest association with reactions to pegaspargase (Pmeta = 3.8\u00d710\u22129 OR 2.13, Pmeta = 2.2\u00d710\u22125 OR 1.96, Pmeta = 2.7\u00d710\u22125 OR 1.96, and Pmeta = 6.3\u00d710\u22125 OR 4.61 respectively, Table 2, Figure 1A)",
              "Moreover, the top DRB1 amino acids are not shared by the top HLA-DRB1 allele hits (HLA-DRB1*07:01, *04:02, and *04:05), and therefore the mechanism of association is not readily explained by the coded amino acids."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-DRB1*04:05",
              "variant_id": "PA165951517",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "pegaspargase",
              "drug_id": "PA164760860",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "HLA-B*50:01",
            "Gene": "HLA-B",
            "Drug(s)": "pegaspargase",
            "PMID": 33768542,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "Meta-analysis P = 5.06E-3, OR = 3.13 in EA patients. Did not reach significance threshold after multiple testing adjustment.",
            "Sentence": "HLA-B*50:01 is associated with increased risk of Side Effect:Hypersensitivity when treated with pegaspargase in people with Disease:Acute Lymphoblastic Leukemia.",
            "Alleles": "*50:01",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "HLA-B*50:01 | 5.06E-3 | 3.13 | 0.00 | 0.636 | 0.008 | 2.86E-1 | 2.53 | 0.009 | 6.08E-3 | 4.07 | 0.007 | 7.55E-1 | 1.39 | 0.009",
              "Four-digit HLA alleles significantly (P < 0.05) associated with hypersensitivity reactions to pegaspargase in EAs (n = 2168) in meta-analysis."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-B*50:01",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "pegaspargase",
              "drug_id": "PA164760860",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "HLA-DQA1*01:03",
            "Gene": "HLA-DQA1",
            "Drug(s)": "pegaspargase",
            "PMID": 33768542,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "Meta-analysis P = 5.82E-3, OR = 0.54 in EA patients. Protective effect but did not reach significance threshold.",
            "Sentence": "HLA-DQA1*01:03 is associated with decreased risk of Side Effect:Hypersensitivity when treated with pegaspargase in people with Disease:Acute Lymphoblastic Leukemia.",
            "Alleles": "*01:03",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "HLA-DQA1*01:03 | 5.82E-3 | 0.54 | 0.00 | 0.852 | 0.065 | 9.16E-2 | 0.41 | 0.066 | 4.20E-2 | 0.57 | 0.066 | 3.31E-1 | 0.56 | 0.063",
              "Four-digit HLA alleles significantly (P < 0.05) associated with hypersensitivity reactions to pegaspargase in EAs (n = 2168) in meta-analysis."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-DQA1*01:03",
              "variant_id": "PA165951282",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "pegaspargase",
              "drug_id": "PA164760860",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "HLA-DQB1*06:02",
            "Gene": "HLA-DQB1",
            "Drug(s)": "pegaspargase",
            "PMID": 33768542,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "Meta-analysis P = 6.74E-3, OR = 0.66 in EA patients. Protective effect but did not reach significance threshold.",
            "Sentence": "HLA-DQB1*06:02 is associated with decreased risk of Side Effect:Hypersensitivity when treated with pegaspargase in people with Disease:Acute Lymphoblastic Leukemia.",
            "Alleles": "*06:02",
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "HLA-DQB1*06:02 | 6.74E-3 | 0.66 | 0.00 | 0.708 | 0.125 | 5.07E-1 | 0.81 | 0.122 | 1.84E-2 | 0.63 | 0.124 | 1.54E-1 | 0.54 | 0.128",
              "Four-digit HLA alleles significantly (P < 0.05) associated with hypersensitivity reactions to pegaspargase in EAs (n = 2168) in meta-analysis."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "HLA-DQB1*06:02",
              "variant_id": "PA165958103",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "pegaspargase",
              "drug_id": "PA164760860",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 10,
            "Variant/Haplotypes": "rs28383308",
            "Gene": "HLA-DQA1",
            "Drug(s)": "pegaspargase",
            "PMID": 33768542,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Top SNP hit in meta-analysis of all patients (all ancestries). P = 4.9E-14, OR = 1.95. Located 9173bp 5' of HLA-DQA1 gene. Tags HLA-DRB1*07:01 (r2=0.85) in EAs.",
            "Sentence": "rs28383308 is associated with increased risk of Side Effect:Hypersensitivity when treated with pegaspargase in people with Disease:Acute Lymphoblastic Leukemia.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "In a meta-analysis combining results from the three cohorts, all genome-wide significant variants fell in the HLA-DRB1 and -DQA1 loci on chromosome 6 (Pmeta < 5\u00d710\u22128, Table S9, Figure 1B). The top hit rs28383308 (Pmeta = 4.9\u00d710\u221214 OR 1.95) locates 9173bp 5' of the HLA-DQA1 gene. Among EA patients rs28383308 tags HLA-DRB1*07:01 (r2 = 0.85) and HLA-DQB1*02:02 to a lesser extent (r2 = 0.62, Table S10A)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs13233308",
              "variant_id": "PA166181264",
              "confidence": 0.8
            },
            "Drug(s)_normalized": {
              "normalized": "pegaspargase",
              "drug_id": "PA164760860",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 11,
            "Variant/Haplotypes": "rs1694129",
            "Gene": "HLA-DQB1",
            "Drug(s)": "pegaspargase",
            "PMID": 33768542,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Top SNP hit in EA patients. P = 1.1E-8, OR = 2.03. Located 1582bp 5' of HLA-DQB1 in histone-binding site. Tags HLA-DQB1*02:02 (r2=0.96) in EAs.",
            "Sentence": "rs1694129 is associated with increased risk of Side Effect:Hypersensitivity when treated with pegaspargase in people with Disease:Acute Lymphoblastic Leukemia.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "The top hit rs1694129 (Pmeta = 1.1\u00d710\u22128, OR 2.03) locates 1582 bp 5' of the HLA-DQB1 gene in a histone-binding site. rs1694129 tags HLA-DQB1*02:02, the top hit among imputed 4-digit HLA alleles in EAs (r2 = 0.96, Table S10B).",
              "The top allele HLA-DQB1*02:02 was tagged by HLA-DQB1 rs1694129 in EAs (r2 = 0.96) and less so in non-EAs.",
              "In a meta-analysis of EA patients in these protocols, all genome-wide significant variants fell in the HLA-DQA1 and -DQB1 locus on chromosome 6 (Pmeta < 5\u00d710\u22128, Table S11, Figure 1C)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1694129",
              "variant_id": "PA166250681",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "pegaspargase",
              "drug_id": "PA164760860",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 12,
            "Variant/Haplotypes": "rs79377225",
            "Gene": "GPBP1",
            "Drug(s)": "pegaspargase",
            "PMID": 33768542,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Genome-wide significant in non-EA patients. P = 2.5E-8, OR = 2.70. Located 43kb 3' of GPBP1.",
            "Sentence": "rs79377225 is associated with increased risk of Side Effect:Hypersensitivity when treated with pegaspargase in people with Disease:Acute Lymphoblastic Leukemia.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "The other two genome-wide significant hits among non-EAs were rs79377225 and rs11739459, located 43kb and 39kb 3' of GC-rich promoter binding protein 1 (*GPBP1*) (*P*_meta_ = 2.5\u00d710^\u22128^, OR 2.70 and *P*_meta_ = 2.7\u00d710^\u22128^, OR 2.50 respectively, Figure 1D, Table S12)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs77913725",
              "variant_id": "PA166156196",
              "confidence": 0.8
            },
            "Drug(s)_normalized": {
              "normalized": "pegaspargase",
              "drug_id": "PA164760860",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 13,
            "Variant/Haplotypes": "rs11739459",
            "Gene": "GPBP1",
            "Drug(s)": "pegaspargase",
            "PMID": 33768542,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Genome-wide significant in non-EA patients. P = 2.7E-8, OR = 2.50. Located 39kb 3' of GPBP1.",
            "Sentence": "rs11739459 is associated with increased risk of Side Effect:Hypersensitivity when treated with pegaspargase in people with Disease:Acute Lymphoblastic Leukemia.",
            "Alleles": null,
            "Specialty Population": "Pediatric",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Acute Lymphoblastic Leukemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "The other two genome-wide significant hits among non-EAs were rs79377225 and rs11739459, located 43kb and 39kb 3' of GC-rich promoter binding protein 1 (*GPBP1*) (*P*_meta_ = 2.5\u00d710^\u22128^, OR 2.70 and *P*_meta_ = 2.7\u00d710^\u22128^, OR 2.50 respectively, [Figure 1D](#F1), [Table S12](#SD1))."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs3828913",
              "variant_id": "PA166157089",
              "confidence": 0.8571428571428571
            },
            "Drug(s)_normalized": {
              "normalized": "pegaspargase",
              "drug_id": "PA164760860",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.7793030948440234,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.1,
            "scores": [
              0.0,
              0.8,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Controls": {
            "mean_score": 0.25,
            "scores": [
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.8520464226603508,
            "scores": [
              0.8566722273826599,
              0.857654869556427,
              0.8486698865890503,
              0.8486698865890503,
              0.8536256551742554,
              0.8486698865890503,
              0.8568784594535828,
              0.8455305099487305
            ]
          },
          "Characteristics Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 0.6875,
            "scores": [
              1.0,
              0.5,
              1.0,
              1.0,
              0.5,
              0.5,
              0.5,
              0.5
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 0.925,
            "scores": [
              1.0,
              0.9,
              1.0,
              1.0,
              1.0,
              0.9,
              0.8,
              0.8
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 0.875,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          }
        },
        "total_samples": 8,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8566722273826599,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1451510821,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1451510773,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "meta-analysis, GWAS",
                "prediction": "GWAS"
              },
              "Study Cases": {
                "ground_truth": 1607.0,
                "prediction": null
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "non European ancestry",
                "prediction": "Non-EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434, rs9958628 in ARHGAP28"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 8.9e-9",
                "prediction": "= 8.9E-9"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 3.69,
                "prediction": 3.69
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.8,
              "Study Controls": 0.0,
              "Characteristics": 0.857654869556427,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.9,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1451510890,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1451510886,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort",
                "prediction": "meta-analysis"
              },
              "Study Cases": {
                "ground_truth": 593.0,
                "prediction": 555
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 1613
              },
              "Characteristics": {
                "ground_truth": "AALL0232 cohort",
                "prediction": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 9.29e-5",
                "prediction": "= 2.22E-5"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 1.94,
                "prediction": 1.99
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.8486698865890503,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1451510724,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1451510720,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "meta-analysis, GWAS",
                "prediction": "meta-analysis"
              },
              "Study Cases": {
                "ground_truth": 2168.0,
                "prediction": 555
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 1613
              },
              "Characteristics": {
                "ground_truth": "meta-analysis",
                "prediction": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 2.74e-5",
                "prediction": "= 2.74E-5"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 1.99,
                "prediction": 1.99
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.8486698865890503,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1451510920,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1451510886,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "meta-analysis, GWAS",
                "prediction": "meta-analysis"
              },
              "Study Cases": {
                "ground_truth": 2168.0,
                "prediction": 555
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 1613
              },
              "Characteristics": {
                "ground_truth": "meta-analysis",
                "prediction": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 3.76e-9",
                "prediction": "= 3.76E-9"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 2.14,
                "prediction": 2.14
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.8536256551742554,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1451510810,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1451510773,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, meta-analysis",
                "prediction": "meta-analysis"
              },
              "Study Cases": {
                "ground_truth": 3897.0,
                "prediction": 555
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 1613
              },
              "Characteristics": {
                "ground_truth": "all patients",
                "prediction": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 1.2e-7",
                "prediction": "= 1.18E-2"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 3.03,
                "prediction": 3.03
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.8486698865890503,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.9,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1451510941,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1451510891,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "meta-analysis, GWAS",
                "prediction": "meta-analysis"
              },
              "Study Cases": {
                "ground_truth": 2168.0,
                "prediction": 555
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 1613
              },
              "Characteristics": {
                "ground_truth": "meta-analysis",
                "prediction": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 2.22e-5",
                "prediction": "= 1.79E-2"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 1.99,
                "prediction": 1.9
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 6,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.8568784594535828,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.8,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1451510741,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1451510720,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort",
                "prediction": "meta-analysis"
              },
              "Study Cases": {
                "ground_truth": 402.0,
                "prediction": 555
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 1613
              },
              "Characteristics": {
                "ground_truth": "TXVI cohort",
                "prediction": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 3.28e-5",
                "prediction": "= 5.06E-3"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 2.91,
                "prediction": 3.13
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 7,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8455305099487305,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 0.8,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1451510895,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1451510891,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort",
                "prediction": "GWAS"
              },
              "Study Cases": {
                "ground_truth": 402.0,
                "prediction": null
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "TXVI cohort",
                "prediction": "Non-EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434, rs79377225 near GPBP1"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 3.289e-5",
                "prediction": "= 2.5E-8"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 2.91,
                "prediction": 2.7
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "meta-analysis, GWAS:non European ancestr",
          "cohort:AALL0232 cohort",
          "meta-analysis, GWAS:meta-analysis",
          "meta-analysis, GWAS:meta-analysis",
          "cohort, meta-analysis:all patients",
          "meta-analysis, GWAS:meta-analysis",
          "cohort:TXVI cohort",
          "cohort:TXVI cohort"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": 555,
            "Study Controls": 1613,
            "Characteristics": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 6.30E-5",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 4.49,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": 555,
            "Study Controls": 1613,
            "Characteristics": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 5.44E-4",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 3.75,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": 555,
            "Study Controls": 1613,
            "Characteristics": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 5.82E-3",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.54,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": 555,
            "Study Controls": 1613,
            "Characteristics": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 6.74E-3",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.66,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": 555,
            "Study Controls": 1613,
            "Characteristics": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 1.81E-2",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.71,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": 555,
            "Study Controls": 1613,
            "Characteristics": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 3.14E-2",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.59,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": 555,
            "Study Controls": 1613,
            "Characteristics": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 3.17E-2",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.61,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": 555,
            "Study Controls": 1613,
            "Characteristics": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 4.05E-2",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.71,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": 555,
            "Study Controls": 1613,
            "Characteristics": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 4.62E-2",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.66,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": 555,
            "Study Controls": 1613,
            "Characteristics": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 4.87E-2",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.78,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "GWAS",
            "Study Cases": 555,
            "Study Controls": 3342,
            "Characteristics": "All patients (all ancestries) with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434, rs28383308",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 4.9E-14",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.95,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "GWAS",
            "Study Cases": 555,
            "Study Controls": 1613,
            "Characteristics": "EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434, rs1694129",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 1.1E-8",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.03,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "GWAS",
            "Study Cases": null,
            "Study Controls": null,
            "Characteristics": "Non-EA patients with pegaspargase hypersensitivity, meta-analysis of TXVI, AALL0232, AALL0434, rs11739459 near GPBP1",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 2.7E-8",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.5,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": null,
            "Study Controls": null,
            "Characteristics": "Non-EA patients with pegaspargase hypersensitivity, SNP2HLA-imputed HLA alleles, HLA-DRB1*07:01",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.011",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.94,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": null,
            "Study Controls": null,
            "Characteristics": "Non-EA patients with pegaspargase hypersensitivity, SNP2HLA-imputed HLA alleles, HLA-DQA1*02:01",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.024",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.09,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": null,
            "Study Controls": null,
            "Characteristics": "Non-EA patients with pegaspargase hypersensitivity, SNP2HLA-imputed HLA alleles, HLA-DQB1*02:02",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.041",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.75,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "GWAS",
            "Study Cases": null,
            "Study Controls": null,
            "Characteristics": "Non-EA patients with pegaspargase hypersensitivity, rs1694129 tagging SNP",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.013",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.01,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": null,
            "Study Controls": null,
            "Characteristics": "AA patients with pegaspargase hypersensitivity, rs9958628 in ARHGAP28",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 3.2E-5",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.03,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "African America/Afro-Caribbean",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "GWAS",
            "Study Cases": 555,
            "Study Controls": 3342,
            "Characteristics": "All patients (all ancestries) with pegaspargase hypersensitivity, rs9958628 top non-HLA hit",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 1.2E-7",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 3.03,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": null,
            "Study Controls": null,
            "Characteristics": "Trans-ancestry meta-analysis, rs11739459",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 8.8E-9",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.6,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "meta-analysis",
            "Study Cases": null,
            "Study Controls": null,
            "Characteristics": "Trans-ancestry meta-analysis, rs79377225",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 1.6E-8",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.74,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC6714829": {
      "var-drug": {
        "overall_score": 0.7360469589107915,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "PMID": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Significance": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Alleles": {
            "mean_score": 0.8783282935619354,
            "scores": [
              0.8797948360443115,
              0.8768617510795593
            ]
          },
          "Specialty Population": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Metabolizer types": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "isPlural": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.5,
            "scores": [
              0.0,
              1.0
            ]
          },
          "PD/PK terms": {
            "mean_score": 0.8290475606918335,
            "scores": [
              0.8363474011421204,
              0.8217477202415466
            ]
          },
          "Multiple drugs And/or": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Population types": {
            "mean_score": 0.9612473249435425,
            "scores": [
              0.9612473249435425,
              0.9612473249435425
            ]
          },
          "Population Phenotypes or diseases": {
            "mean_score": 0.9482986927032471,
            "scores": [
              0.9482986927032471,
              0.9482986927032471
            ]
          },
          "Multiple phenotypes or diseases And/or": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.86797034740448,
            "scores": [
              0.8590789437294006,
              0.8768617510795593
            ]
          },
          "Comparison Metabolizer types": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 2,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 0.0,
              "Significance": 0.0,
              "Alleles": 0.8797948360443115,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 0.0,
              "Is/Is Not associated": 0.0,
              "Direction of effect": 0.0,
              "PD/PK terms": 0.8363474011421204,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.9612473249435425,
              "Population Phenotypes or diseases": 0.9482986927032471,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8590789437294006,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs4149056",
                "prediction": "rs4149056"
              },
              "Gene": {
                "ground_truth": "SLCO1B1",
                "prediction": "SLCO1B1"
              },
              "PMID": {
                "ground_truth": 30336686,
                "prediction": 30336686
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "other"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "no"
              },
              "Alleles": {
                "ground_truth": "TT",
                "prediction": "CC + TC"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "PD/PK terms": {
                "ground_truth": "response to",
                "prediction": "baseline ALT, AST, or lipid levels in"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in people with",
                "prediction": "in patients with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Other:Hypercholesterolemia",
                "prediction": "Disease:Hyperlipidemia"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC + CT",
                "prediction": "TT"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "simvastatin",
                "prediction": "simvastatin"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 0.0,
              "Significance": 0.0,
              "Alleles": 0.8768617510795593,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 0.0,
              "Is/Is Not associated": 0.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.8217477202415466,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.9612473249435425,
              "Population Phenotypes or diseases": 0.9482986927032471,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8768617510795593,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs2306283",
                "prediction": "rs2306283"
              },
              "Gene": {
                "ground_truth": "SLCO1B1",
                "prediction": "SLCO1B1"
              },
              "PMID": {
                "ground_truth": 30336686,
                "prediction": 30336686
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "other"
              },
              "Significance": {
                "ground_truth": "no",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "AG + GG",
                "prediction": "AA"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "PD/PK terms": {
                "ground_truth": "response to",
                "prediction": "ALT levels in"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in people with",
                "prediction": "in patients with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Other:Hypercholesterolemia",
                "prediction": "Disease:Hyperlipidemia"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "AA",
                "prediction": "AG + GG"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "simvastatin",
                "prediction": "simvastatin"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "PA166154579",
          "PA166154547"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "rs2306283",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin",
            "PMID": 30336686,
            "Phenotype Category": "other",
            "Significance": "yes",
            "Notes": "Individuals with the 388AA genotype had higher AST levels than those with the 388AG or 388GG genotypes (P = .002).",
            "Sentence": "Genotype AA is associated with increased AST levels in patients with hyperlipidemia as compared to genotypes AG + GG.",
            "Alleles": "AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "AST levels in",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Hyperlipidemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "AG + GG",
            "Comparison Metabolizer types": null,
            "Citations": [],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2306283",
              "variant_id": "PA166154547",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "rs2306283",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin",
            "PMID": 30336686,
            "Phenotype Category": "other",
            "Significance": "yes",
            "Notes": "After adjustment for covariates, the average HDL-C level was significantly higher in patients with the 388AA genotype than in those with the 388AG or 388GG genotypes (P = .049).",
            "Sentence": "Genotype AA is associated with increased baseline HDL-C levels in patients with hyperlipidemia as compared to genotypes AG + GG.",
            "Alleles": "AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "baseline HDL-C levels in",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Hyperlipidemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "AG + GG",
            "Comparison Metabolizer types": null,
            "Citations": [],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2306283",
              "variant_id": "PA166154547",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "rs2306283",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin",
            "PMID": 30336686,
            "Phenotype Category": "other",
            "Significance": "yes",
            "Notes": "Patients with the 388AA and 521TT genotypes had significantly higher concentrations of ALT (P = .001) and AST (P = .001) compared with the 388G and 521C allele carriers.",
            "Sentence": "Genotypes 388AA + 521TT are associated with increased ALT and AST levels in patients with hyperlipidemia as compared to genotypes 388AG/GG + 521TC/CC.",
            "Alleles": "388AA + 521TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "ALT and AST levels in",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Hyperlipidemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "388AG/GG + 521TC/CC",
            "Comparison Metabolizer types": null,
            "Citations": [],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2306283, rs4149056",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "rs4149056",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin",
            "PMID": 30336686,
            "Phenotype Category": "other",
            "Significance": "yes",
            "Notes": "Patients with the 388AA and 521TT genotypes had significantly higher concentrations of ALT (P = .001) and AST (P = .001) compared with the 388G and 521C allele carriers.",
            "Sentence": "Genotypes 388AA + 521TT are associated with increased ALT and AST levels in patients with hyperlipidemia as compared to genotypes 388AG/GG + 521TC/CC.",
            "Alleles": "388AA + 521TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "ALT and AST levels in",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Hyperlipidemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "388AG/GG + 521TC/CC",
            "Comparison Metabolizer types": null,
            "Citations": [],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2306283, rs4149056",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "rs2306283",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin",
            "PMID": 30336686,
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "Individuals with the 388G allele and 521TT genotype carriers had greater TC and LDL-C reduction in response to simvastatin after 4 weeks of treatment compared to 388G allele and 521C allele carriers.",
            "Sentence": "Genotypes 388G allele + 521TT are associated with increased TC and LDL-C lowering response to simvastatin in patients with hyperlipidemia as compared to genotypes 388G allele + 521C allele carriers.",
            "Alleles": "388G + 521TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "TC and LDL-C lowering response to",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Hyperlipidemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "388G + 521C carriers",
            "Comparison Metabolizer types": null,
            "Citations": [],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2306283, rs4149056",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "rs4149056",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin",
            "PMID": 30336686,
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "Individuals with the 388G allele and 521TT genotype carriers had greater TC and LDL-C reduction in response to simvastatin after 4 weeks of treatment compared to 388G allele and 521C allele carriers.",
            "Sentence": "Genotypes 388G allele + 521TT are associated with increased TC and LDL-C lowering response to simvastatin in patients with hyperlipidemia as compared to genotypes 388G allele + 521C allele carriers.",
            "Alleles": "388G + 521TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "TC and LDL-C lowering response to",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Hyperlipidemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "388G + 521C carriers",
            "Comparison Metabolizer types": null,
            "Citations": [],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2306283, rs4149056",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "rs2306283",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin",
            "PMID": 30336686,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "No significant associations were found between the 521T>C and 388A>G polymorphisms and the lipid-lowering effects of simvastatin treatment after 8 weeks.",
            "Sentence": "Genotypes rs2306283 and rs4149056 are not associated with lipid-lowering response to simvastatin after 8 weeks of treatment in patients with hyperlipidemia.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "lipid-lowering response to",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Hyperlipidemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2306283, rs4149056",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "rs4149056",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin",
            "PMID": 30336686,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "No significant associations were found between the 521T>C and 388A>G polymorphisms and the lipid-lowering effects of simvastatin treatment after 8 weeks.",
            "Sentence": "Genotypes rs2306283 and rs4149056 are not associated with lipid-lowering response to simvastatin after 8 weeks of treatment in patients with hyperlipidemia.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "lipid-lowering response to",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Hyperlipidemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2306283, rs4149056",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "rs2306283",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin",
            "PMID": 30336686,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "No associations between the SLCO1B1 388A>G genotypes and the presence of CK elevations were found.",
            "Sentence": "Genotype rs2306283 is not associated with CK elevations after simvastatin treatment in patients with hyperlipidemia.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "CK elevations after",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Hyperlipidemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2306283",
              "variant_id": "PA166154547",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 9,
            "Variant/Haplotypes": "rs4149056",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin",
            "PMID": 30336686,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "No associations between the SLCO1B1 521T>C genotypes and the presence of CK elevations were found.",
            "Sentence": "Genotype rs4149056 is not associated with CK elevations after simvastatin treatment in patients with hyperlipidemia.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "CK elevations after",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Hyperlipidemia",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs4149056",
              "variant_id": "PA166154579",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.7666666666666667,
        "field_scores": {
          "Study Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Study Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 0.5,
            "scores": [
              0.5,
              0.5
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 2,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.0,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1451226980,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1451226960,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort",
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 542.0,
                "prediction": 542
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "Chinese patients with hyperlipidemia, 388AA vs 388AG+GG genotypes, ALT levels"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "disease"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.016",
                "prediction": "= 0.037"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.0,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1451227040,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1451227020,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort",
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 542.0,
                "prediction": 542
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "Chinese patients with hyperlipidemia, 388AA vs 388AG+GG genotypes, AST levels"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "disease"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.52",
                "prediction": "= 0.002"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "cohort",
          "cohort"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 542,
            "Study Controls": null,
            "Characteristics": "Chinese patients with hyperlipidemia, 388AA vs 388AG+GG genotypes, HDL-C levels (adjusted)",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.049",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 84,
            "Study Controls": 458,
            "Characteristics": "Chinese patients with hyperlipidemia, abnormal ALT (>=40 U/L) vs normal ALT, 388AG+GG genotype",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.018",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.4,
            "Confidence Interval Start": 0.2,
            "Confidence Interval Stop": 0.9,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 88,
            "Study Controls": 454,
            "Characteristics": "Chinese patients with hyperlipidemia, abnormal AST (>=40 U/L) vs normal AST, 388AG+GG genotype",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.038",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.5,
            "Confidence Interval Start": 0.2,
            "Confidence Interval Stop": 1.0,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 542,
            "Study Controls": null,
            "Characteristics": "Chinese patients with hyperlipidemia, 388AA+521TT vs 388AG/GG+521CC/TC genotypes, ALT levels (adjusted)",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 542,
            "Study Controls": null,
            "Characteristics": "Chinese patients with hyperlipidemia, 388AA+521TT vs 388AG/GG+521CC/TC genotypes, AST levels (adjusted)",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 84,
            "Study Controls": 458,
            "Characteristics": "Chinese patients with hyperlipidemia, abnormal ALT vs normal ALT, 388A/521T haplotype frequency",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.35,
            "Allele Of Frequency In Cases": "388A/521T",
            "Frequency In Controls": 0.27,
            "Allele Of Frequency In Controls": "388A/521T",
            "P Value": "= 0.038",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 84,
            "Study Controls": 458,
            "Characteristics": "Chinese patients with hyperlipidemia, abnormal ALT vs normal ALT, 388G/521T haplotype frequency",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.54,
            "Allele Of Frequency In Cases": "388G/521T",
            "Frequency In Controls": 0.62,
            "Allele Of Frequency In Controls": "388G/521T",
            "P Value": "= 0.04",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 88,
            "Study Controls": 454,
            "Characteristics": "Chinese patients with hyperlipidemia, abnormal AST vs normal AST, 388A/521T haplotype frequency",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.36,
            "Allele Of Frequency In Cases": "388A/521T",
            "Frequency In Controls": 0.26,
            "Allele Of Frequency In Controls": "388A/521T",
            "P Value": "= 0.007",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 88,
            "Study Controls": 454,
            "Characteristics": "Chinese patients with hyperlipidemia, abnormal AST vs normal AST, 388G/521T haplotype frequency",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.54,
            "Allele Of Frequency In Cases": "388G/521T",
            "Frequency In Controls": 0.62,
            "Allele Of Frequency In Controls": "388G/521T",
            "P Value": "= 0.032",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC12331468": {
      "var-pheno": {
        "overall_score": 0.931089086830616,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 0.9308433532714844,
            "scores": [
              0.9308433532714844,
              0.9308433532714844,
              0.9308433532714844,
              0.9308433532714844,
              0.9308433532714844
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 0.899218761920929,
            "scores": [
              0.962837278842926,
              0.962837278842926,
              0.8544829487800598,
              0.8602027297019958,
              0.8557335734367371
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Direction of effect": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.9470113396644593,
            "scores": [
              1.0,
              0.9262335896492004,
              0.9509705901145935,
              0.941277027130127,
              0.9165754914283752
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.5339531898498535,
            "scores": [
              0.8730365633964539,
              0.8730365633964539,
              0.9236928224563599,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 5,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 0.9308433532714844,
              "Phenotype Category": 1.0,
              "Alleles": 0.962837278842926,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8730365633964539
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs1695",
                "prediction": "rs1695"
              },
              "Gene": {
                "ground_truth": "GSTP1",
                "prediction": "GSTP1"
              },
              "Drug(s)": {
                "ground_truth": "FOLFOX, XELOX",
                "prediction": "5-fluorouracil, oxaliplatin"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "GG",
                "prediction": "G"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Mucositis",
                "prediction": "Side Effect:Mucositis"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "AA + AG",
                "prediction": "A"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 0.9308433532714844,
              "Phenotype Category": 1.0,
              "Alleles": 0.962837278842926,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9262335896492004,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8730365633964539
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs1695",
                "prediction": "rs1695"
              },
              "Gene": {
                "ground_truth": "GSTP1",
                "prediction": "GSTP1"
              },
              "Drug(s)": {
                "ground_truth": "FOLFOX, XELOX",
                "prediction": "5-fluorouracil, oxaliplatin"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "GG",
                "prediction": "G"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Peripheral Nervous System Diseases, Side Effect:Myelosuppression",
                "prediction": "Side Effect:Neuropathy"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "AA + AG",
                "prediction": "A"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 0.9308433532714844,
              "Phenotype Category": 1.0,
              "Alleles": 0.8544829487800598,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9509705901145935,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9236928224563599
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs1801265",
                "prediction": "rs1801265"
              },
              "Gene": {
                "ground_truth": "DPYD",
                "prediction": "DPYD"
              },
              "Drug(s)": {
                "ground_truth": "FOLFOX, XELOX",
                "prediction": "5-fluorouracil, oxaliplatin"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "AG + GG",
                "prediction": "C"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Peripheral Nervous System Diseases",
                "prediction": "Side Effect:Neuropathy"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "AA",
                "prediction": "T"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 0.9308433532714844,
              "Phenotype Category": 1.0,
              "Alleles": 0.8602027297019958,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.941277027130127,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs11280056",
                "prediction": "rs11280056"
              },
              "Gene": {
                "ground_truth": "TYMS",
                "prediction": "TYMS"
              },
              "Drug(s)": {
                "ground_truth": "FOLFOX, XELOX",
                "prediction": "5-fluorouracil, oxaliplatin"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "TTA/TTA + TTA/TTAAAGTTA",
                "prediction": "DEL/DEL"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Peripheral Nervous System Diseases, Side Effect:Myelosuppression",
                "prediction": "Side Effect:Hematological Disorders"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "INS/INS"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 0.9308433532714844,
              "Phenotype Category": 1.0,
              "Alleles": 0.8557335734367371,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9165754914283752,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs45445694",
                "prediction": "rs45445694"
              },
              "Gene": {
                "ground_truth": "TYMS",
                "prediction": "TYMS"
              },
              "Drug(s)": {
                "ground_truth": "FOLFOX, XELOX",
                "prediction": "5-fluorouracil, oxaliplatin"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3",
                "prediction": "3R/3R"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Hand-foot syndrome, Side Effect:Exanthema, Side Effect:Drug Toxicity",
                "prediction": "Side Effect:Skin and Subcutaneous Tissue Disorders"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "2R/2R, 2R/3R"
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "PA166153648",
          "PA166154249",
          "PA166180936",
          "PA166155331",
          "PA166154249"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "rs11280056",
            "Gene": "TYMS",
            "Drug(s)": "5-fluorouracil, oxaliplatin",
            "PMID": 40786508,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Codominant model DEL/DEL OR = 0.100, p = 0.045. The deletion genotype was protective against gastrointestinal disorders.",
            "Sentence": "rs11280056 Is Associated with decreased risk of Side Effect:Gastrointestinal Disorders when treated with 5-fluorouracil or oxaliplatin in people with Disease:Colorectal Cancer.",
            "Alleles": "DEL/DEL",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Gastrointestinal Disorders",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Colorectal Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "INS/INS",
            "Comparison Metabolizer types": null,
            "Citations": [
              "We identified a protective correlation between the 6bp deletion of the *TYMS* 3'UTR region (rs11280056) and a lower risk of gastrointestinal and hematological disorders in chemotherapy patients.",
              "Codominant | INS/INS | 1.000 | -- | Ref. |\nINS/DEL | 0.152 | 0.007 \u2013 0.991 | 0.093 |\nDEL/DEL | 0.100 | 0.004 \u2013 0.071 | 0.045*"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs11280056",
              "variant_id": "PA166180936",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "5-fluorouracil, oxaliplatin",
              "drug_id": null,
              "confidence": 0.0
            }
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "rs13181",
            "Gene": "ERCC2",
            "Drug(s)": "5-fluorouracil, oxaliplatin",
            "PMID": 40786508,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Codominant model C/C OR = 0.100, p = 0.045. The C/C genotype was correlated with lower risk of gastrointestinal disorders.",
            "Sentence": "rs13181 Is Associated with decreased risk of Side Effect:Gastrointestinal Disorders when treated with 5-fluorouracil or oxaliplatin in people with Disease:Colorectal Cancer.",
            "Alleles": "C/C",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Gastrointestinal Disorders",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Colorectal Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "A/A",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Additionally, the C/C genotype of the *ERCC2* rs13181 polymorphism was correlated with a lower risk of gastrointestinal disorders in our study population.",
              "ERCC2 c.2251A>C (rs13181) | Codominant | A/A | 1.000 | -- | Ref. | A/C | 0.152 | 0.007 \u2013 0.991 | 0.093 | C/C | 0.100 | 0.004 \u2013 0.710 | 0.045*"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs13181",
              "variant_id": "PA166155343",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "5-fluorouracil, oxaliplatin",
              "drug_id": null,
              "confidence": 0.0
            }
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "rs1695",
            "Gene": "GSTP1",
            "Drug(s)": "5-fluorouracil, oxaliplatin",
            "PMID": 40786508,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Dominant model OR = 0.298, p = 0.001; Recessive model G/G OR = 0.157, p = 0.0005. The G allele was protective against hematological disorders.",
            "Sentence": "rs1695 Is Associated with decreased risk of Side Effect:Hematological Disorders when treated with 5-fluorouracil or oxaliplatin in people with Disease:Colorectal Cancer.",
            "Alleles": "G",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Hematological Disorders",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Colorectal Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "A/A",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The G allele of the *GSTP1* rs1695 polymorphism was correlated with a lower risk of hematological and nervous system disorders in treated patients, including a reduced risk of neuropathy.",
              "GSTP1 c.313A>G (rs1695) | Dominant | A/A | 1.000 | -- | Ref. | A/G+G/G | 0.298 | 0.013 \u2013 0.617 | 0.001* | Recessive | A/A+A/G | 1.000 | -- | Ref. | G/G | 0.157 | 0.048 \u2013 0.414 | 0.0005*"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1695",
              "variant_id": "PA166154249",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "5-fluorouracil, oxaliplatin",
              "drug_id": null,
              "confidence": 0.0
            }
          },
          {
            "Variant Annotation ID": 9,
            "Variant/Haplotypes": "rs11479",
            "Gene": "TYMP",
            "Drug(s)": "5-fluorouracil, oxaliplatin",
            "PMID": 40786508,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Dominant model OR = 5.860, p = 0.027. The T allele was associated with increased risk of pain.",
            "Sentence": "rs11479 Is Associated with increased risk of Side Effect:Pain when treated with 5-fluorouracil or oxaliplatin in people with Disease:Colorectal Cancer.",
            "Alleles": "T",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Pain",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Colorectal Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "C/C",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Additionally, we found a direct correlation between the T allele of the *TYMP* rs11479 polymorphism and an increased risk of pain in chemotherapy patients.",
              "TYMP c.1412C>T (rs11479) | Dominant | C/C | 1.000 | -- | Ref. | C/T+T/T | 5.860 | 1.381 \u2013 31.420 | 0.027*",
              "The *TYMP* c.1412C>T (rs11479) genetic variant, is a missense mutation that induces a structural change in the protein, affecting its catalytic activity. In this study it was observed that the T allele was associated with pain development."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs11479",
              "variant_id": "PA166156029",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "5-fluorouracil, oxaliplatin",
              "drug_id": null,
              "confidence": 0.0
            }
          },
          {
            "Variant Annotation ID": 10,
            "Variant/Haplotypes": "rs1128503",
            "Gene": "ABCB1",
            "Drug(s)": "5-fluorouracil, oxaliplatin",
            "PMID": 40786508,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Recessive model C/C OR = 4.200, p = 0.049. The C/C genotype was associated with higher risk of pain.",
            "Sentence": "rs1128503 Is Associated with increased risk of Side Effect:Pain when treated with 5-fluorouracil or oxaliplatin in people with Disease:Colorectal Cancer.",
            "Alleles": "C/C",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Pain",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Colorectal Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "T/T, T/C",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Additionally, we found a direct correlation between the T allele of the *TYMP* rs11479 polymorphism and an increased risk of pain in chemotherapy patients. Similarly, patients carrying the C/C genotype of the *ABCB1* rs1128503 polymorphism exhibited a higher risk of pain.",
              "ABCB1 c.1236T>C (rs1128503) | Recessive | T/T+T/C | 1.000 | -- | Ref. | C/C | 4.200 | 1.038 \u2013 19.256 | 0.049*"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1128503",
              "variant_id": "PA166157288",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "5-fluorouracil, oxaliplatin",
              "drug_id": null,
              "confidence": 0.0
            }
          },
          {
            "Variant Annotation ID": 11,
            "Variant/Haplotypes": "rs1801131",
            "Gene": "MTHFR",
            "Drug(s)": "5-fluorouracil, oxaliplatin",
            "PMID": 40786508,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Dominant model OR = 0.375, p = 0.048. The C allele was protective against pain.",
            "Sentence": "rs1801131 Is Associated with decreased risk of Side Effect:Pain when treated with 5-fluorouracil or oxaliplatin in people with Disease:Colorectal Cancer.",
            "Alleles": "C",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Pain",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Colorectal Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "A/A",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Additionally, we found a direct correlation between the T allele of the *TYMP* rs11479 polymorphism and an increased risk of pain in chemotherapy patients. Similarly, patients carrying the C/C genotype of the *ABCB1* rs1128503 polymorphism exhibited a higher risk of pain. Conversely, the C allele of the *MTHFR* rs1801131 polymorphism was correlated with a lower risk of pain, but a higher risk of nervous system disorders in chemotherapy patients.",
              "MTHFR c.1409A>C (rs1801131) | Codominant | A/A | 1.000 | -- | Ref. | A/C | 0.355 | 0.126 \u2013 0.947 | 0.042* | C/C | 0.750 | 0.028 \u2013 19.827 | 0.842 | Dominant | A/A | 1.000 | -- | Ref. | A/C+C/C | 0.375 | 0.137 \u2013 0.976 | 0.048*"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1801131",
              "variant_id": "PA166153643",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "5-fluorouracil, oxaliplatin",
              "drug_id": null,
              "confidence": 0.0
            }
          },
          {
            "Variant Annotation ID": 12,
            "Variant/Haplotypes": "rs1695",
            "Gene": "GSTP1",
            "Drug(s)": "5-fluorouracil, oxaliplatin",
            "PMID": 40786508,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Recessive model G/G OR = 0.182, p = 0.020. The G/G genotype was protective against nervous system disorders.",
            "Sentence": "rs1695 Is Associated with decreased risk of Side Effect:Nervous System Disorders when treated with 5-fluorouracil or oxaliplatin in people with Disease:Colorectal Cancer.",
            "Alleles": "G/G",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Nervous System Disorders",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Colorectal Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "A/A, A/G",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The G allele of GSTP1 (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036).",
              "The G allele of the *GSTP1* rs1695 polymorphism was correlated with a lower risk of hematological and nervous system disorders in treated patients, including a reduced risk of neuropathy.",
              "Recessive | A/A+A/G | 1.000 | -- | Ref. | G/G | 0.182 | 0.040 \u2013 0.759 | 0.020*"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1695",
              "variant_id": "PA166154249",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "5-fluorouracil, oxaliplatin",
              "drug_id": null,
              "confidence": 0.0
            }
          },
          {
            "Variant Annotation ID": 13,
            "Variant/Haplotypes": "rs1801131",
            "Gene": "MTHFR",
            "Drug(s)": "5-fluorouracil, oxaliplatin",
            "PMID": 40786508,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Dominant model OR = 5.805, p = 0.035. The C allele was associated with increased risk of nervous system disorders.",
            "Sentence": "rs1801131 Is Associated with increased risk of Side Effect:Nervous System Disorders when treated with 5-fluorouracil or oxaliplatin in people with Disease:Colorectal Cancer.",
            "Alleles": "C",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Nervous System Disorders",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Colorectal Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "A/A",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Lastly, the C allele of the *MTHFR* rs1801131 polymorphism was correlated with a lower risk of pain, but a higher risk of nervous system disorders in chemotherapy patients.",
              "MTHFR c.1409A>C (rs1801131) | Dominant | A/A | 1.000 | -- | Ref. | A/C+C/C | 5.805 | 1.324 \u2013 40.992 | 0.035*"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1801131",
              "variant_id": "PA166153643",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "5-fluorouracil, oxaliplatin",
              "drug_id": null,
              "confidence": 0.0
            }
          },
          {
            "Variant Annotation ID": 14,
            "Variant/Haplotypes": "rs11280056",
            "Gene": "TYMS",
            "Drug(s)": "5-fluorouracil, oxaliplatin",
            "PMID": 40786508,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Dominant model OR = 0.098, p = 0.005. The deletion genotype was protective against severe hematological disorders (Grade III-IV).",
            "Sentence": "rs11280056 Is Associated with decreased severity of Side Effect:Hematological Disorders when treated with 5-fluorouracil or oxaliplatin in people with Disease:Colorectal Cancer.",
            "Alleles": "DEL",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "severity of",
            "Phenotype": "Side Effect:Hematological Disorders",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Colorectal Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "INS/INS",
            "Comparison Metabolizer types": null,
            "Citations": [
              "When analyzing the risk of grouped ADR while considering only severe reactions (Grade III-IV), we found that only the *TYMS* 3'UTR 6bp deletion (rs11280056) was the only polymorphism associated with a lower risk of severe hematological disorders (dominant model OR = 0,098, CI 95% 0.013 \u2013 0.441, p-value =0.005).",
              "The *TYMS* deletion genotype (rs11280056) conferred protection against hematological adverse reactions (OR = 0.029; p = 0.001).",
              "We identified a protective correlation between the 6bp deletion of the *TYMS* 3'UTR region (rs11280056) and a lower risk of gastrointestinal and hematological disorders in chemotherapy patients."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs11280056",
              "variant_id": "PA166180936",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "5-fluorouracil, oxaliplatin",
              "drug_id": null,
              "confidence": 0.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.6754595930046505,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.8902272284030914,
            "scores": [
              0.8957003355026245,
              0.8937625288963318,
              0.8583032488822937,
              0.8864501714706421,
              0.9230504631996155,
              0.884096622467041
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 0.9083333333333333,
            "scores": [
              1.0,
              1.0,
              0.95,
              0.5,
              1.0,
              1.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 6,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8957003355026245,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454223681,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454223701,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 82.0,
                "prediction": 82
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Mucositis",
                "prediction": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, mucositis outcome, GSTP1 rs1695 G allele"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.036",
                "prediction": "= 0.036"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 2.27
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8937625288963318,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454223606,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454223600,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 82.0,
                "prediction": 82
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "neuropathy",
                "prediction": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, neuropathy outcome, DPYD rs1801265 C allele, dominant model"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.05",
                "prediction": "= 0.05"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 4.58
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8583032488822937,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.95,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454223623,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454223652,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 82.0,
                "prediction": 82
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Hematological disorders",
                "prediction": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, neuropathy outcome, DPYD rs1801265 T/C genotype, codominant model"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.005",
                "prediction": "= 0.0049"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 30.0
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8864501714706421,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454223621,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454223640,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 82.0,
                "prediction": 82
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "neuropathy",
                "prediction": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, neuropathy outcome, GSTP1 rs1695 G allele"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.02",
                "prediction": "= 0.012"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.147
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9230504631996155,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454223659,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454223625,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 82.0,
                "prediction": 82
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Skin and subcutaneous tissue disorders (recessive)",
                "prediction": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, skin and subcutaneous tissue disorders outcome, TYMS 5'UTR rs45445694 3R/3R genotype, recessive model"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.029",
                "prediction": "= 0.029"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 6.4
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 1.188
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 36.705
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.884096622467041,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454223622,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454223640,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 82.0,
                "prediction": 82
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Hematological disorders",
                "prediction": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, hematological disorders outcome, GSTP1 rs1695 recessive model"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.0005",
                "prediction": "= 0.0005"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.157
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.048
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 0.414
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "None:Mucositis",
          "None:neuropathy",
          "None:Hematological disord",
          "None:neuropathy",
          "None:Skin and subcutaneou",
          "None:Hematological disord"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, gastrointestinal disorders outcome, TYMS 3'UTR 6bp ins-del DEL/DEL genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.045",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.1,
            "Confidence Interval Start": 0.004,
            "Confidence Interval Stop": 0.071,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, gastrointestinal disorders outcome, ERCC2 rs13181 C/C genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.045",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.1,
            "Confidence Interval Start": 0.004,
            "Confidence Interval Stop": 0.71,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, hematological disorders outcome, TYMS 3'UTR 6bp ins-del INS/DEL genotype, codominant model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.002",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.156,
            "Confidence Interval Start": 0.044,
            "Confidence Interval Stop": 0.498,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, hematological disorders outcome, TYMS 3'UTR 6bp ins-del DEL/DEL genotype, codominant model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.029,
            "Confidence Interval Start": 0.004,
            "Confidence Interval Stop": 0.182,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, hematological disorders outcome, TYMS 3'UTR 6bp ins-del dominant model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.107,
            "Confidence Interval Start": 0.03,
            "Confidence Interval Stop": 0.303,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, hematological disorders outcome, TYMS 3'UTR 6bp ins-del recessive model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.015",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.075,
            "Confidence Interval Start": 0.004,
            "Confidence Interval Stop": 0.421,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, hematological disorders outcome, GSTP1 rs1695 dominant model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.298,
            "Confidence Interval Start": 0.013,
            "Confidence Interval Stop": 0.617,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, pain outcome, TYMP rs11479 dominant model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.027",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 5.86,
            "Confidence Interval Start": 1.381,
            "Confidence Interval Stop": 31.42,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, pain outcome, ABCB1 rs1128503 recessive model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.049",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 4.2,
            "Confidence Interval Start": 1.038,
            "Confidence Interval Stop": 19.256,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, pain outcome, MTHFR rs1801131 A/C genotype, codominant model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.042",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.355,
            "Confidence Interval Start": 0.126,
            "Confidence Interval Stop": 0.947,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, pain outcome, MTHFR rs1801131 dominant model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.048",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.375,
            "Confidence Interval Start": 0.137,
            "Confidence Interval Stop": 0.976,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, nervous system disorders outcome, GSTP1 rs1695 G/G genotype, codominant model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.015",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.098,
            "Confidence Interval Start": 0.011,
            "Confidence Interval Stop": 0.57,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, nervous system disorders outcome, GSTP1 rs1695 recessive model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.020",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.182,
            "Confidence Interval Start": 0.04,
            "Confidence Interval Stop": 0.759,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, nervous system disorders outcome, MTHFR rs1801131 dominant model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.035",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 5.805,
            "Confidence Interval Start": 1.324,
            "Confidence Interval Stop": 40.992,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, severe hematological disorders outcome, TYMS 3'UTR 6bp ins-del dominant model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.005",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.098,
            "Confidence Interval Start": 0.013,
            "Confidence Interval Stop": 0.441,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, anemia multivariate model, TYMP rs11479 T/T genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.038",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 23.76,
            "Confidence Interval Start": 1.722,
            "Confidence Interval Stop": 986.648,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, pain multivariate model, ERCC2 rs13181 C/C genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.034",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 6.272,
            "Confidence Interval Start": 1.285,
            "Confidence Interval Stop": 40.539,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 82,
            "Study Controls": null,
            "Characteristics": "Advanced colorectal cancer patients treated with 5-FU-based chemotherapy, pain multivariate model, MTHFR rs1801131 dominant model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.034",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.159,
            "Confidence Interval Start": 0.025,
            "Confidence Interval Stop": 0.778,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC6465603": {
      "var-pheno": {
        "overall_score": 0.9028932216266791,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 0.9129566252231598,
            "scores": [
              0.9053431153297424,
              0.9205701351165771
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              0.0
            ]
          },
          "Phenotype": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.9652837216854095,
            "scores": [
              0.9663923382759094,
              0.9641751050949097
            ]
          }
        },
        "total_samples": 2,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9053431153297424,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9663923382759094
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs116855232",
                "prediction": "rs116855232"
              },
              "Gene": {
                "ground_truth": "NUDT15",
                "prediction": "NUDT15"
              },
              "Drug(s)": {
                "ground_truth": "azathioprine",
                "prediction": "azathioprine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "T"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Leukopenia",
                "prediction": "Side Effect:Leukopenia"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "C"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9205701351165771,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9641751050949097
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs1142345",
                "prediction": "rs1142345"
              },
              "Gene": {
                "ground_truth": "TPMT",
                "prediction": "TPMT"
              },
              "Drug(s)": {
                "ground_truth": "azathioprine",
                "prediction": "azathioprine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "C",
                "prediction": "TC, CC"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Leukopenia",
                "prediction": "Side Effect:Leukopenia"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "T",
                "prediction": "TT"
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "PA166156978",
          "PA166154759"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "rs116855232",
            "Gene": "NUDT15",
            "Drug(s)": "azathioprine",
            "PMID": 31024313,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Dominant model: OR = 89.47 (10.78, 742.53), P < 0.0001. CT and TT genotypes compared to CC.",
            "Sentence": "rs116855232 CT or TT genotype is associated with increased risk of Side Effect:Leukopenia when treated with azathioprine in people with Disease:Autoimmune Hepatitis and Disease:Cirrhosis.",
            "Alleles": "CT, TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Leukopenia",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Autoimmune Hepatitis, Disease:Cirrhosis",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Twelve patients developed leukopenia, and this adverse drug reaction was significantly associated with the T risk allele in NUDT15 [P < 0.00001, odds ratio = 20.41; 95% confidence interval (CI) (7.84, 53.13)], with the sensitivity and specificity of 91.67 and 89.05%, respectively.",
              "Dominant model OR (95% CI) P-value 89.47 (10.78, 742.53) P < 0.0001",
              "Therefore, NUDT15 polymorphism is significantly associated with thiopurine-induced leukopenia in Chinese patients with AIH and related cirrhosis."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs116855232",
              "variant_id": "PA166154759",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "azathioprine",
              "drug_id": "PA448515",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "rs116855232",
            "Gene": "NUDT15",
            "Drug(s)": "azathioprine",
            "PMID": 31024313,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Recessive model: OR = 65.48 (2.95, 1454.21), P = 0.008. TT genotype compared to CC and CT.",
            "Sentence": "rs116855232 TT genotype is associated with increased risk of Side Effect:Leukopenia when treated with azathioprine in people with Disease:Autoimmune Hepatitis and Disease:Cirrhosis.",
            "Alleles": "TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Leukopenia",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Autoimmune Hepatitis, Disease:Cirrhosis",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "CC, CT",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Therapy-induced leukopenia was observed in 9/24 (37.5%) patients with the CT allele and 2/2 (100%) patients with the TT allele. However, only one patient with wild-type homozygote allele experienced leukopenia.",
              "Recessive model OR (95% CI) P-value ... 65.48 (2.95, 1454.21) P = 0.008",
              "Our results found that the rs116855232 but not the rs1142345 genotype was significantly associated with AZA-induced leukopenia and the maintenance dose in Chinese patients with AIH and related cirrhosis."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs116855232",
              "variant_id": "PA166154759",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "azathioprine",
              "drug_id": "PA448515",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.5622568110624949,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.9338521659374237,
            "scores": [
              0.9559689164161682,
              0.9117354154586792
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              0.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              0.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "P Value": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 2,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9559689164161682,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1451237506,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1451237500,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 12.0,
                "prediction": 12
              },
              "Study Controls": {
                "ground_truth": 137.0,
                "prediction": 137
              },
              "Characteristics": {
                "ground_truth": "AZA-induced leukopenia in Chinese patients with AIH",
                "prediction": "Chinese AIH patients with azathioprine-induced leukopenia - NUDT15 rs116855232 dominant model"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "T"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": "T"
              },
              "P Value": {
                "ground_truth": "< 0.0001",
                "prediction": "< 0.0001"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 89.47,
                "prediction": 89.47
              },
              "Confidence Interval Start": {
                "ground_truth": 10.78,
                "prediction": 10.78
              },
              "Confidence Interval Stop": {
                "ground_truth": 742.53,
                "prediction": 742.53
              },
              "Biogeographical Groups": {
                "ground_truth": null,
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9117354154586792,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1451237470,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1451237464,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case/control",
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 12.0,
                "prediction": 12
              },
              "Study Controls": {
                "ground_truth": 137.0,
                "prediction": 137
              },
              "Characteristics": {
                "ground_truth": "AZA-induced leukopenia in Chinese patients with AIH",
                "prediction": "Chinese AIH patients - TPMT rs1142345 genotype distribution"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "disease"
              },
              "Frequency In Cases": {
                "ground_truth": 0.042,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "C",
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": 0.015,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "C",
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.283",
                "prediction": "= 0.283"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": null,
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "case/control:AZA-induced leukopen",
          "case/control:AZA-induced leukopen"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 12,
            "Study Controls": 137,
            "Characteristics": "Chinese AIH patients with azathioprine-induced leukopenia - NUDT15 rs116855232 allele model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": "T",
            "P Value": "< 0.00001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 20.41,
            "Confidence Interval Start": 7.84,
            "Confidence Interval Stop": 53.13,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 12,
            "Study Controls": 137,
            "Characteristics": "Chinese AIH patients with azathioprine-induced leukopenia - NUDT15 rs116855232 recessive model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": "T",
            "P Value": "= 0.008",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 65.48,
            "Confidence Interval Start": 2.95,
            "Confidence Interval Stop": 1454.21,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 12,
            "Study Controls": 137,
            "Characteristics": "Chinese AIH patients with azathioprine-induced leukopenia during first 8 weeks - NUDT15 rs116855232 dominant model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": "T",
            "P Value": "< 0.0001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 89.47,
            "Confidence Interval Start": 10.78,
            "Confidence Interval Stop": 742.53,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 12,
            "Study Controls": 137,
            "Characteristics": "Chinese AIH patients with azathioprine-induced leukopenia during first 8 weeks - NUDT15 rs116855232 recessive model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": "T",
            "P Value": "= 0.008",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 65.48,
            "Confidence Interval Start": 2.95,
            "Confidence Interval Stop": 1454.21,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 12,
            "Study Controls": 137,
            "Characteristics": "Chinese AIH patients with azathioprine-induced leukopenia during first 8 weeks - NUDT15 rs116855232 allele model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": "T",
            "P Value": "< 0.00001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 20.41,
            "Confidence Interval Start": 7.84,
            "Confidence Interval Stop": 53.13,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 12,
            "Study Controls": 137,
            "Characteristics": "Chinese AIH patients - NUDT15 rs116855232 genotype distribution",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 93,
            "Study Controls": null,
            "Characteristics": "Chinese AIH patients - NUDT15 rs116855232 CC vs CT genotype maintenance dosage comparison",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.028",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 61,
            "Study Controls": null,
            "Characteristics": "Chinese AIH patients - NUDT15 rs116855232 CC vs CT genotype 6-TGN concentration comparison",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.002",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 61,
            "Study Controls": null,
            "Characteristics": "Chinese AIH patients - NUDT15 rs116855232 CC vs CT genotype AZA dose to 6-TGN ratio comparison",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.013",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 93,
            "Study Controls": null,
            "Characteristics": "Chinese AIH patients - NUDT15 rs116855232 maintenance dosage dominant model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.13",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.26,
            "Confidence Interval Start": 0.79,
            "Confidence Interval Stop": 6.44,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 93,
            "Study Controls": null,
            "Characteristics": "Chinese AIH patients - NUDT15 rs116855232 maintenance dosage recessive model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.28",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 5.86,
            "Confidence Interval Start": 0.23,
            "Confidence Interval Stop": 147.96,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 93,
            "Study Controls": null,
            "Characteristics": "Chinese AIH patients - NUDT15 rs116855232 maintenance dosage allele model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.08",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.33,
            "Confidence Interval Start": 0.89,
            "Confidence Interval Stop": 6.06,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 149,
            "Study Controls": null,
            "Characteristics": "Chinese AIH patients - NUDT15 rs116855232 therapy interruption dominant model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.21",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.54,
            "Confidence Interval Start": 0.59,
            "Confidence Interval Stop": 10.91,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 149,
            "Study Controls": null,
            "Characteristics": "Chinese AIH patients - NUDT15 rs116855232 therapy interruption recessive model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.05",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 17.38,
            "Confidence Interval Start": 0.99,
            "Confidence Interval Stop": 303.99,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 149,
            "Study Controls": null,
            "Characteristics": "Chinese AIH patients - NUDT15 rs116855232 therapy interruption allele model",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.07",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 3.05,
            "Confidence Interval Start": 0.93,
            "Confidence Interval Stop": 9.99,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC11971672": {
      "var-pheno": {
        "overall_score": 0.9638152942061424,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 0.9182825684547424,
            "scores": [
              0.9252737760543823,
              0.9112913608551025,
              0.9252737760543823,
              0.9112913608551025
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Direction of effect": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.9290781617164612,
            "scores": [
              0.9352667927742004,
              0.9352667927742004,
              0.9228895306587219,
              0.9228895306587219
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.8302033543586731,
            "scores": [
              0.8302033543586731,
              0.8302033543586731,
              0.8302033543586731,
              0.8302033543586731
            ]
          }
        },
        "total_samples": 4,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9252737760543823,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9352667927742004,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8302033543586731
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19*2",
                "prediction": "CYP2C19*2"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19"
              },
              "Drug(s)": {
                "ground_truth": "clopidogrel",
                "prediction": "clopidogrel"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
                "prediction": "*2"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
                "prediction": "Efficacy:Cardiovascular events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*17 + *17/*17",
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9112913608551025,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9352667927742004,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8302033543586731
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19*3",
                "prediction": "CYP2C19*3"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19"
              },
              "Drug(s)": {
                "ground_truth": "clopidogrel",
                "prediction": "clopidogrel"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
                "prediction": "*3"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
                "prediction": "Efficacy:Cardiovascular events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*17 + *17/*17",
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9252737760543823,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9228895306587219,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8302033543586731
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19*2",
                "prediction": "CYP2C19*2"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19"
              },
              "Drug(s)": {
                "ground_truth": "clopidogrel",
                "prediction": "clopidogrel"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
                "prediction": "*2"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
                "prediction": "Efficacy:Recurrent stroke"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*17 + *17/*17",
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9112913608551025,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9228895306587219,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8302033543586731
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19*3",
                "prediction": "CYP2C19*3"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19"
              },
              "Drug(s)": {
                "ground_truth": "clopidogrel",
                "prediction": "clopidogrel"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
                "prediction": "*3"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
                "prediction": "Efficacy:Recurrent stroke"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*17 + *17/*17",
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "cyp2c19*2",
          "cyp2c19*3",
          "cyp2c19+clopidogrel",
          "cyp2c19+clopidogrel"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2C19*2",
            "Gene": "CYP2C19",
            "Drug(s)": "clopidogrel",
            "PMID": 40184070,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "No significant difference in major bleeding between LOF allele carriers (0.6%) and noncarriers (0.8%) (HR 1.29, 95% CI 0.53-3.13, P=0.56).",
            "Sentence": "CYP2C19*2 is not associated with risk of Side Effect:Major bleeding when treated with clopidogrel in people with Disease:Ischemic Stroke as compared to non-carriers.",
            "Alleles": "*2",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Major bleeding",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Ischemic Stroke",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "There was no significant difference between the 2 groups regarding the occurrence of a major bleeding event (11 of 1785 [0.6%] in LOF allele carriers and 9 of 1125 [0.8%] in LOF allele noncarriers; HR, 1.29; 95% CI, 0.53-3.13; P = .56)",
              "No significant differences were observed between CYP2C19 LOF allele carriers and noncarriers regarding the occurrence of major bleeding (0.6% [11 of 1785] vs 0.8% [9 of 1125]; P = .56) and all-cause mortality (0.3% [5] vs 0.1% [1]; P = .27).",
              "There were no significant differences in the incidence of major bleeding or all-cause mortality between carriers and noncarriers."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*2",
              "variant_id": "PA165980635",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "clopidogrel",
              "drug_id": "PA449053",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2C19*3",
            "Gene": "CYP2C19",
            "Drug(s)": "clopidogrel",
            "PMID": 40184070,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "No significant difference in major bleeding between LOF allele carriers (0.6%) and noncarriers (0.8%) (HR 1.29, 95% CI 0.53-3.13, P=0.56).",
            "Sentence": "CYP2C19*3 is not associated with risk of Side Effect:Major bleeding when treated with clopidogrel in people with Disease:Ischemic Stroke as compared to non-carriers.",
            "Alleles": "*3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Major bleeding",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Ischemic Stroke",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "There was no significant difference between the 2 groups regarding the occurrence of a major bleeding event (11 of 1785 [0.6%] in LOF allele carriers and 9 of 1125 [0.8%] in LOF allele noncarriers; HR, 1.29; 95% CI, 0.53-3.13; P = .56)",
              "No significant differences were observed between CYP2C19 LOF allele carriers and noncarriers regarding the occurrence of major bleeding (0.6% [11 of 1785] vs 0.8% [9 of 1125]; P = .56) and all-cause mortality (0.3% [5] vs 0.1% [1]; P = .27).",
              "Based on the result of CYP2C19 genotyping (*1*, *2*, *3*, and *17* alleles), we defined extensive metabolizers as patients with *1/*1*, *1/*17*, and *17/*17* genotypes; intermediate metabolizers as patients with only one *2* or *3* genotypes (*1/*2*, *1/*3*, *2/*17*, and *3/*17*); and poor metabolizers as patients with only *2* or *3* genotypes (*2/*2*, *2/*3*, and *3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*3",
              "variant_id": "PA165980636",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "clopidogrel",
              "drug_id": "PA449053",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2C19*2",
            "Gene": "CYP2C19",
            "Drug(s)": "clopidogrel",
            "PMID": 40184070,
            "Phenotype Category": "other",
            "Significance": "no",
            "Notes": "No significant difference in all-cause mortality between LOF allele carriers (0.3%) and noncarriers (0.1%) (HR 0.31, 95% CI 0.04-2.71, P=0.27).",
            "Sentence": "CYP2C19*2 is not associated with risk of Other:All-cause mortality when treated with clopidogrel in people with Disease:Ischemic Stroke as compared to non-carriers.",
            "Alleles": "*2",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Other:All-cause mortality",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Ischemic Stroke",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In addition, there was no significant difference in all-cause mortality (5 [0.3%] in LOF allele carriers and 1 [0.1%] in LOF allele noncarriers; HR, 0.31; 95% CI, 0.04-2.71; P = .27 for log-rank test)",
              "No significant differences were observed between CYP2C19 LOF allele carriers and noncarriers regarding the occurrence of major bleeding (0.6% [11 of 1785] vs 0.8% [9 of 1125]; P = .56) and all-cause mortality (0.3% [5] vs 0.1% [1]; P = .27).",
              "There were no significant differences in the incidence of major bleeding or all-cause mortality between carriers and noncarriers."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*2",
              "variant_id": "PA165980635",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "clopidogrel",
              "drug_id": "PA449053",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "CYP2C19*3",
            "Gene": "CYP2C19",
            "Drug(s)": "clopidogrel",
            "PMID": 40184070,
            "Phenotype Category": "other",
            "Significance": "no",
            "Notes": "No significant difference in all-cause mortality between LOF allele carriers (0.3%) and noncarriers (0.1%) (HR 0.31, 95% CI 0.04-2.71, P=0.27).",
            "Sentence": "CYP2C19*3 is not associated with risk of Other:All-cause mortality when treated with clopidogrel in people with Disease:Ischemic Stroke as compared to non-carriers.",
            "Alleles": "*3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Other:All-cause mortality",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Ischemic Stroke",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "non-carriers",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In addition, there was no significant difference in all-cause mortality (5 [0.3%] in LOF allele carriers and 1 [0.1%] in LOF allele noncarriers; HR, 0.31; 95% CI, 0.04-2.71; P = .27 for log-rank test)",
              "There were no significant differences in the incidence of major bleeding or all-cause mortality between carriers and noncarriers.",
              "No significant differences were observed between *CYP2C19* LOF allele carriers and noncarriers regarding the occurrence of major bleeding (0.6% [11 of 1785] vs 0.8% [9 of 1125]; *P* = .56) and all-cause mortality (0.3% [5] vs 0.1% [1]; *P* = .27)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*3",
              "variant_id": "PA165980636",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "clopidogrel",
              "drug_id": "PA449053",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.7286434312661488,
        "field_scores": {
          "Study Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Study Controls": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.9296514689922333,
            "scores": [
              0.9337952136993408,
              0.9255077242851257
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 2,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.9337952136993408,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1453096116,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1453096120,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "clinical trial",
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 2910.0,
                "prediction": 1785
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 1125
              },
              "Characteristics": {
                "ground_truth": "PLATELET trial, composite outcome (recurrent stroke, myocardial infarction, and all-cause mortality at 180 days)",
                "prediction": "CYP2C19 LOF allele carriers vs noncarriers, acute ischemic stroke patients treated with clopidogrel, PLATELET trial, composite cardiovascular outcome"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.048",
                "prediction": "= 0.048"
              },
              "Ratio Stat Type": {
                "ground_truth": "HR",
                "prediction": "HR"
              },
              "Ratio Stat": {
                "ground_truth": 0.58,
                "prediction": 0.58
              },
              "Confidence Interval Start": {
                "ground_truth": 0.34,
                "prediction": 0.34
              },
              "Confidence Interval Stop": {
                "ground_truth": 1.0,
                "prediction": 1.0
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.9255077242851257,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1453096140,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1453096120,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "clinical trial",
                "prediction": "clinical trial"
              },
              "Study Cases": {
                "ground_truth": 2910.0,
                "prediction": 1785
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 1125
              },
              "Characteristics": {
                "ground_truth": "PLATELET trial, Recurrent stroke",
                "prediction": "CYP2C19 LOF allele carriers vs noncarriers, acute ischemic stroke patients treated with clopidogrel, PLATELET trial, recurrent stroke"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.047",
                "prediction": "= 0.047"
              },
              "Ratio Stat Type": {
                "ground_truth": "HR",
                "prediction": "HR"
              },
              "Ratio Stat": {
                "ground_truth": 0.56,
                "prediction": 0.56
              },
              "Confidence Interval Start": {
                "ground_truth": 0.32,
                "prediction": 0.32
              },
              "Confidence Interval Stop": {
                "ground_truth": 1.0,
                "prediction": 1.0
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "clinical trial:PLATELET trial, comp",
          "clinical trial:PLATELET trial, Recu"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 1785,
            "Study Controls": 1125,
            "Characteristics": "CYP2C19 LOF allele carriers vs noncarriers, acute ischemic stroke patients treated with clopidogrel, PLATELET trial, major bleeding",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.56",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.29,
            "Confidence Interval Start": 0.53,
            "Confidence Interval Stop": 3.13,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 1785,
            "Study Controls": 1125,
            "Characteristics": "CYP2C19 LOF allele carriers vs noncarriers, acute ischemic stroke patients treated with clopidogrel, PLATELET trial, all-cause mortality",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.27",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.31,
            "Confidence Interval Start": 0.04,
            "Confidence Interval Stop": 2.71,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 1785,
            "Study Controls": 1125,
            "Characteristics": "CYP2C19 LOF allele noncarrier, multivariable Cox regression, acute ischemic stroke patients treated with clopidogrel, PLATELET trial, primary outcome",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.049",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.58,
            "Confidence Interval Start": 0.33,
            "Confidence Interval Stop": 0.99,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": null,
            "Study Controls": null,
            "Characteristics": "CYP2C19 LOF allele carriers vs noncarriers, smokers subgroup, acute ischemic stroke patients treated with clopidogrel, PLATELET trial, primary outcome",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.02",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.09,
            "Confidence Interval Start": 0.01,
            "Confidence Interval Stop": 0.64,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "clinical trial",
            "Study Cases": 1391,
            "Study Controls": 394,
            "Characteristics": "CYP2C19 intermediate metabolizer vs poor metabolizer, acute ischemic stroke patients treated with clopidogrel, PLATELET trial, primary outcome",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.92",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.96,
            "Confidence Interval Start": 0.49,
            "Confidence Interval Stop": 1.88,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC10786722": {
      "var-fa": {
        "overall_score": 0.9886135031779608,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "PMID": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Significance": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 0.8633342583974203,
            "scores": [
              0.870873749256134,
              0.870873749256134,
              0.8482552766799927
            ]
          },
          "Specialty Population": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Assay type": {
            "mean_score": 0.9834123253822327,
            "scores": [
              0.9834123253822327,
              0.9834123253822327,
              0.9834123253822327
            ]
          },
          "Metabolizer types": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "isPlural": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Direction of effect": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Functional terms": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Gene/gene product": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Multiple drugs And/or": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Cell type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.9255234797795614,
            "scores": [
              0.9254112243652344,
              0.9254112243652344,
              0.9257479906082153
            ]
          },
          "Comparison Metabolizer types": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 3,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.870873749256134,
              "Specialty Population": 1.0,
              "Assay type": 0.9834123253822327,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9254112243652344,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs56038477",
                "prediction": "rs56038477"
              },
              "Gene": {
                "ground_truth": "DPYD",
                "prediction": "DPYD"
              },
              "Drug(s)": {
                "ground_truth": null,
                "prediction": null
              },
              "PMID": {
                "ground_truth": 38216550,
                "prediction": 38216550
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "A"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": "plasma dihydrouracil/uracil",
                "prediction": "plasma dihydrouracil/uracil ratio"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "activity of",
                "prediction": "activity of"
              },
              "Gene/gene product": {
                "ground_truth": "DPYD",
                "prediction": "DPYD"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": null
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "G"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.870873749256134,
              "Specialty Population": 1.0,
              "Assay type": 0.9834123253822327,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9254112243652344,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs1801160",
                "prediction": "rs1801160"
              },
              "Gene": {
                "ground_truth": "DPYD",
                "prediction": "DPYD"
              },
              "Drug(s)": {
                "ground_truth": null,
                "prediction": null
              },
              "PMID": {
                "ground_truth": 38216550,
                "prediction": 38216550
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "A"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": "plasma dihydrouracil/uracil",
                "prediction": "plasma dihydrouracil/uracil ratio"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "activity of",
                "prediction": "activity of"
              },
              "Gene/gene product": {
                "ground_truth": "DPYD",
                "prediction": "DPYD"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": null
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "G"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.8482552766799927,
              "Specialty Population": 1.0,
              "Assay type": 0.9834123253822327,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Functional terms": 1.0,
              "Gene/gene product": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Multiple drugs And/or": 1.0,
              "Cell type": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9257479906082153,
              "Comparison Metabolizer types": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs2297595",
                "prediction": "rs2297595"
              },
              "Gene": {
                "ground_truth": "DPYD",
                "prediction": "DPYD"
              },
              "Drug(s)": {
                "ground_truth": null,
                "prediction": null
              },
              "PMID": {
                "ground_truth": 38216550,
                "prediction": 38216550
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "CC + CT",
                "prediction": "G"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Assay type": {
                "ground_truth": "plasma dihydrouracil/uracil",
                "prediction": "plasma dihydrouracil/uracil ratio"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Functional terms": {
                "ground_truth": "activity of",
                "prediction": "activity of"
              },
              "Gene/gene product": {
                "ground_truth": "DPYD",
                "prediction": "DPYD"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": null
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "TT",
                "prediction": "A"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "PA166153889",
          "PA166153647",
          "PA166153696"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "rs3918290",
            "Gene": "DPYD",
            "Drug(s)": null,
            "PMID": 38216550,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "c.1905+1G>A (DPYD*2A, rs3918290) showed significant association with low DPD activity (P < 0.0001). This is one of the most clinically relevant DPYD defective variants. DPD activity was measured using plasma dihydrouracil/uracil ratio.",
            "Sentence": "rs3918290 is associated with decreased activity of DPYD as measured by plasma dihydrouracil/uracil ratio as compared to wild-type.",
            "Alleles": "A",
            "Specialty Population": null,
            "Assay type": "plasma dihydrouracil/uracil ratio",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Functional terms": "activity of",
            "Gene/gene product": "DPYD",
            "When treated with/exposed to/when assayed with": null,
            "Multiple drugs And/or": null,
            "Cell type": null,
            "Comparison Allele(s) or Genotype(s)": "G",
            "Comparison Metabolizer types": null,
            "PMID_norm": "38216550",
            "Variant Annotation ID_norm": "4",
            "Citations": [
              "Dose adjustment based on pretreatment screening for the most clinically relevant DPYD defective variants, i.e. c.1679T>G (DPYD*13*, rs55886062), c.1905+1G>A (DPYD*2A*, rs3918290) and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil",
              "As expected, our data showed a significant association between each of these genetic variants and low DPD activity (Fig. 1).",
              "chr1:97915614 | C | T | Het | 12 | 8 (67%) | 0.20% | c.1905+1G>A | p.(?) | rs3918290 | *2A | splice donor variant"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs3918290",
              "variant_id": "PA166153760",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "rs67376798",
            "Gene": "DPYD",
            "Drug(s)": null,
            "PMID": 38216550,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "c.2846A>T (rs67376798, p.Asp949Val) showed significant association with low DPD activity (P < 0.001). This is one of the most clinically relevant DPYD defective variants. DPD activity was measured using plasma dihydrouracil/uracil ratio.",
            "Sentence": "rs67376798 is associated with decreased activity of DPYD as measured by plasma dihydrouracil/uracil ratio as compared to wild-type.",
            "Alleles": "T",
            "Specialty Population": null,
            "Assay type": "plasma dihydrouracil/uracil ratio",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Functional terms": "activity of",
            "Gene/gene product": "DPYD",
            "When treated with/exposed to/when assayed with": null,
            "Multiple drugs And/or": null,
            "Cell type": null,
            "Comparison Allele(s) or Genotype(s)": "A",
            "Comparison Metabolizer types": null,
            "PMID_norm": "38216550",
            "Variant Annotation ID_norm": "5",
            "Citations": [
              "Dose adjustment based on pretreatment screening for the most clinically relevant *DPYD* defective variants, i.e. c.1679T>G (*DPYD*13*, rs55886062), c.1905+1G>A (*DPYD*2A*, rs3918290) and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil",
              "As expected, our data showed a significant association between each of these genetic variants and low DPD activity (Fig. 1).",
              "Box plot showing DPD pretreatment activity assessed by the dihydrouracil/uracil ([UH2]/[U]) plasma ratio according to the patient genotype."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs67376798",
              "variant_id": "PA166153895",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "rs55886062",
            "Gene": "DPYD",
            "Drug(s)": null,
            "PMID": 38216550,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "c.1679T>G (DPYD*13, rs55886062, p.Ile560Ser) showed significant association with low DPD activity (P < 0.001). This is one of the most clinically relevant DPYD defective variants. DPD activity was measured using plasma dihydrouracil/uracil ratio.",
            "Sentence": "rs55886062 is associated with decreased activity of DPYD as measured by plasma dihydrouracil/uracil ratio as compared to wild-type.",
            "Alleles": "G",
            "Specialty Population": null,
            "Assay type": "plasma dihydrouracil/uracil ratio",
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Functional terms": "activity of",
            "Gene/gene product": "DPYD",
            "When treated with/exposed to/when assayed with": null,
            "Multiple drugs And/or": null,
            "Cell type": null,
            "Comparison Allele(s) or Genotype(s)": "T",
            "Comparison Metabolizer types": null,
            "PMID_norm": "38216550",
            "Variant Annotation ID_norm": "6",
            "Citations": [
              "c.1679T>G (DPYD*13*, rs55886062), c.1905+1G>A (DPYD*2A*, rs3918290) and c.2846A>T (p.Asp949Val or rs67376798), has been shown to improve the safety of chemotherapy regimens based on fluorouracil",
              "As expected, our data showed a significant association between each of these genetic variants and low DPD activity (Fig. 1).",
              "international guidelines now recommend pre-emptive DPYD genotyping for several clinically relevant defective variants: i.e., c.1905+1G>A (DPYD*2A*), c.1679T>G (DPYD*13*), c.2846A>T, and Haplotype B3 (c.1236G>A or c.1129\u20135923C>G) as well as genotype-guided prescribing recommendations"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs55886062",
              "variant_id": "PA166153888",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.5152834004826016,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Controls": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.8959176739056905,
            "scores": [
              0.8962118029594421,
              0.8955907821655273,
              0.895950436592102
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              0.5
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 3,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.8962118029594421,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452352264,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452352260,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 855.0,
                "prediction": 580
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 2392
              },
              "Characteristics": {
                "ground_truth": "plasma dihydrouracil/uracil",
                "prediction": "Partial DPD deficiency ([UH2]/[U] ratio \u226410) vs normal DPD activity, c.2194G>A (rs1801160, DPYD*6, p.Val732Ile)"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "disease"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "A"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "< 0.05",
                "prediction": "< 0.05"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.8955907821655273,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452352360,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452352325,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 1055.0,
                "prediction": 580
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 2392
              },
              "Characteristics": {
                "ground_truth": "plasma dihydrouracil/uracil",
                "prediction": "Partial DPD deficiency ([UH2]/[U] ratio \u226410) vs normal DPD activity, c.1236G>A (rs56038477, hapB3)"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "disease"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "A"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "< 0.01",
                "prediction": "< 0.01"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.895950436592102,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452352324,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452352320,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 1265.0,
                "prediction": 580
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 2392
              },
              "Characteristics": {
                "ground_truth": "plasma dihydrouracil/uracil",
                "prediction": "Partial DPD deficiency ([UH2]/[U] ratio \u226410) vs normal DPD activity, c.496A>G (rs2297595, p.Met166Val)"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "disease"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "G"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "< 0.01",
                "prediction": "< 0.05"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "None:plasma dihydrouracil",
          "None:plasma dihydrouracil",
          "None:plasma dihydrouracil"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 580,
            "Study Controls": 2392,
            "Characteristics": "Partial DPD deficiency ([UH2]/[U] ratio \u226410) vs normal DPD activity, c.2846A>T (rs67376798)",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.0068,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 580,
            "Study Controls": 2392,
            "Characteristics": "Partial DPD deficiency ([UH2]/[U] ratio \u226410) vs normal DPD activity, c.1905+1G>A (rs3918290, DPYD*2A)",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.0067,
            "Allele Of Frequency In Cases": "A",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 580,
            "Study Controls": 2392,
            "Characteristics": "Partial DPD deficiency ([UH2]/[U] ratio \u226410) vs normal DPD activity, c.1679T>G (rs55886062, DPYD*13)",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.0055,
            "Allele Of Frequency In Cases": "G",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 580,
            "Study Controls": 2392,
            "Characteristics": "Partial DPD deficiency vs normal DPD activity, rare variants (MAF <1%)",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.093,
            "Allele Of Frequency In Cases": "rare variants",
            "Frequency In Controls": 0.032,
            "Allele Of Frequency In Controls": "rare variants",
            "P Value": "< 0.00001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 580,
            "Study Controls": 2392,
            "Characteristics": "Partial DPD deficiency vs normal DPD activity, rare deleterious variants (MAF <1%, CADD >15) excluding clinically relevant variants",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.042,
            "Allele Of Frequency In Cases": "rare deleterious variants",
            "Frequency In Controls": 0.016,
            "Allele Of Frequency In Controls": "rare deleterious variants",
            "P Value": "< 0.001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 580,
            "Study Controls": 2392,
            "Characteristics": "Partial DPD deficiency vs normal DPD activity, rare variants (MAF <1%) excluding clinically relevant variants",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.045,
            "Allele Of Frequency In Cases": "rare variants",
            "Frequency In Controls": 0.026,
            "Allele Of Frequency In Controls": "rare variants",
            "P Value": "< 0.03",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 580,
            "Study Controls": 2392,
            "Characteristics": "c.2194G>A (rs1801160, DPYD*6) - patients with partial DPD deficiency",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": 0.28,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 580,
            "Study Controls": 2392,
            "Characteristics": "c.1627A>G (rs1801159, DPYD*5) - patients with partial DPD deficiency",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": 0.19,
            "Allele Of Frequency In Cases": "C",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 580,
            "Study Controls": 2392,
            "Characteristics": "c.1601G>A (rs1801158, DPYD*4) - patients with partial DPD deficiency",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": 0.23,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 580,
            "Study Controls": 2392,
            "Characteristics": "c.85T>C (rs1801265, DPYD*9A) - patients with partial DPD deficiency",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": 0.19,
            "Allele Of Frequency In Cases": "G",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 580,
            "Study Controls": 2392,
            "Characteristics": "c.2846A>T (rs67376798) - patients with partial DPD deficiency",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": 0.68,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 580,
            "Study Controls": 2392,
            "Characteristics": "c.1905+1G>A (rs3918290, DPYD*2A) - patients with partial DPD deficiency",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": 0.67,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 580,
            "Study Controls": 2392,
            "Characteristics": "c.1679T>G (rs55886062, DPYD*13) - patients with partial DPD deficiency",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": 0.55,
            "Allele Of Frequency In Cases": "G",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 580,
            "Study Controls": 2392,
            "Characteristics": "c.3067C>A (rs114096998, p.Pro1023Thr) - patients with partial DPD deficiency",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": 0.6,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 580,
            "Study Controls": 2392,
            "Characteristics": "c.2872A>G (rs141044036, p.Lys958Glu) - patients with partial DPD deficiency",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": 1.0,
            "Allele Of Frequency In Cases": "C",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC12038368": {
      "var-drug": {
        "overall_score": 0.9108736781697524,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "PMID": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Significance": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              0.0
            ]
          },
          "Alleles": {
            "mean_score": 0.9879742562770844,
            "scores": [
              0.9759485125541687,
              1.0
            ]
          },
          "Specialty Population": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Metabolizer types": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "isPlural": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              0.0
            ]
          },
          "PD/PK terms": {
            "mean_score": 0.9182838201522827,
            "scores": [
              0.9182838201522827,
              0.9182838201522827
            ]
          },
          "Multiple drugs And/or": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Population types": {
            "mean_score": 0.9612473249435425,
            "scores": [
              0.9612473249435425,
              0.9612473249435425
            ]
          },
          "Population Phenotypes or diseases": {
            "mean_score": 0.9390944838523865,
            "scores": [
              0.9390944838523865,
              0.9390944838523865
            ]
          },
          "Multiple phenotypes or diseases And/or": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Comparison Metabolizer types": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 2,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.9759485125541687,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.9182838201522827,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.9612473249435425,
              "Population Phenotypes or diseases": 0.9390944838523865,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs4149056",
                "prediction": "rs4149056"
              },
              "Gene": {
                "ground_truth": "SLCO1B1",
                "prediction": "SLCO1B1"
              },
              "PMID": {
                "ground_truth": 40297930,
                "prediction": 40297930
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "CC + CT",
                "prediction": "TC + CC"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "PD/PK terms": {
                "ground_truth": "concentrations of",
                "prediction": "steady-state plasma concentrations of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in people with",
                "prediction": "in patients with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Other:Cardiovascular Disease, Other:Dyslipidaemia",
                "prediction": "Disease:Dyslipidemia, Disease:Coronary artery disease"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": "or",
                "prediction": "or"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "TT",
                "prediction": "TT"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "simvastatin acid",
                "prediction": "simvastatin acid"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 0.0,
              "Alleles": 1.0,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 0.0,
              "Direction of effect": 0.0,
              "PD/PK terms": 0.9182838201522827,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.9612473249435425,
              "Population Phenotypes or diseases": 0.9390944838523865,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs2306283",
                "prediction": "rs2306283"
              },
              "Gene": {
                "ground_truth": "SLCO1B1",
                "prediction": "SLCO1B1"
              },
              "PMID": {
                "ground_truth": 40297930,
                "prediction": 40297930
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "no"
              },
              "Alleles": {
                "ground_truth": "AG + GG",
                "prediction": "AG + GG"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "PD/PK terms": {
                "ground_truth": "concentrations of",
                "prediction": "steady-state plasma concentrations of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in people with",
                "prediction": "in patients with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Other:Cardiovascular Disease, Other:Dyslipidaemia",
                "prediction": "Disease:Dyslipidemia, Disease:Coronary artery disease"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": "or",
                "prediction": "or"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "AA",
                "prediction": "AA"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "simvastatin acid",
                "prediction": "simvastatin acid"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "PA166154579",
          "PA166154547"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "rs4149056",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin lactone",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between SLCO1B1 c.521T>C and simvastatin lactone concentrations (p = 0.33). TC+CC: 0.01 ng/mL vs TT: 0.02 ng/mL.",
            "Sentence": "Genotype TC+CC is not associated with steady-state plasma concentrations of simvastatin lactone in patients with dyslipidemia or coronary artery disease as compared to genotype TT.",
            "Alleles": "TC + CC",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "TT",
            "Comparison Metabolizer types": null,
            "Citations": [
              "patients with the SLCO1B1 c.521TC+CC genotype had a significantly higher SVA compared to those with the c.521TT genotype (0.53 vs. 0.19 ng/mL, respectively) with a p value of 0.03",
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations.",
              "SLCO1B1 | rs4149056 | 521T>C | TT | 80 (89.88) | 0.02 (0.01\u20130.03) | 0.33 | 0.19 (0.11\u20130.41) | 0.03* | TC+CC | 9 (10.12) | 0.01 (0.01\u20130.03) | 0.53 (0.22\u20130.73)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs4149056",
              "variant_id": "PA166154579",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "lovastatin",
              "drug_id": "PA450272",
              "confidence": 0.8648648648648649
            }
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "SLCO1B1*1a",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "SLCO1B1*1b/*15 (decreased function) had significantly higher SVA concentrations compared to SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p < 0.001).",
            "Sentence": "Diplotype *1b/*15 is associated with increased steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to diplotype *1a/*1a.",
            "Alleles": "*1b/*15",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "*1a/*1a",
            "Comparison Metabolizer types": null,
            "Citations": [
              "SLCO1B1*1b/*15 (decrease function) had significantly higher SVA concentrations compared to SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p value < 0.001, Table 4).",
              "Similarly, the SLCO1B1*1b/*15 genotype was associated with higher simvastatin acid levels than SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p < 0.001).",
              "According to the CPIC 2022 guidelines, the SLCO1B1 loss\u2010of\u2010function alleles include *5 and *15, while the normal function allele is *1, comprising *1a and *1b. The diplotype\u2010predicted phenotypes are classified as follows: *1a/*1a, *1a/*1b, and *1b/*1b are considered normal function, whereas *1 (*1a or *1b) combined with *5 or *15 is categorized as decreased function."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "SLCO1B1*1a, SLCO1B1*1b, SLCO1B1*5, SLCO1B1*15",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "SLCO1B1*1b",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "SLCO1B1*1b/*15 (decreased function) had significantly higher SVA concentrations compared to SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p < 0.001).",
            "Sentence": "Diplotype *1b/*15 is associated with increased steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to diplotype *1a/*1a.",
            "Alleles": "*1b/*15",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "*1a/*1a",
            "Comparison Metabolizer types": null,
            "Citations": [
              "SLCO1B1*1b/*15 (decrease function) had significantly higher SVA concentrations compared to SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p value < 0.001, Table 4).",
              "Similarly, the SLCO1B1*1b/*15 genotype was associated with higher simvastatin acid levels than SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p < 0.001).",
              "According to the CPIC 2022 guidelines, the SLCO1B1 loss\u2010of\u2010function alleles include *5 and *15, while the normal function allele is *1, comprising *1a and *1b. The diplotype\u2010predicted phenotypes are classified as follows: *1a/*1a, *1a/*1b, and *1b/*1b are considered normal function, whereas *1 (*1a or *1b) combined with *5 or *15 is categorized as decreased function."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "SLCO1B1*1a, SLCO1B1*1b, SLCO1B1*5, SLCO1B1*15",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "SLCO1B1*5",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "SLCO1B1*1b/*15 (decreased function) had significantly higher SVA concentrations compared to SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p < 0.001).",
            "Sentence": "Diplotype *1b/*15 is associated with increased steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to diplotype *1a/*1a.",
            "Alleles": "*1b/*15",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "*1a/*1a",
            "Comparison Metabolizer types": null,
            "Citations": [
              "SLCO1B1*1b/*15 (decrease function) had significantly higher SVA concentrations compared to SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p value < 0.001, Table 4).",
              "Similarly, the SLCO1B1*1b/*15 genotype was associated with higher simvastatin acid levels than SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p < 0.001).",
              "According to the CPIC 2022 guidelines, the SLCO1B1 loss\u2010of\u2010function alleles include *5 and *15, while the normal function allele is *1, comprising *1a and *1b. The diplotype\u2010predicted phenotypes are classified as follows: *1a/*1a, *1a/*1b, and *1b/*1b are considered normal function, whereas *1 (*1a or *1b) combined with *5 or *15 is categorized as decreased function."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "SLCO1B1*1a, SLCO1B1*1b, SLCO1B1*5, SLCO1B1*15",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "SLCO1B1*15",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "SLCO1B1*1b/*15 (decreased function) had significantly higher SVA concentrations compared to SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p < 0.001).",
            "Sentence": "Diplotype *1b/*15 is associated with increased steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to diplotype *1a/*1a.",
            "Alleles": "*1b/*15",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "*1a/*1a",
            "Comparison Metabolizer types": null,
            "Citations": [
              "SLCO1B1*1b/*15 (decrease function) had significantly higher SVA concentrations compared to SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p value < 0.001, Table 4).",
              "Similarly, the SLCO1B1*1b/*15 genotype was associated with higher simvastatin acid levels than SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p < 0.001).",
              "According to the CPIC 2022 guidelines, the SLCO1B1 loss\u2010of\u2010function alleles include *5 and *15, while the normal function allele is *1, comprising *1a and *1b. The diplotype\u2010predicted phenotypes are classified as follows: *1a/*1a, *1a/*1b, and *1b/*1b are considered normal function, whereas *1 (*1a or *1b) combined with *5 or *15 is categorized as decreased function."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "SLCO1B1*1a, SLCO1B1*1b, SLCO1B1*5, SLCO1B1*15",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "SLCO1B1*1a",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "Patients with decreased OATP1B1 function (*1b/*5 and *1b/*15) showed higher simvastatin acid concentrations compared to normal function, with p value trending towards significance (p = 0.07). 0.53 vs. 0.19 ng/mL.",
            "Sentence": "Decreased OATP1B1 function diplotypes (*1b/*5, *1b/*15) are not associated with steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to normal function diplotypes (*1a/*1a, *1a/*1b, *1b/*1b).",
            "Alleles": "*1b/*5, *1b/*15",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "*1a/*1a, *1a/*1b, *1b/*1b",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Moreover, patients with decreased OATP1B1 function, including those with *1b/*5 and *1b/*15, showed consistent increases in simvastatin acid concentrations compared to patients with normal OATP1B1 function, with a p value trending towards significance (p = 0.07).",
              "patients with the SLCO1B1 c.521TC+CC genotype had a significantly higher SVA compared to those with the c.521TT genotype (0.53 vs. 0.19 ng/mL, respectively) with a p value of 0.03",
              "SLCO1B1*1b/*15 (decrease function) had significantly higher SVA concentrations compared to SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p value < 0.001, Table 4). Moreover, patients with decreased OATP1B1 function, including those with *1b/*5 and *1b/*15, showed consistent increases in simvastatin acid concentrations compared to patients with normal OATP1B1 function, with a p value trending towards significance (p = 0.07)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "SLCO1B1*1a, SLCO1B1*1b, SLCO1B1*5, SLCO1B1*15",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "SLCO1B1*1b",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "Patients with decreased OATP1B1 function (*1b/*5 and *1b/*15) showed higher simvastatin acid concentrations compared to normal function, with p value trending towards significance (p = 0.07). 0.53 vs. 0.19 ng/mL.",
            "Sentence": "Decreased OATP1B1 function diplotypes (*1b/*5, *1b/*15) are not associated with steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to normal function diplotypes (*1a/*1a, *1a/*1b, *1b/*1b).",
            "Alleles": "*1b/*5, *1b/*15",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "*1a/*1a, *1a/*1b, *1b/*1b",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Moreover, patients with decreased OATP1B1 function, including those with *1b/*5 and *1b/*15, showed consistent increases in simvastatin acid concentrations compared to patients with normal OATP1B1 function, with a p value trending towards significance (p = 0.07).",
              "patients with the SLCO1B1 c.521TC+CC genotype had a significantly higher SVA compared to those with the c.521TT genotype (0.53 vs. 0.19 ng/mL, respectively) with a p value of 0.03",
              "SLCO1B1*1b/*15 (decrease function) had significantly higher SVA concentrations compared to SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p value < 0.001, Table 4). Moreover, patients with decreased OATP1B1 function, including those with *1b/*5 and *1b/*15, showed consistent increases in simvastatin acid concentrations compared to patients with normal OATP1B1 function, with a p value trending towards significance (p = 0.07)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "SLCO1B1*1a, SLCO1B1*1b, SLCO1B1*5, SLCO1B1*15",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "SLCO1B1*5",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "Patients with decreased OATP1B1 function (*1b/*5 and *1b/*15) showed higher simvastatin acid concentrations compared to normal function, with p value trending towards significance (p = 0.07). 0.53 vs. 0.19 ng/mL.",
            "Sentence": "Decreased OATP1B1 function diplotypes (*1b/*5, *1b/*15) are not associated with steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to normal function diplotypes (*1a/*1a, *1a/*1b, *1b/*1b).",
            "Alleles": "*1b/*5, *1b/*15",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "*1a/*1a, *1a/*1b, *1b/*1b",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Moreover, patients with decreased OATP1B1 function, including those with *1b/*5 and *1b/*15, showed consistent increases in simvastatin acid concentrations compared to patients with normal OATP1B1 function, with a p value trending towards significance (p = 0.07).",
              "patients with the SLCO1B1 c.521TC+CC genotype had a significantly higher SVA compared to those with the c.521TT genotype (0.53 vs. 0.19 ng/mL, respectively) with a p value of 0.03",
              "SLCO1B1*1b/*15 (decrease function) had significantly higher SVA concentrations compared to SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p value < 0.001, Table 4). Moreover, patients with decreased OATP1B1 function, including those with *1b/*5 and *1b/*15, showed consistent increases in simvastatin acid concentrations compared to patients with normal OATP1B1 function, with a p value trending towards significance (p = 0.07)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "SLCO1B1*1a, SLCO1B1*1b, SLCO1B1*5, SLCO1B1*15",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "SLCO1B1*15",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "Patients with decreased OATP1B1 function (*1b/*5 and *1b/*15) showed higher simvastatin acid concentrations compared to normal function, with p value trending towards significance (p = 0.07). 0.53 vs. 0.19 ng/mL.",
            "Sentence": "Decreased OATP1B1 function diplotypes (*1b/*5, *1b/*15) are not associated with steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to normal function diplotypes (*1a/*1a, *1a/*1b, *1b/*1b).",
            "Alleles": "*1b/*5, *1b/*15",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "*1a/*1a, *1a/*1b, *1b/*1b",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Moreover, patients with decreased OATP1B1 function, including those with *1b/*5 and *1b/*15, showed consistent increases in simvastatin acid concentrations compared to patients with normal OATP1B1 function, with a p value trending towards significance (p = 0.07).",
              "patients with the SLCO1B1 c.521TC+CC genotype had a significantly higher SVA compared to those with the c.521TT genotype (0.53 vs. 0.19 ng/mL, respectively) with a p value of 0.03",
              "SLCO1B1*1b/*15 (decrease function) had significantly higher SVA concentrations compared to SLCO1B1*1a/*1a (0.58 vs. 0.16 ng/mL, p value < 0.001, Table 4). Moreover, patients with decreased OATP1B1 function, including those with *1b/*5 and *1b/*15, showed consistent increases in simvastatin acid concentrations compared to patients with normal OATP1B1 function, with a p value trending towards significance (p = 0.07)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "SLCO1B1*1a, SLCO1B1*1b, SLCO1B1*5, SLCO1B1*15",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "rs2306283",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin lactone",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between SLCO1B1 c.388A>G (rs2306283) and simvastatin lactone concentrations (p = 0.53).",
            "Sentence": "Genotype AG+GG is not associated with steady-state plasma concentrations of simvastatin lactone in patients with dyslipidemia or coronary artery disease as compared to genotype AA.",
            "Alleles": "AG + GG",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "AA",
            "Comparison Metabolizer types": null,
            "Citations": [
              "In contrast, *SLCO1B1* c.388A>G (rs2306283) showed no significant association with simvastatin concentrations in our study, consistent with previous findings [[22](#cts70225-bib-0022), [42](#cts70225-bib-0042)]. This polymorphism has been linked to normal or slightly altered OATP1B1 function, with minimal impact on statin pharmacokinetics unless co\u2010inherited with c.521T>C [[42](#cts70225-bib-0042)].",
              "SLCO1B1 | rs2306283 | 388A>G | AA | 17 (19.10) | 0.02 (0.01\u20130.03) | 0.53 | 0.16 (0.14\u20130.25) | 0.13 | AG+GG | 72 (80.90) | 0.02 (0.01\u20130.03) | 0.23 (0.12\u20130.53)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2306283",
              "variant_id": "PA166154547",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "lovastatin",
              "drug_id": "PA450272",
              "confidence": 0.8648648648648649
            }
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "rs1045642",
            "Gene": "ABCB1",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between ABCB1 rs1045642 and simvastatin acid concentrations (p = 1.00). CT+TT: 0.25 ng/mL vs CC: 0.19 ng/mL.",
            "Sentence": "Genotype CT+TT is not associated with steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to genotype CC.",
            "Alleles": "CT + TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations.",
              "ABCB1 | rs1045642 | 3435C>T | CC | 29 (32.58) | 0.02 (0.01\u20130.04) | 0.70 | 0.19 (0.13\u20130.45) | 1.00 | CT+TT | 60 (67.42) | 0.02 (0.01\u20130.03) | 0.25 (0.12\u20130.44)",
              "In contrast, other SNPs, including ABCB1 (rs1045642), ABCC2 (rs717620, rs3740066), ABCG2 (rs2231142), SLCO1B3 (rs7311158, rs4149117), CYP3A4*1G (rs2242480), and CYP3A5*3 (rs776746), showed no significant association, suggesting a limited impact on simvastatin pharmacokinetics in this cohort."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1045642",
              "variant_id": "PA166157284",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            }
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "rs1045642",
            "Gene": "ABCB1",
            "Drug(s)": "simvastatin lactone",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between ABCB1 rs1045642 and simvastatin lactone concentrations (p = 0.70).",
            "Sentence": "Genotype CT+TT is not associated with steady-state plasma concentrations of simvastatin lactone in patients with dyslipidemia or coronary artery disease as compared to genotype CC.",
            "Alleles": "CT + TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "ABCB1 | rs1045642 | 3435C>T | CC | 29 (32.58) | 0.02 (0.01\u20130.04) | 0.70 | 0.19 (0.13\u20130.45) | 1.00 | CT+TT | 60 (67.42) | 0.02 (0.01\u20130.03) | 0.25 (0.12\u20130.44)",
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations.",
              "In contrast, other SNPs, including *ABCB1* (rs1045642), *ABCC2* (rs717620, rs3740066), *ABCG2* (rs2231142), *SLCO1B3* (rs7311158, rs4149117), *CYP3A4***1G* (rs2242480), and *CYP3A5***3* (rs776746), showed no significant association, suggesting a limited impact on simvastatin pharmacokinetics in this cohort."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1045642",
              "variant_id": "PA166157284",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "lovastatin",
              "drug_id": "PA450272",
              "confidence": 0.8648648648648649
            }
          },
          {
            "Variant Annotation ID": 9,
            "Variant/Haplotypes": "rs717620",
            "Gene": "ABCC2",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between ABCC2 rs717620 and simvastatin acid concentrations (p = 0.67). CT+TT: 0.20 ng/mL vs CC: 0.22 ng/mL.",
            "Sentence": "Genotype CT+TT is not associated with steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to genotype CC.",
            "Alleles": "CT + TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "ABCC2 | rs717620 | \u221224C>T | CC | 55 (61.79) | 0.02 (0.01\u20130.03) | 0.45 | 0.22 (0.13\u20130.48) | 0.67 | CT+TT | 34 (38.21) | 0.02 (0.01\u20130.03) | 0.20 (0.12\u20130.42)",
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs717620",
              "variant_id": "PA166153953",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            }
          },
          {
            "Variant Annotation ID": 10,
            "Variant/Haplotypes": "rs717620",
            "Gene": "ABCC2",
            "Drug(s)": "simvastatin lactone",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between ABCC2 rs717620 and simvastatin lactone concentrations (p = 0.45).",
            "Sentence": "Genotype CT+TT is not associated with steady-state plasma concentrations of simvastatin lactone in patients with dyslipidemia or coronary artery disease as compared to genotype CC.",
            "Alleles": "CT + TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "ABCC2 | rs717620 | \u221224C>T | CC | 55 (61.79) | 0.02 (0.01\u20130.03) | 0.45 | 0.22 (0.13\u20130.48) | 0.67 | CT+TT | 34 (38.21) | 0.02 (0.01\u20130.03) | 0.20 (0.12\u20130.42)",
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs717620",
              "variant_id": "PA166153953",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "lovastatin",
              "drug_id": "PA450272",
              "confidence": 0.8648648648648649
            }
          },
          {
            "Variant Annotation ID": 11,
            "Variant/Haplotypes": "rs3740066",
            "Gene": "ABCC2",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between ABCC2 rs3740066 and simvastatin acid concentrations (p = 0.84). CT+TT: 0.19 ng/mL vs CC: 0.21 ng/mL.",
            "Sentence": "Genotype CT+TT is not associated with steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to genotype CC.",
            "Alleles": "CT + TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "ABCC2 | rs3740066 | 3971C>T | CC | 49 (55.05) | 0.02 (0.01\u20130.03) | 0.96 | 0.21 (0.12\u20130.49) | 0.84 | CT+TT | 40 (44.95) | 0.02 (0.01\u20130.03) | 0.19 (0.12\u20130.44)",
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs3740066",
              "variant_id": "PA166154028",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            }
          },
          {
            "Variant Annotation ID": 12,
            "Variant/Haplotypes": "rs3740066",
            "Gene": "ABCC2",
            "Drug(s)": "simvastatin lactone",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between ABCC2 rs3740066 and simvastatin lactone concentrations (p = 0.96).",
            "Sentence": "Genotype CT+TT is not associated with steady-state plasma concentrations of simvastatin lactone in patients with dyslipidemia or coronary artery disease as compared to genotype CC.",
            "Alleles": "CT + TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "ABCC2 | rs3740066 | 3971C>T | CC | 49 (55.05) | 0.02 (0.01\u20130.03) | 0.96 | 0.21 (0.12\u20130.49) | 0.84 | CT+TT | 40 (44.95) | 0.02 (0.01\u20130.03) | 0.19 (0.12\u20130.44)",
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs3740066",
              "variant_id": "PA166154028",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "lovastatin",
              "drug_id": "PA450272",
              "confidence": 0.8648648648648649
            }
          },
          {
            "Variant Annotation ID": 13,
            "Variant/Haplotypes": "rs2231142",
            "Gene": "ABCG2",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between ABCG2 rs2231142 and simvastatin acid concentrations (p = 0.11). CA+AA: 0.18 ng/mL vs CC: 0.26 ng/mL.",
            "Sentence": "Genotype CA+AA is not associated with steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to genotype CC.",
            "Alleles": "CA + AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "ABCG2 | rs2231142 | 421C>A | C | 72.47 | CC | 55.06 | 0.32 | A | 27.53 | CA | 34.83 | | | AA | 10.11",
              "ABCG2 | rs2231142 | 421C>A | CC | 49 (55.05) | 0.02 (0.01\u20130.03) | 0.54 | 0.26 (0.15\u20130.52) | 0.11 | CA+AA | 40 (44.95) | 0.02 (0.01\u20130.03) | 0.18 (0.10\u20130.34)",
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2231142",
              "variant_id": "PA166156544",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            }
          },
          {
            "Variant Annotation ID": 14,
            "Variant/Haplotypes": "rs2231142",
            "Gene": "ABCG2",
            "Drug(s)": "simvastatin lactone",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between ABCG2 rs2231142 and simvastatin lactone concentrations (p = 0.54).",
            "Sentence": "Genotype CA+AA is not associated with steady-state plasma concentrations of simvastatin lactone in patients with dyslipidemia or coronary artery disease as compared to genotype CC.",
            "Alleles": "CA + AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "ABCG2 | rs2231142 | 421C>A | CC | 49 (55.05) | 0.02 (0.01\u20130.03) | 0.54 | 0.26 (0.15\u20130.52) | 0.11 | CA+AA | 40 (44.95) | 0.02 (0.01\u20130.03) | 0.18 (0.10\u20130.34)",
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2231142",
              "variant_id": "PA166156544",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "lovastatin",
              "drug_id": "PA450272",
              "confidence": 0.8648648648648649
            }
          },
          {
            "Variant Annotation ID": 15,
            "Variant/Haplotypes": "rs7311358",
            "Gene": "SLCO1B3",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between SLCO1B3 rs7311358 and simvastatin acid concentrations (p = 0.86). AA: 0.22 ng/mL vs GG+GA: 0.19 ng/mL.",
            "Sentence": "Genotype AA is not associated with steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to genotype GG+GA.",
            "Alleles": "AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "GG + GA",
            "Comparison Metabolizer types": null,
            "Citations": [
              "SLCO1B3 | rs7311158 | 699G>A | GG+GA | 44 (49.44) | 0.02 (0.01\u20130.03) | 0.46 | 0.19 (0.11\u20130.46) | 0.86 | AA | 45 (50.56) | 0.02 (0.01\u20130.04) | 0.22 (0.13\u20130.40)",
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs7311358",
              "variant_id": "PA166154602",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            }
          },
          {
            "Variant Annotation ID": 16,
            "Variant/Haplotypes": "rs7311358",
            "Gene": "SLCO1B3",
            "Drug(s)": "simvastatin lactone",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between SLCO1B3 rs7311358 and simvastatin lactone concentrations (p = 0.46).",
            "Sentence": "Genotype AA is not associated with steady-state plasma concentrations of simvastatin lactone in patients with dyslipidemia or coronary artery disease as compared to genotype GG+GA.",
            "Alleles": "AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "GG + GA",
            "Comparison Metabolizer types": null,
            "Citations": [
              "SLCO1B3 | rs7311158 | 699G>A | GG+GA | 44 (49.44) | 0.02 (0.01\u20130.03) | 0.46 | 0.19 (0.11\u20130.46) | 0.86",
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs7311358",
              "variant_id": "PA166154602",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "lovastatin",
              "drug_id": "PA450272",
              "confidence": 0.8648648648648649
            }
          },
          {
            "Variant Annotation ID": 17,
            "Variant/Haplotypes": "rs4149117",
            "Gene": "SLCO1B3",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between SLCO1B3 rs4149117 and simvastatin acid concentrations (p = 0.94). GG: 0.21 ng/mL vs TT+TG: 0.19 ng/mL.",
            "Sentence": "Genotype GG is not associated with steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to genotype TT+TG.",
            "Alleles": "GG",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "TT + TG",
            "Comparison Metabolizer types": null,
            "Citations": [
              "SLCO1B3 | rs4149117 | 334T>G | TT+TG | 37 (41.57) | 0.02 (0.01\u20130.03) | 0.21 | 0.19 (0.07\u20130.45) | 0.94 | GG | 52 (58.43) | 0.02 (0.01\u20130.04) | 0.21 (0.13\u20130.43)",
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs4149117",
              "variant_id": "PA166154583",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            }
          },
          {
            "Variant Annotation ID": 18,
            "Variant/Haplotypes": "rs4149117",
            "Gene": "SLCO1B3",
            "Drug(s)": "simvastatin lactone",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between SLCO1B3 rs4149117 and simvastatin lactone concentrations (p = 0.21).",
            "Sentence": "Genotype GG is not associated with steady-state plasma concentrations of simvastatin lactone in patients with dyslipidemia or coronary artery disease as compared to genotype TT+TG.",
            "Alleles": "GG",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "TT + TG",
            "Comparison Metabolizer types": null,
            "Citations": [
              "SLCO1B3 | rs4149117 | 334T>G | T | 24.16 | TT | 6.74 | 0.80 | G | 75.84 | TG | 34.83 | | | | GG | 58.43",
              "SLCO1B3 | rs4149117 | 334T>G | TT+TG | 37 (41.57) | 0.02 (0.01\u20130.03) | 0.21 | 0.19 (0.07\u20130.45) | 0.94 | GG | 52 (58.43) | 0.02 (0.01\u20130.04) | 0.21 (0.13\u20130.43)",
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs4149117",
              "variant_id": "PA166154583",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "lovastatin",
              "drug_id": "PA450272",
              "confidence": 0.8648648648648649
            }
          },
          {
            "Variant Annotation ID": 19,
            "Variant/Haplotypes": "rs2242480",
            "Gene": "CYP3A4",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between CYP3A4*1G (rs2242480) and simvastatin acid concentrations (p = 0.16). GA+AA: 0.19 ng/mL vs GG: 0.23 ng/mL.",
            "Sentence": "Genotype GA+AA is not associated with steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to genotype GG.",
            "Alleles": "GA + AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "GG",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations.",
              "CYP3A4*1G | rs2242480 | 20230G>A | GG | 43 (48.31) | 0.02 (0.01\u20130.04) | 0.92 | 0.23 (0.15\u20130.53) | 0.16 | GA+AA | 46 (51.69) | 0.02 (0.01\u20130.03) | 0.19 (0.07\u20130.41)",
              "In contrast, other SNPs, including ABCB1 (rs1045642), ABCC2 (rs717620, rs3740066), ABCG2 (rs2231142), SLCO1B3 (rs7311158, rs4149117), CYP3A4*1G (rs2242480), and CYP3A5*3 (rs776746), showed no significant association, suggesting a limited impact on simvastatin pharmacokinetics in this cohort."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2242480",
              "variant_id": "PA166157345",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            }
          },
          {
            "Variant Annotation ID": 20,
            "Variant/Haplotypes": "rs2242480",
            "Gene": "CYP3A4",
            "Drug(s)": "simvastatin lactone",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between CYP3A4*1G (rs2242480) and simvastatin lactone concentrations (p = 0.92).",
            "Sentence": "Genotype GA+AA is not associated with steady-state plasma concentrations of simvastatin lactone in patients with dyslipidemia or coronary artery disease as compared to genotype GG.",
            "Alleles": "GA + AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "GG",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations.",
              "CYP3A4*1G | rs2242480 | 20230G>A | GG | 43 (48.31) | 0.02 (0.01\u20130.04) | 0.92 | 0.23 (0.15\u20130.53) | 0.16 | GA+AA | 46 (51.69) | 0.02 (0.01\u20130.03) | 0.19 (0.07\u20130.41)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2242480",
              "variant_id": "PA166157345",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "lovastatin",
              "drug_id": "PA450272",
              "confidence": 0.8648648648648649
            }
          },
          {
            "Variant Annotation ID": 21,
            "Variant/Haplotypes": "rs776746",
            "Gene": "CYP3A5",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between CYP3A5*3 (rs776746) and simvastatin acid concentrations (p = 0.23). AG+GG: 0.22 ng/mL vs AA: 0.17 ng/mL.",
            "Sentence": "Genotype AG+GG is not associated with steady-state plasma concentrations of simvastatin acid in patients with dyslipidemia or coronary artery disease as compared to genotype AA.",
            "Alleles": "AG + GG",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "AA",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No significant relationship was observed between other pharmacokinetic gene polymorphisms and simvastatin lactone or acid concentrations.",
              "CYP3A5*3 | rs776746 | 6986A>G | AA | 14 (15.73) | 0.02 (0.01\u20130.03) | 0.65 | 0.17 (0.05\u20130.44) | 0.23 | AG+GG | 75 (84.27) | 0.02 (0.01\u20130.04) | 0.22\u20130.13\u20100.45)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs776746",
              "variant_id": "PA166157267",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            }
          },
          {
            "Variant Annotation ID": 22,
            "Variant/Haplotypes": "rs776746",
            "Gene": "CYP3A5",
            "Drug(s)": "simvastatin lactone",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "no",
            "Notes": "No significant association between CYP3A5*3 (rs776746) and simvastatin lactone concentrations (p = 0.65).",
            "Sentence": "Genotype AG+GG is not associated with steady-state plasma concentrations of simvastatin lactone in patients with dyslipidemia or coronary artery disease as compared to genotype AA.",
            "Alleles": "AG + GG",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "AA",
            "Comparison Metabolizer types": null,
            "Citations": [
              "CYP3A5*3 | rs776746 | 6986A>G | A | 47.19 | AA | 15.73 | 0.03 | G | 52.81 | AG | 62.92 | | | | GG | 21.35",
              "| CYP3A5*3 | rs776746 | 6986A>G | AA | 14 (15.73) | 0.02 (0.01\u20130.03) | 0.65 | 0.17 (0.05\u20130.44) | 0.23 | AG+GG | 75 (84.27) | 0.02 (0.01\u20130.04) | 0.22\u20130.13\u20100.45)",
              "In contrast, other SNPs, including *ABCB1* (rs1045642), *ABCC2* (rs717620, rs3740066), *ABCG2* (rs2231142), *SLCO1B3* (rs7311158, rs4149117), *CYP3A4***1G* (rs2242480), and *CYP3A5***3* (rs776746), showed no significant association, suggesting a limited impact on simvastatin pharmacokinetics in this cohort."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs776746",
              "variant_id": "PA166157267",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "lovastatin",
              "drug_id": "PA450272",
              "confidence": 0.8648648648648649
            }
          },
          {
            "Variant Annotation ID": 23,
            "Variant/Haplotypes": "rs2306283",
            "Gene": "SLCO1B1",
            "Drug(s)": "simvastatin acid",
            "PMID": 40297930,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "Dose-specific analysis at 10 mg/day showed significantly higher SVA levels in G allele carriers (AG+GG genotype) compared to AA (3.63 vs. 1.59 ng/mL, p = 0.04).",
            "Sentence": "Genotype AG+GG is associated with increased steady-state plasma concentrations of simvastatin acid at 10 mg/day dose in patients with dyslipidemia or coronary artery disease as compared to genotype AA.",
            "Alleles": "AG + GG",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "steady-state plasma concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Dyslipidemia, Disease:Coronary artery disease",
            "Multiple phenotypes or diseases And/or": "or",
            "Comparison Allele(s) or Genotype(s)": "AA",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Additionally, *SLCO1B1* rs2306283 was associated with significantly higher SVA levels in patients carrying the G allele (AG+GG genotype) at the same dose (3.63 vs. 1.59 ng/mL, *p* = 0.04).",
              "The results showed that patients with the *SLCO1B1* c.521T>C (rs4149056) TC+CC genotype exhibited higher steady\u2010state plasma levels of simvastatin acid (SVA) compared to TT carriers at a dose of 10 mg/day (5.83 vs. 1.95 ng/mL, *p* = 0.06). Additionally, *SLCO1B1* rs2306283 was associated with significantly higher SVA levels in patients carrying the G allele (AG+GG genotype) at the same dose (3.63 vs. 1.59 ng/mL, *p* = 0.04).",
              "The study highlights the potential role of SLCO1B1 genotyping, particularly rs4149056 (c.521T>C) and rs2306283 (c.388A>G), in guiding statin therapy for Thai patients, which could help optimize treatment and reduce adverse effects such as statin\u2010induced myotoxicity."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2306283",
              "variant_id": "PA166154547",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "simvastatin",
              "drug_id": "PA451363",
              "confidence": 0.8148148148148148
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.7776002963383992,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.9140044450759888,
            "scores": [
              0.9097891449928284,
              0.9182197451591492
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              0.5
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 2,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9097891449928284,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454052280,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454052260,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cross-sectional"
              },
              "Study Cases": {
                "ground_truth": 89.0,
                "prediction": 89
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "12h simvastatin acid concentrations",
                "prediction": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B1 c.521T>C (rs4149056) TT vs TC+CC genotype comparison for simvastatin acid levels"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.03",
                "prediction": "= 0.03"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9182197451591492,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454052320,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454052282,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cross-sectional"
              },
              "Study Cases": {
                "ground_truth": 89.0,
                "prediction": 89
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "12h simvastatin acid concentrations",
                "prediction": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, CYP3A4*1G rs2242480 GG vs GA+AA genotype comparison for simvastatin acid levels"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.04",
                "prediction": "= 0.16"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "None:12h simvastatin acid",
          "None:12h simvastatin acid"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B1*1b/*15 vs *1a/*1a diplotype comparison for simvastatin acid levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, ABCB1 rs1045642 CC vs CT+TT genotype comparison for simvastatin lactone levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.70",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, ABCB1 rs1045642 CC vs CT+TT genotype comparison for simvastatin acid levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 1.00",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, ABCC2 rs717620 CC vs CT+TT genotype comparison for simvastatin lactone levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.45",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, ABCC2 rs717620 CC vs CT+TT genotype comparison for simvastatin acid levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.67",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, ABCC2 rs3740066 CC vs CT+TT genotype comparison for simvastatin lactone levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.96",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, ABCC2 rs3740066 CC vs CT+TT genotype comparison for simvastatin acid levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.84",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, ABCG2 rs2231142 CC vs CA+AA genotype comparison for simvastatin lactone levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.54",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, ABCG2 rs2231142 CC vs CA+AA genotype comparison for simvastatin acid levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.11",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B1 rs4149056 TT vs TC+CC genotype comparison for simvastatin lactone levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.33",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B1 rs2306283 AA vs AG+GG genotype comparison for simvastatin lactone levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.53",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B1 rs2306283 AA vs AG+GG genotype comparison for simvastatin acid levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.13",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B3 rs7311158 GG+GA vs AA genotype comparison for simvastatin lactone levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.46",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B3 rs7311158 GG+GA vs AA genotype comparison for simvastatin acid levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.86",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B3 rs4149117 TT+TG vs GG genotype comparison for simvastatin lactone levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.21",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B3 rs4149117 TT+TG vs GG genotype comparison for simvastatin acid levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.94",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, CYP3A4*1G rs2242480 GG vs GA+AA genotype comparison for simvastatin lactone levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.92",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, CYP3A5*3 rs776746 AA vs AG+GG genotype comparison for simvastatin lactone levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.65",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, CYP3A5*3 rs776746 AA vs AG+GG genotype comparison for simvastatin acid levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.23",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B1 diplotype *1a/*1b vs *1a/*1a comparison for simvastatin lactone levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.51",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B1 diplotype *1a/*1b vs *1a/*1a comparison for simvastatin acid levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.10",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B1 diplotype *1b/*1b vs *1a/*1a comparison for simvastatin lactone levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.97",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B1 diplotype *1b/*1b vs *1a/*1a comparison for simvastatin acid levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.37",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B1 diplotype *1b/*5 vs *1a/*1a comparison for simvastatin lactone levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.57",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B1 diplotype *1b/*5 vs *1a/*1a comparison for simvastatin acid levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.57",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, SLCO1B1 diplotype *1b/*15 vs *1a/*1a comparison for simvastatin lactone levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.71",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, OATP1B1 normal function vs decreased function comparison for simvastatin lactone levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.41",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 89,
            "Study Controls": null,
            "Characteristics": "Thai patients with dyslipidemia or coronary artery disease on simvastatin treatment, OATP1B1 normal function vs decreased function comparison for simvastatin acid levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.07",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 42,
            "Study Controls": null,
            "Characteristics": "Thai patients on simvastatin 10 mg/day, SLCO1B1 rs2306283 AA vs AG+GG genotype comparison for simvastatin acid levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.04",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cross-sectional",
            "Study Cases": 42,
            "Study Controls": null,
            "Characteristics": "Thai patients on simvastatin 10 mg/day, SLCO1B1 rs4149056 TT vs TC+CC genotype comparison for simvastatin acid levels",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.06",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC10399933": {
      "var-pheno": {
        "overall_score": 0.7082214249031883,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.8571428571428571,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 0.8571428571428571,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Drug(s)": {
            "mean_score": 0.8403485502515521,
            "scores": [
              1.0,
              1.0,
              0.9412199258804321,
              0.9412199258804321,
              1.0,
              1.0,
              0.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.8571428571428571,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Alleles": {
            "mean_score": 0.7912725721086774,
            "scores": [
              0.9050131440162659,
              0.9050131440162659,
              0.9265924096107483,
              0.8515306115150452,
              0.9753793478012085,
              0.9753793478012085,
              0.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.8571428571428571,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.2857142857142857,
            "scores": [
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.772750735282898,
            "scores": [
              0.9044212698936462,
              0.8871487975120544,
              0.9044212698936462,
              0.9044212698936462,
              0.9044212698936462,
              0.9044212698936462,
              0.0
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 0.8571428571428571,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.505723944732121,
            "scores": [
              0.9026914238929749,
              0.9026914238929749,
              0.9026914238929749,
              0.8319933414459229,
              0.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 7,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9050131440162659,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9044212698936462,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9026914238929749
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs4149056",
                "prediction": "rs4149056"
              },
              "Gene": {
                "ground_truth": "SLCO1B1",
                "prediction": "SLCO1B1"
              },
              "Drug(s)": {
                "ground_truth": "simvastatin",
                "prediction": "simvastatin"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "CC",
                "prediction": "C/C"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Discontinuation",
                "prediction": "Side Effect:Statin intolerance"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "TT",
                "prediction": "T/T"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9050131440162659,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.8871487975120544,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9026914238929749
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs4149056",
                "prediction": "rs4149056"
              },
              "Gene": {
                "ground_truth": "SLCO1B1",
                "prediction": "SLCO1B1"
              },
              "Drug(s)": {
                "ground_truth": "simvastatin",
                "prediction": "simvastatin"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "CC",
                "prediction": "C/C"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Discontinuation",
                "prediction": "Side Effect:Statin intolerance with CK measurement"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "TT",
                "prediction": "T/T"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 0.9412199258804321,
              "Phenotype Category": 1.0,
              "Alleles": 0.9265924096107483,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9044212698936462,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9026914238929749
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs4149056",
                "prediction": "rs4149056"
              },
              "Gene": {
                "ground_truth": "SLCO1B1",
                "prediction": "SLCO1B1"
              },
              "Drug(s)": {
                "ground_truth": "atorvastatin, fluvastatin, rosuvastatin",
                "prediction": "atorvastatin"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "CC + CT",
                "prediction": "C/C"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Discontinuation",
                "prediction": "Side Effect:Statin intolerance"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "TT",
                "prediction": "T/T"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 0.9412199258804321,
              "Phenotype Category": 1.0,
              "Alleles": 0.8515306115150452,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9044212698936462,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8319933414459229
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs2231142",
                "prediction": "rs2231142"
              },
              "Gene": {
                "ground_truth": "ABCG2",
                "prediction": "ABCG2"
              },
              "Drug(s)": {
                "ground_truth": "atorvastatin, fluvastatin, rosuvastatin",
                "prediction": "atorvastatin"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "GT + TT",
                "prediction": "C/A or A/A"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Discontinuation",
                "prediction": "Side Effect:Statin intolerance"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "GG",
                "prediction": "C/C"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9753793478012085,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9044212698936462,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C9*2",
                "prediction": "CYP2C9*2"
              },
              "Gene": {
                "ground_truth": "CYP2C9",
                "prediction": "CYP2C9"
              },
              "Drug(s)": {
                "ground_truth": "fluvastatin",
                "prediction": "fluvastatin"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*2/*2 + *2/*3 + *3/*3",
                "prediction": "*2, *3"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Discontinuation",
                "prediction": "Side Effect:Statin intolerance"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*2 + *1/*3",
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9753793478012085,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9044212698936462,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C9*3",
                "prediction": "CYP2C9*3"
              },
              "Gene": {
                "ground_truth": "CYP2C9",
                "prediction": "CYP2C9"
              },
              "Drug(s)": {
                "ground_truth": "fluvastatin",
                "prediction": "fluvastatin"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*2/*2 + *2/*3 + *3/*3",
                "prediction": "*2, *3"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Discontinuation",
                "prediction": "Side Effect:Statin intolerance"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*2 + *1/*3",
                "prediction": null
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "cyp2c9*2",
          "cyp2c9*3",
          "PA166154579",
          "PA166156544",
          "PA166154579",
          "PA166154579"
        ],
        "unmatched_ground_truth": [
          {
            "Variant Annotation ID": 1452196120,
            "Variant/Haplotypes": "CYP2C9*1",
            "Gene": "CYP2C9",
            "Drug(s)": "fluvastatin",
            "PMID": 37490620,
            "Phenotype Category": "Toxicity",
            "Significance": "no",
            "Notes": "effect is described as \"Statin switch\" as measured by changes in prescription refills in the medical record, and attributed to muscle side effects (therefore tagged as toxicity). \"The sample sizes for fluvastatin and pravastatin were relatively small\"\"No statistically significant association was found for fluvastatin\"",
            "Sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .",
            "Alleles": "*2/*2 + *2/*3 + *3/*3",
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Discontinuation",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *1/*3",
            "Comparison Metabolizer types": "normal metabolizer and intermediate metabolizer",
            "PMID_norm": "37490620",
            "Variant Annotation ID_norm": "1452196120",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C9*1, CYP2C9*2, CYP2C9*3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "fluvastatin",
              "drug_id": "PA449688",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          }
        ],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "rs4149056",
            "Gene": "SLCO1B1",
            "Drug(s)": "rosuvastatin",
            "PMID": 37490620,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "No significant association was observed between SLCO1B1 c.521T>C and rosuvastatin intolerance. HR for c.521T/C or C/C vs T/T was 0.67 (95% CI 0.32-1.43, P=0.301) for statin switch phenotype.",
            "Sentence": "rs4149056 is not associated with risk of Side Effect:Statin intolerance when treated with rosuvastatin.",
            "Alleles": "T/C or C/C",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Statin intolerance",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "T/T",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No significant association was observed with atorvastatin and rosuvastatin.",
              "Rosuvastatin had total of 184 users of whom 32 were categorized as statin switchers. Rosuvastatin dose of 10 mg was associated with increased risk of statin intolerance when compared to 5 mg dose, but the *SLCO1B1* or *ABCG2* genotypes were not associated with statin intolerance",
              "c.521T/C or C/C | 65 | 10 | 0.67 (0.32\u20131.43) | 0.301"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs4149056",
              "variant_id": "PA166154579",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "rosuvastatin",
              "drug_id": "PA134308647",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "rs2231142",
            "Gene": "ABCG2",
            "Drug(s)": "rosuvastatin",
            "PMID": 37490620,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "No significant association was observed between ABCG2 c.421C>A and rosuvastatin intolerance. HR for c.421C/A or A/A vs C/C was 0.81 (95% CI 0.31-2.10, P=0.660) for statin switch phenotype.",
            "Sentence": "rs2231142 is not associated with risk of Side Effect:Statin intolerance when treated with rosuvastatin.",
            "Alleles": "C/A or A/A",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Statin intolerance",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "C/C",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No significant association was observed with atorvastatin and rosuvastatin.",
              "c.421C/C | 153 | 27 |   |   |\n| c.421C/A or A/A | 31 | 5 | 0.81 (0.31\u20132.10) | 0.660 |",
              "the SLCO1B1 or ABCG2 genotypes were not associated with statin intolerance (Table 4)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2231142",
              "variant_id": "PA166156544",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "rosuvastatin",
              "drug_id": "PA134308647",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "rs4149056",
            "Gene": "SLCO1B1",
            "Drug(s)": "fluvastatin",
            "PMID": 37490620,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "No statistically significant association was found between SLCO1B1 c.521T>C and fluvastatin intolerance. HR for c.521T/C or C/C vs T/T was 1.42 (95% CI 0.67-3.01, P=0.36) for statin switch phenotype.",
            "Sentence": "rs4149056 is not associated with risk of Side Effect:Statin intolerance when treated with fluvastatin.",
            "Alleles": "T/C or C/C",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Statin intolerance",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "T/T",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No statistically significant association was found for fluvastatin (Table 5).",
              "c.521T/C or C/C | 31 | 16 | 1.42 (0.67\u20133.01) | 0.36",
              "The sample sizes for fluvastatin and pravastatin were relatively small, but SLCO1B1 c.521T>C carriers had an increased risk of pravastatin intolerance defined by statin switching when compared to homozygous reference T/T genotype (HR 2.11, 95% CI 1.01\u20134.39, P = 0.047)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs4149056",
              "variant_id": "PA166154579",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "fluvastatin",
              "drug_id": "PA449688",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "rs2231142",
            "Gene": "ABCG2",
            "Drug(s)": "fluvastatin",
            "PMID": 37490620,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "No statistically significant association was found between ABCG2 c.421C>A and fluvastatin intolerance. HR for c.421C/A or A/A vs C/C was 2.06 (95% CI 0.84-5.05, P=0.113) for statin switch phenotype.",
            "Sentence": "rs2231142 is not associated with risk of Side Effect:Statin intolerance when treated with fluvastatin.",
            "Alleles": "C/A or A/A",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Statin intolerance",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "C/C",
            "Comparison Metabolizer types": null,
            "Citations": [
              "No statistically significant association was found for fluvastatin (Table 5).",
              "c.421C/C | 61 | 25 |   |   |\n| c.421C/A or A/A | 9 | 6 | 2.06 (0.84\u20135.05) | 0.113 |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2231142",
              "variant_id": "PA166156544",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "fluvastatin",
              "drug_id": "PA449688",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 10,
            "Variant/Haplotypes": "rs4149056",
            "Gene": "SLCO1B1",
            "Drug(s)": "pravastatin",
            "PMID": 37490620,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "SLCO1B1 c.521T/C or C/C genotype was associated with increased risk of pravastatin intolerance defined by statin switching (HR 2.11, 95% CI 1.01-4.39, P=0.047) compared to T/T genotype.",
            "Sentence": "rs4149056 (c.521T/C or C/C genotype) is associated with increased risk of Side Effect:Statin intolerance when treated with pravastatin as compared to c.521T/T genotype.",
            "Alleles": "T/C or C/C",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Statin intolerance",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "T/T",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The sample sizes for fluvastatin and pravastatin were relatively small, but SLCO1B1 c.521T>C carriers had an increased risk of pravastatin intolerance defined by statin switching when compared to homozygous reference T/T genotype (HR 2.11, 95% CI 1.01\u20134.39, P = 0.047).",
              "*SLCO1B1* c.521T/C or C/C genotype was associated with an increased risk of pravastatin switching when compared to homozygous reference T/T genotype (HR 2.11, 95% CI 1.01\u20134.39, *P* = 0.047; Table 6)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs4149056",
              "variant_id": "PA166154579",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "pravastatin",
              "drug_id": "PA451089",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.6215079975128174,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.9226199626922608,
            "scores": [
              0.9159294366836548,
              0.909377932548523,
              0.8977243900299072,
              0.9314382076263428,
              0.9343833327293396,
              0.9340129494667053,
              0.9300335049629211,
              0.9297609329223633,
              0.9270287752151489,
              0.9165101647377014
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 0.9,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.3,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 0.4,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 0.4,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 0.4,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 10,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9159294366836548,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452195945,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452195940,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 916.0,
                "prediction": 232
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Statin switch",
                "prediction": "Simvastatin users, statin switch phenotype, SLCO1B1 c.521C/C vs T/T"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.025",
                "prediction": "= 0.025"
              },
              "Ratio Stat Type": {
                "ground_truth": "HR",
                "prediction": "HR"
              },
              "Ratio Stat": {
                "ground_truth": 1.88,
                "prediction": 1.88
              },
              "Confidence Interval Start": {
                "ground_truth": 1.08,
                "prediction": 1.08
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.25,
                "prediction": 3.25
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.909377932548523,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452195960,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452195947,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 92.0,
                "prediction": 29
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Statin switch",
                "prediction": "Pravastatin users, statin switch phenotype, SLCO1B1 c.521T/C or C/C vs T/T"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.047",
                "prediction": "= 0.047"
              },
              "Ratio Stat Type": {
                "ground_truth": "HR",
                "prediction": "HR"
              },
              "Ratio Stat": {
                "ground_truth": 2.11,
                "prediction": 2.11
              },
              "Confidence Interval Start": {
                "ground_truth": 1.01,
                "prediction": 1.01
              },
              "Confidence Interval Stop": {
                "ground_truth": 4.39,
                "prediction": 4.39
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8977243900299072,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452195946,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452195940,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 916.0,
                "prediction": 22
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Statin switch",
                "prediction": "Simvastatin users, statin switch + CK measurement phenotype, SLCO1B1 c.521C/C vs T/T"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.011",
                "prediction": "= 0.011"
              },
              "Ratio Stat Type": {
                "ground_truth": "HR",
                "prediction": "HR"
              },
              "Ratio Stat": {
                "ground_truth": 5.44,
                "prediction": 5.44
              },
              "Confidence Interval Start": {
                "ground_truth": 1.49,
                "prediction": 1.49
              },
              "Confidence Interval Stop": {
                "ground_truth": 19.9,
                "prediction": 19.9
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9314382076263428,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452196060,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452196040,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 780.0,
                "prediction": 232
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Statin switch, atorvastatin",
                "prediction": "Simvastatin users, statin switch phenotype, 10 mg dose"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.759",
                "prediction": ""
              },
              "Ratio Stat Type": {
                "ground_truth": "Unknown",
                "prediction": "HR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9343833327293396,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452196045,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452196040,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 70.0,
                "prediction": 31
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Statin switch, fluvastatin",
                "prediction": "Fluvastatin users, statin switch phenotype, SLCO1B1 c.521T/C or C/C vs T/T"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.36",
                "prediction": "= 0.36"
              },
              "Ratio Stat Type": {
                "ground_truth": "Unknown",
                "prediction": "HR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 1.42
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.67
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 3.01
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9340129494667053,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452196046,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452196040,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 184.0,
                "prediction": 32
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Statin switch, rosuvastatin",
                "prediction": "Rosuvastatin users, statin switch phenotype, SLCO1B1 c.521T/C or C/C vs T/T"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.301",
                "prediction": "= 0.301"
              },
              "Ratio Stat Type": {
                "ground_truth": "Unknown",
                "prediction": "HR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.67
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.32
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 1.43
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 6,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9300335049629211,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452196101,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452196080,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 780.0,
                "prediction": 128
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Statin switch, atorvastatin",
                "prediction": "Atorvastatin users, statin switch phenotype, ABCG2 c.421C/A or A/A vs C/C"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.877",
                "prediction": "= 0.877"
              },
              "Ratio Stat Type": {
                "ground_truth": "Unknown",
                "prediction": "HR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 1.04
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.63
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 1.71
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 7,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9297609329223633,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452196085,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452196080,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 70.0,
                "prediction": 31
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Statin switch, fluvastatin",
                "prediction": "Fluvastatin users, statin switch phenotype, ABCG2 c.421C/A or A/A vs C/C"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.113",
                "prediction": "= 0.113"
              },
              "Ratio Stat Type": {
                "ground_truth": "Unknown",
                "prediction": "HR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 2.06
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.84
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 5.05
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 8,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9270287752151489,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452196100,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452196080,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 184.0,
                "prediction": 32
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Statin switch, rosuvastatin",
                "prediction": "Rosuvastatin users, statin switch phenotype, ABCG2 c.421C/A or A/A vs C/C"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.660",
                "prediction": "= 0.660"
              },
              "Ratio Stat Type": {
                "ground_truth": "Unknown",
                "prediction": "HR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.81
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.31
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 2.1
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 9,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9165101647377014,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452196130,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452196120,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 70.0,
                "prediction": 31
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Statin switch, fluvastatin",
                "prediction": "Fluvastatin users, statin switch phenotype, CYP2C9 PM or IM vs NM"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.394",
                "prediction": "= 0.394"
              },
              "Ratio Stat Type": {
                "ground_truth": "Unknown",
                "prediction": "HR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 1.36
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.67
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 2.78
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "None:Statin switch",
          "None:Statin switch",
          "None:Statin switch",
          "None:Statin switch, atorv",
          "None:Statin switch, fluva",
          "None:Statin switch, rosuv",
          "None:Statin switch, atorv",
          "None:Statin switch, fluva",
          "None:Statin switch, rosuv",
          "None:Statin switch, fluva"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 232,
            "Study Controls": null,
            "Characteristics": "Simvastatin users, statin switch phenotype, 20 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.498",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.13,
            "Confidence Interval Start": 0.8,
            "Confidence Interval Stop": 1.6,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 232,
            "Study Controls": null,
            "Characteristics": "Simvastatin users, statin switch phenotype, 40 mg or 80 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.035",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.48,
            "Confidence Interval Start": 1.03,
            "Confidence Interval Stop": 2.12,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 232,
            "Study Controls": null,
            "Characteristics": "Simvastatin users, statin switch phenotype, SLCO1B1 c.521T/C vs T/T",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.640",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.94,
            "Confidence Interval Start": 0.7,
            "Confidence Interval Stop": 1.24,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 22,
            "Study Controls": null,
            "Characteristics": "Simvastatin users, statin switch + CK measurement phenotype, 20 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.284",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 2.0,
            "Confidence Interval Start": 0.56,
            "Confidence Interval Stop": 7.14,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 22,
            "Study Controls": null,
            "Characteristics": "Simvastatin users, statin switch + CK measurement phenotype, 40 mg or 80 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.379",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.84,
            "Confidence Interval Start": 0.47,
            "Confidence Interval Stop": 7.12,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 22,
            "Study Controls": null,
            "Characteristics": "Simvastatin users, statin switch + CK measurement phenotype, SLCO1B1 c.521T/C vs T/T",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.226",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.75,
            "Confidence Interval Start": 0.71,
            "Confidence Interval Stop": 4.31,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 128,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch phenotype, SLCO1B1, 20 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.463",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.86,
            "Confidence Interval Start": 0.58,
            "Confidence Interval Stop": 1.28,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 128,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch phenotype, SLCO1B1, 40 mg or 80 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.907",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.03,
            "Confidence Interval Start": 0.65,
            "Confidence Interval Stop": 1.62,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 128,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch phenotype, SLCO1B1 c.521T/C vs T/T",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.339",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.82,
            "Confidence Interval Start": 0.55,
            "Confidence Interval Stop": 1.23,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 128,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch phenotype, SLCO1B1 c.521C/C vs T/T",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.759",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.13,
            "Confidence Interval Start": 0.52,
            "Confidence Interval Stop": 2.44,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 18,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch + CK measurement phenotype, SLCO1B1, 20 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.745",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.85,
            "Confidence Interval Start": 0.32,
            "Confidence Interval Stop": 2.24,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 18,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch + CK measurement phenotype, SLCO1B1, 40 mg or 80 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.151",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.22,
            "Confidence Interval Start": 0.03,
            "Confidence Interval Stop": 1.73,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 18,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch + CK measurement phenotype, SLCO1B1 c.521T/C vs T/T",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.667",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.25,
            "Confidence Interval Start": 0.46,
            "Confidence Interval Stop": 3.38,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 18,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch + CK measurement phenotype, SLCO1B1 c.521C/C vs T/T",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.799",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.3,
            "Confidence Interval Start": 0.17,
            "Confidence Interval Stop": 10.1,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 128,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch phenotype, ABCG2, 20 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.428",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.85,
            "Confidence Interval Start": 0.57,
            "Confidence Interval Stop": 1.27,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 128,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch phenotype, ABCG2, 40 mg or 80 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.955",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.01,
            "Confidence Interval Start": 0.64,
            "Confidence Interval Stop": 1.6,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 18,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch + CK measurement phenotype, ABCG2, 20 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.759",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.86,
            "Confidence Interval Start": 0.33,
            "Confidence Interval Stop": 2.26,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 18,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch + CK measurement phenotype, ABCG2, 40 mg or 80 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.154",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.22,
            "Confidence Interval Start": 0.03,
            "Confidence Interval Stop": 1.75,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 18,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch + CK measurement phenotype, ABCG2 c.421C/A or A/A vs C/C",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.706",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.27,
            "Confidence Interval Start": 0.37,
            "Confidence Interval Stop": 4.39,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 128,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch phenotype, risk alleles, 20 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.430",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.85,
            "Confidence Interval Start": 0.57,
            "Confidence Interval Stop": 1.27,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 128,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch phenotype, risk alleles, 40 mg or 80 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.949",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.02,
            "Confidence Interval Start": 0.64,
            "Confidence Interval Stop": 1.6,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 128,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch phenotype, 2-4 risk alleles vs 0-1 alleles",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.843",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.94,
            "Confidence Interval Start": 0.51,
            "Confidence Interval Stop": 1.74,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 18,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch + CK measurement phenotype, risk alleles, 20 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.762",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.86,
            "Confidence Interval Start": 0.33,
            "Confidence Interval Stop": 2.27,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 18,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch + CK measurement phenotype, risk alleles, 40 mg or 80 mg dose vs 10 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.157",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.23,
            "Confidence Interval Start": 0.03,
            "Confidence Interval Stop": 1.77,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 18,
            "Study Controls": null,
            "Characteristics": "Atorvastatin users, statin switch + CK measurement phenotype, 2-4 risk alleles vs 0-1 alleles",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.600",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.58,
            "Confidence Interval Start": 0.08,
            "Confidence Interval Stop": 4.39,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 32,
            "Study Controls": null,
            "Characteristics": "Rosuvastatin users, statin switch phenotype, SLCO1B1, 10 mg dose vs 5 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.038",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 3.55,
            "Confidence Interval Start": 1.07,
            "Confidence Interval Stop": 11.8,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 32,
            "Study Controls": null,
            "Characteristics": "Rosuvastatin users, statin switch phenotype, SLCO1B1, 20 or 40 mg dose vs 5 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.681",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.45,
            "Confidence Interval Start": 0.24,
            "Confidence Interval Stop": 8.78,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 32,
            "Study Controls": null,
            "Characteristics": "Rosuvastatin users, statin switch phenotype, ABCG2, 10 mg dose vs 5 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.038",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 3.56,
            "Confidence Interval Start": 1.07,
            "Confidence Interval Stop": 11.8,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 32,
            "Study Controls": null,
            "Characteristics": "Rosuvastatin users, statin switch phenotype, ABCG2, 20 or 40 mg dose vs 5 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.644",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.53,
            "Confidence Interval Start": 0.25,
            "Confidence Interval Stop": 9.34,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 32,
            "Study Controls": null,
            "Characteristics": "Rosuvastatin users, statin switch phenotype, risk alleles, 10 mg dose vs 5 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.036",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 3.61,
            "Confidence Interval Start": 1.09,
            "Confidence Interval Stop": 12.0,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 32,
            "Study Controls": null,
            "Characteristics": "Rosuvastatin users, statin switch phenotype, risk alleles, 20 or 40 mg dose vs 5 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.700",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.43,
            "Confidence Interval Start": 0.23,
            "Confidence Interval Stop": 8.68,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 32,
            "Study Controls": null,
            "Characteristics": "Rosuvastatin users, statin switch phenotype, 2-4 risk alleles vs 0-1 alleles",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.149",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.23,
            "Confidence Interval Start": 0.03,
            "Confidence Interval Stop": 1.69,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 31,
            "Study Controls": null,
            "Characteristics": "Fluvastatin users, statin switch phenotype, SLCO1B1, 40 mg dose vs 20 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.868",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.91,
            "Confidence Interval Start": 0.31,
            "Confidence Interval Stop": 2.73,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 31,
            "Study Controls": null,
            "Characteristics": "Fluvastatin users, statin switch phenotype, SLCO1B1, 80 mg dose vs 20 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.303",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.62,
            "Confidence Interval Start": 0.65,
            "Confidence Interval Stop": 4.05,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 31,
            "Study Controls": null,
            "Characteristics": "Fluvastatin users, statin switch phenotype, ABCG2, 40 mg dose vs 20 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.825",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.88,
            "Confidence Interval Start": 0.3,
            "Confidence Interval Stop": 2.64,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 31,
            "Study Controls": null,
            "Characteristics": "Fluvastatin users, statin switch phenotype, ABCG2, 80 mg dose vs 20 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.466",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.39,
            "Confidence Interval Start": 0.58,
            "Confidence Interval Stop": 3.34,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 31,
            "Study Controls": null,
            "Characteristics": "Fluvastatin users, statin switch phenotype, CYP2C9, 40 mg dose vs 20 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.832",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.89,
            "Confidence Interval Start": 0.3,
            "Confidence Interval Stop": 2.65,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 31,
            "Study Controls": null,
            "Characteristics": "Fluvastatin users, statin switch phenotype, CYP2C9, 80 mg dose vs 20 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.465",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.39,
            "Confidence Interval Start": 0.58,
            "Confidence Interval Stop": 3.34,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 31,
            "Study Controls": null,
            "Characteristics": "Fluvastatin users, statin switch phenotype, risk alleles, 40 mg dose vs 20 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.928",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.95,
            "Confidence Interval Start": 0.32,
            "Confidence Interval Stop": 2.85,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 31,
            "Study Controls": null,
            "Characteristics": "Fluvastatin users, statin switch phenotype, risk alleles, 80 mg dose vs 20 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.273",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.65,
            "Confidence Interval Start": 0.67,
            "Confidence Interval Stop": 4.04,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 31,
            "Study Controls": null,
            "Characteristics": "Fluvastatin users, statin switch phenotype, 2-4 risk alleles vs 0-1 alleles",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.094",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.88,
            "Confidence Interval Start": 0.9,
            "Confidence Interval Stop": 3.96,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 29,
            "Study Controls": null,
            "Characteristics": "Pravastatin users, statin switch phenotype, SLCO1B1, 40 mg dose vs 20 mg",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.376",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.43,
            "Confidence Interval Start": 0.65,
            "Confidence Interval Stop": 3.17,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC11062152": {
      "var-pheno": {
        "overall_score": 0.5743408509426646,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Drug(s)": {
            "mean_score": 0.6367148558298746,
            "scores": [
              0.955072283744812,
              0.955072283744812,
              0.955072283744812,
              0.955072283744812,
              0.0,
              0.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Alleles": {
            "mean_score": 0.6480368177096049,
            "scores": [
              0.9920046925544739,
              0.9909753799438477,
              0.9546118378639221,
              0.9506289958953857,
              0.0,
              0.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.6665015816688538,
            "scores": [
              0.9995047450065613,
              0.9995047450065613,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.2986262043317159,
            "scores": [
              0.8958786129951477,
              0.8958786129951477,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 6,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 0.955072283744812,
              "Phenotype Category": 1.0,
              "Alleles": 0.9920046925544739,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9995047450065613,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8958786129951477
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "UGT1A1*6",
                "prediction": "UGT1A1*6"
              },
              "Gene": {
                "ground_truth": "UGT1A1",
                "prediction": "UGT1A1"
              },
              "Drug(s)": {
                "ground_truth": "fluorouracil, irinotecan, leucovorin",
                "prediction": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*6/*6 + *28/*28 + *6/*28",
                "prediction": "*6/*6, *6/*28"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Neutropenia, Side Effect:Leukopenia",
                "prediction": "Side Effect:Leukopenia, Side Effect:Neutropenia"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "wild-type (\u2013/\u2013), heterozygous (+/\u2013)"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 0.955072283744812,
              "Phenotype Category": 1.0,
              "Alleles": 0.9909753799438477,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9995047450065613,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8958786129951477
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "UGT1A1*28",
                "prediction": "UGT1A1*28"
              },
              "Gene": {
                "ground_truth": "UGT1A1",
                "prediction": "UGT1A1"
              },
              "Drug(s)": {
                "ground_truth": "fluorouracil, irinotecan, leucovorin",
                "prediction": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*6/*6 + *28/*28 + *6/*28",
                "prediction": "*28/*28, *6/*28"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Neutropenia, Side Effect:Leukopenia",
                "prediction": "Side Effect:Leukopenia, Side Effect:Neutropenia"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "wild-type (\u2013/\u2013), heterozygous (+/\u2013)"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 0.955072283744812,
              "Phenotype Category": 1.0,
              "Alleles": 0.9546118378639221,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "UGT1A1*28",
                "prediction": "UGT1A1*28"
              },
              "Gene": {
                "ground_truth": "UGT1A1",
                "prediction": "UGT1A1"
              },
              "Drug(s)": {
                "ground_truth": "fluorouracil, irinotecan, leucovorin",
                "prediction": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*6 + *28",
                "prediction": "*28"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Diarrhea",
                "prediction": "Side Effect:Diarrhea"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 0.955072283744812,
              "Phenotype Category": 1.0,
              "Alleles": 0.9506289958953857,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "UGT1A1*6",
                "prediction": "UGT1A1*6"
              },
              "Gene": {
                "ground_truth": "UGT1A1",
                "prediction": "UGT1A1"
              },
              "Drug(s)": {
                "ground_truth": "fluorouracil, irinotecan, leucovorin",
                "prediction": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*6 + *28",
                "prediction": "*6"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Diarrhea",
                "prediction": "Side Effect:Diarrhea"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": null
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "ugt1a1*6",
          "ugt1a1*28",
          "ugt1a1*6",
          "ugt1a1*28"
        ],
        "unmatched_ground_truth": [
          {
            "Variant Annotation ID": 1452474670,
            "Variant/Haplotypes": "UGT1A1*1",
            "Gene": "UGT1A1",
            "Drug(s)": "fluorouracil, irinotecan, leucovorin",
            "PMID": 38707740,
            "Phenotype Category": "Toxicity",
            "Significance": "no",
            "Notes": "\"Diarrhea during nal-IRI/FL treatment was observed in seven (24.1%) of 29 patients, who had not been prescribed any antidiarrhea medication at the commencing time of nal-IRI. The rest of seven patients were excluded, since they received loperamide for diarrhea symptoms at the start of therapy. The incidence of grade \u22651 diarrhea in patients with UGT1A1*6 or *28 (\u2013/\u2013), (+/\u2013), and (+/+) were 27.3%, 21.4%, and 25.0%, respectively (Figure 1). Multivariate analysis did not extract any risk factors, which significantly affected the development of diarrhea possibly induced by nal-IRI/FL\"",
            "Sentence": "UGT1A1 *6 + *28 is not associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.",
            "Alleles": "*6 + *28",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Diarrhea",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "and",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Pancreatic Neoplasms, Other:Metastatic neoplasm",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "38707740",
            "Variant Annotation ID_norm": "1452474670",
            "Variant/Haplotypes_normalized": {
              "normalized": "UGT1A1*1, UGT1A1*6, UGT1A1*28",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "irinotecan",
              "drug_id": "PA450085",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1452474678,
            "Variant/Haplotypes": "UGT1A1*1",
            "Gene": "UGT1A1",
            "Drug(s)": "fluorouracil, irinotecan, leucovorin",
            "PMID": 38707740,
            "Phenotype Category": "Toxicity",
            "Significance": "no",
            "Notes": "\"Grade 3 or 4 leukopenia and neutropenia in the UGT1A1*6 or *28 (+/+) group demonstrated an incidence rate of 50.0%, indicating a higher tendency than those in UGT1A1*6 or *28 (\u2013/\u2013) and (+/\u2013) groups at 7.1% and 12.5%, respectively (p=0.085 for each) (Figure 2C and D). Multiple regression analyses revealed that the UGT1A1*6 or *28 (+/+) genotype, high AST value before the nal-IRI/FL therapy, and pancreatic head cancer were significantly associated with decreased white blood cell count (p=0.009, 0.019, and 0.030, respectively) (Table III), and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017)\"",
            "Sentence": "UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.",
            "Alleles": "*6/*6 + *28/*28 + *6/*28",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Neutropenia, Side Effect:Leukopenia",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "and",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Pancreatic Neoplasms, Other:Metastatic neoplasm",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "38707740",
            "Variant Annotation ID_norm": "1452474678",
            "Variant/Haplotypes_normalized": {
              "normalized": "UGT1A1*1, UGT1A1*6, UGT1A1*28",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "irinotecan",
              "drug_id": "PA450085",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          }
        ],
        "unmatched_predictions": []
      },
      "study-parameters": {
        "overall_score": 0.7174970282448663,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.9291220903396606,
            "scores": [
              0.9320830702781677,
              0.9295251965522766,
              0.9257580041885376
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 0.8333333333333334,
            "scores": [
              1.0,
              1.0,
              0.5
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 3,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9320830702781677,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452474688,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452474678,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 31.0,
                "prediction": 36
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "predictive factors for neutropenia (multiple regression) during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
                "prediction": "Metastatic pancreatic cancer patients treated with nal-IRI/FL, multiple regression analysis for decreased neutrophil count, UGT1A1*6 or *28 (+/+) genotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.017",
                "prediction": "= 0.017"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9295251965522766,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452474729,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452474678,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 31.0,
                "prediction": 36
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "predictive factors for leukopenia (multiple regression) during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
                "prediction": "Metastatic pancreatic cancer patients treated with nal-IRI/FL, multiple regression analysis for decreased white blood cell count, UGT1A1*6 or *28 (+/+) genotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.009",
                "prediction": "= 0.009"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9257580041885376,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452474677,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452474670,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 29.0,
                "prediction": 36
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "diarrhea greater than grade 1 during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
                "prediction": "Metastatic pancreatic cancer patients treated with nal-IRI/FL, grade 3 or 4 neutropenia incidence by UGT1A1*6 or *28 genotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.943",
                "prediction": "= 0.085"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "None:predictive factors f",
          "None:predictive factors f",
          "None:diarrhea greater tha"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 36,
            "Study Controls": null,
            "Characteristics": "Metastatic pancreatic cancer patients treated with nal-IRI/FL, UGT1A1*6 or *28 homozygous (+/+) vs wild-type and heterozygous, white blood cell count nadir",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.033",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 36,
            "Study Controls": null,
            "Characteristics": "Metastatic pancreatic cancer patients treated with nal-IRI/FL, UGT1A1*6 or *28 homozygous (+/+) vs wild-type and heterozygous, neutrophil count nadir",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.043",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 36,
            "Study Controls": null,
            "Characteristics": "Metastatic pancreatic cancer patients treated with nal-IRI/FL, multiple regression analysis for decreased white blood cell count, high AST value before therapy",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.019",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 36,
            "Study Controls": null,
            "Characteristics": "Metastatic pancreatic cancer patients treated with nal-IRI/FL, multiple regression analysis for decreased white blood cell count, pancreatic head cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.030",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 36,
            "Study Controls": null,
            "Characteristics": "Metastatic pancreatic cancer patients treated with nal-IRI/FL, grade 3 or 4 leukopenia incidence by UGT1A1*6 or *28 genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.085",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 36,
            "Study Controls": null,
            "Characteristics": "Metastatic pancreatic cancer patients treated with nal-IRI/FL, initial nal-IRI dose by UGT1A1*6 or *28 genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.011",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC4706412": {
      "var-drug": {
        "overall_score": 0.6581706985046989,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "PMID": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Significance": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Alleles": {
            "mean_score": 0.7043269872665405,
            "scores": [
              0.9582873582839966,
              0.9582873582839966,
              0.9582873582839966,
              0.9582873582839966,
              0.9346194863319397,
              0.8668469786643982,
              0.0,
              0.0
            ]
          },
          "Specialty Population": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Metabolizer types": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "isPlural": {
            "mean_score": 0.625,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "PD/PK terms": {
            "mean_score": 0.7186920493841171,
            "scores": [
              0.9582560658454895,
              0.9582560658454895,
              0.9582560658454895,
              0.9582560658454895,
              0.9582560658454895,
              0.9582560658454895,
              0.0,
              0.0
            ]
          },
          "Multiple drugs And/or": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Population types": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Population Phenotypes or diseases": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Multiple phenotypes or diseases And/or": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.7072242349386215,
            "scores": [
              0.9723937511444092,
              0.9723937511444092,
              0.9723937511444092,
              0.9723937511444092,
              0.9421090483665466,
              0.8261098265647888,
              0.0,
              0.0
            ]
          },
          "Comparison Metabolizer types": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Drug(s)": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 8,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.9582873582839966,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.9582560658454895,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.0,
              "Population Phenotypes or diseases": 0.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9723937511444092,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C9*1",
                "prediction": "CYP2C9*1"
              },
              "Gene": {
                "ground_truth": "CYP2C9",
                "prediction": "CYP2C9"
              },
              "PMID": {
                "ground_truth": 26745506,
                "prediction": 26745506
              },
              "Phenotype Category": {
                "ground_truth": "Dosage",
                "prediction": "dosage"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *8",
                "prediction": "*1/*2, *1/*3, *1/*4, *1/*5, *1/*6, *1/*8, *1/*11, *2/*2, *2/*3, *2/*5, *3/*5, *3/*6"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "PD/PK terms": {
                "ground_truth": "dose of",
                "prediction": "dose requirements of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": null,
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": null,
                "prediction": "Disease:Thromboembolic disorders"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1/*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "warfarin",
                "prediction": "warfarin"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.9582873582839966,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.9582560658454895,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.0,
              "Population Phenotypes or diseases": 0.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9723937511444092,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C9*2",
                "prediction": "CYP2C9*2"
              },
              "Gene": {
                "ground_truth": "CYP2C9",
                "prediction": "CYP2C9"
              },
              "PMID": {
                "ground_truth": 26745506,
                "prediction": 26745506
              },
              "Phenotype Category": {
                "ground_truth": "Dosage",
                "prediction": "dosage"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *8",
                "prediction": "*1/*2, *1/*3, *1/*4, *1/*5, *1/*6, *1/*8, *1/*11, *2/*2, *2/*3, *2/*5, *3/*5, *3/*6"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "PD/PK terms": {
                "ground_truth": "dose of",
                "prediction": "dose requirements of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": null,
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": null,
                "prediction": "Disease:Thromboembolic disorders"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1/*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "warfarin",
                "prediction": "warfarin"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.9582873582839966,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.9582560658454895,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.0,
              "Population Phenotypes or diseases": 0.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9723937511444092,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C9*3",
                "prediction": "CYP2C9*3"
              },
              "Gene": {
                "ground_truth": "CYP2C9",
                "prediction": "CYP2C9"
              },
              "PMID": {
                "ground_truth": 26745506,
                "prediction": 26745506
              },
              "Phenotype Category": {
                "ground_truth": "Dosage",
                "prediction": "dosage"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *8",
                "prediction": "*1/*2, *1/*3, *1/*4, *1/*5, *1/*6, *1/*8, *1/*11, *2/*2, *2/*3, *2/*5, *3/*5, *3/*6"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "PD/PK terms": {
                "ground_truth": "dose of",
                "prediction": "dose requirements of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": null,
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": null,
                "prediction": "Disease:Thromboembolic disorders"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1/*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "warfarin",
                "prediction": "warfarin"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.9582873582839966,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.9582560658454895,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.0,
              "Population Phenotypes or diseases": 0.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9723937511444092,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C9*8",
                "prediction": "CYP2C9*8"
              },
              "Gene": {
                "ground_truth": "CYP2C9",
                "prediction": "CYP2C9"
              },
              "PMID": {
                "ground_truth": 26745506,
                "prediction": 26745506
              },
              "Phenotype Category": {
                "ground_truth": "Dosage",
                "prediction": "dosage"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *8",
                "prediction": "*1/*2, *1/*3, *1/*4, *1/*5, *1/*6, *1/*8, *1/*11, *2/*2, *2/*3, *2/*5, *3/*5, *3/*6"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "PD/PK terms": {
                "ground_truth": "dose of",
                "prediction": "dose requirements of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": null,
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": null,
                "prediction": "Disease:Thromboembolic disorders"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": "*1/*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "warfarin",
                "prediction": "warfarin"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.9346194863319397,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.9582560658454895,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.0,
              "Population Phenotypes or diseases": 0.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.9421090483665466,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs9923231",
                "prediction": "rs9923231"
              },
              "Gene": {
                "ground_truth": "VKORC1",
                "prediction": "VKORC1"
              },
              "PMID": {
                "ground_truth": 26745506,
                "prediction": 26745506
              },
              "Phenotype Category": {
                "ground_truth": "Dosage",
                "prediction": "dosage"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "AA, GA"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "PD/PK terms": {
                "ground_truth": "dose of",
                "prediction": "dose requirements of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": null,
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": null,
                "prediction": "Disease:Thromboembolic disorders"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "GG"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "warfarin",
                "prediction": "warfarin"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.8668469786643982,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 0.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.9582560658454895,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.0,
              "Population Phenotypes or diseases": 0.0,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8261098265647888,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs1800566",
                "prediction": "rs1800566"
              },
              "Gene": {
                "ground_truth": "NQO1",
                "prediction": "NQO1"
              },
              "PMID": {
                "ground_truth": 26745506,
                "prediction": 26745506
              },
              "Phenotype Category": {
                "ground_truth": "Dosage",
                "prediction": "dosage"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "AA + AG",
                "prediction": "*1/*2, *2/*2"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "PD/PK terms": {
                "ground_truth": "dose of",
                "prediction": "dose requirements of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": null,
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": null,
                "prediction": "Disease:Thromboembolic disorders"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "GG",
                "prediction": "*1/*1"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "warfarin",
                "prediction": "warfarin"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "cyp2c9*1",
          "cyp2c9*2",
          "cyp2c9*3",
          "cyp2c9*8",
          "PA166155091",
          "PA166155017"
        ],
        "unmatched_ground_truth": [
          {
            "Variant Annotation ID": 1447682700,
            "Variant/Haplotypes": "CYP4F2*1",
            "Gene": "CYP4F2",
            "Drug(s)": "warfarin",
            "PMID": 26745506,
            "Phenotype Category": "Dosage",
            "Significance": "yes",
            "Notes": "The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: the derivation cohort was 99% male.",
            "Sentence": "CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1.",
            "Alleles": "*3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "dose of",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "26745506",
            "Variant Annotation ID_norm": "1447682700",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP4F2*1, CYP4F2*3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "warfarin",
              "drug_id": "PA451906",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1447682700,
            "Variant/Haplotypes": "CYP4F2*3",
            "Gene": "CYP4F2",
            "Drug(s)": "warfarin",
            "PMID": 26745506,
            "Phenotype Category": "Dosage",
            "Significance": "yes",
            "Notes": "The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: the derivation cohort was 99% male.",
            "Sentence": "CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1.",
            "Alleles": "*3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "dose of",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "26745506",
            "Variant Annotation ID_norm": "1447682700",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP4F2*1, CYP4F2*3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "warfarin",
              "drug_id": "PA451906",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          }
        ],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2C9*4",
            "Gene": "CYP2C9",
            "Drug(s)": "warfarin",
            "PMID": 26745506,
            "Phenotype Category": "dosage",
            "Significance": "yes",
            "Notes": "CYP2C9 polymorphisms combined explained 5% of observed inter-individual variability in dose requirements, associated with average 18% decrement in warfarin dose per variant allele. CYP2C9*2: -7% effect on dose (p=0.014), CYP2C9*3: -16% effect (p=0.015), CYP2C9*8: -31% effect (p=0.098).",
            "Sentence": "CYP2C9 variant alleles (*2, *3, *4, *5, *6, *8, *11) are associated with decreased dose requirements of warfarin in people with thromboembolic disorders as compared to CYP2C9*1/*1 wild-type.",
            "Alleles": "*1/*2, *1/*3, *1/*4, *1/*5, *1/*6, *1/*8, *1/*11, *2/*2, *2/*3, *2/*5, *3/*5, *3/*6",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "dose requirements of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Thromboembolic disorders",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The number of loss-of-function *CYP2C9* polymorphisms combined explained another 5% of the observed inter-individual variability in dose requirements, and it was associated with an average of 18% decrement in the warfarin dose per variant allele.",
              "CYP2C9*2 | -0.245 | 0.1654 | 0.613 | -7% | 0.014 | CYP2C9*3 | -0.544 | 0.2224 | 0.625 | -16% | 0.015 | CYP2C9*8 | -1.00 | 0.6014 | 0.638 | -31%; -18%d | 0.098",
              "The numerical designations of \"0\" for the *CYP2C9**1/*1 genotype (wild-type); \"1\" for the *1/*n genotypes (n stands for *3,*5,*6,*8,*11 \"loss-of-function\" variants detected in the genotyping assay) and \"2\" for *n/*n genotypes (e.g., *2/*2, *3/*3, *3/*5) were used to correspond to the relative capacity of the CYP system to metabolize warfarin."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "warfarin",
              "drug_id": "PA451906",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2C9*5",
            "Gene": "CYP2C9",
            "Drug(s)": "warfarin",
            "PMID": 26745506,
            "Phenotype Category": "dosage",
            "Significance": "yes",
            "Notes": "CYP2C9 polymorphisms combined explained 5% of observed inter-individual variability in dose requirements, associated with average 18% decrement in warfarin dose per variant allele. CYP2C9*2: -7% effect on dose (p=0.014), CYP2C9*3: -16% effect (p=0.015), CYP2C9*8: -31% effect (p=0.098).",
            "Sentence": "CYP2C9 variant alleles (*2, *3, *4, *5, *6, *8, *11) are associated with decreased dose requirements of warfarin in people with thromboembolic disorders as compared to CYP2C9*1/*1 wild-type.",
            "Alleles": "*1/*2, *1/*3, *1/*4, *1/*5, *1/*6, *1/*8, *1/*11, *2/*2, *2/*3, *2/*5, *3/*5, *3/*6",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "dose requirements of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Thromboembolic disorders",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The number of loss-of-function *CYP2C9* polymorphisms combined explained another 5% of the observed inter-individual variability in dose requirements, and it was associated with an average of 18% decrement in the warfarin dose per variant allele.",
              "CYP2C9*2 | -0.245 | 0.1654 | 0.613 | -7% | 0.014 | CYP2C9*3 | -0.544 | 0.2224 | 0.625 | -16% | 0.015 | CYP2C9*8 | -1.00 | 0.6014 | 0.638 | -31%; -18%d | 0.098",
              "The numerical designations of \"0\" for the *CYP2C9**1/*1 genotype (wild-type); \"1\" for the *1/*n genotypes (n stands for *3,*5,*6,*8,*11 \"loss-of-function\" variants detected in the genotyping assay) and \"2\" for *n/*n genotypes (e.g., *2/*2, *3/*3, *3/*5) were used to correspond to the relative capacity of the CYP system to metabolize warfarin."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "warfarin",
              "drug_id": "PA451906",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2C9*6",
            "Gene": "CYP2C9",
            "Drug(s)": "warfarin",
            "PMID": 26745506,
            "Phenotype Category": "dosage",
            "Significance": "yes",
            "Notes": "CYP2C9 polymorphisms combined explained 5% of observed inter-individual variability in dose requirements, associated with average 18% decrement in warfarin dose per variant allele. CYP2C9*2: -7% effect on dose (p=0.014), CYP2C9*3: -16% effect (p=0.015), CYP2C9*8: -31% effect (p=0.098).",
            "Sentence": "CYP2C9 variant alleles (*2, *3, *4, *5, *6, *8, *11) are associated with decreased dose requirements of warfarin in people with thromboembolic disorders as compared to CYP2C9*1/*1 wild-type.",
            "Alleles": "*1/*2, *1/*3, *1/*4, *1/*5, *1/*6, *1/*8, *1/*11, *2/*2, *2/*3, *2/*5, *3/*5, *3/*6",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "dose requirements of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Thromboembolic disorders",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The number of loss-of-function *CYP2C9* polymorphisms combined explained another 5% of the observed inter-individual variability in dose requirements, and it was associated with an average of 18% decrement in the warfarin dose per variant allele.",
              "CYP2C9*2 | -0.245 | 0.1654 | 0.613 | -7% | 0.014 | CYP2C9*3 | -0.544 | 0.2224 | 0.625 | -16% | 0.015 | CYP2C9*8 | -1.00 | 0.6014 | 0.638 | -31%; -18%d | 0.098",
              "The numerical designations of \"0\" for the *CYP2C9**1/*1 genotype (wild-type); \"1\" for the *1/*n genotypes (n stands for *3,*5,*6,*8,*11 \"loss-of-function\" variants detected in the genotyping assay) and \"2\" for *n/*n genotypes (e.g., *2/*2, *3/*3, *3/*5) were used to correspond to the relative capacity of the CYP system to metabolize warfarin."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "warfarin",
              "drug_id": "PA451906",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2C9*11",
            "Gene": "CYP2C9",
            "Drug(s)": "warfarin",
            "PMID": 26745506,
            "Phenotype Category": "dosage",
            "Significance": "yes",
            "Notes": "CYP2C9 polymorphisms combined explained 5% of observed inter-individual variability in dose requirements, associated with average 18% decrement in warfarin dose per variant allele. CYP2C9*2: -7% effect on dose (p=0.014), CYP2C9*3: -16% effect (p=0.015), CYP2C9*8: -31% effect (p=0.098).",
            "Sentence": "CYP2C9 variant alleles (*2, *3, *4, *5, *6, *8, *11) are associated with decreased dose requirements of warfarin in people with thromboembolic disorders as compared to CYP2C9*1/*1 wild-type.",
            "Alleles": "*1/*2, *1/*3, *1/*4, *1/*5, *1/*6, *1/*8, *1/*11, *2/*2, *2/*3, *2/*5, *3/*5, *3/*6",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "dose requirements of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Thromboembolic disorders",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The number of loss-of-function *CYP2C9* polymorphisms combined explained another 5% of the observed inter-individual variability in dose requirements, and it was associated with an average of 18% decrement in the warfarin dose per variant allele.",
              "CYP2C9*2 | -0.245 | 0.1654 | 0.613 | -7% | 0.014 | CYP2C9*3 | -0.544 | 0.2224 | 0.625 | -16% | 0.015 | CYP2C9*8 | -1.00 | 0.6014 | 0.638 | -31%; -18%d | 0.098",
              "The numerical designations of \"0\" for the *CYP2C9**1/*1 genotype (wild-type); \"1\" for the *1/*n genotypes (n stands for *3,*5,*6,*8,*11 \"loss-of-function\" variants detected in the genotyping assay) and \"2\" for *n/*n genotypes (e.g., *2/*2, *3/*3, *3/*5) were used to correspond to the relative capacity of the CYP system to metabolize warfarin."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "warfarin",
              "drug_id": "PA451906",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "rs2108622",
            "Gene": "CYP4F2",
            "Drug(s)": "warfarin",
            "PMID": 26745506,
            "Phenotype Category": "dosage",
            "Significance": "yes",
            "Notes": "CYP4F2*3 (rs2108622, V433M) was independently associated with 17% increase of dose per variant allele (p=0.014). Allele frequency 0.11 in Caribbean Hispanics.",
            "Sentence": "CYP4F2*3 allele is associated with increased dose requirements of warfarin in people with thromboembolic disorders as compared to CYP4F2*1/*1 wild-type.",
            "Alleles": "*1/*3, *3/*3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "dose requirements of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Thromboembolic disorders",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The frequencies of the *CYP4F2**3 (g.18000G>A, p.V433M, *rs2108622)* and *NQO1**2 (g.559C>T, p.P187S, *rs1800566)* \"resistant\" polymorphisms in the study population were 0.11 (95%CI: 0.09\u20130.14) and 0.10 (95%CI: 0.07\u20130.13), respectively.",
              "Notably, *CYP4F2**3 and *NQO1**2 variants were independently associated with a 17% and 10% increase of the dose per variant allele, respectively; whereas, the admixed status of the admixture index decreases the dose by 7%.",
              "CYP4F2*3 | 0.560 | 0.2274 | 0.673 | 17% | 0.014"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2108622",
              "variant_id": "PA166155381",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "warfarin",
              "drug_id": "PA451906",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "rs104894540",
            "Gene": "VKORC1",
            "Drug(s)": "warfarin",
            "PMID": 26745506,
            "Phenotype Category": "dosage",
            "Significance": "yes",
            "Notes": "VKORC1 c.134T>C (rs104894540, p.V45A) is an autosomal dominant warfarin resistance genotype. One patient identified as heterozygous for this rare variant.",
            "Sentence": "Genotype TC is associated with increased dose requirements of warfarin in people with thromboembolic disorders as compared to genotype TT.",
            "Alleles": "TC",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "dose requirements of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Thromboembolic disorders",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "TT",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Moreover, one patient (# WPR274) was identified as heterozygous for the \"rare\" missense variant c.134T>C transition in the *VKORC1* gene (*rs104894540*), which is an autosomal dominant warfarin resistance genotype resulting in a valine-to-alanine substitution at codon 45 (p.V45A).",
              "VKORC1 (c.134T>C, p.V45A, rs104894540): Resistant\nTT\t254; 99.6% (97.6\u201399.9; 0.0129)\nTC\t1; 0.39% (0.01\u20132.42; 0.0129)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs104894540",
              "variant_id": "PA166155138",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "warfarin",
              "drug_id": "PA451906",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.6757843250320071,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.8658511553491864,
            "scores": [
              0.8726109862327576,
              0.8666142821311951,
              0.8818534016609192,
              0.8677965402603149,
              0.8660078048706055,
              0.8599821925163269,
              0.8460928797721863
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 0.9851994344166347,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.8963960409164429
            ]
          },
          "Frequency In Controls": {
            "mean_score": 0.2857142857142857,
            "scores": [
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 0.2857142857142857,
            "scores": [
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "P Value": {
            "mean_score": 0.8571428571428571,
            "scores": [
              0.5,
              0.5,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 0.8571428571428571,
            "scores": [
              1.0,
              0.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 7,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8726109862327576,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1447682693,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1447682688,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, retrospective",
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 255.0,
                "prediction": 255
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "NCT01318057; VKORC1 rs9923231 AA partial reg. coeff. -0.896 (SE 0.2169), adj R sq .0.641",
                "prediction": "Caribbean Hispanic warfarin-treated patients, pharmacogenetic algorithm comparison, high-risk patients"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "< 0.0001",
                "prediction": "< 0.001"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8666142821311951,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1447682695,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1447682688,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, retrospective",
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 255.0,
                "prediction": 255
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "NCT01318057; VKORC1 rs9923231 AG partial reg. coeff. -0.379 (SE 0.1391), adj R sq .0.659",
                "prediction": "Caribbean Hispanic warfarin-treated patients, carriers vs non-carriers comparison"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.007",
                "prediction": "= 0.0001"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8818534016609192,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1447682664,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1447682605,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, retrospective",
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 255.0,
                "prediction": 255
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Study Cohort: NCT01318057; CYP2C9 *3 partial reg. coeff. -0.544 (SE 0.2224), adj R sq 0.625",
                "prediction": "Caribbean Hispanic warfarin-treated patients from VACHS, derivation cohort"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.05,
                "prediction": 0.05
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*3",
                "prediction": "*3"
              },
              "Frequency In Controls": {
                "ground_truth": 0.83,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*1",
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.015",
                "prediction": "= 0.015"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8677965402603149,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1447682655,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1447682605,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, retrospective",
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 255.0,
                "prediction": 255
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "NCT01318057; CYP2C9 *2 partial reg. coeff. -0.245 (SE 0.1654), adj R sq0.613",
                "prediction": "Caribbean Hispanic warfarin-treated patients from VACHS, derivation cohort"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.09,
                "prediction": 0.09
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*2",
                "prediction": "*2"
              },
              "Frequency In Controls": {
                "ground_truth": 0.83,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*1",
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.014",
                "prediction": "= 0.014"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8660078048706055,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1447682687,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1447682605,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, retrospective",
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 255.0,
                "prediction": 255
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "NCT01318057; CYP2C9 *8 partial reg. coeff. -1.00 (SE 0.6014), adj R sq 0.638",
                "prediction": "Caribbean Hispanic warfarin-treated patients from VACHS, derivation cohort"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.006,
                "prediction": 0.006
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*8",
                "prediction": "*8"
              },
              "Frequency In Controls": {
                "ground_truth": 0.83,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*1",
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.098",
                "prediction": "= 0.098"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8599821925163269,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1447682702,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1447682700,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, retrospective",
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 255.0,
                "prediction": 255
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "NCT01318057; CYP4F3 *3 partial reg. coeff. 0.560 (SE 0.2274), adj R sq0.0.673",
                "prediction": "Caribbean Hispanic warfarin-treated patients from VACHS, derivation cohort"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.115,
                "prediction": 0.115
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*3",
                "prediction": "*3"
              },
              "Frequency In Controls": {
                "ground_truth": 0.885,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "*1",
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.014",
                "prediction": "= 0.014"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 6,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8460928797721863,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.8963960409164429,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1447682724,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1447682722,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, retrospective",
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 255.0,
                "prediction": 255
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "NCT01318057; NQO1 rs1800566 A allele partial reg. coeff. 0.346 (SE 0.2246), adj R sq .0.689",
                "prediction": "Caribbean Hispanic warfarin-treated patients from VACHS, derivation cohort"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.098,
                "prediction": 0.098
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "A",
                "prediction": "*2"
              },
              "Frequency In Controls": {
                "ground_truth": 0.902,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "G",
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.125",
                "prediction": "= 0.125"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "cohort, retrospective:NCT01318057; VKORC1 ",
          "cohort, retrospective:NCT01318057; VKORC1 ",
          "cohort, retrospective:Study Cohort: NCT013",
          "cohort, retrospective:NCT01318057; CYP2C9 ",
          "cohort, retrospective:NCT01318057; CYP2C9 ",
          "cohort, retrospective:NCT01318057; CYP4F3 ",
          "cohort, retrospective:NCT01318057; NQO1 rs"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 255,
            "Study Controls": null,
            "Characteristics": "Caribbean Hispanic warfarin-treated patients from VACHS, derivation cohort",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.37,
            "Allele Of Frequency In Cases": "A",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 255,
            "Study Controls": null,
            "Characteristics": "Caribbean Hispanic warfarin-treated patients from VACHS, derivation cohort, VKORC1-1639 GA genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.486,
            "Allele Of Frequency In Cases": "GA",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.007",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 55,
            "Study Controls": null,
            "Characteristics": "Puerto Rican warfarin-treated patients from Brownstone Clinic Hartford CT, validation cohort",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Latino",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC5508045": {
      "var-drug": {
        "overall_score": 0.6189916220150495,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "PMID": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Significance": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              0.0,
              1.0,
              0.0
            ]
          },
          "Alleles": {
            "mean_score": 0.6712249517440796,
            "scores": [
              0.8746106624603271,
              0.9400281310081482,
              0.870261013507843,
              0.0
            ]
          },
          "Specialty Population": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Metabolizer types": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "isPlural": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              0.0,
              1.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              0.0,
              1.0,
              0.0
            ]
          },
          "PD/PK terms": {
            "mean_score": 0.6725180447101593,
            "scores": [
              0.8966907262802124,
              0.8966907262802124,
              0.8966907262802124,
              0.0
            ]
          },
          "Multiple drugs And/or": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Population types": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Population Phenotypes or diseases": {
            "mean_score": 0.702350378036499,
            "scores": [
              0.936467170715332,
              0.936467170715332,
              0.936467170715332,
              0.0
            ]
          },
          "Multiple phenotypes or diseases And/or": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.7147474437952042,
            "scores": [
              0.9421090483665466,
              1.0,
              0.91688072681427,
              0.0
            ]
          },
          "Comparison Metabolizer types": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Drug(s)": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0
            ]
          }
        },
        "total_samples": 4,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.8746106624603271,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 0.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.8966907262802124,
              "Multiple drugs And/or": 1.0,
              "Population types": 1.0,
              "Population Phenotypes or diseases": 0.936467170715332,
              "Multiple phenotypes or diseases And/or": 0.0,
              "Comparison Allele(s) or Genotype(s)": 0.9421090483665466,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs9923231",
                "prediction": "rs9923231"
              },
              "Gene": {
                "ground_truth": "VKORC1",
                "prediction": "VKORC1"
              },
              "PMID": {
                "ground_truth": 28550460,
                "prediction": 28550460
              },
              "Phenotype Category": {
                "ground_truth": "Dosage",
                "prediction": "dosage"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "AA"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Are",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "PD/PK terms": {
                "ground_truth": "dose of",
                "prediction": "stable weekly dose requirements of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in people with",
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Disease:Atrial Fibrillation, Disease:Heart valve replacement, Disease:Pulmonary Hypertension, Disease:Pulmonary Embolism, Disease:Venous Thrombosis",
                "prediction": "Disease:thromboembolic diseases"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": "or",
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "GG"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "warfarin",
                "prediction": "warfarin"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 0.0,
              "Alleles": 0.9400281310081482,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 0.0,
              "Is/Is Not associated": 0.0,
              "Direction of effect": 0.0,
              "PD/PK terms": 0.8966907262802124,
              "Multiple drugs And/or": 1.0,
              "Population types": 1.0,
              "Population Phenotypes or diseases": 0.936467170715332,
              "Multiple phenotypes or diseases And/or": 0.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs2108622",
                "prediction": "rs2108622"
              },
              "Gene": {
                "ground_truth": "CYP4F2",
                "prediction": "CYP4F2"
              },
              "PMID": {
                "ground_truth": 28550460,
                "prediction": 28550460
              },
              "Phenotype Category": {
                "ground_truth": "Dosage",
                "prediction": "dosage"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "no"
              },
              "Alleles": {
                "ground_truth": "TT",
                "prediction": "CT + TT"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "PD/PK terms": {
                "ground_truth": "dose of",
                "prediction": "stable weekly dose requirements of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in people with",
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Disease:Atrial Fibrillation, Disease:Heart valve replacement, Disease:Pulmonary Hypertension, Disease:Pulmonary Embolism, Disease:Venous Thrombosis",
                "prediction": "Disease:thromboembolic diseases"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": "and",
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "CC"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "warfarin",
                "prediction": "warfarin"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 0.870261013507843,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 0.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 0.8966907262802124,
              "Multiple drugs And/or": 1.0,
              "Population types": 1.0,
              "Population Phenotypes or diseases": 0.936467170715332,
              "Multiple phenotypes or diseases And/or": 0.0,
              "Comparison Allele(s) or Genotype(s)": 0.91688072681427,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs887829",
                "prediction": "rs887829"
              },
              "Gene": {
                "ground_truth": "UGT1A1",
                "prediction": "UGT1A1"
              },
              "PMID": {
                "ground_truth": 28550460,
                "prediction": 28550460
              },
              "Phenotype Category": {
                "ground_truth": "Dosage",
                "prediction": "dosage"
              },
              "Significance": {
                "ground_truth": "no",
                "prediction": "no"
              },
              "Alleles": {
                "ground_truth": "C",
                "prediction": "CT + TT"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Are"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": null
              },
              "PD/PK terms": {
                "ground_truth": "dose of",
                "prediction": "stable weekly dose requirements of"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Population types": {
                "ground_truth": "in people with",
                "prediction": "in people with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Disease:Atrial Fibrillation, Disease:Heart valve replacement, Disease:Pulmonary Hypertension, Disease:Pulmonary Embolism, Disease:Venous Thrombosis",
                "prediction": "Disease:thromboembolic diseases"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": "and",
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "T",
                "prediction": "CC"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "warfarin",
                "prediction": "warfarin"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "PA166155091",
          "PA166155381",
          "PA166155607"
        ],
        "unmatched_ground_truth": [
          {
            "Variant Annotation ID": 1448624168,
            "Variant/Haplotypes": "rs1057910",
            "Gene": "CYP2C9",
            "Drug(s)": "warfarin",
            "PMID": 28550460,
            "Phenotype Category": "Dosage",
            "Significance": "yes",
            "Notes": null,
            "Sentence": "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.",
            "Alleles": "AC + CC",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "dose of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Atrial Fibrillation, Disease:Heart valve replacement, Disease:Pulmonary Hypertension, Disease:Pulmonary Embolism, Disease:Venous Thrombosis",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "AA",
            "Comparison Metabolizer types": null,
            "PMID_norm": "28550460",
            "Variant Annotation ID_norm": "1448624168",
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1057910",
              "variant_id": "PA166153959",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "warfarin",
              "drug_id": "PA451906",
              "confidence": 1.0
            }
          }
        ],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "rs9923231",
            "Gene": "VKORC1",
            "Drug(s)": "warfarin",
            "PMID": 28550460,
            "Phenotype Category": "dosage",
            "Significance": "yes",
            "Notes": "Patients with GA genotype required 27.7% lower warfarin stable weekly doses (SWDs) compared to GG genotype (p < 0.001). VKORC1 -1639G>A GA genotype accounted for 3.7% of warfarin dose variability in multivariate analysis.",
            "Sentence": "Genotype GA is associated with decreased stable weekly dose requirements of warfarin in people with thromboembolic diseases as compared to genotype GG.",
            "Alleles": "GA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "stable weekly dose requirements of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:thromboembolic diseases",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "GG",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Patients with AA and GA genotypes of *VKORC1* \u2212 1639G > A required 49.7% and 27.7% significantly lower averages of SWDS of warfarin as compared with those with wild-type GG genotype (*p* < 0.001).",
              "The warfarin SWDs were decreased by 9.7 mg and 18.1 mg in the patients with GA and AA genotypes of *VKORC1* \u2212 1639G > A as compared with those with wild-type GG genotype (*p* < 0.001)",
              "VKORC1 (\u22121639G > A) GA genotype | \u22129.745 | 37.0 | 3.7 | < 0.001"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs9923231",
              "variant_id": "PA166155091",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "warfarin",
              "drug_id": "PA451906",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2C9*1",
            "Gene": "CYP2C9",
            "Drug(s)": "warfarin",
            "PMID": 28550460,
            "Phenotype Category": "dosage",
            "Significance": "yes",
            "Notes": "Patients with CYP2C9*1/*3 genotype required 34.1% lower warfarin SWDs than *1/*1 patients (p = 0.006). CYP2C9*1/*3 accounted for 2.7% of warfarin dose variability in multivariate analysis.",
            "Sentence": "Genotype *1/*3 is associated with decreased stable weekly dose requirements of warfarin in people with thromboembolic diseases as compared to genotype *1/*1.",
            "Alleles": "*1/*3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "stable weekly dose requirements of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:thromboembolic diseases",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The averages of warfarin SWDs were 64.6% and 34.1% lower in *CYP2C9 *3/*3* and **1/*3* patients than in **1/*1* patients (*p* = 0.006).",
              "Similarly, the warfarin SWDs were decreased by 7.9 mg and 25.9 mg in the patients with *CYP2C9 *1/*3* and *CYP2C9 *3/*3* genotypes as compared with those with wild-type **1/*1* genotype (*p* < 0.001)",
              "The present study showed that the *CYP2C9*3* allele could explain about 6.0% of the warfarin dose variance (3.3% from *CYP2C9*3/*3* and 2.7% from *CYP2C9*1/*3*)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C9*1, CYP2C9*3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "warfarin",
              "drug_id": "PA451906",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2C9*3",
            "Gene": "CYP2C9",
            "Drug(s)": "warfarin",
            "PMID": 28550460,
            "Phenotype Category": "dosage",
            "Significance": "yes",
            "Notes": "Patients with CYP2C9*1/*3 genotype required 34.1% lower warfarin SWDs than *1/*1 patients (p = 0.006). CYP2C9*1/*3 accounted for 2.7% of warfarin dose variability in multivariate analysis.",
            "Sentence": "Genotype *1/*3 is associated with decreased stable weekly dose requirements of warfarin in people with thromboembolic diseases as compared to genotype *1/*1.",
            "Alleles": "*1/*3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "stable weekly dose requirements of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:thromboembolic diseases",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The averages of warfarin SWDs were 64.6% and 34.1% lower in *CYP2C9 *3/*3* and **1/*3* patients than in **1/*1* patients (*p* = 0.006).",
              "Similarly, the warfarin SWDs were decreased by 7.9 mg and 25.9 mg in the patients with *CYP2C9 *1/*3* and *CYP2C9 *3/*3* genotypes as compared with those with wild-type **1/*1* genotype (*p* < 0.001)",
              "The present study showed that the *CYP2C9*3* allele could explain about 6.0% of the warfarin dose variance (3.3% from *CYP2C9*3/*3* and 2.7% from *CYP2C9*1/*3*)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C9*1, CYP2C9*3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "warfarin",
              "drug_id": "PA451906",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2C9*1",
            "Gene": "CYP2C9",
            "Drug(s)": "warfarin",
            "PMID": 28550460,
            "Phenotype Category": "dosage",
            "Significance": "yes",
            "Notes": "Patients with CYP2C9*3/*3 genotype required 64.6% lower warfarin SWDs than *1/*1 patients (p = 0.006). CYP2C9*3/*3 accounted for 3.3% of warfarin dose variability in multivariate analysis.",
            "Sentence": "Genotype *3/*3 is associated with decreased stable weekly dose requirements of warfarin in people with thromboembolic diseases as compared to genotype *1/*1.",
            "Alleles": "*3/*3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "stable weekly dose requirements of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:thromboembolic diseases",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The averages of warfarin SWDs were 64.6% and 34.1% lower in *CYP2C9 *3/*3* and **1/*3* patients than in **1/*1* patients (*p* = 0.006).",
              "Similarly, the warfarin SWDs were decreased by 7.9 mg and 25.9 mg in the patients with *CYP2C9 *1/*3* and *CYP2C9 *3/*3* genotypes as compared with those with wild-type **1/*1* genotype (*p* < 0.001)",
              "CYP2C9*3/*3 | \u221225.921 | 40.3 | 3.3 | < 0.001"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C9*1, CYP2C9*3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "warfarin",
              "drug_id": "PA451906",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2C9*3",
            "Gene": "CYP2C9",
            "Drug(s)": "warfarin",
            "PMID": 28550460,
            "Phenotype Category": "dosage",
            "Significance": "yes",
            "Notes": "Patients with CYP2C9*3/*3 genotype required 64.6% lower warfarin SWDs than *1/*1 patients (p = 0.006). CYP2C9*3/*3 accounted for 3.3% of warfarin dose variability in multivariate analysis.",
            "Sentence": "Genotype *3/*3 is associated with decreased stable weekly dose requirements of warfarin in people with thromboembolic diseases as compared to genotype *1/*1.",
            "Alleles": "*3/*3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "stable weekly dose requirements of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:thromboembolic diseases",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The averages of warfarin SWDs were 64.6% and 34.1% lower in *CYP2C9 *3/*3* and **1/*3* patients than in **1/*1* patients (*p* = 0.006).",
              "Similarly, the warfarin SWDs were decreased by 7.9 mg and 25.9 mg in the patients with *CYP2C9 *1/*3* and *CYP2C9 *3/*3* genotypes as compared with those with wild-type **1/*1* genotype (*p* < 0.001)",
              "CYP2C9*3/*3 | \u221225.921 | 40.3 | 3.3 | < 0.001"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C9*1, CYP2C9*3",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "warfarin",
              "drug_id": "PA451906",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "rs2108622",
            "Gene": "CYP4F2",
            "Drug(s)": "warfarin",
            "PMID": 28550460,
            "Phenotype Category": "dosage",
            "Significance": "yes",
            "Notes": "In multivariate analysis, CYP4F2 rs2108622 TT genotype accounted for 1.2% of warfarin dose variability (p = 0.016). Warfarin SWDs were increased by 4.1 mg in patients with TT genotype compared to CC genotype.",
            "Sentence": "Genotype TT is associated with increased stable weekly dose requirements of warfarin in people with thromboembolic diseases as compared to genotype CC.",
            "Alleles": "TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "stable weekly dose requirements of",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:thromboembolic diseases",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Multivariate analysis, however, showed that CYP4F2 rs2108622 TT genotype accounted for a modest part of warfarin dose variability (1.2%).",
              "warfarin SWDs were increased by 4.1 mg in the patients with the TT variant genotype of CYP4F2 rs2108622 as compared with those with the wild-type CC genotype (p = 0.016)",
              "CYP4F2 rs2108622 TT genotype | 4.149 | 49.5 | 1.2 | 0.016"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2108622",
              "variant_id": "PA166155381",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "warfarin",
              "drug_id": "PA451906",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.6850682886441549,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.9254655838012695,
            "scores": [
              0.9313104152679443,
              0.9318662881851196,
              0.905514657497406,
              0.9331709742546082
            ]
          },
          "Characteristics Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 0.675,
            "scores": [
              1.0,
              0.9,
              0.8,
              0.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 0.9255587458610535,
            "scores": [
              0.9359741806983948,
              0.9663923382759094,
              0.8560625314712524,
              0.9438059329986572
            ]
          },
          "Frequency In Controls": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "P Value": {
            "mean_score": 0.75,
            "scores": [
              1.0,
              0.5,
              0.5,
              1.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 4,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9313104152679443,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.9359741806983948,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1448624167,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1448624157,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, retrospective",
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 250.0,
                "prediction": 250
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "warfarin; CT genotype assoc. w/avg decrease of 9.7 mg, and TT of 18.1 mg vs CC",
                "prediction": "Thai patients with stable warfarin doses, VKORC1 -1639G>A allele frequency"
              },
              "Characteristics Type": {
                "ground_truth": "Drug",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.832,
                "prediction": 0.832
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "T",
                "prediction": "A"
              },
              "Frequency In Controls": {
                "ground_truth": 0.168,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "C",
                "prediction": null
              },
              "P Value": {
                "ground_truth": "< 0.001",
                "prediction": "< 0.001"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9318662881851196,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 0.9,
              "Allele Of Frequency In Cases": 0.9663923382759094,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 0.5,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1448624180,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1448624178,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, retrospective",
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 250.0,
                "prediction": 250
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "warfarin; TT genotype assoc. w/avg increase of 4.1 mg vs CC",
                "prediction": "Thai patients with stable warfarin doses, UGT1A1 rs887829 CC genotype"
              },
              "Characteristics Type": {
                "ground_truth": "Drug",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.774,
                "prediction": 0.768
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "C",
                "prediction": "CC"
              },
              "Frequency In Controls": {
                "ground_truth": 0.226,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "T",
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.016",
                "prediction": "= 0.921"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.905514657497406,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 0.8,
              "Allele Of Frequency In Cases": 0.8560625314712524,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 0.5,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1448624190,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1448624188,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, retrospective",
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 250.0,
                "prediction": 250
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "warfarin",
                "prediction": "Thai patients with stable warfarin doses, CYP2C9 *1/*1 genotype"
              },
              "Characteristics Type": {
                "ground_truth": "Drug",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.88,
                "prediction": 0.956
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "C",
                "prediction": "*1/*1"
              },
              "Frequency In Controls": {
                "ground_truth": 0.12,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "T",
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.921",
                "prediction": "= 0.006"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9331709742546082,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.9438059329986572,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1448624170,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1448624168,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, retrospective",
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 250.0,
                "prediction": 250
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "warfarin; CC genotype assoc. w/avg decrease of 25.9 mg, and AC of 7.9 mg vs AA",
                "prediction": "Thai patients with stable warfarin doses, VKORC1 -1639G>A AA genotype"
              },
              "Characteristics Type": {
                "ground_truth": "Drug",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.976,
                "prediction": 0.692
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "A",
                "prediction": "AA"
              },
              "Frequency In Controls": {
                "ground_truth": 0.024,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "C",
                "prediction": null
              },
              "P Value": {
                "ground_truth": "< 0.001",
                "prediction": "< 0.001"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "cohort, retrospective:warfarin; CT genotyp",
          "cohort, retrospective:warfarin; TT genotyp",
          "cohort, retrospective:warfarin",
          "cohort, retrospective:warfarin; CC genotyp"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, VKORC1 -1639G>A GG genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.028,
            "Allele Of Frequency In Cases": "GG",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, VKORC1 -1639G>A GA genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.28,
            "Allele Of Frequency In Cases": "GA",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, CYP2C9 *1/*3 genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.04,
            "Allele Of Frequency In Cases": "*1/*3",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.006",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, CYP2C9 *3/*3 genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.004,
            "Allele Of Frequency In Cases": "*3/*3",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.006",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, CYP2C9*3 allele frequency",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.024,
            "Allele Of Frequency In Cases": "*3",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.006",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, CYP4F2 rs2108622 CC genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.612,
            "Allele Of Frequency In Cases": "CC",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.172",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, CYP4F2 rs2108622 CT genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.324,
            "Allele Of Frequency In Cases": "CT",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.172",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, CYP4F2 rs2108622 TT genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.064,
            "Allele Of Frequency In Cases": "TT",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.172",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, CYP4F2 rs2108622 T allele frequency",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.226,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.172",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, UGT1A1 rs887829 CT genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.224,
            "Allele Of Frequency In Cases": "CT",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.921",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, UGT1A1 rs887829 TT genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.008,
            "Allele Of Frequency In Cases": "TT",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.921",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, UGT1A1 rs887829 T allele frequency",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.12,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.921",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, multiple linear regression, VKORC1 -1639G>A AA genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, multiple linear regression, VKORC1 -1639G>A GA genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, multiple linear regression, CYP2C9*3/*3 genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, multiple linear regression, CYP2C9*1/*3 genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 250,
            "Study Controls": null,
            "Characteristics": "Thai patients with stable warfarin doses, multiple linear regression, CYP4F2 rs2108622 TT genotype",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.016",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC12035587": {
      "var-pheno": {
        "overall_score": 0.9990528623263041,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Direction of effect": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.9943171739578247,
            "scores": [
              0.9943171739578247
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          }
        },
        "total_samples": 1,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9943171739578247,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "NUDT15*3",
                "prediction": "NUDT15*3"
              },
              "Gene": {
                "ground_truth": "NUDT15",
                "prediction": "NUDT15"
              },
              "Drug(s)": {
                "ground_truth": "mercaptopurine",
                "prediction": "mercaptopurine"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*3/*3",
                "prediction": "*3/*3"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Myelosuppression, Side Effect:Toxic liver disease, Side Effect:Alopecia",
                "prediction": "Side Effect:Myelosuppression, Side Effect:Hepatotoxicity, Side Effect:Alopecia"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": null
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "PA166131621"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": []
      },
      "study-parameters": {
        "overall_score": 0.7311862468719482,
        "field_scores": {
          "Study Type": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.0,
            "scores": [
              0.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.9677937030792236,
            "scores": [
              0.9677937030792236
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 0.0,
            "scores": [
              0.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "P Value": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.0,
            "scores": [
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          }
        },
        "total_samples": 1,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 1.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9677937030792236,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1453076188,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1453076180,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "case series",
                "prediction": "case series"
              },
              "Study Cases": {
                "ground_truth": 0.0,
                "prediction": 1
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "41-year-old South Asian female, severe mercaptopurine toxicity secondary to an inherited NUDT15 protein deficiency, resulting in myelosuppression, hepatotoxicity and alopecia.",
                "prediction": "41-year-old South Asian female with acute promyelocytic leukaemia treated with mercaptopurine, homozygous NUDT15 *3/*3 loss-of-function alleles"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": "*3/*3"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": null,
                "prediction": ""
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Central/South Asian",
                "prediction": "Central/South Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "case series:41-year-old South As"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": []
      }
    },
    "PMC10275785": {
      "var-drug": {
        "overall_score": 0.9969909630323711,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "PMID": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Significance": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Specialty Population": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Metabolizer types": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "isPlural": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Direction of effect": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "PD/PK terms": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Multiple drugs And/or": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Population types": {
            "mean_score": 0.9612473249435425,
            "scores": [
              0.9612473249435425,
              0.9612473249435425
            ]
          },
          "Population Phenotypes or diseases": {
            "mean_score": 0.9815809726715088,
            "scores": [
              0.9815809726715088,
              0.9815809726715088
            ]
          },
          "Multiple phenotypes or diseases And/or": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Comparison Metabolizer types": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 2,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 1.0,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 1.0,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.9612473249435425,
              "Population Phenotypes or diseases": 0.9815809726715088,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs2043211",
                "prediction": "rs2043211"
              },
              "Gene": {
                "ground_truth": "CARD8",
                "prediction": "CARD8"
              },
              "PMID": {
                "ground_truth": 37332933,
                "prediction": 37332933
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "TT",
                "prediction": "TT"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "PD/PK terms": {
                "ground_truth": "response to",
                "prediction": "response to"
              },
              "Multiple drugs And/or": {
                "ground_truth": "or",
                "prediction": "or"
              },
              "Population types": {
                "ground_truth": "in people with",
                "prediction": "in patients with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Other:Rheumatoid arthritis",
                "prediction": "Disease:Rheumatoid Arthritis"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "AA + AT",
                "prediction": "AA + AT"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "etanercept, infliximab",
                "prediction": "etanercept or infliximab"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "PMID": 1.0,
              "Phenotype Category": 1.0,
              "Significance": 1.0,
              "Alleles": 1.0,
              "Specialty Population": 1.0,
              "Metabolizer types": 1.0,
              "isPlural": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "PD/PK terms": 1.0,
              "Multiple drugs And/or": 1.0,
              "Population types": 0.9612473249435425,
              "Population Phenotypes or diseases": 0.9815809726715088,
              "Multiple phenotypes or diseases And/or": 1.0,
              "Comparison Allele(s) or Genotype(s)": 1.0,
              "Comparison Metabolizer types": 1.0,
              "Drug(s)": 1.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs4612666",
                "prediction": "rs4612666"
              },
              "Gene": {
                "ground_truth": "NLRP3",
                "prediction": "NLRP3"
              },
              "PMID": {
                "ground_truth": 37332933,
                "prediction": 37332933
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes"
              },
              "Alleles": {
                "ground_truth": "TT",
                "prediction": "TT"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": null
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "PD/PK terms": {
                "ground_truth": "response to",
                "prediction": "response to"
              },
              "Multiple drugs And/or": {
                "ground_truth": "or",
                "prediction": "or"
              },
              "Population types": {
                "ground_truth": "in people with",
                "prediction": "in patients with"
              },
              "Population Phenotypes or diseases": {
                "ground_truth": "Other:Rheumatoid arthritis",
                "prediction": "Disease:Rheumatoid Arthritis"
              },
              "Multiple phenotypes or diseases And/or": {
                "ground_truth": null,
                "prediction": null
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC + CT",
                "prediction": "CC + CT"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": null
              },
              "Drug(s)": {
                "ground_truth": "etanercept, infliximab",
                "prediction": "etanercept or infliximab"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "PA166305763",
          "PA166305782"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "rs2043211",
            "Gene": "CARD8",
            "Drug(s)": "etanercept or infliximab",
            "PMID": 37332933,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "TT genotype associated with higher TNF-\u03b1 serum levels (mean 14.25 pg/mL vs 5.64 pg/mL for AA, P < 0.0001) and higher IL-1\u03b2 serum levels (mean 4.55 pg/mL vs 1.05 pg/mL for AA, P < 0.0001).",
            "Sentence": "Genotype TT is associated with increased serum levels of TNF-\u03b1 and IL-1\u03b2 in patients with rheumatoid arthritis as compared to genotype AA.",
            "Alleles": "TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "serum levels of",
            "Multiple drugs And/or": "or",
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Rheumatoid Arthritis",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "AA",
            "Comparison Metabolizer types": null,
            "Citations": [
              "CARD8 (rs2043211) TT genotype was more frequent in patients with higher DAS-28 (P < 0.0001) and higher TNF-\u03b1 and IL-1\u03b2 serum levels (P < 0.0001 for both).",
              "Comparison of SNPs genotypes with pro-inflammatory cytokines. A significant difference in the CARD8 (rs2043211) genotypes (P < 0.0001 for TNF-\u03b1 and IL- 1\u03b2)",
              "TNF-\u03b1 | 5.64 (3.56) | 7.39 (5.59) | 14.25 (4.67) | <0.0001 | IL- 1\u03b2 | 1.05 (0.34) | 2.25 (0.57) | 4.55 (0.64)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2043211",
              "variant_id": "PA166305763",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "etanercept",
              "drug_id": "PA449515",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "rs4612666",
            "Gene": "NLRP3",
            "Drug(s)": "etanercept or infliximab",
            "PMID": 37332933,
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "TT genotype associated with higher TNF-\u03b1 serum levels (mean 14.74 pg/mL vs 5.56 pg/mL for CC, P < 0.0001) and higher IL-1\u03b2 serum levels (mean 4.86 pg/mL vs 1.18 pg/mL for CC, P < 0.0001).",
            "Sentence": "Genotype TT is associated with increased serum levels of TNF-\u03b1 and IL-1\u03b2 in patients with rheumatoid arthritis as compared to genotype CC.",
            "Alleles": "TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "serum levels of",
            "Multiple drugs And/or": "or",
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Rheumatoid Arthritis",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Also, NLRP3 (rs4612666) TT genotype was more frequent in patients with higher DAS-28 (P < 0.0001) and higher TNF-\u03b1 and IL- 1\u03b2 serum levels (P < 0.0001 for both).",
              "Comparison of SNPs genotypes with pro-inflammatory cytokines. A significant difference in the CARD8 (rs2043211) genotypes (P < 0.0001 for TNF-\u03b1 and IL- 1\u03b2) as well as, NLRP3 (rs4612666) genotypes (P < 0.0001 for TNF-\u03b1 and IL- 1\u03b2)",
              "NLRP3 rs4612666 Genotypes... CC... CT... TT... Cytokines Mean (SD)... TNF-\u03b1... 5.56 (3.31)... 8.58 (6.17)... 14.74 (4.61)... IL- 1\u03b2... 1.18 (0.39)... 2.59 (0.69)... 4.86 (0.50)"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs4612666",
              "variant_id": "PA166305782",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "etanercept",
              "drug_id": "PA449515",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "rs2043211",
            "Gene": "CARD8",
            "Drug(s)": "etanercept or infliximab",
            "PMID": 37332933,
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "TT genotype associated with higher DAS-28 scores (mean 4.65 vs 3.51 for AA, P < 0.0001), indicating higher disease activity and worse treatment outcomes.",
            "Sentence": "Genotype TT is associated with increased DAS-28 score after treatment with etanercept or infliximab in patients with rheumatoid arthritis as compared to genotype AA.",
            "Alleles": "TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "DAS-28 score after treatment with",
            "Multiple drugs And/or": "or",
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Rheumatoid Arthritis",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "AA",
            "Comparison Metabolizer types": null,
            "Citations": [
              "CARD8 (rs2043211) TT genotype was more frequent in patients with higher DAS-28 (P < 0.0001) and higher TNF-\u03b1 and IL-1\u03b2 serum levels (P < 0.0001 for both).",
              "The CARD8 (rs2043211) TT genotype was more common in patients with higher DAS-28 (P < 0.0001).",
              "DAS-28 Mean (SD) | AA | AT | TT | p-value | 3.51 (0.90) | 3.92 (1.00) | 4.65 (0.65) | <0.0001"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2043211",
              "variant_id": "PA166305763",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "etanercept",
              "drug_id": "PA449515",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "rs4612666",
            "Gene": "NLRP3",
            "Drug(s)": "etanercept or infliximab",
            "PMID": 37332933,
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "TT genotype associated with higher DAS-28 scores (mean 4.72 vs 3.52 for CC, P < 0.0001), indicating higher disease activity and worse treatment outcomes.",
            "Sentence": "Genotype TT is associated with increased DAS-28 score after treatment with etanercept or infliximab in patients with rheumatoid arthritis as compared to genotype CC.",
            "Alleles": "TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "DAS-28 score after treatment with",
            "Multiple drugs And/or": "or",
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Rheumatoid Arthritis",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Also, NLRP3 (rs4612666) TT genotype was more frequent in patients with higher DAS-28 (P < 0.0001) and higher TNF-\u03b1 and IL- 1\u03b2 serum levels (P < 0.0001 for both). Interestingly, this study revealed that CARD8 (rs2043211) and NLRP3 (rs4612666) variant genotypes are associated with lower response to anti-TNF-\u03b1 drugs.",
              "DAS-28Mean (SD) |  | 3.51 (0.90) | 3.92 (1.00) | 4.65 (0.65) | <0.0001 | 3.52 (0.89) | 4.08 (1.00) | 4.72 (0.55) | <0.0001 |",
              "NLRP3 (rs4612666), C Allele bearing genotypes (wild homozygous and heterozygous genotypes) are associated with lower DAS-28 as compared with T allele bearing genotypes (Variant homozygous and heterozygous genotypes (P < 0.0001 and 0.003 respectively), this supposing that NLRP3 (rs4612666) variant genotypes are extremely associated with higher disease progression and lower response to anti-TNF-\u03b1 drugs."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs4612666",
              "variant_id": "PA166305782",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "etanercept",
              "drug_id": "PA449515",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.5531006391843161,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Study Controls": {
            "mean_score": 0.9,
            "scores": [
              0.9,
              0.9
            ]
          },
          "Characteristics": {
            "mean_score": 0.89650958776474,
            "scores": [
              0.8899468779563904,
              0.9030722975730896
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "P Value": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              0.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 2,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 0.9,
              "Characteristics": 0.8899468779563904,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452143420,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452143400,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 66.0,
                "prediction": 66
              },
              "Study Controls": {
                "ground_truth": 33.0,
                "prediction": 34
              },
              "Characteristics": {
                "ground_truth": "Cases = responders, controls = non-responders",
                "prediction": "NLRP3 rs4612666 recessive model (CC vs CT+TT) association with anti-TNF-\u03b1 response"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.197,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "T",
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": 0.559,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "T",
                "prediction": null
              },
              "P Value": {
                "ground_truth": "< 0.0001",
                "prediction": "< 0.0001"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 0.131,
                "prediction": 0.131
              },
              "Confidence Interval Start": {
                "ground_truth": 0.047,
                "prediction": 0.047
              },
              "Confidence Interval Stop": {
                "ground_truth": 0.36,
                "prediction": 0.36
              },
              "Biogeographical Groups": {
                "ground_truth": "Near Eastern",
                "prediction": "Near Eastern"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 0.9,
              "Characteristics": 0.9030722975730896,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 0.0,
              "Allele Of Frequency In Cases": 0.0,
              "Frequency In Controls": 0.0,
              "Allele Of Frequency In Controls": 0.0,
              "P Value": 0.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452143368,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452143360,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "case/control"
              },
              "Study Cases": {
                "ground_truth": 66.0,
                "prediction": 66
              },
              "Study Controls": {
                "ground_truth": 33.0,
                "prediction": 34
              },
              "Characteristics": {
                "ground_truth": "Cases = responders, controls = non-responders",
                "prediction": "CARD8 rs2043211 recessive model (AA vs AT+TT) association with anti-TNF-\u03b1 response"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.265,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "T",
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": 0.647,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": "T",
                "prediction": null
              },
              "P Value": {
                "ground_truth": "< 0.0001",
                "prediction": "= 0.001"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 0.183,
                "prediction": 0.183
              },
              "Confidence Interval Start": {
                "ground_truth": 0.063,
                "prediction": 0.063
              },
              "Confidence Interval Stop": {
                "ground_truth": 0.531,
                "prediction": 0.531
              },
              "Biogeographical Groups": {
                "ground_truth": "Near Eastern",
                "prediction": "Near Eastern"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "None:Cases = responders, ",
          "None:Cases = responders, "
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": 100,
            "Characteristics": "CARD8 rs2043211 genotype distribution in RA patients vs healthy controls",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.395,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": 0.305,
            "Allele Of Frequency In Controls": "T",
            "P Value": "= 0.17",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": 100,
            "Characteristics": "CARD8 rs2043211 allele frequency in RA patients vs healthy controls",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.395,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": 0.305,
            "Allele Of Frequency In Controls": "T",
            "P Value": "= 0.059",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": 100,
            "Characteristics": "NLRP3 rs4612666 genotype distribution in RA patients vs healthy controls",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.32,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": 0.31,
            "Allele Of Frequency In Controls": "T",
            "P Value": "= 0.08",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": 100,
            "Characteristics": "NLRP3 rs4612666 allele frequency in RA patients vs healthy controls",
            "Characteristics Type": "disease",
            "Frequency In Cases": 0.32,
            "Allele Of Frequency In Cases": "T",
            "Frequency In Controls": 0.31,
            "Allele Of Frequency In Controls": "T",
            "P Value": "= 0.879",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "CARD8 rs2043211 TT genotype association with DAS-28 in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "NLRP3 rs4612666 TT genotype association with DAS-28 in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "CARD8 rs2043211 genotype distribution by disease activity in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.033",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "NLRP3 rs4612666 genotype distribution by disease activity in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.008",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 66,
            "Study Controls": 34,
            "Characteristics": "CARD8 rs2043211 genotype association with anti-TNF-\u03b1 response (responders vs non-responders)",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 66,
            "Study Controls": 34,
            "Characteristics": "NLRP3 rs4612666 genotype association with anti-TNF-\u03b1 response (responders vs non-responders)",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "CARD8 rs2043211 genotype association with serum TNF-\u03b1 levels in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "CARD8 rs2043211 genotype association with serum IL-1\u03b2 levels in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "NLRP3 rs4612666 genotype association with serum TNF-\u03b1 levels in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "NLRP3 rs4612666 genotype association with serum IL-1\u03b2 levels in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 66,
            "Study Controls": 34,
            "Characteristics": "CARD8 rs2043211 dominant model (AA+AT vs TT) association with anti-TNF-\u03b1 response",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.019,
            "Confidence Interval Start": 0.002,
            "Confidence Interval Stop": 0.157,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 66,
            "Study Controls": 34,
            "Characteristics": "NLRP3 rs4612666 dominant model (CC+CT vs TT) association with anti-TNF-\u03b1 response",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.037,
            "Confidence Interval Start": 0.004,
            "Confidence Interval Stop": 0.304,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "CARD8 rs2043211 dominant model association with DAS-28 in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "CARD8 rs2043211 recessive model association with DAS-28 in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.003",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "NLRP3 rs4612666 dominant model association with DAS-28 in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.003",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "NLRP3 rs4612666 recessive model association with DAS-28 in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "CARD8 rs2043211 recessive model association with disease activity in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.029",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "NLRP3 rs4612666 recessive model association with disease activity in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.002",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "CARD8 rs2043211 dominant model association with serum TNF-\u03b1 levels in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "CARD8 rs2043211 dominant model association with serum IL-1\u03b2 levels in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "CARD8 rs2043211 recessive model association with serum TNF-\u03b1 levels in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "CARD8 rs2043211 recessive model association with serum IL-1\u03b2 levels in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "NLRP3 rs4612666 recessive model association with serum TNF-\u03b1 levels in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.002",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 100,
            "Study Controls": null,
            "Characteristics": "NLRP3 rs4612666 recessive model association with serum IL-1\u03b2 levels in RA patients",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC10946077": {
      "var-pheno": {
        "overall_score": 0.7984510131535076,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Gene": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Drug(s)": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Alleles": {
            "mean_score": 0.8621983272688729,
            "scores": [
              0.8432134389877319,
              0.8432134389877319,
              0.8432134389877319,
              0.9074300527572632,
              0.8661059737205505,
              0.8661059737205505,
              0.8661059737205505
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.42857142857142855,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.9654859048979623,
            "scores": [
              0.9682322144508362,
              0.9670361876487732,
              0.9499444365501404,
              0.9879756569862366,
              0.9682322144508362,
              0.9670361876487732,
              0.9499444365501404
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 7,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.8432134389877319,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9682322144508362,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "UGT1A1*6",
                "prediction": "UGT1A1*6"
              },
              "Gene": {
                "ground_truth": "UGT1A1",
                "prediction": "UGT1A1"
              },
              "Drug(s)": {
                "ground_truth": "irinotecan",
                "prediction": "irinotecan"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*6",
                "prediction": "GG, GA, AA"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Diarrhea",
                "prediction": "Side Effect:Neutropenia"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.8432134389877319,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9670361876487732,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "UGT1A1*6",
                "prediction": "UGT1A1*6"
              },
              "Gene": {
                "ground_truth": "UGT1A1",
                "prediction": "UGT1A1"
              },
              "Drug(s)": {
                "ground_truth": "irinotecan",
                "prediction": "irinotecan"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*6",
                "prediction": "GG, GA, AA"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Diarrhea",
                "prediction": "Side Effect:Leukopenia"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.8432134389877319,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9499444365501404,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "UGT1A1*6",
                "prediction": "UGT1A1*6"
              },
              "Gene": {
                "ground_truth": "UGT1A1",
                "prediction": "UGT1A1"
              },
              "Drug(s)": {
                "ground_truth": "irinotecan",
                "prediction": "irinotecan"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*6",
                "prediction": "GG, GA, AA"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Diarrhea",
                "prediction": "Side Effect:Diarrhea"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9074300527572632,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9879756569862366,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "UGT1A1*6",
                "prediction": "UGT1A1*6"
              },
              "Gene": {
                "ground_truth": "UGT1A1",
                "prediction": "UGT1A1"
              },
              "Drug(s)": {
                "ground_truth": "irinotecan",
                "prediction": "irinotecan"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "*6 + *28",
                "prediction": "GG, GA, AA"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Overall survival, Efficacy:Progression-free survival",
                "prediction": "Efficacy:Progression-free survival"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.8661059737205505,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9682322144508362,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "UGT1A1*28",
                "prediction": "UGT1A1*28"
              },
              "Gene": {
                "ground_truth": "UGT1A1",
                "prediction": "UGT1A1"
              },
              "Drug(s)": {
                "ground_truth": "irinotecan",
                "prediction": "irinotecan"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*28",
                "prediction": "TA6/TA6, TA6/TA7, TA7/TA7"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Diarrhea",
                "prediction": "Side Effect:Neutropenia"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.8661059737205505,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9670361876487732,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "UGT1A1*28",
                "prediction": "UGT1A1*28"
              },
              "Gene": {
                "ground_truth": "UGT1A1",
                "prediction": "UGT1A1"
              },
              "Drug(s)": {
                "ground_truth": "irinotecan",
                "prediction": "irinotecan"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*28",
                "prediction": "TA6/TA6, TA6/TA7, TA7/TA7"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Diarrhea",
                "prediction": "Side Effect:Leukopenia"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 6,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.8661059737205505,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 0.0,
              "Phenotype": 0.9499444365501404,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "UGT1A1*28",
                "prediction": "UGT1A1*28"
              },
              "Gene": {
                "ground_truth": "UGT1A1",
                "prediction": "UGT1A1"
              },
              "Drug(s)": {
                "ground_truth": "irinotecan",
                "prediction": "irinotecan"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*28",
                "prediction": "TA6/TA6, TA6/TA7, TA7/TA7"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": null
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Diarrhea",
                "prediction": "Side Effect:Diarrhea"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": null
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "ugt1a1*6",
          "ugt1a1*28",
          "ugt1a1*28",
          "ugt1a1*6",
          "ugt1a1+irinotecan",
          "ugt1a1+irinotecan",
          "ugt1a1+irinotecan"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "UGT1A1*6",
            "Gene": "UGT1A1",
            "Drug(s)": "irinotecan",
            "PMID": 38497131,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "p=0.6821 for OS. No significant difference in OS among UGT1A1*6 genotypes after dose adjustment (GG 9.3m vs GA 9.3m vs AA NA).",
            "Sentence": "UGT1A1*6 is not associated with Efficacy:Overall survival when treated with irinotecan in people with Disease:Gastric Cancer.",
            "Alleles": "GG, GA, AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Efficacy:Overall survival",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Gastric Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "Among 107 patients, there were no significant differences in PFS (4.8 m vs 4.9 m vs 4.4 m; p = 0.5249) and OS (9.3 m vs 9.3 m vs NA; p = 0.6821) among patients with GG/GA/AA subtypes after dose adjustment.",
              "In this study, it did not affect the PFS (GG type 4.8 m vs GA type 4.9 m vs AA type 4.4 m; p = 0.5249), or OS (GG type 9.3 m vs GA type 9.3 m vs AA type NA; p = 0.6821).",
              "In the present study, univariable and multivariate analysis revealed no relation between PFS and UGT1A1*6 or UGT1A1*28"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "UGT1A1*6",
              "variant_id": "PA166115858",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "irinotecan",
              "drug_id": "PA450085",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 9,
            "Variant/Haplotypes": "UGT1A1*28",
            "Gene": "UGT1A1",
            "Drug(s)": "irinotecan",
            "PMID": 38497131,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "No significant difference in PFS among UGT1A1*28 genotypes (TA6/TA6 4.7m vs TA6/TA7 5.0m vs TA7/TA7 5.3m).",
            "Sentence": "UGT1A1*28 is not associated with Efficacy:Progression-free survival when treated with irinotecan in people with Disease:Gastric Cancer.",
            "Alleles": "TA6/TA6, TA6/TA7, TA7/TA7",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Efficacy:Progression-free survival",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Gastric Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "The median PFS was 4.7 months (95% CI = 4.3-5.3) in the *TA6/TA6* group, 5.0 months (95% CI = 4.1-6.2) in the *TA6/TA7* group, 5.3 months (95% CI = 2.8-NA) in the *TA7/TA7* group",
              "In the present study, univariable and multivariate analysis revealed no relation between PFS and *UGT1A1*6* or *UGT1A1*28*",
              "There were no significant differences in PFS and OS among patients with different alleles or after dose adjustment (p > 0.05)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "UGT1A1*28",
              "variant_id": "PA166115842",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "irinotecan",
              "drug_id": "PA450085",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 10,
            "Variant/Haplotypes": "UGT1A1*28",
            "Gene": "UGT1A1",
            "Drug(s)": "irinotecan",
            "PMID": 38497131,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "No significant difference in OS among UGT1A1*28 genotypes (TA6/TA6 9.5m vs TA6/TA7 9.0m vs TA7/TA7 11.2m).",
            "Sentence": "UGT1A1*28 is not associated with Efficacy:Overall survival when treated with irinotecan in people with Disease:Gastric Cancer.",
            "Alleles": "TA6/TA6, TA6/TA7, TA7/TA7",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Efficacy:Overall survival",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Gastric Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "And the median OS was 9.5 months (95% CI = 8.8-10.2) in the TA6/TA6 group, 9.0 months (95% CI = 8.3-NA) in the TA6/TA7 group, 11.2 months (95% CI = 9.1-NA) in the TA7/TA7 group",
              "There were no significant differences in PFS and OS among patients with different alleles or after dose adjustment (p > 0.05).",
              "In the present study, univariable and multivariate analysis revealed no relation between PFS and UGT1A1*6 or UGT1A1*28"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "UGT1A1*28",
              "variant_id": "PA166115842",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "irinotecan",
              "drug_id": "PA450085",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 11,
            "Variant/Haplotypes": "UGT1A1*6",
            "Gene": "UGT1A1",
            "Drug(s)": "irinotecan",
            "PMID": 38497131,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "p=0.477. No significant difference in hemoglobin reduction among UGT1A1*6 genotypes.",
            "Sentence": "UGT1A1*6 is not associated with risk of Side Effect:Anemia when treated with irinotecan in people with Disease:Gastric Cancer.",
            "Alleles": "GG, GA, AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Anemia",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Gastric Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "Patients with *UGT1A1*6* or *UGT1A1*28* genetype showed no significant difference in thrombocytopenia and hemoglobin reduction.",
              "Hemoglobinia | Grade 0 | 38 (57%) | 16 (46%) | 3 (60%) | 0.477"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "UGT1A1*6",
              "variant_id": "PA166115858",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "irinotecan",
              "drug_id": "PA450085",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 12,
            "Variant/Haplotypes": "UGT1A1*6",
            "Gene": "UGT1A1",
            "Drug(s)": "irinotecan",
            "PMID": 38497131,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "p=0.814. No significant difference in thrombocytopenia among UGT1A1*6 genotypes.",
            "Sentence": "UGT1A1*6 is not associated with risk of Side Effect:Thrombocytopenia when treated with irinotecan in people with Disease:Gastric Cancer.",
            "Alleles": "GG, GA, AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Thrombocytopenia",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Gastric Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "Patients with *UGT1A1*6* or *UGT1A1*28* genetype showed no significant difference in thrombocytopenia and hemoglobin reduction.",
              "| Thrombocytopenia |   |   |   |   |   |   |   |   |\n| Grade 0 | 41 (61%) | 20 (58%) | 3 (60%) | 0.814 | 48 (64%) | 15 (54%) | 2 (50%) | 0.450 |\n| Grade 1-2 | 23 (35%) | 11 (31%) | 2 (40%) | 23 (31%) | 10 (35%) | 1 (25%) |  |  |\n| Grade 3-4 | 3 (4%) | 4 (11%) | 0 (0%) | 4 (5%) | 3 (11%) | 1 (25%) |  |  |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "UGT1A1*6",
              "variant_id": "PA166115858",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "irinotecan",
              "drug_id": "PA450085",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 13,
            "Variant/Haplotypes": "UGT1A1*28",
            "Gene": "UGT1A1",
            "Drug(s)": "irinotecan",
            "PMID": 38497131,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "p=0.151. No significant difference in hemoglobin reduction among UGT1A1*28 genotypes.",
            "Sentence": "UGT1A1*28 is not associated with risk of Side Effect:Anemia when treated with irinotecan in people with Disease:Gastric Cancer.",
            "Alleles": "TA6/TA6, TA6/TA7, TA7/TA7",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Anemia",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Gastric Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "Patients with *UGT1A1*6* or *UGT1A1*28* genetype showed no significant difference in thrombocytopenia and hemoglobin reduction.",
              "In addition, there were no significant differences in diarrhea (*p *= 0.136), neutropenia (*p *= 0.991), and leukopenia (*p *= 0.857) in *UGT1A1*28* subgroups."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "UGT1A1*28",
              "variant_id": "PA166115842",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "irinotecan",
              "drug_id": "PA450085",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 14,
            "Variant/Haplotypes": "UGT1A1*28",
            "Gene": "UGT1A1",
            "Drug(s)": "irinotecan",
            "PMID": 38497131,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "p=0.450. No significant difference in thrombocytopenia among UGT1A1*28 genotypes.",
            "Sentence": "UGT1A1*28 is not associated with risk of Side Effect:Thrombocytopenia when treated with irinotecan in people with Disease:Gastric Cancer.",
            "Alleles": "TA6/TA6, TA6/TA7, TA7/TA7",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Thrombocytopenia",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Gastric Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "Patients with *UGT1A1*6* or *UGT1A1*28* genetype showed no significant difference in thrombocytopenia and hemoglobin reduction.",
              "In addition, there were no significant differences in diarrhea (*p *= 0.136), neutropenia (*p *= 0.991), and leukopenia (*p *= 0.857) in *UGT1A1*28* subgroups."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "UGT1A1*28",
              "variant_id": "PA166115842",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "irinotecan",
              "drug_id": "PA450085",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.6943132576488313,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.9,
            "scores": [
              0.9,
              0.9,
              0.9,
              0.9,
              0.9,
              0.9,
              0.9
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.8789845790181842,
            "scores": [
              0.8919357061386108,
              0.8874395489692688,
              0.88287353515625,
              0.8378890752792358,
              0.8730705976486206,
              0.8994003534317017,
              0.8802832365036011
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 0.6357142857142858,
            "scores": [
              1.0,
              1.0,
              1.0,
              0.95,
              0.5,
              0.0,
              0.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 7,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.9,
              "Study Controls": 1.0,
              "Characteristics": 0.8919357061386108,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452426968,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452426961,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 110.0,
                "prediction": 107
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Leukopenia grade 3-4",
                "prediction": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*6 GG genotype vs GA genotype vs AA genotype, leukopenia toxicity"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.003",
                "prediction": "= 0.003"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.9,
              "Study Controls": 1.0,
              "Characteristics": 0.8874395489692688,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452426890,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452426882,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 110.0,
                "prediction": 107
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Leukopenia grade 3-4",
                "prediction": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*28 TA6/TA6 vs TA6/TA7 vs TA7/TA7 genotype, leukopenia toxicity"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.857",
                "prediction": "= 0.857"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.9,
              "Study Controls": 1.0,
              "Characteristics": 0.88287353515625,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452426891,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452426882,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 110.0,
                "prediction": 107
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Diarrhea grade 3-4",
                "prediction": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*28 TA6/TA6 vs TA6/TA7 vs TA7/TA7 genotype, diarrhea toxicity"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.136",
                "prediction": "= 0.136"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.9,
              "Study Controls": 1.0,
              "Characteristics": 0.8378890752792358,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.95,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452426880,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452426860,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 110.0,
                "prediction": 107
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "OS for *6",
                "prediction": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*6 GG vs GA vs AA genotype, overall survival"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.703",
                "prediction": "= 0.6821"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.9,
              "Study Controls": 1.0,
              "Characteristics": 0.8730705976486206,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452426889,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452426882,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 110.0,
                "prediction": 107
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Neutopenia grade 3-4",
                "prediction": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*28 TA6/TA6 vs TA6/TA7 vs TA7/TA7 genotype, neutropenia toxicity"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.136",
                "prediction": "= 0.991"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.9,
              "Study Controls": 1.0,
              "Characteristics": 0.8994003534317017,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452426980,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452426961,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 110.0,
                "prediction": 107
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Neutropenia grade 3-4",
                "prediction": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*6 GG genotype vs GA genotype vs AA genotype, neutropenia toxicity"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "< 0.001",
                "prediction": "= 0.000"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 6,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.9,
              "Study Controls": 1.0,
              "Characteristics": 0.8802832365036011,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1452426969,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1452426961,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective"
              },
              "Study Cases": {
                "ground_truth": 110.0,
                "prediction": 107
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Diarrhea grade 3-4",
                "prediction": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*6 GG genotype vs GA genotype vs AA genotype, diarrhea toxicity"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "< 0.001",
                "prediction": "= 0.000"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "East Asian"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "None:Leukopenia grade 3-4",
          "None:Leukopenia grade 3-4",
          "None:Diarrhea grade 3-4",
          "None:OS for *6",
          "None:Neutopenia grade 3-4",
          "None:Neutropenia grade 3-",
          "None:Diarrhea grade 3-4"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 107,
            "Study Controls": null,
            "Characteristics": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*6 AA+GA vs GG genotype, progression-free survival univariate analysis",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.283",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.29,
            "Confidence Interval Start": 0.811,
            "Confidence Interval Stop": 2.052,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 107,
            "Study Controls": null,
            "Characteristics": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*28 TA7/TA7+TA6/TA7 vs TA6/TA6 genotype, progression-free survival univariate analysis",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.528",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.855,
            "Confidence Interval Start": 0.525,
            "Confidence Interval Stop": 1.392,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 107,
            "Study Controls": null,
            "Characteristics": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*6 AA+GA vs GG genotype, progression-free survival multivariate analysis",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.284",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.325,
            "Confidence Interval Start": 0.792,
            "Confidence Interval Stop": 2.219,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 107,
            "Study Controls": null,
            "Characteristics": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*28 TA7/TA7+TA6/TA7 vs TA6/TA6 genotype, progression-free survival multivariate analysis",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.887",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.962,
            "Confidence Interval Start": 0.565,
            "Confidence Interval Stop": 1.637,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 107,
            "Study Controls": null,
            "Characteristics": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*6 AA+GA vs GG genotype, overall survival univariate analysis",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.951",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.016,
            "Confidence Interval Start": 0.61,
            "Confidence Interval Stop": 1.692,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 107,
            "Study Controls": null,
            "Characteristics": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*28 TA7/TA7+TA6/TA7 vs TA6/TA6 genotype, overall survival univariate analysis",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.708",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 1.108,
            "Confidence Interval Start": 0.648,
            "Confidence Interval Stop": 1.893,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 107,
            "Study Controls": null,
            "Characteristics": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*6 AA+GA vs GG genotype, overall survival multivariate analysis",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.703",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.894,
            "Confidence Interval Start": 0.504,
            "Confidence Interval Stop": 1.588,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 107,
            "Study Controls": null,
            "Characteristics": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*28 TA7/TA7+TA6/TA7 vs TA6/TA6 genotype, overall survival multivariate analysis",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.981",
            "Ratio Stat Type": "HR",
            "Ratio Stat": 0.992,
            "Confidence Interval Start": 0.529,
            "Confidence Interval Stop": 1.861,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "retrospective",
            "Study Cases": 107,
            "Study Controls": null,
            "Characteristics": "Advanced gastric cancer patients receiving irinotecan second-line therapy, UGT1A1*6 GG vs GA vs AA genotype, progression-free survival",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.5249",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC12036300": {
      "var-pheno": {
        "overall_score": 0.6298898123204707,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Drug(s)": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.3333333333333333,
            "scores": [
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Alleles": {
            "mean_score": 0.6177928547064463,
            "scores": [
              0.9324533939361572,
              0.9324533939361572,
              0.9201368689537048,
              0.9217134714126587,
              0.0,
              0.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.6195499201615652,
            "scores": [
              0.9564809203147888,
              0.8667105436325073,
              0.971265971660614,
              0.9228420853614807,
              0.0,
              0.0
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 0.6666666666666666,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.5595552921295166,
            "scores": [
              0.8393329381942749,
              0.8393329381942749,
              0.8393329381942749,
              0.8393329381942749,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 6,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9324533939361572,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9564809203147888,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8393329381942749
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19*2",
                "prediction": "CYP2C19*2"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19"
              },
              "Drug(s)": {
                "ground_truth": "clopidogrel",
                "prediction": "clopidogrel"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "*1/*2 + *2/*2 + *2/*17",
                "prediction": "*2"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Major Adverse Cardiac Events (MACE)",
                "prediction": "Efficacy:Major adverse cardiac events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9324533939361572,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.8667105436325073,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8393329381942749
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19*2",
                "prediction": "CYP2C19*2"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19"
              },
              "Drug(s)": {
                "ground_truth": "clopidogrel",
                "prediction": "clopidogrel"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "*1/*2 + *2/*2 + *2/*17",
                "prediction": "*2"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Major Adverse Cardiac Events (MACE)",
                "prediction": "Efficacy:Refractory angina symptoms"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 0.0,
              "Alleles": 0.9201368689537048,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.971265971660614,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8393329381942749
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19*2",
                "prediction": "CYP2C19*2"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19"
              },
              "Drug(s)": {
                "ground_truth": "clopidogrel",
                "prediction": "clopidogrel"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*1/*17 + *17/*17 + *2/*17",
                "prediction": "*2"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Hemorrhage",
                "prediction": "Side Effect:Bleeding events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 0.0,
              "Alleles": 0.9217134714126587,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9228420853614807,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8393329381942749
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19*17",
                "prediction": "CYP2C19*17"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19"
              },
              "Drug(s)": {
                "ground_truth": "clopidogrel",
                "prediction": "clopidogrel"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*1/*2 + *2/*2 + *2/*17",
                "prediction": "*17"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Major Adverse Cardiac Events (MACE)",
                "prediction": "Side Effect:Bleeding events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "non-carriers"
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "cyp2c19*1",
          "cyp2c19*2",
          "cyp2c19*2",
          "cyp2c19+clopidogrel"
        ],
        "unmatched_ground_truth": [
          {
            "Variant Annotation ID": 1454052160,
            "Variant/Haplotypes": "CYP2C19*1",
            "Gene": "CYP2C19",
            "Drug(s)": "clopidogrel",
            "PMID": 40295977,
            "Phenotype Category": "Efficacy",
            "Significance": "no",
            "Notes": "\"Our results indicated that carriers of the CYP2C19*17 variant experienced a higher incidence of bleeding events (16.67%) compared to non-carriers (6.9%). Despite this observed difference, it is important to note that the statistical analysis found no significant difference between the two groups (P\u2009=\u20090.567; see Table 7). Similarly, there was no statistically significant difference in bleeding events between CYP2C19*2 carriers and non-carriers (P\u2009=\u20090.0952; see Table 7), although a higher proportion of bleeding events was observed among carriers.\"",
            "Sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.",
            "Alleles": "*1/*17 + *17/*17 + *2/*17",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:Hemorrhage",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "40295977",
            "Variant Annotation ID_norm": "1454052160",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "clopidogrel",
              "drug_id": "PA449053",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1454052160,
            "Variant/Haplotypes": "CYP2C19*17",
            "Gene": "CYP2C19",
            "Drug(s)": "clopidogrel",
            "PMID": 40295977,
            "Phenotype Category": "Efficacy",
            "Significance": "no",
            "Notes": "\"Our results indicated that carriers of the CYP2C19*17 variant experienced a higher incidence of bleeding events (16.67%) compared to non-carriers (6.9%). Despite this observed difference, it is important to note that the statistical analysis found no significant difference between the two groups (P\u2009=\u20090.567; see Table 7). Similarly, there was no statistically significant difference in bleeding events between CYP2C19*2 carriers and non-carriers (P\u2009=\u20090.0952; see Table 7), although a higher proportion of bleeding events was observed among carriers.\"",
            "Sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.",
            "Alleles": "*1/*17 + *17/*17 + *2/*17",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:Hemorrhage",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "40295977",
            "Variant Annotation ID_norm": "1454052160",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*17",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "clopidogrel",
              "drug_id": "PA449053",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          }
        ],
        "unmatched_predictions": []
      },
      "study-parameters": {
        "overall_score": 0.6641383349895478,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.9620750248432159,
            "scores": [
              0.9636206030845642,
              0.9605294466018677
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 2,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9636206030845642,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454052120,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454052100,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 41.0,
                "prediction": 50
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "MACE, DAPT with a double maintenance dose of clopidogrel 150 mg/day (for at least one month after PCI).",
                "prediction": "Syrian CAD patients on DAPT with doubled maintenance dose of clopidogrel (150 mg/day) after PCI"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.08,
                "prediction": 0.08
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*2",
                "prediction": "*2"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.2744",
                "prediction": ""
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Near Eastern",
                "prediction": "Near Eastern"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9605294466018677,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454052180,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454052160,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 41.0,
                "prediction": 50
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "Bleeding events, DAPT with a double maintenance dose of clopidogrel 150 mg/day (for at least one month after PCI).",
                "prediction": "Syrian CAD patients on DAPT with doubled maintenance dose of clopidogrel (150 mg/day) after PCI"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": 0.17,
                "prediction": 0.17
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "*17",
                "prediction": "*17"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.567",
                "prediction": ""
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null
              },
              "Biogeographical Groups": {
                "ground_truth": "Near Eastern",
                "prediction": "Near Eastern"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "None:MACE, DAPT with a do",
          "None:Bleeding events, DAP"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 50,
            "Study Controls": null,
            "Characteristics": "Syrian CAD patients on DAPT with doubled maintenance dose of clopidogrel (150 mg/day) after PCI",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.0,
            "Allele Of Frequency In Cases": "*3",
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 41,
            "Study Controls": null,
            "Characteristics": "CYP2C19*2 carriers vs non-carriers - refractory angina symptoms in Syrian CAD patients on doubled clopidogrel dose",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "> 0.9999",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 41,
            "Study Controls": null,
            "Characteristics": "CYP2C19*2 carriers vs non-carriers - MACE in Syrian CAD patients on doubled clopidogrel dose",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.2744",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 41,
            "Study Controls": null,
            "Characteristics": "CYP2C19*17 carriers vs non-carriers - bleeding events in Syrian CAD patients on doubled clopidogrel dose",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.567",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 41,
            "Study Controls": null,
            "Characteristics": "CYP2C19*2 carriers vs non-carriers - bleeding events in Syrian CAD patients on doubled clopidogrel dose",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.0952",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Near Eastern",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC12319246": {
      "var-pheno": {
        "overall_score": 0.8033344807724158,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.875,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 0.875,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Drug(s)": {
            "mean_score": 0.875,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.5,
            "scores": [
              1.0,
              0.0,
              0.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0
            ]
          },
          "Alleles": {
            "mean_score": 0.8487341403961182,
            "scores": [
              0.9427328109741211,
              0.9427328109741211,
              0.9622328281402588,
              1.0,
              1.0,
              0.9421746730804443,
              1.0,
              0.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.875,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.875,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.8361826986074448,
            "scores": [
              0.979566752910614,
              0.9710120558738708,
              0.8571829795837402,
              1.0,
              0.979566752910614,
              1.0,
              0.902133047580719,
              0.0
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 0.875,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.3195471614599228,
            "scores": [
              0.8458930253982544,
              0.8335406184196472,
              0.8769436478614807,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 8,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9427328109741211,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.979566752910614,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8458930253982544
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs2740574",
                "prediction": "rs2740574"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4"
              },
              "Drug(s)": {
                "ground_truth": "tacrolimus",
                "prediction": "tacrolimus"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "TT",
                "prediction": "AA"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Transplant rejection",
                "prediction": "Efficacy:Acute Rejection"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC + CT",
                "prediction": "GA"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 0.0,
              "Alleles": 0.9427328109741211,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.9710120558738708,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8335406184196472
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs9282564",
                "prediction": "rs9282564"
              },
              "Gene": {
                "ground_truth": "ABCB1",
                "prediction": "ABCB1"
              },
              "Drug(s)": {
                "ground_truth": "tacrolimus",
                "prediction": "tacrolimus"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "other"
              },
              "Alleles": {
                "ground_truth": "TT",
                "prediction": "AA"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Death",
                "prediction": "Other:Death"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC + CT",
                "prediction": "AG"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 0.0,
              "Alleles": 0.9622328281402588,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.8571829795837402,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.8769436478614807
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs2273697",
                "prediction": "rs2273697"
              },
              "Gene": {
                "ground_truth": "ABCC2",
                "prediction": "ABCC2"
              },
              "Drug(s)": {
                "ground_truth": "tacrolimus",
                "prediction": "tacrolimus"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "other"
              },
              "Alleles": {
                "ground_truth": "GG",
                "prediction": "GA"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Overall survival",
                "prediction": "Other:Death"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "AA + AG",
                "prediction": "GG"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs4244285",
                "prediction": "rs4244285"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19"
              },
              "Drug(s)": {
                "ground_truth": "tacrolimus",
                "prediction": "tacrolimus"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "AA",
                "prediction": "AA"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Nephrotoxicity",
                "prediction": "Side Effect:Nephrotoxicity"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "GG, GA"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.979566752910614,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs4149056",
                "prediction": "rs4149056"
              },
              "Gene": {
                "ground_truth": "SLCO1B1",
                "prediction": "SLCO1B1"
              },
              "Drug(s)": {
                "ground_truth": "tacrolimus",
                "prediction": "tacrolimus"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy"
              },
              "Alleles": {
                "ground_truth": "TT",
                "prediction": "TT"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Transplant rejection",
                "prediction": "Efficacy:Acute Rejection"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "TC"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.9421746730804443,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs2306283",
                "prediction": "rs2306283"
              },
              "Gene": {
                "ground_truth": "SLCO1B1",
                "prediction": "SLCO1B1"
              },
              "Drug(s)": {
                "ground_truth": "tacrolimus",
                "prediction": "tacrolimus"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "AA + AG",
                "prediction": "AA"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Nephrotoxicity",
                "prediction": "Side Effect:Nephrotoxicity"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "GG"
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 6,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 0.0,
              "Alleles": 1.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 0.902133047580719,
              "When treated with/exposed to/when assayed with": 1.0,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "rs3745274",
                "prediction": "rs3745274"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6"
              },
              "Drug(s)": {
                "ground_truth": "tacrolimus",
                "prediction": "tacrolimus"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "other"
              },
              "Alleles": {
                "ground_truth": "GT",
                "prediction": "GT"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Transplant rejection",
                "prediction": "Other:Tumor Occurrence"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "TT"
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "PA166157367",
          "PA166155409",
          "PA166154547",
          "PA166157435",
          "PA166154007",
          "PA166154579",
          "PA166154053"
        ],
        "unmatched_ground_truth": [
          {
            "Variant Annotation ID": 1454211280,
            "Variant/Haplotypes": "rs776746",
            "Gene": "CYP3A5",
            "Drug(s)": "tacrolimus",
            "PMID": 40761554,
            "Phenotype Category": "Efficacy",
            "Significance": "no",
            "Notes": "\"Although the CYP3A5 rs776746 did not show a significant association with survival in logistic regression, the Kaplan-Meier curve was also represented (Fig. 1C) due to its special relevance and clinical evidence on the response to tacrolimus. No significant difference was observed by log-rank either, but it should not be discarded that the GG variant (\u22173/\u22173) could offer an advantage, especially at late post-transplantation stages.\" Alleles complemented. No *1*1 shown on kaplan meier, graph marked as recipient",
            "Sentence": "Genotype CC is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CT.",
            "Alleles": "CC",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Overall survival",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Kidney Transplantation",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "CT",
            "Comparison Metabolizer types": null,
            "PMID_norm": "40761554",
            "Variant Annotation ID_norm": "1454211280",
            "Variant/Haplotypes_normalized": {
              "normalized": "rs776746",
              "variant_id": "PA166157267",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "tacrolimus",
              "drug_id": "PA451578",
              "confidence": 1.0
            }
          }
        ],
        "unmatched_predictions": [
          {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "rs2273697",
            "Gene": "ABCC2",
            "Drug(s)": "tacrolimus",
            "PMID": 40761554,
            "Phenotype Category": "other",
            "Significance": "yes",
            "Notes": "AA variant in donor ABCC2 rs2273697 was significantly associated (p-value: 0.043) with increased risk (OR: 13.091, 95% CI: 1.241-138.105) of tumor occurrence during follow-up.",
            "Sentence": "rs2273697 AA genotype in donor is associated with increased risk of tumor occurrence when treated with tacrolimus in people with kidney transplantation.",
            "Alleles": "AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Other:Tumor Occurrence",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Kidney Transplantation",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "GG",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Conversely, a significant (p-value: 0.043) association with an increased risk (OR: 13.09) of tumor appearance during the follow-up was found in patients receiving a kidney with the AA variant in ABCC2 rs2273697.",
              "Increased tumor risk correlated with ABCC2 variants in donors and decreased risk with CYP2B6 rs3745274 in recipients."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2273697",
              "variant_id": "PA166154007",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "tacrolimus",
              "drug_id": "PA451578",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "rs2235013",
            "Gene": "ABCB1",
            "Drug(s)": "tacrolimus",
            "PMID": 40761554,
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "GA variant in donor ABCB1 rs2235013 was associated with reduced risk of chronic rejection (p-value: 0.016; OR: 0.133, 95% CI: 0.028-0.643).",
            "Sentence": "rs2235013 GA genotype in donor is associated with decreased risk of chronic rejection when treated with tacrolimus in people with kidney transplantation.",
            "Alleles": "GA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Efficacy:Chronic Rejection",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Kidney Transplantation",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "the GA variant in ABCB1 rs2235013 is associated with a reduced risk of chronic rejection (p-value: 0.016; OR: 0.13)",
              "Chronic rejection | ABCB1_rs2235013 | GA | D | 0.012 | 0.016 | 0.133 | 0.028 | 0.643"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2235013",
              "variant_id": "PA166157335",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "tacrolimus",
              "drug_id": "PA451578",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 8,
            "Variant/Haplotypes": "rs3745274",
            "Gene": "CYP2B6",
            "Drug(s)": "tacrolimus",
            "PMID": 40761554,
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "GT variant in donor CYP2B6 rs3745274 was associated with reduced risk of acute rejection (OR: 0.199, p-value: 0.027).",
            "Sentence": "rs3745274 GT genotype in donor is associated with decreased risk of acute rejection when treated with tacrolimus in people with kidney transplantation.",
            "Alleles": "GT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Efficacy:Acute Rejection",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Kidney Transplantation",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "TT",
            "Comparison Metabolizer types": null,
            "Citations": [
              "The presence of the TT variant in SLCO1B1 rs4149056 in the recipient and the GT variant in CYP2B6 rs3745274 in the donor were also statistically associated with a reduced risk (OR: 0.16 and 0.2, respectively) of acute rejection.",
              "CYP2B6_rs3745274 | GT | D | 0.020 | 0.027 | 0.199 | 0.051 | 0.777"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs3745274",
              "variant_id": "PA166155409",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "tacrolimus",
              "drug_id": "PA451578",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 9,
            "Variant/Haplotypes": "rs6714486",
            "Gene": "UGT1A9",
            "Drug(s)": "tacrolimus",
            "PMID": 40761554,
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "TA variant in donor UGT1A9 rs6714486 was associated with increased risk of acute rejection (OR: 32.116, p-value: 0.020).",
            "Sentence": "rs6714486 TA genotype in donor is associated with increased risk of acute rejection when treated with tacrolimus in people with kidney transplantation.",
            "Alleles": "TA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Efficacy:Acute Rejection",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Kidney Transplantation",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "On the contrary, the TA variant in UGT1A9 in rs6714486 of donor showed an association with an increased risk of acute rejection, although the imbalanced distribution of patient genotypes prevents us from considering such a high odds ratio.",
              "UGT1A9_rs6714486 | TA | D | 0.015 | 0.020 | 32.116 | 1.952 | 528.327"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs6714486",
              "variant_id": "PA166155748",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "tacrolimus",
              "drug_id": "PA451578",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 11,
            "Variant/Haplotypes": "rs2306283",
            "Gene": "SLCO1B1",
            "Drug(s)": "tacrolimus",
            "PMID": 40761554,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "AG variant in recipient SLCO1B1 rs2306283 was associated with reduced risk of nephrotoxicity (OR: 0.227, p-value: 0.051).",
            "Sentence": "rs2306283 AG genotype is associated with decreased risk of nephrotoxicity when treated with tacrolimus in people with kidney transplantation.",
            "Alleles": "AG",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Nephrotoxicity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Kidney Transplantation",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "GG",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Increased nephrotoxicity risk was associated with CYP2C19 rs4244285 and reduced by SLCO1B1 rs2306283 AA and AG variants.",
              "When considering nephrotoxicity, results indicate that the AA and AG variants in SLCO1B1 in the recipient, and the AA variant in this SNP in the donor, were associated with a reduced risk of nephrotoxicity (OR: 0.08, 0.23, and 0.11, respectively)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2306283",
              "variant_id": "PA166154547",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "tacrolimus",
              "drug_id": "PA451578",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 12,
            "Variant/Haplotypes": "rs2066844",
            "Gene": "NOD2",
            "Drug(s)": "tacrolimus",
            "PMID": 40761554,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "CC variant in donor NOD2 rs2066844 was associated with reduced risk of nephrotoxicity (OR: 0.015, p-value: 0.035).",
            "Sentence": "rs2066844 CC genotype in donor is associated with decreased risk of nephrotoxicity when treated with tacrolimus in people with kidney transplantation.",
            "Alleles": "CC",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Nephrotoxicity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Kidney Transplantation",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "When considering nephrotoxicity, results indicate that the AA and AG variants in SLCO1B1 in the recipient, and the AA variant in this SNP in the donor, were associated with a reduced risk of nephrotoxicity (OR: 0.08, 0.23, and 0.11, respectively). The CC variant in donor NOD2 rs2066844 could also reduce that risk (OR: 0.015).",
              "| Nephrotoxicity | SLCO1B1_rs2306283 | AA | R | 0.007 | 0.009 | 0.076 | 0.012 | 0.492 |\n| AG | R | 0.038 | 0.051 | 0.227 | 0.056 | 0.919 |  |  |\n| NOD2_rs2066844 | CC | D | 0.026 | 0.035 | 0.015 | 0.000 | 0.598 |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2066844",
              "variant_id": "PA166155027",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "tacrolimus",
              "drug_id": "PA451578",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 13,
            "Variant/Haplotypes": "rs2306283",
            "Gene": "SLCO1B1",
            "Drug(s)": "tacrolimus",
            "PMID": 40761554,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "AG variant in donor SLCO1B1 rs2306283 was associated with reduced risk of nephrotoxicity (OR: 0.108, p-value: 0.024).",
            "Sentence": "rs2306283 AG genotype in donor is associated with decreased risk of nephrotoxicity when treated with tacrolimus in people with kidney transplantation.",
            "Alleles": "AG",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Nephrotoxicity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Kidney Transplantation",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "GG",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Increased nephrotoxicity risk was associated with CYP2C19 rs4244285 and reduced by SLCO1B1 rs2306283 AA and AG variants.",
              "When considering nephrotoxicity, results indicate that the AA and AG variants in SLCO1B1 in the recipient, and the AA variant in this SNP in the donor, were associated with a reduced risk of nephrotoxicity (OR: 0.08, 0.23, and 0.11, respectively).",
              "AG variant in donor SLCO1B1 rs2306283 was associated with reduced risk of nephrotoxicity (OR: 0.108, p-value: 0.024)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs2306283",
              "variant_id": "PA166154547",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "tacrolimus",
              "drug_id": "PA451578",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 15,
            "Variant/Haplotypes": "rs1142345",
            "Gene": "TPMT",
            "Drug(s)": "tacrolimus",
            "PMID": 40761554,
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "AA variant in donor TPMT rs1142345 was associated with reduced risk of re-transplantation (OR: 0.048, p-value: 0.020).",
            "Sentence": "rs1142345 AA genotype in donor is associated with decreased risk of re-transplantation when treated with tacrolimus in people with kidney transplantation.",
            "Alleles": "AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Efficacy:Re-transplantation",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Kidney Transplantation",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "Lastly, a reduced risk of re-transplantation was observed in patients whose implanted kidneys carried the AA variant in TPMT rs1142345 and the CC variant in CYP2C9 rs1799853 (OR: 0.048, p-value: 0.02; and OR: 0.10, p-value: 0.042, respectively).",
              "| Re-transplantation | TPMT_rs1142345 | AA | D | 0.015 | 0.020 | 0.048 | 0.004 | 0.559 |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1142345",
              "variant_id": "PA166156978",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "tacrolimus",
              "drug_id": "PA451578",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 16,
            "Variant/Haplotypes": "rs1799853",
            "Gene": "CYP2C9",
            "Drug(s)": "tacrolimus",
            "PMID": 40761554,
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "CC variant in donor CYP2C9 rs1799853 was associated with reduced risk of re-transplantation (OR: 0.102, p-value: 0.042).",
            "Sentence": "rs1799853 CC genotype in donor is associated with decreased risk of re-transplantation when treated with tacrolimus in people with kidney transplantation.",
            "Alleles": "CC",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Efficacy:Re-transplantation",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Kidney Transplantation",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Citations": [
              "Lastly, a reduced risk of re-transplantation was observed in patients whose implanted kidneys carried the AA variant in TPMT rs1142345 and the CC variant in CYP2C9 rs1799853 (OR: 0.048, p-value: 0.02; and OR: 0.10, p-value: 0.042, respectively).",
              "| Re-transplantation | TPMT_rs1142345 | AA | D | 0.015 | 0.020 | 0.048 | 0.004 | 0.559 |\n| CYP2C9_rs1799853 | CC | D | 0.031 | 0.042 | 0.102 | 0.013 | 0.810 |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1799853",
              "variant_id": "PA166153972",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "tacrolimus",
              "drug_id": "PA451578",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 17,
            "Variant/Haplotypes": "rs1045642",
            "Gene": "ABCB1",
            "Drug(s)": "tacrolimus",
            "PMID": 40761554,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "CC variant in recipient ABCB1 rs1045642 was associated with reduced risk of infections (OR: 0.087, p-value: 0.003).",
            "Sentence": "rs1045642 CC genotype is associated with decreased risk of infections when treated with tacrolimus in people with kidney transplantation.",
            "Alleles": "CC",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Infections",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Kidney Transplantation",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "TC, TT",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Severe infections in transplanted patients were classified as de novo infections.",
              "ABCB1 gene could influence the risk of chronic rejection (GA variant in donor's rs2235013 SNP; OR: 0.13) and severe infections, either reducing it (CC variant in recipient's ABCB1 rs1045642; OR: 0.087) or increasing it (AA variant in donor's ABCB1 rs9282564; OR: 23.8).",
              "| Infections | ABCB1_rs1045642 | CC | R | 0.002 | 0.003 | 0.087 | 0.019 | 0.393 |"
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs1045642",
              "variant_id": "PA166157284",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "tacrolimus",
              "drug_id": "PA451578",
              "confidence": 1.0
            }
          },
          {
            "Variant Annotation ID": 18,
            "Variant/Haplotypes": "rs9282564",
            "Gene": "ABCB1",
            "Drug(s)": "tacrolimus",
            "PMID": 40761554,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "AA variant in donor ABCB1 rs9282564 was associated with increased risk of infections (OR: 23.800, p-value: 0.005).",
            "Sentence": "rs9282564 AA genotype in donor is associated with increased risk of infections when treated with tacrolimus in people with kidney transplantation.",
            "Alleles": "AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Infections",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Kidney Transplantation",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "AG",
            "Comparison Metabolizer types": null,
            "Citations": [
              "Acute rejection was associated with variants in CYP3A4, CYP2B6, UGT1A9 metabolism genes (with CYP3A4 and CYP2B6 having protective roles and UGT1A9 increasing risk), and the SLCO1B1 transporter gene, where the TT variant in recipient rs4149056 showed a reduced risk of acute rejection (OR: 0.157). Regarding the need for re-transplantation, variants in TPMT and CYP2C9 genes were associated with a protective role, though we could not determine the underlying rationale in the literature.",
              "Our results indicate that the ABCB1 gene could influence the risk of chronic rejection (GA variant in donor's rs2235013 SNP; OR: 0.13) and severe infections, either reducing it (CC variant in recipient's ABCB1 rs1045642; OR: 0.087) or increasing it (AA variant in donor's ABCB1 rs9282564; OR: 23.8)."
            ],
            "Variant/Haplotypes_normalized": {
              "normalized": "rs9282564",
              "variant_id": "PA166157435",
              "confidence": 1.0
            },
            "Drug(s)_normalized": {
              "normalized": "tacrolimus",
              "drug_id": "PA451578",
              "confidence": 1.0
            }
          }
        ]
      },
      "study-parameters": {
        "overall_score": 0.6906779969731967,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Study Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.92266995459795,
            "scores": [
              0.9308220744132996,
              0.9427960515022278,
              0.9425719380378723,
              0.9409169554710388,
              0.9336385130882263,
              0.9046720266342163,
              0.8875969648361206,
              0.8983451128005981
            ]
          },
          "Characteristics Type": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          },
          "P Value": {
            "mean_score": 0.9375,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.5
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 0.125,
            "scores": [
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 0.125,
            "scores": [
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 0.125,
            "scores": [
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 0.125,
            "scores": [
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 1.0,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0
            ]
          }
        },
        "total_samples": 8,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9308220744132996,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454211329,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454211323,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 79.0,
                "prediction": 79
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "nephrotoxicity during 12-year follow-up",
                "prediction": "Kidney transplant recipients, 12-year follow-up, nephrotoxicity, donor CYP2C19 rs4244285 AA genotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.026",
                "prediction": "= 0.026"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 11.652,
                "prediction": 11.652
              },
              "Confidence Interval Start": {
                "ground_truth": 1.509,
                "prediction": 1.509
              },
              "Confidence Interval Stop": {
                "ground_truth": 89.957,
                "prediction": 89.957
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "Unknown"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9427960515022278,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454211336,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454211330,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 79.0,
                "prediction": 79
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "acute rejection during 12-year follow-up, recipient",
                "prediction": "Kidney transplant recipients, 12-year follow-up, acute rejection, recipient CYP3A4 rs2740574 AA genotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.047",
                "prediction": "= 0.047"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.08
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.008
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 0.833
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "Unknown"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9425719380378723,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454211406,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454211400,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 79.0,
                "prediction": 79
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "nephrotoxicity during 12-year follow-up, donor",
                "prediction": "Kidney transplant recipients, 12-year follow-up, nephrotoxicity, donor SLCO1B1 rs2306283 AG genotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.024",
                "prediction": "= 0.024"
              },
              "Ratio Stat Type": {
                "ground_truth": "Unknown",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.108
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.017
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 0.679
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "Unknown"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9409169554710388,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454211353,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454211347,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 79.0,
                "prediction": 79
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "acute rejection during 12-year follow-up, donor",
                "prediction": "Kidney transplant recipients, 12-year follow-up, acute rejection, donor CYP2B6 rs3745274 GT genotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.027",
                "prediction": "= 0.027"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.199
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.051
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 0.777
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "Unknown"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9336385130882263,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454211346,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454211340,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 79.0,
                "prediction": 79
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "acute rejection during 12-year follow-up, recipient",
                "prediction": "Kidney transplant recipients, 12-year follow-up, acute rejection, recipient SLCO1B1 rs4149056 TT genotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.024",
                "prediction": "= 0.024"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.157
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.034
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 0.725
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "Unknown"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.9046720266342163,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454211266,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454211260,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 79.0,
                "prediction": 79
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "exitus during 12-year follow-up",
                "prediction": "Kidney transplant recipients, 12-year follow-up, exitus outcome, donor ABCB1 rs9282564 AA genotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.029",
                "prediction": "= 0.029"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.116
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.019
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 0.726
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "Unknown"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 6,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8875969648361206,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454211277,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454211271,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 79.0,
                "prediction": 79
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "survival during 12-year follow-up",
                "prediction": "Kidney transplant recipients, 12-year follow-up, infections, recipient ABCB1 rs1045642 CC genotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.003",
                "prediction": "= 0.003"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.087
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.019
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 0.393
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "Unknown"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          },
          {
            "sample_id": 7,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 1.0,
              "Study Controls": 1.0,
              "Characteristics": 0.8983451128005981,
              "Characteristics Type": 1.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 0.5,
              "Ratio Stat Type": 0.0,
              "Ratio Stat": 0.0,
              "Confidence Interval Start": 0.0,
              "Confidence Interval Stop": 0.0,
              "Biogeographical Groups": 1.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1454211300,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1454211280,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 79.0,
                "prediction": 79
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Characteristics": {
                "ground_truth": "survival during 12-year follow-up",
                "prediction": "Kidney transplant recipients, 12-year follow-up, tumor occurrence, donor ABCC2 rs2273697 AA genotype"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.138",
                "prediction": "= 0.043"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 13.091
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 1.241
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 138.105
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "Unknown"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "None:nephrotoxicity durin",
          "None:acute rejection duri",
          "None:nephrotoxicity durin",
          "None:acute rejection duri",
          "None:acute rejection duri",
          "None:exitus during 12-yea",
          "None:survival during 12-y",
          "None:survival during 12-y"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 79,
            "Study Controls": null,
            "Characteristics": "Kidney transplant recipients, 12-year follow-up, exitus outcome, donor ABCC2 rs2273697 GA genotype",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.021",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 4.133,
            "Confidence Interval Start": 1.301,
            "Confidence Interval Stop": 13.125,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 79,
            "Study Controls": null,
            "Characteristics": "Kidney transplant recipients, 12-year follow-up, exitus outcome, recipient CYP2B6 rs3745274 GT genotype",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.060",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.224,
            "Confidence Interval Start": 0.052,
            "Confidence Interval Stop": 0.96,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 79,
            "Study Controls": null,
            "Characteristics": "Kidney transplant recipients, 12-year follow-up, exitus outcome, recipient CYP3A5 rs776746 GG genotype",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.066",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.264,
            "Confidence Interval Start": 0.071,
            "Confidence Interval Stop": 0.989,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 79,
            "Study Controls": null,
            "Characteristics": "Kidney transplant recipients, 12-year follow-up, tumor occurrence, recipient CYP2B6 rs3745274 GT genotype",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.048",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.099,
            "Confidence Interval Start": 0.012,
            "Confidence Interval Stop": 0.85,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 79,
            "Study Controls": null,
            "Characteristics": "Kidney transplant recipients, 12-year follow-up, tumor occurrence, donor ABCC2 rs2273697 GA genotype",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.058",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 3.394,
            "Confidence Interval Start": 1.037,
            "Confidence Interval Stop": 11.103,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 79,
            "Study Controls": null,
            "Characteristics": "Kidney transplant recipients, 12-year follow-up, tumor occurrence, donor ABCB1 rs9282564 AA genotype",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.057",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.12,
            "Confidence Interval Start": 0.015,
            "Confidence Interval Stop": 0.93,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 79,
            "Study Controls": null,
            "Characteristics": "Kidney transplant recipients, 12-year follow-up, chronic rejection, donor ABCB1 rs2235013 GA genotype",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.016",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.133,
            "Confidence Interval Start": 0.028,
            "Confidence Interval Stop": 0.643,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 79,
            "Study Controls": null,
            "Characteristics": "Kidney transplant recipients, 12-year follow-up, acute rejection, donor UGT1A9 rs6714486 TA genotype",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.020",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 32.116,
            "Confidence Interval Start": 1.952,
            "Confidence Interval Stop": 528.327,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 79,
            "Study Controls": null,
            "Characteristics": "Kidney transplant recipients, 12-year follow-up, nephrotoxicity, recipient SLCO1B1 rs2306283 AA genotype",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.009",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.076,
            "Confidence Interval Start": 0.012,
            "Confidence Interval Stop": 0.492,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 79,
            "Study Controls": null,
            "Characteristics": "Kidney transplant recipients, 12-year follow-up, nephrotoxicity, recipient SLCO1B1 rs2306283 AG genotype",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.051",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.227,
            "Confidence Interval Start": 0.056,
            "Confidence Interval Stop": 0.919,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 79,
            "Study Controls": null,
            "Characteristics": "Kidney transplant recipients, 12-year follow-up, nephrotoxicity, donor NOD2 rs2066844 CC genotype",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.035",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.015,
            "Confidence Interval Start": 0.0,
            "Confidence Interval Stop": 0.598,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 79,
            "Study Controls": null,
            "Characteristics": "Kidney transplant recipients, 12-year follow-up, re-transplantation, donor TPMT rs1142345 AA genotype",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.020",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.048,
            "Confidence Interval Start": 0.004,
            "Confidence Interval Stop": 0.559,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 79,
            "Study Controls": null,
            "Characteristics": "Kidney transplant recipients, 12-year follow-up, re-transplantation, donor CYP2C9 rs1799853 CC genotype",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.042",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.102,
            "Confidence Interval Start": 0.013,
            "Confidence Interval Stop": 0.81,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 79,
            "Study Controls": null,
            "Characteristics": "Kidney transplant recipients, 12-year follow-up, diabetes mellitus de novo, recipient CYP2B6 rs3745274 GT genotype",
            "Characteristics Type": "disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.056",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.273,
            "Confidence Interval Start": 0.072,
            "Confidence Interval Stop": 1.033,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 79,
            "Study Controls": null,
            "Characteristics": "Kidney transplant recipients, 12-year follow-up, infections, donor ABCB1 rs9282564 AA genotype",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.005",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 23.8,
            "Confidence Interval Start": 2.776,
            "Confidence Interval Stop": 204.039,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    },
    "PMC6435416": {
      "var-pheno": {
        "overall_score": 0.29228118028905653,
        "field_scores": {
          "Variant/Haplotypes": {
            "mean_score": 0.13333333333333333,
            "scores": [
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Gene": {
            "mean_score": 0.4,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Drug(s)": {
            "mean_score": 0.4,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Phenotype Category": {
            "mean_score": 0.4,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Alleles": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Is/Is Not associated": {
            "mean_score": 0.4,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Direction of effect": {
            "mean_score": 0.4,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Phenotype": {
            "mean_score": 0.4,
            "scores": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "When treated with/exposed to/when assayed with": {
            "mean_score": 0.34808166027069093,
            "scores": [
              0.8702041506767273,
              0.8702041506767273,
              0.8702041506767273,
              0.8702041506767273,
              0.8702041506767273,
              0.8702041506767273,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          "Comparison Allele(s) or Genotype(s)": {
            "mean_score": 0.0,
            "scores": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          }
        },
        "total_samples": 15,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 0.8702041506767273,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*1",
                "prediction": "CYP2D6"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "risperidone",
                "prediction": "risperidone"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:adverse events",
                "prediction": "Side Effect:Adverse Events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "due to",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 1,
            "field_scores": {
              "Variant/Haplotypes": 1.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 0.8702041506767273,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*1",
                "prediction": "CYP2D6"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "risperidone",
                "prediction": "risperidone"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:adverse events",
                "prediction": "Side Effect:Adverse Events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "due to",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 2,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 0.8702041506767273,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*1",
                "prediction": "poor"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "risperidone",
                "prediction": "risperidone"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:adverse events",
                "prediction": "Side Effect:Adverse Events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "due to",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 3,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 0.8702041506767273,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*1",
                "prediction": "metabolizer"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "risperidone",
                "prediction": "risperidone"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:adverse events",
                "prediction": "Side Effect:Adverse Events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "due to",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 4,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 0.8702041506767273,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*1",
                "prediction": "intermediate"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "risperidone",
                "prediction": "risperidone"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:adverse events",
                "prediction": "Side Effect:Adverse Events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "due to",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
                "prediction": null
              }
            },
            "dependency_issues": []
          },
          {
            "sample_id": 5,
            "field_scores": {
              "Variant/Haplotypes": 0.0,
              "Gene": 1.0,
              "Drug(s)": 1.0,
              "Phenotype Category": 1.0,
              "Alleles": 0.0,
              "Is/Is Not associated": 1.0,
              "Direction of effect": 1.0,
              "Phenotype": 1.0,
              "When treated with/exposed to/when assayed with": 0.8702041506767273,
              "Comparison Allele(s) or Genotype(s)": 0.0
            },
            "field_values": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*1",
                "prediction": "metabolizer"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6"
              },
              "Drug(s)": {
                "ground_truth": "risperidone",
                "prediction": "risperidone"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity"
              },
              "Alleles": {
                "ground_truth": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
                "prediction": null
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:adverse events",
                "prediction": "Side Effect:Adverse Events"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "due to",
                "prediction": "when treated with"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
                "prediction": null
              }
            },
            "dependency_issues": []
          }
        ],
        "aligned_variants": [
          "cyp2d6*1",
          "cyp2d6*1xn",
          "cyp2d6+risperidone",
          "cyp2d6+risperidone",
          "cyp2d6+risperidone",
          "cyp2d6+risperidone"
        ],
        "unmatched_ground_truth": [
          {
            "Variant Annotation ID": 1450932846,
            "Variant/Haplotypes": "CYP2D6*4xN",
            "Gene": "CYP2D6",
            "Drug(s)": "risperidone",
            "PMID": 30661084,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
            "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
            "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer and poor metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:adverse events",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "due to",
            "Multiple drugs And/or": null,
            "Population types": "in children",
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
            "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer",
            "PMID_norm": "30661084",
            "Variant Annotation ID_norm": "1450932846",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "risperidone",
              "drug_id": "PA451257",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1450932846,
            "Variant/Haplotypes": "CYP2D6*5",
            "Gene": "CYP2D6",
            "Drug(s)": "risperidone",
            "PMID": 30661084,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
            "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
            "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer and poor metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:adverse events",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "due to",
            "Multiple drugs And/or": null,
            "Population types": "in children",
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
            "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer",
            "PMID_norm": "30661084",
            "Variant Annotation ID_norm": "1450932846",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "risperidone",
              "drug_id": "PA451257",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1450932846,
            "Variant/Haplotypes": "CYP2D6*6",
            "Gene": "CYP2D6",
            "Drug(s)": "risperidone",
            "PMID": 30661084,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
            "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
            "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer and poor metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:adverse events",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "due to",
            "Multiple drugs And/or": null,
            "Population types": "in children",
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
            "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer",
            "PMID_norm": "30661084",
            "Variant Annotation ID_norm": "1450932846",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "risperidone",
              "drug_id": "PA451257",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1450932846,
            "Variant/Haplotypes": "CYP2D6*9",
            "Gene": "CYP2D6",
            "Drug(s)": "risperidone",
            "PMID": 30661084,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
            "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
            "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer and poor metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:adverse events",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "due to",
            "Multiple drugs And/or": null,
            "Population types": "in children",
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
            "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer",
            "PMID_norm": "30661084",
            "Variant Annotation ID_norm": "1450932846",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "risperidone",
              "drug_id": "PA451257",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1450932846,
            "Variant/Haplotypes": "CYP2D6*10",
            "Gene": "CYP2D6",
            "Drug(s)": "risperidone",
            "PMID": 30661084,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
            "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
            "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer and poor metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:adverse events",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "due to",
            "Multiple drugs And/or": null,
            "Population types": "in children",
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
            "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer",
            "PMID_norm": "30661084",
            "Variant Annotation ID_norm": "1450932846",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "risperidone",
              "drug_id": "PA451257",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1450932846,
            "Variant/Haplotypes": "CYP2D6*17",
            "Gene": "CYP2D6",
            "Drug(s)": "risperidone",
            "PMID": 30661084,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
            "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
            "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer and poor metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:adverse events",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "due to",
            "Multiple drugs And/or": null,
            "Population types": "in children",
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
            "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer",
            "PMID_norm": "30661084",
            "Variant Annotation ID_norm": "1450932846",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "risperidone",
              "drug_id": "PA451257",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1450932846,
            "Variant/Haplotypes": "CYP2D6*29",
            "Gene": "CYP2D6",
            "Drug(s)": "risperidone",
            "PMID": 30661084,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
            "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
            "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer and poor metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:adverse events",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "due to",
            "Multiple drugs And/or": null,
            "Population types": "in children",
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
            "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer",
            "PMID_norm": "30661084",
            "Variant Annotation ID_norm": "1450932846",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "risperidone",
              "drug_id": "PA451257",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1450932846,
            "Variant/Haplotypes": "CYP2D6*35",
            "Gene": "CYP2D6",
            "Drug(s)": "risperidone",
            "PMID": 30661084,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
            "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
            "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer and poor metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:adverse events",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "due to",
            "Multiple drugs And/or": null,
            "Population types": "in children",
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
            "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer",
            "PMID_norm": "30661084",
            "Variant Annotation ID_norm": "1450932846",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "risperidone",
              "drug_id": "PA451257",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          },
          {
            "Variant Annotation ID": 1450932846,
            "Variant/Haplotypes": "CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "risperidone",
            "PMID": 30661084,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
            "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
            "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
            "Specialty Population": "Pediatric",
            "Metabolizer types": "intermediate metabolizer and poor metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:adverse events",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "due to",
            "Multiple drugs And/or": null,
            "Population types": "in children",
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
            "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer",
            "PMID_norm": "30661084",
            "Variant Annotation ID_norm": "1450932846",
            "Variant/Haplotypes_normalized": {
              "normalized": "CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41",
              "variant_id": null,
              "confidence": 0.0
            },
            "Drug(s)_normalized": {
              "normalized": "risperidone",
              "drug_id": "PA451257",
              "confidence": 1.0
            },
            "_expanded_from_multi_variant": true
          }
        ],
        "unmatched_predictions": []
      },
      "study-parameters": {
        "overall_score": 0.6630742351214091,
        "field_scores": {
          "Study Type": {
            "mean_score": 0.0,
            "scores": [
              0.0
            ]
          },
          "Study Cases": {
            "mean_score": 0.0,
            "scores": [
              0.0
            ]
          },
          "Study Controls": {
            "mean_score": 0.0,
            "scores": [
              0.0
            ]
          },
          "Characteristics": {
            "mean_score": 0.9461135268211365,
            "scores": [
              0.9461135268211365
            ]
          },
          "Characteristics Type": {
            "mean_score": 0.0,
            "scores": [
              0.0
            ]
          },
          "Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Allele Of Frequency In Cases": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Allele Of Frequency In Controls": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "P Value": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Ratio Stat Type": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Ratio Stat": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Confidence Interval Start": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Confidence Interval Stop": {
            "mean_score": 1.0,
            "scores": [
              1.0
            ]
          },
          "Biogeographical Groups": {
            "mean_score": 0.0,
            "scores": [
              0.0
            ]
          }
        },
        "total_samples": 1,
        "detailed_results": [
          {
            "sample_id": 0,
            "field_scores": {
              "Study Parameters ID": 0.0,
              "Variant Annotation ID": 0.0,
              "Study Type": 0.0,
              "Study Cases": 0.0,
              "Study Controls": 0.0,
              "Characteristics": 0.9461135268211365,
              "Characteristics Type": 0.0,
              "Frequency In Cases": 1.0,
              "Allele Of Frequency In Cases": 1.0,
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": 1.0,
              "P Value": 1.0,
              "Ratio Stat Type": 1.0,
              "Ratio Stat": 1.0,
              "Confidence Interval Start": 1.0,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": 0.0
            },
            "field_values": {
              "Study Parameters ID": {
                "ground_truth": 1450932850,
                "prediction": null
              },
              "Variant Annotation ID": {
                "ground_truth": 1450932846,
                "prediction": null
              },
              "Study Type": {
                "ground_truth": "cohort, retrospective",
                "prediction": "cohort"
              },
              "Study Cases": {
                "ground_truth": 257.0,
                "prediction": 33
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 224
              },
              "Characteristics": {
                "ground_truth": "multivariate analysis adjusted for age, sex, race, and initial risperidone dose",
                "prediction": "Children \u226418 years with risperidone exposure, CYP2D6 poor/intermediate metabolizers vs normal/ultrarapid metabolizers, multivariate analysis adjusted for age, sex, race, and initial dose"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null
              },
              "P Value": {
                "ground_truth": "= 0.03",
                "prediction": "= 0.03"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR"
              },
              "Ratio Stat": {
                "ground_truth": 2.4,
                "prediction": 2.4
              },
              "Confidence Interval Start": {
                "ground_truth": 1.1,
                "prediction": 1.1
              },
              "Confidence Interval Stop": {
                "ground_truth": 5.1,
                "prediction": 5.1
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, White Hispanic, White non-Hispanic, African American, Asian/Pacific Islander, Native American or 'Unknown' ethnicities",
                "prediction": "Multiple Groups"
              }
            },
            "dependency_issues": [],
            "penalty_info": {
              "total_penalty": 0.0,
              "penalized_fields": {},
              "issues_by_field": {}
            }
          }
        ],
        "aligned_variants": [
          "cohort, retrospective:multivariate analysi"
        ],
        "unmatched_ground_truth": [],
        "unmatched_predictions": [
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 33,
            "Study Controls": 224,
            "Characteristics": "Children \u226418 years with risperidone exposure, CYP2D6 poor/intermediate metabolizers vs normal/ultrarapid metabolizers, adverse events outcome",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.455,
            "Allele Of Frequency In Cases": "poor/intermediate metabolizer",
            "Frequency In Controls": 0.272,
            "Allele Of Frequency In Controls": "poor/intermediate metabolizer",
            "P Value": "= 0.04",
            "Ratio Stat Type": "OR",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 20,
            "Study Controls": 204,
            "Characteristics": "Normal/ultrarapid metabolizers with concomitant strong CYP2D6 inhibitor vs without, adverse events outcome",
            "Characteristics Type": "drug",
            "Frequency In Cases": 0.3,
            "Allele Of Frequency In Cases": "with CYP2D6 inhibitor",
            "Frequency In Controls": 0.27,
            "Allele Of Frequency In Controls": "without CYP2D6 inhibitor",
            "P Value": "= 0.8",
            "Ratio Stat Type": "OR",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          },
          {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "cohort",
            "Study Cases": 20,
            "Study Controls": 204,
            "Characteristics": "Normal/ultrarapid metabolizers with concomitant strong CYP2D6 inhibitor, multivariate analysis adjusted for risperidone dose, age, sex, and race",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.7",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.2,
            "Confidence Interval Start": 0.4,
            "Confidence Interval Stop": 3.3,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
          }
        ]
      }
    }
  }
}